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Abstract  
Chronic lymphocytic leukemia (CLL) is a lymphoid neoplasm characterized by an 
accumulation of mature B lymphocytes in blood and peripheral lymphoid organs which highly 
depend on a tumor-supportive microenvironment. Altered T-cell distribution and function have 
since long been observed in the CLL microenvironment, but the exact pathological role of the 
different T-cell subsets remains uncertain. 
In the present work, the spectrum of CLL-associated T-cell phenotypes were investigated 
by using leading-edge single-cell technologies. Mass cytometry analyses of lymph nodes (LN), 
peripheral blood and bone marrow of CLL patients together with reactive lymph nodes (rLNs) 
of donors without cancer identified the CLL LN as a distinct niche, where CD8+ effector memory 
T-cells with an exhausted phenotype accumulate. Single-cell transcriptome and TCR-clonality 
analyses of LN T-cells further revealed a clonal expansion restricted to effector memory CD8+ 
T-cells, and enabled the characterization of the specific cross-talk between CLL cells and T-
cell subsets. Besides, the single-cell transcriptome of T-cells from the Eµ-TCL1 mouse model 
of CLL was examined and shown to be similar to that of T-cells from CLL patients. 
Since genome-wide association studies have identified that a single-nucleotide 
polymorphism affecting the T-cell master regulator EOMES is associated with CLL 
development, the role of this transcription factor in the disease was investigated. Epigenetic 
and single-cell RNA sequencing analyses revealed that EOMES is not expressed in CLL cells 
but in T-cells, and that its levels are highest in exhausted CD8+ T-cells. Interestingly, Eomes 
deficiency in CD8+ T-cells prevented their expansion and led to a decreased leukemia control 
in the TCL1 mouse model, providing a novel layer of evidence for an anti-tumor role of CD8+ 
T-cells in CLL. 
Furthermore, mass cytometry and single-cell RNA-sequencing analyses revealed an 
increase of T regulatory type 1 (TR1) CD4+ T-cells in CLL LNs compared to rLNs. Such 
accumulation was likewise confirmed in spleen of Eµ-TCL1 mice using flow cytometry. 
Strikingly, TR1 cells failed to expand from Eomes-deficient CD4+ T-cells adoptively transferred 
in leukemic mice, and consequently were less capable of controlling leukemia development. 
Moreover, TR1 cell-mediated CLL control required IL-10 receptor signaling, as Il10rb-/- CD4+ T-
cells showed impaired anti-leukemia activity. 
Taken together, the data generated herein comprehensively and deeply characterize the 
composition and phenotype of the T-cell compartment of CLL patients in comparison to 
individuals without cancer, and significantly improve our understanding of the function of 
distinct T-cell subsets in CLL.







Chronisch lymphatische Leukämie (CLL) ist eine lymphoide Neoplasie, die durch eine 
Akkumulation reifer, maligner B-Lymphozyten charakterisiert ist, die stark von einer 
tumorunterstützenden Mikroumgebung abhängen. Eine veränderte T-Zellverteilung und 
funktionelle T-Zelldefekte wurden in der CLL-Mikroumgebung seit langem beobachtet, aber 
die spezifische pathologische Rolle der verschiedenen T-Zellsubpopulationen bleibt bisher 
unklar. 
In der vorliegenden Arbeit wurde das Spektrum der CLL-assoziierten T-Zellphänotypen 
unter Verwendung modernster Einzelzellentechnologien analysiert. 
Massenzytometrieanalysen von Lymphknoten (LN), peripherem Blut und Knochenmark von 
Patienten mit CLL, sowie reaktiver Lymphknoten (rLNs) gesunder Spender charakterisierten 
die CLL LNs als eine spezifische Nische, in der sich CD8+ Effektor-Gedächtnis-T-Zellen mit 
einem erschöpften Phänotyp ansammeln. Einzelzell-Transkriptom- und TCR-Zellrezeptor-
Klonalitätsanalysen von Zellen aus LN zeigten, dass die klonale Expansion der CD8+ T-Zellen 
auf die Effektor-Gedächtniszellen beschränkt ist, und ermöglichten die Charakterisierung der 
spezifischen Wechselwirkungen zwischen CLL-Zellen und den T-Zell-Subtypen. Außerdem 
wurde das Einzelzell-Transkriptom von T-Zellen aus dem Eµ-TCL1 Mausmodell für CLL 
untersucht und es wurde gezeigt, dass es dem von T-Zellen aus Patienten mit CLL ähnelt. 
Da genomweite Assoziationsstudien gezeigt haben, dass ein Einzelnukleotid-
Polymorphismus, der das T-Zell-Masterregulatorgen EOMES betrifft, mit der Entwicklung von 
CLL assoziiert ist, wurde die Rolle dieses Transkriptionsfaktors in CLL untersucht. 
Epigenetische Analysen und Einzelzell-RNA-Sequenzierungen ergaben, dass EOMES nicht 
in CLL-Zellen, sondern in T-Zellen exprimiert wird, und eine maximale Expression in 
erschöpften CD8+ T-Zellen zeigt. Interessanterweise verhinderte das Fehlen von Eomes in 
CD8+ T-Zellen deren Expansion im CLL-Mausmodell, was zu einer verminderten 
Leukämiekontrolle führte. Diese Daten unterstützen die Hypothese, dass CD8+ T-Zellen eine 
Antitumor-Aktivität in CLL haben. 
Darüber hinaus zeigten Massenzytometrie- und Einzelzell-RNA-Sequenzierungsanalysen 
eine Anhäufung von CD4+ regulatorischen Typ 1 T-Zellen (TR1) in CLL LNs im Vergleich zu 
rLNs. Eine solche Akkumulation wurde ebenfalls in der Milz von Eµ-TCL1 Mäusen unter 
Verwendung von Durchflusszytometrie bestätigt. Interessanterweise konnte keine Expansion 
von TR1-Zellen aus Eomes-defizienten CD4+ T-Zellen, die in Mäusen mit CLL injiziert wurden, 
beobachtet werden, was eine beschleunigte Leukämieentwicklung im Vergleich zu Tieren mit 
wildtyp T-Zellen zur Folge hatte. Darüber hinaus zeigten diese Studien, dass die TR1-Zell-
vermittelte Kontrolle von CLL im Mausmodell vom IL-10-Rezeptorsignalweg abhängt, da 
Il10rb-defiziente CD4+ T-Zellen eine beeinträchtigte Anti-CLL-Aktivität aufwiesen. 
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Zusammengenommen charakterisieren die in dieser Arbeit generierten Daten in einer 
bisher nicht verfügbaren Tiefe und umfassenden Form die Zusammensetzung und den 
Phänotyp des T-Zell-Kompartiments bei CLL im Vergleich zu Individuen ohne Krebs und 
verbessern dadurch unser Verständnis der Funktion verschiedener T-Zell-Subpopulationen in 
CLL erheblich. 
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1 Introduction 
 The tumor microenvironment as a hallmark of cancer 
Over the last decades, it became clear that the process of tumorigenesis not only 
encompasses cancer cells, but also the complex surrounding tissue, composed of multiple cell 
types. Consequently, in the revised description of the ‘hallmarks of cancer’ first proposed by 
Douglas Hanahan and Robert A. Weinberg, adaptations of the tumor microenvironment that 
help promote tissue inflammation and avoid immunosurveillance are also considered as part 
of the multistep process that enables tumor development and metastasis (Hanahan and 
Weinberg 2011). 
The cells present in the tumor microenvironment (TME) can generally be divided into three 
types: infiltrating immune cells, cancer-associated fibroblasts (CAFs), and angiogenic vascular 
cells (comprising endothelial cells and pericytes) (Hanahan and Coussens 2012). Each group 
contributes to supporting tumor initiation, growth, and dissemination by helping sustain 
proliferative signaling, evading growth suppressors, inducing angiogenesis and metabolism 
reprogramming, activating invasion and metastasis, as well as escaping immune destruction 
(Hanahan and Coussens 2012). As an example, the mechanisms by which endothelial cells 
promote the formation of new blood vessels that help provide oxygen and nutrients to cancer 
cells has been extensively described (Folkman 1974; Folkman et al. 1989; Butler et al. 2010). 
Besides, while normal fibroblasts serve as epithelial tumor growth suppressors (Bissell and 
Hines 2011), CAFs promote loosening of cell-cell contacts and increase tumor cell motility that 
facilitates metastasis (Kalluri and Zeisberg 2006). Tumor-infiltrating immune cells operate in 
the TME in opposing ways, as leukocytes with both anti- and pro-tumorigenic properties can 
be found within the tumor. The major mechanisms by which immune cells and tumor cells 
interact and influence each other are summarized in the succeeding Sections 1.1.1 and 1.1.2. 
 
1.1.1 Tumor-promoting inflammation 
As part of the repair process in normal tissues, pro-inflammatory cues that promote cell 
proliferation are strictly followed by anti-inflammatory mechanisms ensuring homeostasis 
restoration (Medzhitov 2008). Instead, during chronic inflammation, the initiating factors persist 
and the mechanisms to resolve the inflammatory response fail, contributing to the onset of 
neoplastic lesions. In this line, under the observation that tumors are an aberrant and 
prolonged form of tissue growth and repair, Dvorak defined tumor as ‘wounds that do not heal’ 
(Dvorak 1986). Tumor development is, in fact, often linked to chronic infection, obesity, 
inhalation of pollutants, tobacco consumption or autoimmunity, conditions in which the 
underlying common factor is chronic inflammation (Jemal et al. 2010; Elinav et al. 2013). The 
1 Introduction   1.1 The tumor microenvironment as a hallmark of cancer 
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influence of inflammatory signals on carcinogenesis involves several processes that promote 
proliferation and survival signaling, as well as genomic destabilization. More specifically, 
cytokines secreted by infiltrating immune cells, including interleukin (IL) 6 (IL-6) and IL-1 
together with tumor necrosis factor (TNF), induce signal transducer and activator of 
transcription 3 (STAT3) and nuclear factor-kB (NF-kB) respectively, thereby leading to cell 
cycle progression and inhibition of apoptosis (Greten et al. 2004; Pikarsky et al. 2004; Karin 
and Greten 2005; Yu et al. 2009; Grivennikov et al. 2010). At the same time, increased DNA 
damage can be induced by elevated levels of reactive oxygen species (ROS) and reactive 
nitrogen species (RNS), released by activated neutrophils and macrophages (Campregher et 
al. 2008). Similarly, several cytokines such as TNF, IL-1b, IL-4, IL-13, and tumor growth factor 
b (TGF-b) promote the ectopic expression of activation-induced cytidine deaminase (AID), 
which induces genomic instability and may entail mutations in critical cancer genes like TP53 
and MYC (Okazaki et al. 2007; Colotta et al. 2009; Takai et al. 2009). Besides, mismatch repair 
factors, that are necessary for DNA repair, can be repressed by hypoxia-inducible factor 1a 
(HIF-1a), the expression of which is induced by TNF, IL-1b and ROS (Colotta et al. 2009; 
Schetter et al. 2010). 
Importantly, tumor cells themselves modulate their microenvironment via soluble mediators, 
thus shaping the inflammatory response. Recruited leukocytes, from both myeloid and 
lymphoid lineages are skewed to support cancer cell survival and proliferation, angiogenesis 
as well as metastasis, and at the same time suppress anti-tumor responses (Hanahan and 
Coussens 2012). For example, tumor associated macrophages (TAMs) – a significant 
component of the TME in many cancers – produce numerous angiogenic factors, like vascular 
endothelial growth factor (VEGF), implicated in vessel formation (Ono et al. 1999; Torisu et al. 
2000). In addition, together with mast cells and neutrophils, they secrete matrix 
metalloproteinases (MMPs), which degrade components of the extracellular matrix and thus 
favor tumor spread and metastasis (Coussens et al. 2000; Egeblad and Werb 2002; Nozawa 
et al. 2006; Pahler et al. 2008).  
 
1.1.2 Cancer immunosurveillance and immunoediting 
As previously mentioned, infiltrating immune cells can also exert an anti-tumor response. 
Known as tumor immune surveillance, the process by which the immune system detects and 
eliminates tumor cells has been studied for decades (Burnet 1957; Burnet 1970; Dunn et al. 
2002). Historically, the first evidence for the role of cellular immunity in preventing malignant 
growth came from the increased incidence of spontaneous tumors in immunodeficient mice as 
well as in immunosuppressed patients (Penn and Starzl 1970; Gatti and Good 1971; Sheil 
1986; Shankaran et al. 2001; Street et al. 2001). Additionally, tumor infiltration by lymphocytes 
(particularly CD8+ T-cells and natural killer (NK) cells) positively correlates with increased 
1 Introduction   1.1 The tumor microenvironment as a hallmark of cancer 
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patient survival in several tumor entities, such as melanoma, breast, bladder, colon and 
prostate cancer (Epstein and Fatti 1976; Clark et al. 1989; Rilke et al. 1991; Lipponen et al. 
1992; Naito et al. 1998). The mechanism by which the immune system is able to recognize 
and kill tumor cells is based on the integrated response of both its innate and adaptive arms. 
This process is initiated when innate immune cells become ‘alerted’ to the presence of a 
growing tumor by inflammatory signals (Matzinger 1994; Smyth et al. 2006). NK cells, 
macrophages, gd+ T-cells, and NKT-cells are recruited to the tumor site and recognize 
molecules such as the stress-induced ligand for killer cell lectin like receptor K1 (also known 
as NKG2D) (Girardi et al. 2001; Gasser et al. 2005; Strid et al. 2008). This initial immune 
response is mediated and amplified via secretion of several cytokines, including IL-12 and 
interferon gamma (IFNg) (Bancroft et al. 1991; Hodge-Dufour et al. 1997; MacMicking et al. 
1997). The latter induces macrophages to express tumoricidal molecules like ROS, and 
activates NK cells, which in turn, kill tumor cells via TNF-related apoptosis-inducing ligand- 
(TRAIL) or perforin-dependent mechanisms (Schreiber et al. 1983; MacMicking et al. 1997; 
Smyth et al. 2001; Takeda et al. 2001; Hayakawa et al. 2002). In parallel, an adaptive immune 
response is driven by the presence of tumor antigens. These include differentiation antigens 
(like melanocyte differentiation antigen), products of mutated genes (such as TP53), 
overexpressed genes (like HER2), or carcinogenic infectious antigens (like human 
papillomavirus proteins) (Cheever et al. 2009; Schreiber et al. 2011). Cytokine-activated 
dendritic cells acquire and present these tumor antigens to T-cells in the lymph nodes (LNs) 
(Huang et al. 1994; Wculek et al. 2020). Upon antigen recognition, activated CD4+ T helper 
cells 1 (TH1) and cytotoxic CD8+ T-cells subsequently participate in the killing of tumor cells. 
CD4+ TH1 cells achieve this by providing help in activating and polarizing other immune cells, 
whereas CD8+ T-cells directly kill tumor cells inducing granule exocytosis- and death receptor-
mediated apoptosis (de Visser et al. 2006; Zhu and Paul 2008; Halle et al. 2017). 
 
The coexistence of tumor-promoting inflammation and protective tumor immunity can be 
explained as a dynamically interconnected process named ‘cancer immunoediting’ (Dunn et 
al. 2002) (Figure 1). In short, cancer immunoediting consists of three phases (elimination, 
equilibrium and escape), where tumor progression is promoted by either a Darwinian selection 
of the fittest tumor cells, and/or by establishing conditions in the TME that facilitate tumor 
outgrowth (Dunn et al. 2002). In the elimination phase, both innate and adaptive immunity 
cooperate to eliminate developing tumors. If a malignant cell escapes, it may enter an 
equilibrium phase, where the tumor is maintained in a state of dormancy, as its outgrowth is 
controlled by immunologic mechanisms (Aguirre-Ghiso 2007). In such a situation, which can 
be sustained for years, tumor editing occurs, eventually leading to a selection of tumor cells 
than can escape immune recognition, become insensitive to immune 
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Figure 1: The three phases of cancer immunoediting. Normal cells can be transformed into 
tumor cells as a result of acquired oncogenic mechanisms and the failure of intrinsic tumor-
suppressor mechanisms. In the elimination phase, previously known as cancer 
immunosurveillance, innate and adaptive immunity recognize and destroy tumor cells via 
secretion of effector molecules like IFNg, IFN-a/b, TNF, NKG2D and perforin. However, if the 
elimination of tumor cells is incomplete, the tumor enters an equilibrium phase, where 
outgrowth is controlled by adaptive immunity and the tumor remains in state of dormancy. 
During this phase, tumor cells undergo a process of immunoediting, which eventually allows 
them to evade tumor recognition, killing or control by immune cells and become a progressive 
and clinically detectable tumor (the escape phase). CTLA-4 = cytotoxic T lymphocyte 
associated protein 4, IDO = indoleamine 2,3-deoxygenase, IFN = interferon, IL = interleukin, 
TNF = tumor necrosis factor, PD-L1 = programmed death-ligand 1, TGF-b = transforming 
growth factor b, iNOS = inducible nitric oxide synthase, NK = natural killer cell, MDSC = myeloid 
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effector function, or induce immunosuppression within the TME. Upon acquisition of any of 
these abilities, the tumor enters the escape phase, and emerges as a progressively growing 
and visible tumor (Schreiber et al. 2011) (Figure 1). 
Escaping tumor cells are able to interfere with the antitumor immune response via multiple 
mechanisms that ultimately allow them to evade cell killing and reprogram the immune cells 
into an immunosuppressive phenotype. Intrinsic mechanisms include the downregulation of 
major histocompatibility complex (MHC) molecules or upregulation of apoptosis inhibitors like 
B-cell lymphoma-extra large (BCL-XL) and CASP8 and FADD like apoptosis regulator 
(CFLAR) (Kataoka et al. 1998; Hinz et al. 2000). By secreting soluble factors like VEGF, they 
can also suppress dendritic cell maturation and thus prevent them to present tumor antigens 
in the LNs (Gabrilovich et al. 1999). In addition, secretion of immunosuppressive cytokines 
including TGF-b, galectin and IL-10, of other molecules like indoleamine 2,3-dioxygenase 1 
(IDO1), or expression of ligands such as programmed death-ligand 1 (PD-L1), directly impact 
T-cell function by inhibiting their activation and proliferation, or by inducing apoptosis (Vesely 
et al. 2011). Moreover, tumor cells recruit and modulate regulatory T-cells (Tregs) and myeloid-
derived suppressor cells (MDSCs), the two major immunosuppressive leukocyte populations 
(Gabrilovich and Nagaraj 2009; Facciabene et al. 2012). Tregs produce IL-10, TGF-b, and 
express T-cell co-inhibitory molecules like PD-L1 and cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) (Terabe and Berzofsky 2004; Facciabene et al. 2012). MDSCs, which 
comprise a heterogeneous group of myeloid cells, also inhibit lymphocyte function by several 
mechanisms. They produce TGF-b and IL-10, deprive the TME of arginine or cysteine, needed 
by T-cells to proliferate (Gabrilovich and Nagaraj 2009), and produce arginase and inducible 
nitric oxide synthase (iNOS) that inhibit T-cell function (Bronte and Zanovello 2005; Rodriguez 
and Ochoa 2008).  
Importantly, as the understanding of the cancer immunoediting process improves, 
therapeutic strategies that target molecular players from each of the three phases are being 
developed. More specifically, substantial work has been invested into developing 
immunotherapies that aim to increase the quality and quantity of immune effector cells and/or 
eliminate the tumor-induced immunosuppression. These include, for example, vaccines that 
elicit strong and specific immune responses against tumor antigens (Thomas and Prendergast 
2016; Sahin and Tureci 2018). Additionally, approaches involving the adoptive transfer of in 
vitro expanded or genetically engineered tumor-specific lymphocytes (such as chimeric 
antigen receptor (CAR) T-cell products) are currently being investigated and have shown 
promising outcomes in high-grade B-cell malignancies (Dudley et al. 2002; Rosenberg et al. 
2011; Labanieh et al. 2018; Majzner and Mackall 2019). Last, methodologies that inhibit or 
eliminate the molecular or cellular mediators of cancer-induced immunosuppression are being 
developed, including the antibody-based blockade of immune-checkpoint receptors like 
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programmed cell death 1 (PD-1)/PD-1 ligand (PD-L1) and CTLA-4, or the targeting and 
depletion of Tregs. (Leach et al. 1996; Iwai et al. 2002; Hodi et al. 2010; Topalian et al. 2012; 
Sharma and Allison 2015).  
 
1.1.3 T-cell exhaustion in cancer 
During acute infection, antigen-presenting cells (APCs) exhibit pathogen-derived antigen 
peptides through the MHC type I complex, which binds to the T-cell receptor (TCR) of naïve 
CD8+ T-cells. Upon selective recognition of the MHC-antigen complex together with co-
stimulatory signals, T-cells get activated, clonally expand, and differentiate into effector cells. 
They express cytotoxic molecules, like perforin and granzymes, and secrete cytokines like 
IFNg and TNFa to ultimately kill target cells. Once the antigen is cleared, most effector CD8+ 
T-cells undergo apoptosis, and only a small fraction differentiates into memory cells. Memory 
CD8+ T-cells persist in the absence of antigens and can rapidly expand and exert effector 
functions in response to antigen re-exposure (Wherry and Ahmed 2004; Williams and Bevan 
2007) (Figure 2).  
In contrast, during chronic viral infection and cancer, where the immune response fails and 
antigen exposure persists, effector T-cells become ‘exhausted’, a dysfunctional state that 
renders them uncapable of eradicating the infection or tumor. The acquisition of such 
phenotype is considered an evolutionarily conserved adaptation to chronic antigen presence 
and TCR stimulation (Blank et al. 2019). In other words, it represents a compromise between 
the need of the organism to resolve the tumor or infection and the amount of inflammation-
induced damage that it can tolerate (Speiser et al. 2014). Exhausted T-cells (TEX) are 
characterized by a reduced capacity to secrete cytokines and effector molecules, and express 
higher levels of inhibitory receptors, including PD-1, CTLA-4, T-cell immunoglobulin and 
mucin-domain containing-3 (TIM-3), lymphocyte-activation gene 3 (LAG3), and T-cell 
immunoreceptor with Ig and ITIM domains (TIGIT) (Wherry 2011). Recently, high levels of the 
ectoenzyme ectonucleoside triphosphate diphosphohydrolase-1 (CD39) that converts 
extracellular ATP and ADP into AMP have been reported in tumor-reactive TEX cells (Gupta et 
al. 2015; Simoni et al. 2018). Besides, these hyporesponsive cells are distinct from anergic 
and senescent T-cells, with an aberrant transcriptional program, a dysregulated metabolism, 
and a unique epigenetic landscape (Wherry et al. 2007; Alfei and Zehn 2017; McLane et al. 
2019) (Figure 2). Chronic TCR stimulation is the main driver of T-cell exhaustion, as evidenced 
by the role of TCR signaling-driven transcription factors in upregulating the expression of 
inhibitory receptors, and at the same time maintaining the long-term survival of TEX cells. This 
includes TFs like the nuclear factor of activated T-cells 1 (NFATC1), interferon regulatory factor 
4 (IRF4), basic leucine zipper ATF-like transcription factor (BATF), nuclear receptor subfamily 
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4 group (NR4A), and thymocyte selection associated high mobility group box (TOX) (Martinez 
et al. 2015; Man et al. 2017; Chen et al. 2019; Khan et al. 2019; Yao et al. 2019).  
Besides, soluble mediators have been shown to promote exhaustion, including IL-10 and 
TGF-b (Li et al. 2006; Brooks et al. 2008; Tinoco et al. 2009; Ni et al. 2015) (Figure 2). To date, 
TEX cells have been described in tumor mouse models and in numerous cancer entities, 
including melanoma, chronic myeloid leukemia, non-small cell carcinoma, colorectal cancer, 
ovarian cancer, Hodgkin lymphoma, and chronic lymphocytic leukemia (Mumprecht et al. 
2009; Matsuzaki et al. 2010; Zhang et al. 2010; Baitsch et al. 2011; Riches et al. 2013; 
Schietinger et al. 2016; Zhang et al. 2018b). 
Single-cell RNA sequencing and mass cytometry analyses have recently shown that TEX 
cells represent a heterogeneous population with a gradual degree of dysfunction (van der Leun 
et al. 2020). Moreover, a subset of PD-1+ precursor cells with self-renewal capacity that gives 
rise to the terminally differentiated TEX population has been identified in mouse models of 
chronic viral infection and cancer (Paley et al. 2012; Im et al. 2016; Utzschneider et al. 2016; 
Siddiqui et al. 2019) (Figure 2). These progenitors of exhausted cells are characterized by 
lower levels of PD-1, depend on the transcription factor T-cell factor 7 (TCF7), and express 
slam family member 6 (SLAMF6), as well as C-X-C chemokine receptor type 5 (CXCR5) (Im 
et al. 2016; Utzschneider et al. 2016; Brummelman et al. 2018; Miller et al. 2019; Siddiqui et 
al. 2019). Aside from the expression of such TFs, their gene expression profile is similar to that 
of CD8+ memory precursor cells, CD4+ follicular helper T-cells (TFH), and hematopoietic stem 
cells (Wu et al. 2016b; Hashimoto et al. 2018). They can additionally be distinguished from the 
terminally exhausted subset based on the expression of the transcription factors 
Eomesodermin (EOMES) and T-box transcription factor 21 (or also known as TBET): precursor 
cells are PD-1int TBEThi, whereas terminally differentiated TEX are PD-1hi EOMEShi (Paley et al. 
2012). Evidence of their progenitor potential comes from experiments showing that, upon 
adoptive transfer into virus-infected or tumor-bearing mice, these cells can proliferate and 
generate terminally differentiated TEX cells. Instead, the latter only expand to a limited extent 
and retain the same PD-1hi terminally differentiated phenotype (Im et al. 2016; Utzschneider 
et al. 2016; Wu et al. 2016b; Sade-Feldman et al. 2018; Kurtulus et al. 2019; Siddiqui et al. 
2019). Crucially, mouse experiments showed that precursor cells are necessary for the 
response upon PD-1 blockade (Im et al. 2016; Utzschneider et al. 2016; Kurtulus et al. 2019; 
Miller et al. 2019). While aPD-1 therapy does not alter the distinct epigenomic state of TEX cells 
and, thus, only restores their effector function transiently, it induces the proliferation and 
differentiation of precursor cells into terminally differentiated TEX cells (Pauken et al. 2016; 
Miller et al. 2019). 
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Figure 2: Development of CD8+ T-cell exhaustion. During initial viral infection, naïve CD8+ 
T-cells become activated upon antigen recognition, proliferate and differentiate into effector T-
cells to kill infected target cells. Once the pathogenic agent is cleared, effector T-cells undergo 
apoptosis and only a small population of memory T-cells (TM) persists (top). In case of chronic 
viral infection or cancer, effector T-cells gradually acquire an exhausted phenotype with 
reduced proliferation and effector function, and increased expression of inhibitory receptors 
(IRs). Within the heterogeneous population of exhausted cells, precursor cells (PD-1int TCF1+ 
TBEThi) have self-renewal capacity and give rise to terminally differentiated TEX cells (PD-1hi 
TCF1- EOMEShi) (middle). Described factors involved in the induction of an exhaustion 
phenotype are a persistent antigen presentation by APCs and subsequent TCR stimulation. 
Besides, inhibitory receptors provide negative signals to T-cells, preventing a normal T-cell 
effector response. Additionally, immunoregulatory cells, APCs and tumor cells contribute to a 
persistent state of inflammation by secreting inhibitory cytokines (like IL-10 or TGF-b) that 
further contribute to exhaustion. Altogether these signals contribute to the distinct 
transcriptional and epigenetic state of TEX cells, driven by transcription factors such as TOX. 
IR = inhibitory receptor. Figure created with BioRender.com. 
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Even though the altered pathways and the molecular mechanisms leading to T-cell 
exhaustion are not completely understood, the knowledge acquired up until today has unveiled 
many potential opportunities for therapeutic interventions. For example, the combination of 
checkpoint inhibitors with agents targeting other co-inhibitory molecules (like LAG3, TIGIT, or 
CD39), soluble factors, or epigenetic programs represents a promising approach for improving 
immunotherapy outcomes (Jin et al. 2010; Johnston et al. 2014; Zhang et al. 2014; Chauvin et 
al. 2015). Finally, current efforts focus on elucidating how the re-invigoration of T-cell 
responses upon checkpoint blockade can be improved and prolonged to achieve a complete 
eradication of tumor cells in cancer patients (Hashimoto et al. 2018; Blank et al. 2019).  
 
1.1.4 CD4+ type 1 regulatory T-cells (TR1) and their role in cancer 
CD4+ T-cells comprise several subsets of cells with distinct phenotypes and functions. 
Generally, they can be divided into conventional CD4+ T-cells and regulatory cells (Tregs) 
expressing forkhead box protein P3 (FOXP3). Conventional CD4+ T-cells are also referred to 
as CD4+ T helper (TH) cells and assist in the polarization and activation of other immune cells 
by establishing direct ligand-receptor interactions as well as releasing cytokines (Zhu et al. 
2010)). Depending on the cytokines they produce and the expression pattern of their surface 
molecules, activated TH cells can be differentiated into TH1, TH 2 and TH17, each having a 
distinct impact on the cellular and humoral immune response (Zhu et al. 2010). Instead, Tregs 
are specialized to suppress the immune response, in order to restore tissue homeostasis and 
maintain self-tolerance (Romano et al. 2019).  
In addition to Tregs, CD4+ type 1 regulatory T-cells (TR1) have been identified as another 
suppressive T-cell type. These TR1 cells were first described more than thirty years ago by 
Groux et al. as an IL-10-producing CD4+ T-cell subset that suppressed antigen-specific T-cell 
responses but was FOXP3-negative (Groux et al. 1997). Aside from IL-10, TR1 cells express 
the surface markers PD-1, LAG3, and CD49b, yet they represent a heterogeneous population 
and the expression of any of these markers is not exclusive to these cells (Akdis et al. 2004; 
Gagliani et al. 2013; Okamura et al. 2015; Roncarolo et al. 2018). TR1 cells are induced by IL-
10 receptor signaling and TCR activation, but the molecular mechanisms underlying their 
development are not completely understood, and only recently, B lymphocyte-induced 
maturation protein 1 (BLIMP1), c-MAF, aryl hydrocarbon receptor (AHR), and EOMES TFs 
have been shown to promote a TR1 cell phenotype (Quintana et al. 2008; Pot et al. 2009; 
Heinemann et al. 2014; Zhang et al. 2017; Roncarolo et al. 2018). TR1 cells induce immune 
suppression through several mechanisms. These include the secretion of cytokines such as 
IL-10 and TGF-b (de Waal Malefyt et al. 1991; Levings et al. 2001; Gregori et al. 2010; 
Roncarolo et al. 2014), as well as the expression of PD-1 and CTLA-4, which inhibits the 
function of both T-cells and APCs (Akdis et al. 2004; Okamura et al. 2015; Facciotti et al. 
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2016). Besides, they disrupt T-cell metabolism by CD39 and CD73 expression, and directly kill 
APCs via secretion of granzyme B (GZMB) and perforin 1 (PRF1), thus preventing the latter 
to promote T-cell activation (Tree et al. 2010; Magnani et al. 2011). 
Notably, high frequencies of TR1 cells have been described in some tumor entities such as 
head and neck squamous cell carcinoma, liver cancer, and metastatic melanoma (Bergmann 
et al. 2008; Pedroza-Gonzalez et al. 2015; Yan et al. 2017). Moreover, a highly suppressive 
function of these cells was observed in Hodgkin’s lymphoma, head and neck squamous cell 
carcinoma, and hepatocellular carcinoma (Dennis et al. 2013; Roncarolo et al. 2018). 
However, the limited available data on their presence and function in cancer emphasizes the 
need for additional studies to help address the question whether TR1 cells play a similar role 
in other malignancies such as leukemia. 
 
 Chronic Lymphocytic Leukemia (CLL) 
1.2.1 Epidemiology, diagnosis and clinical staging 
Chronic lymphocytic leukemia (CLL) is one of the most prevalent leukemias in western 
countries, with an estimated age-adjusted incidence rate of 4.6 newly diagnosed cases per 
year per 100,000 people in the US (Howlader N 2017). It affects mostly elderly people, with a 
median age of 72 at diagnosis, and higher prevalence in males than females (male/ female 
ratio of 1.7:1) (Howlader N 2017). 
According to the 2008 World Health Organization criteria, CLL is diagnosed by 
lymphocytosis with more than 5,000 B lymphocytes per microliter in peripheral blood (PB) 
(Swerdlow et al. 2016). The leukemia cells are characteristically small and phenotypically 
mature when inspected in blood smears, and flow cytometric or immunohistochemical 
analyses distinguish them from other types of lymphoma by the co-expression of CD19, CD20, 
CD23, and the T-cell antigen CD5 (Kipps et al. 2017; Hallek et al. 2018). Patients with CLL 
can also present symptoms of autoimmune cytopenia, develop lymphadenopathy, 
hepatomegaly and splenomegaly (Nabhan and Rosen 2014). The majority of patients, 
however, are asymptomatic at the time of diagnosis, and the clinical course is highly variable, 
ranging from remaining symptom-free for decades, to rapidly developing symptoms or high-
risk disease that requires treatment (Kipps et al. 2017).  
Disease staging is performed according to the Rai (0, I/II, and III/IV) and Binet (A, B and C) 
systems (Rai et al. 1975; Binet et al. 1981). Both of them classify patients into low, 
intermediate, and high risk according to similar clinical features including lymphocytosis, 
lymphadenopathy, anemia and thrombocytopenia (Rai et al. 1975; Binet et al. 1981). The Rai 
staging system is more commonly used in the US, whereas the Binet classification is regularly 
applied in Europe (Kipps et al. 2017). While the two staging systems help to stratify patients, 
additional biomarkers are routinely measured to provide valuable prognostic information 
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(Hallek et al. 2018; Parikh 2018). Factors associated with poorer outcome include expression 
of zeta chain of T-cell receptor associated protein kinase 70 (ZAP-70), CD38, and CD49d by 
leukemia cells (Damle et al. 1999; Orchard et al. 2004; Rassenti et al. 2004; Shanafelt et al. 
2008), cytogenetic lesions (further discussed in the Section 1.2.3), as well as elevated levels 
of soluble b2-microglobulin and thymidine kinase in serum (Hallek et al. 1996; Pflug et al. 2014). 
Patients are also stratified based on the degree of somatic mutations in the immunoglobulin 
(Ig) heavy chain variable gene (IGHV) expressed by the CLL cells (Damle et al. 1999; Hamblin 
et al. 1999). Patients with mutated IGHV, which is defined as a greater than 2% difference 
from the germline sequence, have a higher median overall survival than those with unmutated 
IGHV (Damle et al. 1999; Hamblin et al. 1999). These two groups of patients also harbor 
differences in the underlying tumor genetic lesions, the degree of clonal evolution, epigenetic 
changes, and active signaling pathways present in the leukemia cells, as well as in the kind of 
interactions established within the tumor microenvironment (Allsup et al. 2005; Herve et al. 
2005; Fabbri and Dalla-Favera 2016; Ten Hacken and Burger 2016). In fact, these profound 
divergences between IGHV-unmutated and -mutated patients have been suggested to relate 
to a different cell of origin of the leukemia (Fabbri and Dalla-Favera 2016). 
 
1.2.2 The cellular origin of CLL 
1.2.2.1 Normal B-cell development 
B lymphocyte development and maturation is a tightly regulated, multistep process. It is 
initiated in the bone marrow (BM), where hematopoietic stem cells (HSCs) give rise to common 
lymphoid progenitor cells, that in turn differentiate into B-cell or T-cell lineages (De Obaldia 
and Bhandoola 2015; Melchers 2015). In a specific niche that influences the process, pro-B-
cells transition to pre-B-cells by undergoing a stepwise recombination of immunoglobulin 
variable region genes, prior to the assembly of the complete B-cell receptor (BCR) genetic 
locus (Brack et al. 1978; Schatz et al. 1989; Melchers 2015). After this, each B-cell expresses 
a unique BCR, and those showing high affinity against self-antigens (which is estimated to be 
75 % of B-cells (Wardemann et al. 2003)) undergo additional rounds of receptor editing, or, 
upon failure, are eliminated by apoptosis induction (LeBien 2000; Cambier et al. 2007). 
Immature B-cells leave the BM and migrate to the B-cell follicles within the secondary lymphoid 
organs (SLOs), i.e. LNs and spleen. Upon antigen encounter, B-cells get activated and engage 
in an intricate cross-talk with surrounding cells forming the germinal centers (GCs), which 
results in their expansion, diversification, and differentiation to express high-affinity BCRs 
(Victora and Nussenzweig 2012; Pieper et al. 2013). More specifically, B-cells enter the dark 
zone of the GCs and experience rapid proliferation and somatic hypermutation, the process in 
which point mutations are introduced in the IGHV and the immunoglobulin light chain V region 
(IGLV) genes to increase the immunoglobulin repertoire diversity (Methot and Di Noia 2017). 
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In the light zone, those B-cells expressing BCRs with the highest antigen affinity are positively 
selected, expand, and may undergo class switch recombination, replacing IgM and IgD with 
IgA, IgG, or IgE (Methot and Di Noia 2017). Ultimately, B-cells differentiate into either memory 
B-cells, which can rapidly respond to microbial antigens upon re-encounter, or long-lived 
antibody-secreting plasma cells (Shapiro-Shelef and Calame 2005; Klein and Dalla-Favera 
2008).  
The majority of B-cells that reside in SLOs, including follicular B-cells (also named B-2), and 
marginal zone B-cells, originate from the above-described developmental process, and are 
central to adaptive immune responses (Wang et al. 2020). A third type of B-cells, instead, is 
part of the innate immune system, and derives from progenitor cells found in the fetal liver 
(Baumgarth 2017; Wang et al. 2020). These so-called B-1 cells, which are CD5+, are mostly 
present in the peritoneal and pleural cavities, and constitute a major source of antibodies, 
produced without the ‘help’ from T-cells. Of note, even though transitional and mature CD5+ 
B-cells have been identified in human PB, these cells have predominantly been described in 
mice, and their origin and role in humans is poorly understood (Baumgarth 2017).  
 
1.2.2.2 The putative cell of origin of CLL 
The exact B-cell phenotype from which CLL cells originate remains controversial (Forconi 
et al. 2010; Chiorazzi and Ferrarini 2011). Some of the genetic and epigenetic lesions leading 
to CLL development may already occur in hematopoietic stem cells (HSCs), as evidenced by 
several studies (Fabbri and Dalla-Favera 2016) (Figure 3). For example, HSCs from CLL 
patients engrafted in immunodeficient mice generate clonal B-cells, and are frequently CD5+ 
and CD23+, similarly to CLL cells (Kikushige et al. 2011). Besides, common mutations present 
in CLL cells have been found in multipotent progenitor cells from CLL patients, and clonal 
hematopoiesis has been linked to an increased risk of developing CLL (Damm et al. 2014; 
Genovese et al. 2014; Jaiswal et al. 2014). The characteristic expression of CD5 on CLL cells 
led to the conception, for decades, that CLL cells derive from the B-1 lineage (Stall et al. 1988; 
Caligaris-Cappio 1996). In addition, CD5+ B-1 cells of neonatal origin give rise to a CLL-like 
disease with restricted BCRs and up-regulated c-Myc expression in aged mice (Hayakawa et 
al. 2016). However, several studies have demonstrated that CLL cells have transcriptional and 
phenotypic characteristics that are incompatible with a B-1 lineage. Klein et al. and others 
showed that the gene expression profile of CLL cells is largely homogeneous – irrespective of 
the IGHV mutation status – and similar to that of antigen-experienced CD27+ memory B-cells 
(Klein et al. 2001; Rosenwald et al. 2001; Seifert et al. 2012). Moreover, subsets of circulating 
CD27+ memory-like B-cells with mutated and unmutated IGHV genes have been described 
(Klein et al. 1998). Collectively, these results support the idea that IGHV-mutated CLL derives 
from antigen-experienced, T-cell dependent, post-GC memory B-cells that have undergone 
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somatic hypermutation, while IGHV-unmutated CLL cells originate from conventional naïve B-
cells that have not entered the GCs (Fabbri and Dalla-Favera 2016) (Figure 3). In agreement 
with this hypothesis, epigenomic analysis of CLL cells revealed that DNA methylation patterns 
of IGHV-unmutated leukemia cells resemble those of CD5+ naïve B-cells, whereas IGHV-
mutated cells appear more similar to memory B-cells (Kulis et al. 2012). More recently, work 
from Oakes et al. elegantly showed that DNA methylation patterns of CLL cells resemble those 
of normal B-cells with different degree of maturation, thus indicating that leukemia cells likely 
derive from a continuum of B-cell developmental stages (Oakes et al. 2016). 
The current model of leukemogenesis supports a multistep process where genetic and/or 
epigenetic alterations, subsequent antigen-driven clonal selection and expansion, as well as 
microenvironmental signals give rise to monoclonal B-cell lymphocytosis (MBL), the CLL 
precursor state, and ultimately CLL (Strati and Shanafelt 2015). The fact that both CLL 
subtypes harbor a highly restricted and biased BCR repertoire indicates that a strong antigen-
driven selective pressure plays a significant role in malignant transformation (Vardi et al. 2014; 
Stamatopoulos et al. 2017). Approximately one third of CLL patients can be classified into 
groups based on shared motifs within the heavy chain complementarity-determining region 3 
Figure 3: The putative cellular origin of CLL cells. CLL transformation may start at HSC 
stage, were first genetic and epigenetic changes occur. IGHV-unmutated (IGHV-UM) CLL cells 
may arise from naïve pre-GC CD5+ CD27- B-cells, while mutated-IGHV (IGHV-M) CLL cells 
are likely to originate from CD5+ CD27+ post-GC B-cells. In addition to genetic and epigenetic 
aberrations, BCR stimulation and signals from the microenvironment contribute to the 
generation of the MBL precursor state, prior to CLL transformation. HSC = hematopoietic stem 
cell, GC = germinal center, TH = CD4+ helper T-cell, FDC = follicular dendritic cell, MBL = 
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(CDR3, also referred to as stereotyped BCR). Such grouping also reflects similar epigenetic, 
genetic and functional characteristics of the disease, with patients in each group showing a 
similar course and outcome (Ghiotto et al. 2004; Tobin et al. 2004; Stamatopoulos et al. 2007; 
Vardi et al. 2014; Stamatopoulos et al. 2017). IGHV-unmutated CLL cells frequently express 
BCRs with low-affinity and poly-reactivity or self-reactivity, whereas IGHV-mutated ones tend 
to have oligo-reactive or mono-reactive BCRs with high affinity to unknown but likely 
exogenous antigens (Herve et al. 2005; Chu et al. 2008; Binder et al. 2010; Ten Hacken and 
Burger 2016). 
 
1.2.3 Genetic alterations in CLL 
The advent of whole-exome and whole-genome sequencing has tremendously helped to 
unravel the genetic landscape of CLL. Notably, CLL patients carry a wide range of genetic 
variability, and unlike other tumor entities, no single main oncogenic driver has been identified 
(Puente et al. 2011; Quesada et al. 2011; Landau et al. 2015; Puente et al. 2015). Instead, 
genetic and epigenetic alterations, including chromosomal aberrations, somatic mutations, 
epigenetic modifications, as well as changes in miRNA expression, contribute to CLL 
pathogenesis and determine the clinical course of the disease (Kipps et al. 2017). 
Nevertheless, compared to most of other solid tumors and hematological malignancies, CLL 
displays a low mutational burden, with a slightly higher number of somatic mutations in IGHV-
mutated versus -unmutated patients (Puente et al. 2011; Lawrence et al. 2013; Landau et al. 
2015). 
Cytogenetic alterations can be detected in 80 % of CLL patients, and because their 
presence impacts CLL development, a hierarchical model for patient classification based on 
chromosomal abnormalities has been proposed to identify patients with higher risk of disease 
progression and poor survival (Dohner et al. 2000). The four most common chromosomal 
alterations are deletions on chromosomes 13 (del(13q)), 11 (del(11q)), and 17 (del(17p)), as 
well as trisomy 12 (Dohner et al. 2000; Zenz et al. 2010; Fabbri and Dalla-Favera 2016). 
Deletion 13q14.3 is the most frequent genetic lesion, present in > 50 % of patients, and is 
associated with a favorable prognosis (Dohner et al. 2000; Dal Bo et al. 2011; Ouillette et al. 
2011). The deleted region contains the DLEU2-mir-15a/16-1 cluster, which controls the 
expression of negative regulators of apoptosis, as well as proteins involved in cell cycle 
progression (Calin et al. 2008; Klein et al. 2010). Del(17p), can be found in 7 % of patients, 
and it involves the inactivation of the tumor suppressor gene TP53 (Wattel et al. 1994; Dohner 
et al. 1995; Dohner et al. 2000; Landau et al. 2015). Del(11q) is present in 18 % of CLL patients, 
and is frequently associated with alterations in the ataxia telangiectasia mutated (ATM) gene, 
which is part of the DNA repair machinery (Schaffner et al. 1999; Dohner et al. 2000; Stankovic 
and Skowronska 2014). Both TP53 and ATM losses are associated with genomic instability, 
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resistance to chemotherapy and overall poor prognosis (Dohner et al. 2000; Austen et al. 2007; 
Stankovic and Skowronska 2014). Last, trisomy 12 is found in approximately 15 % of patients 
with CLL, and even though it is linked with a higher risk of progressing into the more aggressive 
lymphoma Richter syndrome, or with the development of secondary tumors, the exact 
mechanisms that link this chromosomal abnormality to CLL pathogenesis remain unclear 
(Chigrinova et al. 2013; Fabbri et al. 2013; Strati et al. 2015). 
Somatic mutations present in CLL cells have been found to affect genes involved in multiple 
cellular processes. These include genes related to the DNA damage response (for example 
TP53 and ATM), RNA processing (for example splicing factor 3B subunit 1 (SF3B1), and 
exportin 1 (XPO1)), and chromatin modification (like histone H1.4 (HIST1H1E), chromodomain 
helicase DNA binding protein 2 (CHD2) and zinc finger MYM-type containing 3 (ZMYM3)). 
Notch signaling (including the notch receptor 1 (NOTCH1) gene itself), B-cell activity pathways, 
and pathways related to an inflammatory response (like myeloid differentiation primary 
response 88 (MYD88)) can be affected as well (Quesada et al. 2011; Wang et al. 2011; 
Quesada et al. 2012; Landau et al. 2013; Landau et al. 2015; Mansouri et al. 2015; Puente et 
al. 2015). Mutations in some of these genes, such as NOTCH1 and SF3B1, are of substantial 
prognostic value and allow for a better stratification of patients (Baliakas et al. 2015; Rossi et 
al. 2015). Besides, driver mutations like SF3B1 and TP53 have been shown to be present in 
tumor subclones that expand in CLL patients after treatment, and serve as a predictive factor 
for disease progression (Landau et al. 2013). 
 
Although the majority of cases develop sporadically, some genetic factors are involved in 
familial predisposition for CLL, as first-degree relatives of CLL patients have an 8.5-fold higher 
risk to develop the disease (Cerhan and Slager 2015). Using genome-wide association 
studies, more than 40 genetic loci have been linked to CLL susceptibility (Di Bernardo et al. 
2008; Crowther-Swanepoel et al. 2010; Slager et al. 2012; Berndt et al. 2013; Speedy et al. 
2014). Despite a modest impact of each individual locus on disease development, a large 
number of risk alleles leads to higher CLL susceptibility (Crowther-Swanepoel et al. 2010). The 
majority of CLL-associated single nucleotide polymorphisms (SNPs) are located in areas of 
open chromatin, but, interestingly, only few are found within or next to genes whose function 
might impact disease development, and thus their role in CLL pathogenesis remains poorly 
understood (Speedy et al. 2014).  
 
1.2.4 Current and emerging therapies for CLL 
Treatment for CLL is usually not applied in patients who have an asymptomatic, early stage 
disease, as it has been shown that overall survival in indolent cases does not improve after 
treatment (Dighiero et al. 1998). These patients are monitored and only treated when evidence 
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of disease progression or symptoms appear (Hallek et al. 2018). Despite multiple treatment 
options being available, CLL remains incurable (Burger 2020). Exceptionally, allogeneic stem 
cell transplantation is considered a curative strategy, but its application is restricted to patients 
of younger age and limited by donor availability, plus complications like graft-versus-host 
disease and immunosuppression often occur (Gribben et al. 2005; Dreger et al. 2010). For 
decades, standard treatments for CLL were based on alkylating agents (including 
chlorambucil, bendamustine and cyclophosphamide) and purine analogue chemotherapies 
(fluradabine, pentostatin and cladribine) (Nabhan and Rosen 2014; Parikh 2018). Notably, the 
introduction of monoclonal antibodies targeting the CD20 antigen expressed on the surface of 
B-cells (like rituximab and obinutuzumab) has strongly impacted CLL management 
(Stilgenbauer et al. 2009). Combining the latter with chemotherapeutics – an approach called 
chemoimmunotherapy – has significantly improved both overall survival and progression-free 
survival (PFS), and is the current standard first-line therapy (Parikh 2018).  
Importantly, research from the last 10 years has underscored the importance of the BCR 
signaling pathway in CLL pathogenesis (Herishanu et al. 2011; Stevenson et al. 2011; Le Roy 
et al. 2012; Burger and Chiorazzi 2013; Ferrer and Montserrat 2018). BCR engagement leads 
to cell survival and proliferation signals in healthy B-cells as well as CLL cells and, 
consequently, the use of small molecule inhibitors of BCR-downstream kinases has led to a 
clinical success (Kipps et al. 2017; Sharma and Rai 2019; Yosifov et al. 2019). For example, 
treatment with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, or the phosphatidylinositol-
3 kinase delta (PI3Kd) inhibitor idelalisib has been approved in the United States and Europe 
for treatment of patients with relapsed CLL, as it improves PFS as well as overall survival in 
these patients (Byrd et al. 2014; Furman et al. 2014). In addition, ibrutinib is currently the first 
treatment option for patients carrying TP53 mutations and del(17p). Interestingly, treatment 
with these inhibitors results in significant LN and spleen shrinkage, together with a transiently 
increased lymphocytosis, likely due to a mobilization of CLL cells from the secondary lymphoid 
organs to the periphery (Ponader et al. 2012; Woyach et al. 2014; Chen et al. 2016). Besides 
BCR signaling inhibitors, selective B-cell lymphoma 2 (BCL-2) inhibitors are showing promising 
results for relapsed or refractory patients. In fact, the small molecule inhibitor venetoclax has 
been approved for second-line treatment of relapsed or refractory CLL patients with del(17p) 
(Parikh 2018).  
Finally, based on the emerging success of immunotherapeutic strategies in several solid 
and hematological cancers (Fesnak et al. 2016; Ribas and Wolchok 2018), cellular 
immunotherapies and immune checkpoint inhibitors are currently being tested in clinical trials 
(NCT03331198, NCT02329847, NCT02332980, NCT02362035). For example, the use of 
genetically modified T-cells expressing a CAR targeting CD19 on B-cells induced durable 
remission in several pilot studies with relapsed/refractory CLL patients, but its efficacy was 
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modest when compared to that in patients with acute lymphoblastic leukemia (Porter et al. 
2015; Turtle et al. 2017). As results with single-agent treatment using a blocking antibody 
against PD-1 led to disappointing results in CLL (Ding et al. 2017), ongoing investigations focus 
on the combination of immune checkpoint blockade (ICB) and kinase inhibitors 
(NCT02329847, NCT02332980, NCT02362035). 
 
1.2.5 The Eµ-TCL1 mouse model of CLL 
Several murine models reproducing common CLL genetic lesions have been developed, 
including mouse lines with a deletion of chromosome 14qC3, which corresponds to human 
del(13q), or of the IRF4 gene. Other mouse lines overexpress genes that are altered in CLL, 
like T-cell leukemia/lymphoma 1a (TCL1), tumor necrosis factor superfamily member 13 
(TNFSF13), and BCL-2, or harbor a SF3B1 mutation and ATM deletion (Bichi et al. 2002; Stein 
et al. 2002; Zapata et al. 2004; Klein et al. 2010; Lia et al. 2012; Shukla et al. 2013; Yin et al. 
2019). To date, the Eµ-TCL1 model is the most widely used mouse model to investigate CLL 
(Simonetti et al. 2014; Bresin et al. 2016). Bichi et al. established this mouse line by 
exogenously placing the human TCL1 gene under the control of the Ig heavy chain promoter 
(Bichi et al. 2002). Practically 100 % of the transgenic mice start to show CD5+ B-cell 
proliferation at 2 months of age, and these cells can be detected in spleen at 3-5 months of 
age, and in BM at 5-8 months of age (Bichi et al. 2002). At the age of 13-18 months, mice 
become manifestly ill, with splenomegaly, lymphadenopathy and elevated CD5+ B-cell counts 
in PB, BM and SLOs (Bichi et al. 2002). The malignant B-cells show unmutated IGHV genes 
and a stereotyped BCR, suggesting that the model mimics the more aggressive form of human 
CLL (Yan et al. 2006). Indeed, the highest levels of TCL1 expression are found in IGHV-
unmutated patients, and TCL1 expression correlates with ZAP-70 expression, as well as with 
the presence of del(11q) (Herling et al. 2006; Pekarsky et al. 2006). Functionally, the TCL1 
gene acts as an oncogene by transporting AKT serine/threonine kinase 1 (AKT1) into the 
nucleus and by enhancing its enzymatic activity, which leads to both apoptosis resistance and 
enhanced proliferation (Russo et al. 1989; Mok et al. 1999; Pekarsky et al. 2000; Noguchi et 
al. 2007). It also increases nuclear factor kappa light chain enhancer of (NF-kB) activity, thus 
supporting CLL cell survival and proliferation (Pekarsky et al. 2008; Gaudio et al. 2012). 
Besides, higher levels of TCL1 expression and co-recruitment of TCL1-AKT to the BCR 
membrane complex in CLL cells correlate with BCR signaling intensity (Herling et al. 2009). 
Of note, the long latency of the disease in the mice suggests that the TCL1 overexpression 
likely serves as an initial trigger, and additional genetic lesions and microenvironmental factors 
may be required for a complete malignant transformation (Simonetti et al. 2014).  
To overcome this latency and the high heterogeneity in tumor onset in the transgenic mouse 
line, adoptive transfer (AT) of Eµ-TCL1 leukemic cells into wild-type (WT) C57BL/6 mice is 
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commonly performed. Such approach represents a reproducible and more homogeneous 
system where mice develop a CLL-like disease within few weeks or months (Hofbauer et al. 
2011; McClanahan et al. 2015b; Hanna et al. 2019). 
The use of the Eµ-TCL1 mouse model has significantly advanced the understanding of the 
molecular and cellular pathomechanisms of CLL. For example, the role of the BCR signaling 
or the Toll-like receptor signaling, as well as the importance of continuous autoantigen 
stimulation in CLL development were examined with the use of this model system (Holler et 
al. 2009; Bertilaccio et al. 2011; Nganga et al. 2013; Woyach et al. 2014). Likewise, because 
it is fully immunocompetent, it recapitulates the tumor microenvironment and has been 
successfully used to understand the cross-talk between leukemic cells and the surrounding 
cells (Kern et al. 2004; Gorgun et al. 2009; Scielzo et al. 2010; Troeger et al. 2012), as well as 
for preclinical studies of novel therapies (McClanahan et al. 2015a; Wierz et al. 2018; Hanna 
et al. 2020).  
 
 The tumor microenvironment in CLL 
1.3.1 The complex interplay between CLL cells and their microenvironment 
Normal B-cells are programmed to interact with their microenvironment during the 
processes of differentiation, antigen presentation, maturation, and antibody secretion, in order 
to execute a well-coordinated and tightly regulated immune response against infection 
(Herishanu et al. 2013). It is thus unsurprising that CLL cells retain the ability to communicate 
with their microenvironment, even though the normal compartmentalization and regulation of 
the immune response is altered. In fact, CLL cells are highly reliant on the interactions with the 
microenvironment for their survival and proliferation, especially in BM and secondary lymphoid 
structures. Such strong dependency is evidenced by the fact that in vitro cultured CLL cells 
rapidly undergo apoptosis, whereas their survival is significantly extended when co-cultured 
with non-malignant cells such as monocyte-derived nurse-like cells (NLCs) or mesenchymal 
bone marrow stromal cells (BMSCs) (Burger et al. 2000; Deaglio and Malavasi 2009). Besides, 
proliferation of CLL cells in patients is restricted to the pseudofollicles of secondary lymphoid 
organs, where tight interactions with the surrounding cells that shape the transcriptomic profile 
of CLL cells occur (Messmer et al. 2005; Herishanu et al. 2011). More specifically, CLL cells 
residing in the LNs overexpress genes related to BCR signaling as well as genes downstream 
of the NF-kB and NFAT pathways compared to PB and BM CLL cells (Herishanu et al. 2011).  
 
Multiple cell types constitute the CLL TME, including mesenchymal-stromal cells, 
endothelial cells, fibroblasts, neutrophils, monocytes, macrophages, dendritic cells, T-cells and 
NK cells. Through adhesion molecules, ligand-receptor interactions and soluble factors, these 
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cells establish a crosstalk with CLL cells, the complexity of which remains incompletely defined 
(Burger 2011; Kipps et al. 2017). The main cellular and molecular components of the CLL 
microenvironment are summarized in Figure 4.  
The majority of studies investigating the role of stromal cells in CLL have been performed 
using BMSCs. These cells provide attachment and growth factors in in vitro co-cultures with 
CLL cells via the CXCR4-CXCL12 axis, and protect CLL cells from spontaneous and drug-
induced apoptosis (Panayiotidis et al. 1996; Lagneaux et al. 1998; Burger et al. 1999; Kurtova 
et al. 2009). Other cytokines, chemokines, proangiogenic factors, and extracellular matrix 
components secreted by mesenchymal cells promote CLL cell migration and survival. These 
include integrins b1 and b2, vascular cell adhesion molecule 1 (VCAM1), VEGF, and MMP9 
(Lagneaux et al. 1998; de la Fuente et al. 2002; Ringshausen et al. 2004; Redondo-Munoz et 
al. 2006; Gehrke et al. 2011). Importantly, the interaction between CLL cells and stromal cells 
results in the activation of both cell types and induces the release of C-C motif chemokine 
ligand (CCL) 3 (CCL3) and CCL4 by CLL cells for the recruitment of other leukocytes like T-
cells (Burger et al. 2009; Ding et al. 2009). 
Endothelial and follicular dendritic cells (FDCs) play a similarly important role in homing CLL 
cells and providing protection from apoptosis (Badoux et al. 2011; Cols et al. 2012; Maffei et 
al. 2012). Activation and proliferation of malignant cells occur upon binding to integrins as well 
as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) expressed by 
microvascular endothelial cells (Cols et al. 2012).  
Burger et al. first described a critical involvement of monocytes in supporting CLL with the 
observation that PB monocytes co-cultured with CLL cells differentiate into ‘nurse-like cells’ 
that prolong leukemic cell survival (Burger et al. 2000). This in vitro model system has been 
extensively used to examine the mechanisms by which monocytes and macrophages support 
leukemia cells. For example, NLCs attract and enhance CLL cell survival via secretion of 
chemokines CXCL12 and CXCL13, as well as through BAFF and APRIL expression (Burger 
et al. 2000; Nishio et al. 2005; Burkle et al. 2007). Additional supporting interactions include 
the binding of CD38 – the expression of which in CLL cells is associated with poor prognosis 
– with CD31, and of semaphorin CD100 to Plexin B1 (Granziero et al. 2003; Deaglio et al. 
2005). Besides, CLL cells contribute to an inflammatory microenvironment by secreting 
exosomes that induce monocytes to secrete CCL2 (Haderk et al. 2017), which in turn, recruits 
more monocytes, and CD14, which improves CLL cell survival in vitro (Seiffert et al. 2010; 
Schulz et al. 2011). Of note, NLCs exhibit a gene expression profile similar to TAMs, which 
have been found in spleen and LNs of CLL patients (Tsukada et al. 2002; Burkle et al. 2007). 
Moreover, monocytes isolated from PB of CLL patients show a skewed phenotype from 
classical inflammatory CD14+ CD16- to patrolling CD14low CD16+ with a deregulation of genes 
involved in inflammation and phagocytosis (Maffei et al. 2013). Murine experiments have 
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recently confirmed the pro-tumorigenic role of myeloid cells: their depletion using clodronate 
liposomes led to a significantly improved control of CLL development, as well as a partial 
Figure 4: Cellular and molecular components of the CLL tumor microenvironment 
(TME). CLL cells receive pro-survival, proliferation and drug resistance-inducing signals from 
multiple cells present in their microenvironment. CLL cells are recruited to the LNs via CXCL12 
and CXCL13 secreted by stromal and myeloid cells. In SLOs, myeloid cells and endothelial 
cells support CLL cell survival and proliferation via cytokines including BAFF and APRIL. 
FDCs, stromal cells and T-cells further contribute in supporting CLL cells by expression of 
VCAM1 and CD40L, respectively. CLL cells in turn, secrete CCL3 and CCL4 to recruit 
leukocytes. In addition, CLL cells promote an immunosuppressive TME by expressing PD-L1, 
and inducing Treg differentiation. Tres, in turn, express CTLA-4 and secrete IL-10 and TGF-b. 
Myeloid cells contribute to the inhibition of T-cell function by PD-L1 expression and IDO1 
secretion. CLL T-cells exhibit an exhausted phenotype, with elevated expression of inhibitory 
receptors including PD-1, TIM-3 and CD244. PD-1 = programmed cell death protein 1, PD-L1 
= PD-1 ligand, CTLA-4 = cytotoxic T-lymphocyte-associated protein 4, Tim-3 = T-cell 
Immunoglobulin and mucin-domain containing-3, CD40L = CD40 ligand, IL4I1 = interleukin 4 
induced gene 1, IL-10 = interleukin 10, TGFb = transforming growth factor b, IDO1 = 
indoleamine 2,3-dioxygenase, Treg = regulatory T-cell, FDC = follicular dendritic cell, CCL3, 
CCL4 = chemokine ligand 3 and 4, CXCL12 and 13 = C-X-C motif chemokine 12 and 13, BAFF 
= B-cell activating factor, BAFFR = BAFF receptor, APRIL = a protein-inducing ligand, BCMA 
= B-cell maturation antigen, TACI = transmembrane activator and CAML interactor, VCAM1 = 
vascular cell adhesion protein 1, VLA-4 = Integrin a4b1. This figure includes a schematic 
representation of the main components of the CLL TME. A complete description of the 
interactions identified thus far has been reviewed by ten Hacken and Burger (Ten Hacken and 
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restoration of systemic inflammation (Galletti et al. 2016; Hanna et al. 2016). 
CLL cells modify their microenvironment to evade immune surveillance via multiple 
mechanisms. They produce IL-10 and TGF-b, and express high levels of PD-L1 that directly 
affect T-cell function. (Lotz et al. 1994; Fayad et al. 2001; Ramsay et al. 2012; Brusa et al. 
2013). Treg cell numbers are increased in PB and LNs of CLL patients, and have been shown 
to be correlated with tumor load and higher Binet and Rai stages (Beyer et al. 2005; 
Giannopoulos et al. 2008; D'Arena et al. 2011; Biancotto et al. 2012; Palma et al. 2017). These 
suppressor cells also express higher levels of CTLA-4, and produce increased amounts of IL-
10 and TGF-b compared to control Tregs (Beyer et al. 2005; Motta et al. 2005; Biancotto et al. 
2012). Further contributing to an immunosuppressive microenvironment, myeloid cells exhibit 
increased expression of IDO1, interleukin 4 induced gene 1 (IL4I1), as well as PD-L1, which 
help suppress T-cell function and induce Treg differentiation in vitro (Giannoni et al. 2014; 
Jitschin et al. 2014; Sadik et al. 2020). Last, circulating DCs from CLL patients are reported to 
harbor an immature phenotype and are unable to stimulate an effective T-cell response (Orsini 
et al. 2003). 
 
1.3.2 The role of T-cells in the CLL microenvironment 
The role of T-cells in CLL remains one of the most debated subjects in CLL research. Both 
CD4+ and CD8+ T-cell numbers are increased in PB of CLL patients, and a higher proportion 
of these cells exhibit an antigen-experienced effector or memory phenotype in contrast to 
healthy donor T-cells (Catovsky et al. 1974; Totterman et al. 1989; Christopoulos et al. 2011; 
Palma et al. 2017; Elston et al. 2020; Roessner et al. 2020b). However, it is unclear whether 
these cells are expanded because of tumor recognition, antigen-independent inflammatory 
signals, or infection-derived antigens, which are more prevalent in CLL patients (Burger 2011).  
CD4+ T-cells isolated form CLL patients display a higher expression of the activation 
markers CD160 and human leukocyte antigen (HLA)-DR, as well as the proliferation marker 
KI-67, but also express higher levels of the inhibitory receptors PD-1 and TIGIT (Riches et al. 
2013; Catakovic et al. 2017; Palma et al. 2017; Elston et al. 2020). Both TH1 and TH2 T-cell 
subsets have been reported to be predominant in PB of CLL patients (Podhorecka et al. 2002; 
Gorgun et al. 2005; Buggins et al. 2008; Roessner et al. 2020b). Additionally, cytokines 
secreted by either TH1 cells (IL-2, IFNg, and TNFa) or TH2 cells (IL-4) have been shown to 
improve CLL cell survival and proliferation in in vitro cultures (Foa et al. 1990; Dancescu et al. 
1992; Buschle et al. 1993; Trentin et al. 1996; de Totero et al. 1999; Monserrat et al. 2014). 
However, these reports investigated T-cells isolated from PB, and thus provide limited 
information about the phenotype and role of CD4+ T-cells residing in the LNs, where 
interactions with CLL cells occur. In lymphoid tissues, one of the most abundant T-cell subsets 
are CD4+ T follicular helper cells (TFH), which express CXCR5+ as well as inducible T-cell 
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costimulatory (ICOS), and support B-cell differentiation via CD40L- CD40 and ICOS- ICOS 
ligand (ICOSL) binding (King et al. 2008). In fact, CD40 signaling in CLL cells induces their 
survival and proliferation via PI3K/AKT and NF-kB pathways (Fluckiger et al. 1992; Romano 
et al. 1998; Furman et al. 2000; Cuni et al. 2004; Os et al. 2013). Similarly, the TFH cytokine IL-
21 promotes CLL cell proliferation in vitro, altogether suggesting that these cells provide crucial 
support to CLL cell survival (Ahearne et al. 2013; Pascutti et al. 2013). Mouse experiments 
aimed at deciphering the influence of CD4+ T-cells on CLL progression have reported 
contradictory results: autologous CD4+ T-cells were necessary for CLL cell proliferation in 
patient-derived xenograft (PDX) mouse models (Os et al. 2013), whereas an anti-tumoral effect 
by these cells was described using PDX as well as the Eµ-TCL1 mouse models (Bagnara et 
al. 2011; Kocher et al. 2016). More recently, the depletion of TBET-expressing TH1 CD4+ T-
cells in TCL1 mice was shown to have no effect in leukemia progression (Roessner et al. 
2020b). Of note, no data about the presence, phenotype or function of TR1 cells in CLL has 
been reported to date. Additional functional analyses are thus required to elucidate the role of 
CD4+ T-cell subsets in CLL.  
Evidence for an anti-tumoral effect by CD8+ T-cells comes from a described spontaneous 
regression of the disease in some patients, in addition to the identification of mutations 
resulting in neo-antigens that potentially induce a CD8+ T-cell response (Del Giudice et al. 
2009; Rajasagi et al. 2014). Besides, in vivo studies using the TCL1 AT mouse model showed 
that CLL progresses significantly faster in the absence of CD8+ T-cells (Hanna et al. 2019). As 
reported in other tumor entities, however, CD8+ T-cells from PB of CLL patients exhibit an 
activation-induced exhaustion phenotype, with increased expression of activation markers as 
well as inhibitory receptors, including human leukocyte antigen -DR isotype (HLA-DR), CD69, 
PD-1, CD244, TIM-3 and CTLA-4, and an altered transcriptional and epigenetic state 
(Totterman et al. 1989; Gorgun et al. 2005; Motta et al. 2005; Nunes et al. 2012; Brusa et al. 
2013; Riches et al. 2013; Wu et al. 2016a; Taghiloo et al. 2017; Hanna et al. 2019; Elston et 
al. 2020). Moreover, T-cells from CLL patients are unable to form effective immunological 
synapses due to cytoskeleton aberrations, and further show defects in proliferation and 
cytotoxicity (Gorgun et al. 2005; Ramsay et al. 2008; Riches et al. 2013). Nevertheless, as in 
CD4+ T-cell-centered studies, most research has focused on PB CD8+ T-cells, and very limited 
data on their phenotype in LNs exists. Importantly, Hanna et al. recently reported that CD8+ T-
cell exhaustion is more pronounced in SLOs compared to PB, with higher levels of PD-1 and 
reduced production of GZMB and TNFa after in vitro stimulation (Hanna et al. 2019). In a 
similar manner, exhausted T-cells are enriched in spleen compared to blood of TCL1 AT mice 
(Hanna et al. 2019). With the aim to assess the effect of immune check point blockade in CLL, 
several studies have used this mouse model and observed encouraging results. For example, 
anti-PD-L1, as well as dual anti-PD-1 and anti-LAG3 treatment in the mice reinvigorated CD8+ 
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T-cell function and improved CLL control (McClanahan et al. 2015a; Wierz et al. 2018). 
However, as previously mentioned, the respective treatment in CLL patients has so far been 
ineffective (Ding et al. 2017), hence highlighting the need for a better understanding of the T-
cell compartment in CLL patients. 
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2 Aims of the thesis 
Even though the recent development of novel targeted agents and combinatorial strategies 
have substantially improved therapeutic effectiveness in CLL, it is still considered an incurable 
disease. Drug resistance remains highly prevalent, and thus highlights the need for the 
creation of innovative methods to treat patients with CLL. Because CLL cells strongly rely on 
signals form their microenvironment to survive and proliferate, understanding the interplay 
between leukemia cells and bystander cells could be central to identify new treatment 
approaches targeting these interactions. However, whether T-cells exert pro- or anti-tumoral 
effects within the CLL microenvironment remains under debate. Besides, the phenotype of 
these cells in the secondary lymphoid organs, where the interactions with tumor cells occur, 
has been poorly studied hitherto. 
 
 Characterization of the T-cell compartment in CLL 
In order to address these open questions, the central aim of this work was to characterize 
the phenotype of T-cells isolated from CLL patients at a new level of resolution using single-
cell technologies. For this purpose, CD8+ T-cells from CLL lymph nodes, peripheral blood and 
bone marrow, together with lymph nodes of individuals without cancer were 
immunophenotyped using mass cytometry. Additionally, to evaluate the transcriptomic and 
clonal profile of nodal T-cells at the single-cell level, the 10x Genomics platform was used. At 
the same time, this approach enabled the study of the specific interactions established 
between T-cell subsets and CLL cells. 
Currently, the Eµ-TCL1 mouse model represents the most suitable tool for the in vivo 
investigation of the precise role of immune cell subsets in the context of CLL. Thus, in addition 
to the abovementioned analyses, the transcriptomes of individual T-cells isolated form 
splenocytes of leukemia-bearing mice were analyzed to assess their resemblance with LNs 
from CLL patients. 
 
 Exploring the role of the transcription factor EOMES in CD8+ T-
cells in CLL 
EOMES is a known master regulator of T-cell differentiation and function, and has recently 
been linked to T-cell exhaustion. Hence, another goal of the present study was to investigate 
the role of EOMES in T-cell function in the context of CLL. To this end, EOMES expression 
patterns in human and murine T-cell subsets were investigated using single-cell transcriptome 
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and mass cytometry analyses, and its functional role was assessed in vivo using the TCL1 
mouse model. 
 
 Defining the role of TR1 cells in CLL 
While an immunosuppressive role of TR1 CD4+ T-cells has been described in several tumor 
entities, their existence and function in CLL has not been explored thus far. The aim of the 
present work was therefore to investigate the presence and phenotype of TR1 cells in CLL 
patients using mass cytometry and transcriptome single-cell data. Besides, the TCL1 mouse 
model was employed to investigate the molecular mediators regulating TR1 cell function and 
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3 Materials and Methods 
 Materials 
3.1.1 Human samples 
Lymph node (LN), peripheral blood (PB), and bone marrow (BM) samples from CLL 
patients, and reactive lymph node (rLN) samples from heathy controls were obtained after 
informed consent and according to the guidelines of the Hospital Clínic Ethics Committee, the 
Ethics Committee of the University of Heidelberg, and the Declaration of Helsinki. Patients with 
CLL were diagnosed following the World Health Organization (WHO) classification criteria 
(Swerdlow 2017). All clinical information of the patients analyzed in this work is provided in 
Table 1,  Table S12, and Table S13. 
 
Table 1: Clinical data of CLL patients and healthy controls.  
Patient 

















BC1 LN CLL ACC M 72 70 - M 92 Untreated B I 26.3 74.9 
BC1 PB CLL ACC M 72 70 - M 41.80 Untreated B I 26.3 74.9 
BC10 LN CLL TR F 61 59 0 U 64.80 Treated A III 22.3 28.2 
BC11 BM CLL M 53 52 0 U 70 Treated A I 6.5 121.7 
BC12 LN CLL M 77 77 0 U 53.94 Untreated B I - - 
BC12 PB CLL M 77 77 0 U 67.76 Untreated B I - - 
BC13 LN CLL M 72 67 0 U 53.28 Treated A 0 52.2 - 
BC13 PB CLL M 72 67 0 U 75.60 Treated A 0 52.2 - 
BC14 LN CLL M 72 60 0 U 91 Treated A 0 122.4 - 
BC14 PB CLL M 72 60 0 U 94 Treated A 0 122.4 - 
BC15 LN CLL F 58 56 0 U 70.56 Treated A 0 19.6 140.5 
BC15 LN CLL F 65 56 0 U 78.40 Treated A 0 19.6 140.5 
BC15 PB CLL F 65 56 0 U 69 Treated A 0 19.60 140.47 
BC2 LN CLL ACC M 70 69 0 U 88 Untreated B I 2.9 - 
BC3 LN CLL F 58 57 0 U 79.20 Untreated B I - - 
BC3 BM CLL F 58 57 0 U 83.42 Untreated B I - - 
BC4 LN CLL M 56 53 NA M 76.26 Treated A 0 39.3 - 
BC5 LN CLL F 47 46 0 M 32.80 Untreated A I - - 
BC5 LN CLL F 46 46 0 M 64.17 Untreated A I - - 
BC5 PB CLL F 46 46 0 M 45.10 Untreated - - - - 
BC6 LN CLL ACC M 84 62 - - 68 Treated A 0 69 282.4 
BC7 LN CLL M 43 43 0 M 83.30 Untreated A I - - 
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BC8 LN CLL M 75 73 0 U 59.40 Treated A I 0.0 51.2 
BC8 PB CLL M 76 73 0 U 60 Treated A I 0.0 51.2 
BC9 LN CLL M 54 53 0 U 86 Treated A III 14.9 56.4 
BC9 PB CLL M 54 53 0 U 84 Treated A III 14.9 56.4 
BC9 BM CLL M 54 53 0 U 94 Treated A III 14.9 56.4 
HD1 LN CLL M 72 56 0 M 95 Pretreated A III 8.1 - 
HD10 LN CLL M 71 71 0 M 89 Untreated B III - - 
HD11 LN CLL M 70 62 1 - 88 Treated A IV 19.3 - 
HD2 LN CLL M 78 78 0 M 77.2 Untreated B I - - 
HD3 LN CLL M 69 69 0 M 75 Untreated B I 5.0 - 
HD4 LN CLL M 79 79 0 M 88.6 Untreated B I 1.0 - 
HD5 LN CLL M 72 71 0 U 88.9 Untreated B I 14.7 - 
HD6 LN CLL M 76 75 0 M 78.6 Untreated A I 6.5 - 
HD7 LN CLL M 53 53 0 U 91.4 Untreated C III 0.3 - 
HD8 LN CLL M 72 71 0 M NA Untreated A III 16.4 39.7 
HD9 LN CLL M 75 76 - - 84.3 Untreated - - - - 
rLN1 LN rLN M -          
rLN10 LN rLN F 52          
rLN11 LN rLN F 34          
rLN12 LN rLN M 30          
rLN13 LN rLN M 59          
rLN2 LN rLN M 32          
rLN3 LN rLN M 50          
rLN4 LN rLN F 39          
rLN5 LN rLN M 20          
rLN6 LN rLN M 49          
rLN7 LN rLN M 18          
rLN8 LN rLN M 33          
rLN9 LN rLN M 20          
Note: TL = tumor load, TFS = treatment-free survival, OS = overall survival, LN = lymph node, 
PB = peripheral blood, BM = bone marrow, CLL = chronic lymphocytic leukemia, CLL ACC = 
accelerated CLL, CLL TR = CLL with Hodgkin transformed cells, rLN = reactive LN, M = male, 
F = female, - = not available. 
 
3.1.2 Mouse lines  
Mice used in this work were obtained from the central animal facility of the German Cancer 
Research Center (DKFZ, Heidelberg), kindly provided by external research groups, or 
purchased from Janvier Labs (Saint-Berthevin) or Jackson laboratories (Bar Harbor). A list of 
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the specific mouse strains used, including their respective background and supplier, is 
provided in Table 2. Mice were kept under specific pathogen-free conditions in the animal 
facility of DKFZ. Experimental and control groups were sex- and age-matched in all studies 
performed. Mice were euthanized with carbon dioxide (CO2) overdose or cervical dislocation. 
All animal experiments were conducted in accordance with the governmental regulations and 
authorized by the local authorities under the G-25/16, G-98/16 and G-53/15 and G-36/14 
experimental projects.  
 
Table 2: Mouse lines used in this work.  
Short name Full name Background Supplier 
Eomes-/- 
Lck-cre x Eomesfl/fl x Foxp3-
IRES-mRFP (FIR) x Il10-GFP 
(tiger) (Wan and Flavell 2005) 
129Sv/C57BL/6 J Dr. Ana Izcue1 




TCL1A)3Cro 75 (Bichi et al. 
2002) 
CD45.2-C57BL/6 N Dr. Carlo Croce2 
Eµ-TCL1 
B6.Cg-Tg(Igh-V186.2- 
TCL1A)3Cro 75 (Bichi et al. 
2002) 
CD45.2-C57BL/6 J Dr. Carlo Croce2 
Il10rb-/- STOCK-Il10rbtm1Agt (Spencer et al. 1998) CD45.2-C57BL/6 J 
Jackson 
laboratories3 
Il10 reporter (Fir 
x tiger) 
B6-Foxp3tm1Flv Il10tm1Flv / 





(Shinkai et al. 1992) 
CD45.2-C57BL/6 J DKFZ central animal facility 
WT C57BL/6 J NA CD45.2-C57BL/6 J Janvier Labs4 
WT C57BL/6 N NA CD45.2-C57BL/6 N Janvier Labs4 
Note: NA = Not Available. 1 = Max-Planck Institute of Immunology and Epigenetics, Freiburg, 
2 = Ohio State University, Columbus, 3 = Bar Harbor, 4 = Saint-Berthevin. 
 
3.1.3 Antibodies 
Table 3: Mass cytometry antibodies.  
Antibody Isotope Clone Reference Supplier Staining 
2B4 (CD244) 113In*# C1.7 329502 Biolegend Surface 
CD127/IL-7Ra 149Sm A019D5 314901B Fluidigm Surface 
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CD134/OX40 158Gd ACT35 315801B Fluidigm Surface 
CD137/4-1BB 173Yb 4B4-1 317301B Fluidigm Surface 
CD152/CTLA-4 170Er 14D3 317000B Fluidigm Surface 
CD185/CXCR5 171Yb 51505 317100B Fluidigm Surface 
CD19 139La*# HIB19 302202 Biolegend Surface 
CD197/CCR7 167Er* G043H7 353202 Biolegend Surface 
CD223/LAG3 165Ho 11C3C65 316503B Fluidigm Surface 
CD25 169Tm 2A3 316900B Fluidigm Surface 
CD27 155Gd L128 315500B Fluidigm Surface 
CD278/ICOS 148Nd C398.4A 314801B Fluidigm Surface 
CD279/PD-1 174Yb EH12.2H7 317402B Fluidigm Surface 
CD3 141Pr* UCHT1 300402 Biolegend Surface 
CD357/GITR 159Tb 621 315902B Fluidigm Surface 
CD38 144Nd HIT2 314401B Fluidigm Surface 
CD39 160Gd A1 316000B Fluidigm Surface 
CD4 145Nd* RPA-T4 300502 Biolegend Surface 
CD44 166Er BJ18 316600B Fluidigm Surface 
CD45 89Y HI30 308900B Fluidigm Surface 
CD45RA 143Nd H100 314300B Fluidigm Surface 
CD45RO 164Dy UCHL1 316400B Fluidigm Surface 
CD47 209Bi CC2C6 320900B Fluidigm Surface 
CD56/NCAM 176Yb NCAM16.2 317600B Fluidigm Surface 
CD7 147Sm CD7-6B7 314700B Fluidigm Surface 
CD73 168Er AD2 316801B Fluidigm Surface 
CD8a 146Nd* RPA-T8 301002 Biolegend Surface 
CD95/FAS 152Sm DX2 315201B Fluidigm Surface 








EOMES 175Lu* WD1928 14-4877-82 ebioscience Intracellular 
FOXP3 162Dy 259D/C7 3162024A Fluidigm Intracellular 
Granzyme K 142Nd* GM26E7 370502 Biolegend Intracellular 
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HELIOS 156Gd* 22F6 137202 Biolegend Intracellular 
HLA-DR 151Eu G46-6 3151023B Fluidigm Surface 
KI-67 172Yb B56 3172024B Fluidigm Intracellular 
KLRG1 115In*# SA231A2 367702 Biolegend Surface 
TBET 161Dy 4B10 3161014B Fluidigm Intracellular 
TCF7 163Dy* 7F11A10 655202 Biolegend Intracellular 
TIGIT 153Eu MBSA43 3153019B Fluidigm Surface 
TIM-3 154Sm F38-2E2 3154010B Fluidigm Surface 
TOX 150Nd* TXRX10 14-6502-82 ebioscience Intracellular 
Note: * = Isotopes conjugated in-house to respective purified monoclonal IgG antibodies in the 
Department of Oncology in the Luxembourg Institute of Health (LIH, Luxembourg). # = Isotopes 
were purchased from Trace Sciences International (113ln) or Sigma (115ln, 139, LA). 
 
Table 4: Flow cytometry antibodies. 
Marker Fluorochrome Species 
reactivity 
Clone Supplier Reference 
CD107A PE Mouse 1D4B eBioscience 12-1071-83 
CD11B eFluor® 450 Mouse M1/70 eBioscience 48-0112-82 
CD11B PerCP-Cy5.5 Mouse M1/70 eBioscience 45-0112-82 
CD127 PE Mouse A7R34  Biozol Diagnostica BLD-
135010 
CD127 PE-Dazzle Mouse A7R34 Biozol Diagnostica BLD-
135032 
CD127 BV605 Mouse A7R34  Biozol Diagnostica BLD-
135041 
CD127 PE-Cy7 Mouse A7R34 Biolegend 25-1371-82 
CD127 APC Mouse A7R34 Biozol Diagnostica BLD-
135012 
CD19 FITC Mouse 1D3 eBioscience 11-0193-86 
CD19 PE-Dazzle Mouse 6D5 Biolegend 115554 
CD19 AF700 Mouse 1D3 eBioscience 56-0193-82 
CD19 PE-Cy7 Mouse 1D3 eBioscience 25-0193-81 
CD19 PE Mouse 1D3 eBioscience 12-0193-83 
CD19 FITC Human HIB19 Biolegend 302206 
3 Materials and Methods   3.1 Materials 
 44 
CD244 APC Mouse eBio244F4 eBioscience 17-2441-82 
CD3 V450 Mouse 500A2 BD Bioscience 560801 
CD3 APC Mouse 145-2C11 Biolegend 100321 
CD3 PE Human HIT3a BD Bioscience 555340 
CD3E BV605 Mouse 145-2C11 Biolegend BLD-
100351  
CD3E FITC Mouse 145-2C11 Biolegend 100306 
CD4 eFluor®450 Mouse GK1.5 eBioscience 48-0041-82 
CD4 BV605 Mouse RM4-5  Biolegend BLD-
100548 
CD4 PerCP-Cy5.5 Mouse RM4-4 Biolegend 116012 
CD4 APC-Cy7 Mouse RM4-5 Biolegend 100526 
CD4 APC Mouse RM4-4 Biozol Diagnostica BLD-
100516 
CD44 AF700 Mouse IM7 eBioscience 56-0441-82 
CD44 PerCP-Cy5.5 Human/ 
Mouse 
IM7 Biozol Diagnostica BLD-
103032 
CD44 FITC Human/ 
Mouse 
IM7 eBioscience 11-0441-85 
CD45 PerCP-Cy5.5 Mouse 30-F11 Biolegend BLD-
103132 
CD45 BV711 Mouse 30-F11 Biolegend 103147 
CD45 AF700 Mouse 30-F11 Biolegend 103128 
CD5 APC Mouse 53-7.3 Biolegend 100626 
CD5 BV605 Mouse 53-7.3 BD Bioscience 563194 
CD5 PE Mouse 53-7.3 eBioscience 12-0051-81 
CD5 APC Human UCHT2 Biolegend 300612 
CD69 PE-Dazzle Mouse H1.2F3 Biolegend BLD-
104536  
CD8A APC-Cy7 Mouse 53-6.7 Biolegend 100714 
CD8A BV605 Mouse 53-6.7 Biolegend 100744 
CX3CR1 PE-Dazzle Mouse SA011F11 Biolegend 149014 





Dan11mag  eBioscience  46-4875-80 
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FOXP3 PeCy7 Mouse FJK-16s eBioscience 25-5773-80 
FOXP3 AF700 Mouse FJK-16s eBioscience 56-5773-82 
GZMB V450 Mouse NGZB eBioscience 48-8898-82 
GZMB FITC Mouse NGZB eBioscience 11-8898-80 
IFNG PerCP-Cy5.5 Mouse XMG1.2 eBioscience 45-7311-82 
IL-2 APC Mouse JES6-5H4 Biolegend 503810 
IL-2 PE-Cy7 Mouse JES6-5H4 eBioscience 25-7021-82 
KI-67 FITC Mouse SolA15 eBioscience 11-5698-82 
KI-67 PE Mouse MIB-1 Biozol Diagnostica 652404 
LAG3 PE Mouse eBioC9B7W eBioscience 12-2231-82 
NK1.1 FITC Mouse PK135 Biolegend 108706 
PD-1 PE-Cy7 Mouse RPM1-30 Biolegend 109110 
PD-1 APC Mouse RPM1-30 Biolegend 109112 
PD-1 PE-Dazzle Mouse RPM1-30 Biolegend 109116 
PD-1 PE Mouse RPM1-30 Biolegend 169104 
TNF eFluor® 450 Mouse MP6-XT22 eBioscience 48-7321-82 
 
3.1.4  Chemicals and reagents  




10 % Tween 20 scRNA 
sequencing 
Biomol GmbH, Hamburg E108 







Sigma-Aldrich, Steinheim D9542-1MG 




Beckman Coulter, Brea A63881 
Cotrim K-ratiopharm 240 mg  Mouse 
experiments 
Ratiopharm, Ulm  3788230 
Dimethylsulfoxid (DMSO)  Freezing medium Sigma-Aldrich, Steinheim  41639 
DirectPCR Lysis Reagent 
(Mouse Tail) 50 mL 
PCR Viagen Biotech, Los 
Angeles 
101-T  
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Dulbecco’s Modified Eagle’s 
Medium (DMEM)  
Cell culture Sigma-Aldrich, Steinheim  D6046  
Dulbecco’s Phosphate 
Buffered Saline (PBS)  





10x Genomics, Pleasanton PN-
2000048 




Thermo Fisher Scientific, 
Waltham 
00-5333-57  
eBioscience Cell Stimulation 
Cocktail (500X) 
T-cell stimulation Thermo Fisher Scientific, 
Waltham  
00-4970-93  
eBioscience Fixable Viability 
Dye eFluor 506  
Flow cytometry 
staining 
Thermo Fisher Scientific, 
Waltham 
65-0866-14  
eBioscience Protein Transport 
Inhibitor Cocktail  
T-cell stimulation Thermo Fisher Scientific, 
Waltham  
00-4980-93  
Ethanol Misc. Fisher Scientific GmbH, 
Schwerte  
10342652 
Ethidium Bromide Solution (1 
%)  
PCR Carl Roth, Karlsruhe  2218 
Fetal Bovine Serum (FBS) Misc. Sigma-Aldrich, Steinheim F7524  
GeneRuler 1 kb Plus DNA 
Ladder  
PCR Fisher Scientific Oy, 
Vantaa 
11581625 
Gibco HEPES (1 M)  Cell culture Thermo Fisher Scientific, 
Waltham  
15630056 
Gibco L-Glutamine (200 mM)  Cell culture Thermo Fisher Scientific, 
Waltham  
25030024 
Gibco MEM Non-Essential 
Amino Acids Solution (100X) 




(10,000 U/mL)  
Cell culture Thermo Fisher Scientific, 
Waltham  
15140122 




BioVision BV, Milpitas B1012-100 





Santa Clara  
5067-5585  





Santa Clara, USA  
5067-5593  
Invitrogen 123count eBeads 
Counting Beads  
Flow Cytometry 
Staining 
Thermo Fisher Scientific, 
Waltham 
01-1234-42  
Normal Rat Serum  Cell isolation Jackson ImmunoResearch 
Laboratories, West Grove  
012-000-
120  
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Proteinase K PCR Thermo Fisher Scientific, 
Waltham 
11826724 
RNase free water  Misc. Ambion, Carlsbad  AM9937  
RPMI 1640  Cell culture Sigma-Aldrich, Steinheim R8758  
Sodium Pyruvate (100 mM)  Cell culture Thermo Fisher Scientific, 
Waltham  
11360039 
Note: Misc. = Miscellaneous, U = Units. 
 
3.1.5 Buffers and solutions 
Table 6: Buffers and solutions used in this work.  
Buffer  Experiment/ Purpose Composition/ Supplier Catalog #  
eBioscience Foxp3 / 
Transcription Factor 
Staining Buffer Set  




Fixation Buffer  





Buffer (10X)  
Flow Cytometry Staining Thermo Fisher Scientific, 
Waltham  
00-8333-56 
FACS buffer  Flow Cytometry Staining PBS + 2% FBS NA 
Freezing Media  Cryopreservation 90% FBS + 10% DMSO  NA  
MACS Buffer  Cell isolation Miltenyi Biotec, Bergisch 
Gladbach  
130-091-221  
Qiagen Buffer EB  scRNA sequencing Qiagen, Hilden 19086 
RBC Lysis Buffer 
(10X)  
Cell isolation Biolegend, San Diego  420301 
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3.1.6 Kits 
Table 7: Commercial kits used in this work. 
Name Experiment/ Purpose Supplier Reference 




Chromium™ i7 Multiplex Kit, 
96 rxns 
scRNA sequencing 10x Genomics, 
Pleasanton 
120262 
Chromium™ Single Cell 3'/5' 
Library Construction Kit, 16 
rxns 
scRNA sequencing 10x Genomics, 
Pleasanton 
PN-1000020 
Chromium™ Single Cell 3’ 
Library & Gel Bead Kit v2, 4 
rxns 
scRNA sequencing 10x Genomics, 
Pleasanton 
PN-120267 
Chromium™ Single Cell 5’ 
Library & Gel Bead Kit, 4 rxns 
scRNA sequencing 10x Genomics, 
Pleasanton 
PN-1000014 
Chromium™ Single Cell A 
Chip Kit, 16 rxns  
scRNA sequencing 10x Genomics, 
Pleasanton 
PN-1000009 
Chromium™ Single Cell V(D)J 
Enrichment Kit, Human T Cell, 
96 rxns 
scRNA sequencing 10x Genomics, 
Pleasanton 
PN-1000005 
Chromium™ Single Cell V(D)J 
Enrichment Kit, Mouse T Cell, 
96 rxns 
scRNA sequencing 10x Genomics, 
Pleasanton 
PN-1000071 
QIAamp DNA Micro Kit (50) DNA isolation Qiagen, Hilden 56304 
QIAquick PCR Purification Kit PCR product purification Qiagen, Hilden 28104 
EasySep Mouse CD4+ T cell 
isolation kit  




EasySep Mouse CD8+ T cell 
isolation kit  




Easysep Mouse Pan-B Cell 
Isolation Kit  








Note: Rxn = reaction. 
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3.1.7 Consumables 




96-Well U Bottom Plate  Miscellaneous Techno Plastic Products 
(TPP), Trasadingen 
TPP92197  
Cell Culture Dish 100/20 
mm    
Miscellaneous Greiner Bio-one, 
Frickenhausen 
664160 
Conical Tubes (15 mL, 50 
mL)  





Serological Pipettes (5mL, 
10 mL, 25 mL, 50 mL)  









Corning, New York CLS4870-
5EA 




DNA LoBind Tubes, DNA 
LoBind, 1,5 mL 
scRNAseq/ Cell 
sorting 
Eppendorf, Hamburg  22431021 
Eppendorf Safe-Lock 
Microcentrifuge Tubes 
(1.5 mL, 2 mL, 5mL)  
Miscellaneous Eppendorf, Hamburg  22363204 
Falcon Polystrene Round 
Bottom Tubes (5 mL) 
Flow Cytometry 
Staining 
Corning, New York   352052 
Falcon® 70 μm Cell 
Strainer 
Tissue dissociation Corning, New York  352350 
Fine Dosage Syringes, 
Injekt®-F Solo 
Cell injection VWR International, Radnor  720-2561 




High Sensitivity D1000 
ScreenTape  
scRNA sequencing Agilent Technologies, Santa 
Clara  
5067-5584  
High Sensitivity D5000 
ScreenTape  
scRNA sequencing Agilent Technologies, Santa 
Clara  
5067-5592  








Blood collection Greiner Bio-one, 
Frickenhausen 
450532 
Mr. Frosty™ Freezing 
Container 
Cryopreservation Nunc, Rosklide 5100-0001 
NEOJECT® Hypodermic 
Needles (23G, 25G and 
27G)  
Cell injection Dispomed Witt, Gelnhausen  10025, 
10089, 
10127 
Pipette Tips (10 μL, 20 μL, 
100 μL, 200 μL, 1000 μL) 







Vi-CELL™ XR Cell counting Beckman Coulter, Brea  383721 
 
3.1.8 Equipment and devices 
Table 9: Equipment and devices used in this work. 
Name Experiment/ Purpose Supplier 
10x Magnetic Separator  scRNA sequencing 10x Genomics, Pleasanton 
10x Vortex Adapter  scRNA sequencing 10x Genomics, Pleasanton 
4200 TapeStation scRNA sequencing Agilent Technologies, Santa Clara  
Accu-jet® pro Pipette Controller Misc. BrandTech, Essex  
BD FACSAriaTM II Cell sorting BD (Becton, Dickinson & 
Company), Franklin Lakes 
BD FACSArisa Fusion Cell sorting BD (Becton, Dickinson & 
Company), Franklin Lakes 
BD FACSCanto II Flow Cytometry 
Staining 
BD (Becton, Dickinson & 
Company), Franklin Lakes 
BD LSR II Flow Cytometry 
Staining 
BD (Becton, Dickinson & 
Company), Franklin Lakes 
BD LSRFortessaTM  Flow Cytometry 
Staining 
BD (Becton, Dickinson & 
Company), Franklin Lakes 
C1000 Touch™ Thermal Cycler scRNA sequencing Bio-Rad Laboratories, Hercules 
Cell Culture Safety Cabinet, 
Herasafe KS  
Cell culture Thermo Fisher Scientific, Waltham  
Centrifuge 5810 R  Miscellaneous Eppendorf, Hamburg  
Centrifuge Heraeus Fresco 17 Miscellaneous Thermo Fisher Scientific, Waltham  
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Chromium Next GEM 
Secondary Holder  
scRNA sequencing 10x Genomics, Pleasanton 
Chromium Single Cell Controller 
Instrument  
scRNA sequencing 10x Genomics, Pleasanton 
Easysep Magnet Cell isolation Stemcell Technologies, Vancouver  
Eppendorf ThermoMixer C scRNA sequencing Eppendorf, Hamburg, Germany  
FastGene Mini Centrifuge scRNA sequencing Nippon Genetics, Düren 
Gammacell 40 Exactor Mouse irradiation Best Theratronics, Ottawa  
GentleMACS Dissociator Tissue dissociation Miltenyi Biotec, Bergisch Gladbach  
Heracell 150i Incubator  Cell culture Thermo Fisher Scientific, Waltham  
Heracell 240i Incubator  Cell culture Thermo Fisher Scientific, Waltham  
MACS Magnet Stand  Cell isolation Miltenyi Biotec, Bergisch Gladbach 
MasterCycler EP Gradient S  PCR Eppendorf, Hamburg  
PIPETMAN L Multichannel 
P8x200L, 20-200 μL  
Miscellaneous Gilson, Middleton 
Pipettes (2 μL, 20 μL, 100 μL, 
200 μL, 1000 μL)  
Miscellaneous Gilson, Middleton 
QuadroMACS Separator  Cell isolation Miltenyi Biotec, Bergisch Gladbach  
Qubit 4.0 Fluorometer  scRNA sequencing Thermo Fisher Scientific, Waltham  
Scissors Surgical 11,5 cm 
Curved ST/ST  
Tissue extraction DKFZ Lagermaterial, Heidelberg 
Tweezers Anatomical 10,5 cm 
Straight 
Tissue extraction DKFZ Lagermaterial, Heidelberg 
Tweezers Surgical 10,5 cm 
Curved 
Tissue extraction DKFZ Lagermaterial, Heidelberg 
UV-Gel Documentation System  PCR BioRad, Hercules 
Vi-CELL XR 2.03 Cell counting Beckman Coulter Inc.,Brea 
Vortex Mixer Neolab 7-2020  Miscellaneous neoLab Migge, Heidelberg 
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3.1.9 Software 
Table 10: Software used in this work. 
Name Experiment/Purpose Source Version 
Affinity Designer Figure creation Serif Ltd, West Bridgford 1.8.2.620 
BD FACSDivaTM Flow cytometry data acquisition 
BD (Becton, Dickinson & 
Company), Franklin Lakec 3149011B 
CyTOF® Software Mass cytometry data acquisition 
Fluidigm Corporation, South 
San Francisco 6.7.1014 
EndNoteTM X9 Bibliography management Thomson Reuters, Carlsbad 19.3.1.13758 
FlowJo Flow cytometry analysis BD (Becton, Dickinson & Company), Franklin Lakes X 10.0.7 
GraphPad Prism Statistical analysis, graph creation 
GraphPad Software, San 
Diesgo 5.04/7 
Microsoft Excel  Miscellaneous Microsoft, Redmond 2016 
Microsoft 
PowerPoint  Miscellaneous Microsoft, Redmond 2016 








R Bioinformatic analyses The R Foundation 3.5 
 
 Methods 
3.2.1 Human tissue processing and conservation 
LN samples obtained in the Hospital Clínic (Barcelona) were processed as follows: one half 
of the resected LN underwent routine histopathological and flow cytometry immunological 
evaluation. The other half was homogenized using a 70 µm cell strainer (Falcon, 352350) to 
obtain a single-cell suspension, which was resuspended in Roswell Park Memorial Institute 
(RPMI 1640, Sigma-Aldrich, R8758) medium containing 10 % dimethyl sulfoxide (DMSO, 
Sigma-Aldrich, D4540) and 60 % heat-inactivated fetal bovine serum (FBS; Thermo Fisher 
Scientific, F7524). Single-cell suspensions of peripheral blood (PB) and bone marrow (BM) 
were obtained via Ficoll-Paque sedimentation (GE-Healthcare, GE17-1440-02) and 
cryopreserved as described above. Lymph nodes collected at the University of Heidelberg 
(Heidelberg) were minced and suspended in RPMI 1640 medium (Sigma-Aldrich, R8758) 
supplemented with 10 % FBS (Thermo Fisher Scientific, F7524), 2 mM L-Glutamine (Thermo 
Fisher Scientific, 25030024), and penicillin and streptomycin (P/S, Thermo Fisher Scientific, 
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15140122) at a final concentration of 100 U/mL and 100 µg/mL, respectively. Cells were next 
filtered through a 40 µm strainer (Sigma-Aldrich, CLS431750), washed once with phosphate-
buffered saline (PBS, Thermo Fisher Scientific, 10010023), and resuspended in RPMI 1640 
medium (Sigma-Aldrich, R8758) supplemented with 20 % FBS (Thermo Fisher Scientific, 
F7524) and 10 % DMSO (SERVA Electrophoresis GmbH, 20385.01). All samples were 
cryopreserved in liquid nitrogen until further analysis. 
 
3.2.2 Tumor models 
3.2.2.1 Transgenic Eµ-TCL1 mice 
Eµ-TCL1 (TCL1) transgenic mice were bred in the central animal facility of the German 
Cancer Research Center (DKFZ, Heidelberg). The mouse line was maintained by crossing 
heterozygous TCL1 with wild-type (WT) C57BL/6 littermates, resulting in an approximately 1:1 
ratio of WT and heterozygous TCL1 mice. Two colonies of TCL1 mice were bred separately in 
order to maintain the N and J C57BL/6 substrains. The respective substrain background was 
confirmed via SNP analysis of tissue DNA using the Genome Scanning Service from The 
Jackson Laboratory (Bar Harbor). TCL1 mice were closely monitored for signs of illness, and 
leukemia development was confirmed by palpable splenomegaly and detection of CD5+ CD19+ 
leukemia cells in PB at an age of 10 to 15 months. Mice were sacrificed when reaching a 
specified time point or moribund state, and spleens were collected, processed and 
cryopreserved as described in Section 3.2.2.5. 
Mice genotyping was performed using tail tissue DNA. Briefly, tissue was enzymatically 
digested by incubation in DirectPCR Lysis Reagent (Viagen Biotech, 101-T) containing 
Proteinase K (20 mg/mL, Thermo Fisher Scientific, 11826724) at 56 °C overnight followed by 
an incubation at 80 °C for 45 min the next day. PCR master mix was then prepared by adding 
1:20 of lysate and 0.5 mM of forward (5-GCCGAGTGCCCGACACTC-3) and reverse (5-
CATCTGGCAGCAGCTCGA-3) primers to 1X Prima Amp Hot Start Master Mix (Steinbenner 
Laborsysteme, SL-9714-10ml). The PCR reaction was performed in a MasterCycler EP 
Gradient S (Eppendorf) with the following settings:  
Step Temperature Time (hh:mm:ss) 
1 95 °C 00:02:00 
2 95 °C 00:00:10 
3 59 °C 00:00:10 
4 72 °C 00:00:25 
5 Go to Step 2, x34 (35 cycles) 
6 72 °C 00:03:00 
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Samples were run on a 1 % (w/v) agarose gel, stained with ethidium bromide (Carl Roth, 
2218), and imaged using a UV-Gel documentation system (BioRad). 
 
3.2.2.2 TCL1 Adoptive Transfer 
TCL1 mice with tumor loads of more than 85 % were used for a first round of adoptive 
transfer (AT) of leukemia cells into C57BL/6 wild type (WT) recipients. In short, single-cell 
suspensions of TCL1 splenocytes were prepared and 1-1.5 x107 cells were injected into the 
tail vein (i.v.) or the peritoneal cavity (i.p.) of 8-12 weeks-old WT female mice. These 
transplanted mice reached end-stage disease between 3 and 5 months. One-time expanded 
leukemia cells were next used for the actual AT experiments in which WT, Rag2-/-, Il10 reporter 
(Fir x Tiger), or bone marrow chimeric mice were injected. The specific procedure used for 
adoptive transfer in Rag2-/- and bone marrow chimeric mice is detailed in Sections 3.2.2.3 and 
3.2.2.4 respectively. The AT experiments in WT mice were conducted as follows: splenocytes 
from TCL1 AT mice were thawed, washed, and enriched for leukemic B-cells by using the 
EasySepTM Mouse Pan-B Cell Isolation Kit (Stemcell Technologies, 19844) according to 
manufacturer’s instructions. Specifically, single-cell suspensions were resuspended in MACS 
buffer (Miltenyi Biotec, 130-091-221) at a concentration of 1 x108 cells/mL, and 50 µL/mL 
Normal Rat Serum (Jackson ImmunoResearch Laboratories, 012-000-120) was added prior 
to incubation with 50 μL/mL antibody Isolation Cocktail (Stemcell Technologies, 19844) for 5 
min at room temperature. Next, 50 μL/mL RapidSpheres™ were added following a 2.5 min 
incubation step at room temperature. Sample-containing tubes were subsequently placed into 
an Easysep Magnet (Stemcell Technologies) and magnetic-based cell separation was allowed 
by incubation for 2.5 min at room temperature. B-cells were recovered by pouring the non-
bound cell suspension into a new collection tube. Finally, cells were counted using a Vi-CELL 
XR 2.03 cell counter (Beckman Coulter Inc.) and resuspended to a concentration of 1 x108 
cells/mL in PBS in order to intravenously inject 1 x107 cells. Tumor growth in injected mice was 
monitored by flow cytometry staining of CD5+ CD19+ cells from PB every two weeks. 
Importantly, all adoptive transplantations were performed with animals of the same J or N 
substrain for donor and recipient mice, to avoid allograft rejection (Ozturk et al. 2019). TCL1 
AT experiments in WT and Fir x Tiger mice were conducted in collaboration with Dr. Philipp 
Rößner and Dr. Bola Hanna from the Department of Molecular Genetics in the German Cancer 
Research Center (DKFZ), Heidelberg. 
 
3.2.2.3 Adoptive T-cell and tumor transfer into Rag2 KO mice 
Adoptive transfer of T-cells and TCL1 AT tumor cells into Rag2-/- mice was performed over 
two sequential days. On day 1, Eomes-/-, Il10rb-/- and their respective WT control mice Eomes+/+ 
and C57BL/6 J, were sacrificed and spleens were collected and processed as detailed in 
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Section 3.2.2.5 for obtaining single-cell suspensions. Next, CD4+ or CD8+ T-cells were isolated 
using the EasySep Mouse CD4+ T-cell isolation kit or the EasySep Mouse CD8+ T-cell isolation 
kit (both from Stemcell Technologies, 19852 and 19853) respectively, applying the 
manufacturer’s instructions. In brief, cells were resuspended at a concentration of 2 x108 
cells/mL in MACS Buffer (Miltenyi Biotec, 130-091-221) and 50 µL/mL Normal Rat Serum 
(Jackson ImmunoResearch Laboratories, 012-000-120) was added. Cells were next incubated 
for 10 min at room temperature with 50 μL/mL antibody Isolation Cocktail before 125 μL/mL 
RapidSpheres™ were added to the mix and incubated for 10 min at room temperature. Lastly, 
cells were placed into the Easysep Magnet (Stemcell Technologies) for 2.5 min at room 
temperature, and unbound T-cells were collected in new tubes. Finally, cells were counted, 
resuspended in PBS, and 1 x106 cells were intravenously injected. T-cells were isolated from 
2-3 mice and pooled together for injection. On day 2, frozen splenocytes from TCL1 AT were 
retrieved and T-cell depleted using CD90.2 beads (CD90.2 MicroBeads, 130-121-278) 
following the provider’s recommendations. First, thawed cells were washed by centrifugation 
at 300 g for 5 min and resuspended in PBS. Next, cells were resuspended in ice-cold MACS 
buffer (90 μL per 1 x107 cells) and incubated with CD90.2 beads (10 μL per 1 x107 cells) for 
15 min at 4 °C. Excess beads were removed by addition of MACS buffer and centrifugation at 
300 g for 5 min before adjusting cell concentration to 0.5 x108 cells/mL. Thereafter, the cell 
suspension was applied onto a magnetic LS column (Miltenyi Biotec, 130-042-401) located in 
a QuadroMACS Separator (Miltenyi Biotec) and the run-through solution containing non-T-
cells was collected in a new tube. Finally, cells were counted, adjusted to a concentration of 5 
x107 cells/mL and 100 μL of cell suspension were injected intravenously in 6-8 weeks old Rag2-
/- female mice. The purity of both T-cells and tumor cells was typically above 90 %, as assessed 
by fluorescence-activated cell sorting (FACS) immunostaining. Tumor and T-cell expansion in 
Rag2-/- mice was measured weekly by submandibular blood withdrawal and subsequent whole-
blood FACS staining, as detailed in Section 3.2.3.3. Mice were closely monitored for disease 
symptoms and were sacrificed at the study endpoint, 4-5 weeks after AT, by increasing CO2 
concentration. Spleen and inguinal LNs were dissected and processed as described in Section 
3.2.2.5.  
 
3.2.2.4 Generation of Eomes bone marrow chimeric mice 
Rag2-/- mice, which lack mature T- and B-cells (Shinkai et al. 1992), were used as recipient 
for the generation of BM chimera, as it was previously observed that irradiation does not 
entirely deplete T-cells in host C57BL/6 mice, resulting in incomplete chimerism in the T-cell 
compartment of C57BL/6 chimera (data not shown, inhouse observation). Mice were subjected 
to whole-body irradiation in a Gammacell 40 Exactor (Best Theratronics) receiving two doses 
of 550 Rad at two time points 3 h apart. The following day, lethally irradiated Rag2-/- mice were 
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reconstituted with BM cells from Eomes-/- or Eomes+/+ mice. BM cell suspensions were 
prepared as follows: Eomes-/- and Eomes+/+ mice were sacrificed, their femurs and tibias were 
dissected, and BM cells were flashed out by injection of PBS + 2 % FBS into the bone marrow 
with a 25 G needle. For removal of cell clumps and generation of single-cell suspensions, cells 
were filtered through a 70 μm cell strainer (Corning, 352350), and subsequently washed once 
by centrifuging at 300 g for 5 min and resuspending in PBS + 2 % FBS. Next, mature T-cells 
were depleted by incubation with CD90.2 beads (CD90.2 MicroBeads, Miltenyi Biotec, 130-
121-278) and subsequent column-based magnetic cell isolation strictly applying 
manufacturer’s instructions. Cells were washed with PBS and centrifuged at 300 g for 5 min 
prior to incubation with CD90.2 beads (10 μL per 1 x107 cells) in MACS buffer (90 μL per 1 
x107 cells, Miltenyi Biotec, 130-091-221) for 15 min at 4 °C. After a washing step, cells were 
resuspended at a concentration of 0.5 x108 cells/mL in MACS buffer and applied to a LS 
column placed in a QuadroMACS Separator (Miltenyi Biotec). Non-labeled cells flowing 
through the column were collected, centrifuged and resuspended in PBS to adjust the 
concentration at 2.5 x107 cells/mL. Finally, 200 μL of the cell suspension were intravenously 
injected into Rag2-/- mice. After BM transplantation, mice were provided for 3 weeks with soft 
food and water containing 400 mg/mL antibiotic Cotrim K (contains Trimethoprim and 
sulfamethoxazole, Ratiopharm, 3788230) to prevent infections. Four weeks later, complete 
BM reconstitution was evaluated by FACS immunostaining of major immune cell types present 
in peripheral blood (as assessed by CD3, CD19, CD4, CD8, CD11b, CX3CR1, and CD45). 
Once complete chimerism was achieved, i.e. 6 weeks after BM injection, leukemia cells were 
retrieved from frozen TCL1 AT splenocytes and depleted of T-cells using CD90.2 beads 
(CD90.2 MicroBeads, Miltenyi Biotec, 130-121-278) as detailed above. The resulting cell 
suspension was adjusted to a concentration of 5 x107 cell/mL and 100 μL were i.p. transferred 
to mice. Tumor growth was monitored every second week by peripheral blood immunostaining, 
as explained in Section 3.2.3.3. At the experimental endpoint, mice were sacrificed by 
increasing CO2 concentration and spleens were dissected to be processed (see Section 
3.2.2.5) and immunostained for FACS analysis (see 3.2.3.3). 
 
3.2.2.5 Mouse organ collection and processing 
PB was obtained via submandibular vein or cardiac puncture, collected in 
ethylenediaminetetraacetic acid (EDTA)-coated tubes (Greiner Bio-one, 450532) and stained 
for FACS analysis as described in Section 3.2.3.3.  
Dissected inguinal LNs were dissociated using a 70 µm Falcon Cell strainer (Corning, 
352350) and single cells were collected in tubes with PBS supplemented with 2 % FBS. Cells 
were counted and centrifuged for 5 min at 300 g in order to be subsequently resuspended in 
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PBS containing 2 % FBS at a concentration of 3 x107 viable cells/mL for immunostainings (see 
Section 3.2.3.1).  
Spleens were collected in Gentle MACS tubes C (Miltenyi Biotec, 130-093-237) with RPMI 
medium (Sigma-Aldrich, R8758) supplemented with 10 % FBS and 1 % P/S and single-cell 
suspensions were generated with a gentleMACS tissue dissociator (Miltenyi Biotec). 
Erythrocytes were lysed by incubation with red blood cell (RBC) Lysis Buffer (Biolegend, 
420301) for 5 min at room temperature. The reaction was stopped by addition of PBS and cells 
were centrifuged at 300 g for 5 min. For removal of clumps, cells resuspended in ice-cold PBS 
were filtered through a 70 μm cell strainer (Corning, 352350). After counting, the cell 
concentration was adjusted according to the subsequent use: for immunostainings to 3 x107 
cells/mL in FACS buffer (PBS + 2 % FBS) (see Sections 3.2.3.1 and 3.2.3.2), or for 
cryopreservation in liquid nitrogen to 1 x108 cells/mL in freezing media (90 % FBS + 10 % 
DMSO).  
 
3.2.3 Flow Cytometry analysis 
3.2.3.1 Cell surface staining 
Single-cell suspensions were immunostained with antibodies against cell surface proteins 
(Table 4) in FACS buffer containing 0.1 % fixable viability dye (Thermo Fisher Scientific, 65-
0866-14) for 30 min at 4 °C. Cells were subsequently washed twice by centrifuging at 300 g 
for 5 min and resuspending in FACS buffer. When direct analysis was not possible, cells were 
fixed with IC fixation buffer (Thermo Fisher Scientific, 00-8222-49) for 30 min at room 
temperature, washed twice with FACS buffer, and stored in FACS buffer at 4 °C in dark 
conditions until being analyzed by flow cytometry. 
 
3.2.3.2 Staining of intracellular proteins and transcription factors  
For transcription factor or intracellular cytokine staining, cell surface-stained cells were fixed 
for 30 min at room temperature with Foxp3 fixation/permeabilization buffer (Thermo Fisher 
Scientific, 00-5523-00). After a washing step with FACS buffer, cells were permeabilized for 
30 min at room temperature with 1X permeabilization buffer (Thermo Fisher Scientific, 00-
8333-56). Intracellular staining with antibodies against transcription factors or cytokines (Table 
4) was performed in 1X permeabilization buffer for 30 min at room temperature. Excess 
antibodies were washed twice with 1X permeabilization buffer and cells were resuspended in 
1X permeabilization buffer and stored at 4°C in dark conditions until they were analyzed by 
flow cytometry. 
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3.2.3.3 Whole-blood staining 
In order to analyze peripheral blood of mice by FACS immunostaining, 25 µL of blood were 
stained with antibodies against cell surface proteins (Table 4) for 30 min at 4 °C. Blood was 
then incubated with 2 mL of 1X 1-Step Fix/Lyse Solution (Thermo Fisher Scientific, 00-5333-
57) for 15 min at room temperature in dark conditions for erythrocytes lysis and cell fixation. 
Cells were spun down at 600 g, and the pellet was resuspended in 150 µL of PBS. To obtain 
absolute cell numbers, 25 µL of 123count eBeads™ (Thermo Fisher Scientific, 01-1234-42) 
were added to the samples right before flow cytometric measurement. Absolute cell numbers 







3.2.3.4 Cell sorting 
Single-cell suspensions from LNs of CLL patients were retrieved by partially thawing vials 
of cryopreserved cells in order to preserve unused cells. Single-cell suspensions from TCL1 
AT splenocytes were prepared as detailed in Section 3.2.2.5. Samples were stained for cell 
surface proteins for 30 min. After two washing steps with PBS, cells were resuspended in PBS 
+ 5 % FBS containing 0.2 µg/mL 4’,6-diamidino-2-phenylindole (DAPI) prior cell sorting. The 
gating strategy for CD3+ T-cell and CLL cell sorting is depicted in Figure 5. Cells were sorted 
in PBS + 2 % FBS using a BD FACSAriaTM II or BD FACSArisa Fusion (both from BD 
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Figure 5: Gating strategy for FACS sorting of CLL cells and CD3+ T-cells from human 
LN and murine spleen. Cell debris (identified by SSC-A vs. FSC-A) and doublets (identified 
by FSC-H vs. FSC-A) were first excluded followed by selection of viable cells (cells negative 
for viability dye). Leukocytes were then selected (CD45+) and CLL cells were identified as 
CD5+ CD19+, and T-cells as CD3+ CD19-. 
3 Materials and Methods   3.2 Methods 
 59 
Biosciences) cell sorter with FACSDiva Software (BD Biosciences). The purity of cells after 
sorting was above 95 %. 
 
3.2.3.5 Data acquisition and analysis 
Cell fluorescence was assessed using a BD LSRFortessaTM or a FACS Canto II (both from 
BD Biosciences) flow cytometer, and data was analyzed using FlowJo X 10.0.7 software 
(FlowJo). In each experiment, single fluorochrome stainings were used to compensate for 
spectral overlap, which was corrected both before sample acquisition and when analyzing the 
data with FlowJo. Fluorescence minus one (FMO) controls were employed for proper gating 
of positive cell populations. FMO-normalized Mean Fluorescence Intensity (nMFI) for unimodal 
distributions or percentage of positive cells for bimodal distributions were determined for 
populations of interest. The standard gating strategy for analysis of CLL cells and T-cells is 
depicted in Figure 6. 
 
 
Figure 6: Gating strategy for T-cell subsets and tumor identification from murine spleen. 
(A) Gating of leukocytes was performed by exclusion of cell debris (identified by SSC-A vs. 
FSC-A) and doublets (identified by FSC-H vs. FSC-A), selection of live cells (cells negative for 
viability dye) and selection of CD45+ cells (SSC-A vs. CD45+). (B) T-cell gating was performed 
on leukocytes and based on CD3+ CD8+ for CD8+ T-cells as exemplified, or CD3+ CD4+ for 
CD4+ T-cells. Naïve (CD127+ CD44-), memory (CD127+ CD44+) and effector (CD127- CD44+) 
cell subsets were identified as well. (C) CLL cells were gated as CD5+ CD19+ cells after 
leukocyte selection. 
 
3.2.4 Ex vivo T-cell functional assays 
Single-cell suspensions of mouse splenocytes were resuspended in DMEM medium 
(Sigma-Aldrich, D6046) supplemented with 10 % FBS (Sigma-Aldrich, F7524), 100 µg/mL P/S 
(Thermo Fisher Scientific, 15140122), 2mM L-glutamine (Thermo Fisher Scientific, 25030024), 
10 mM Hydroxyetyl-Piperazineethane-Solfonic Acid (HEPES, Thermo Fisher Scientific, 
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15630056), 55 µM ß-mercaptoethanol (Thermo Fisher Scientific, 21985-023), 1 mM sodium 
pyruvate (Thermo Fisher Scientific, 11360039) and 100 µM non-essential amino acids 
(Thermo Fisher Scientific, 11140035), at a concentration of 3x107 cells/mL. Cells were seeded 
in 96-well plates and cultured with cell stimulation cocktail (Thermo Fisher Scientific, 00-4970-
93) and protein transport inhibitor cocktail (Thermo Fisher Scientific, 00-4980-93) for 6 h at 
37°C and 5 % CO2. CD107a antibody (Thermo Fisher Scientific, 12-1071-83) was added to 
the culture for assessment of degranulation capacity. Next, cells were washed twice with FACS 
buffer and immunostained for cell surface and intracellular proteins as described in Section 
3.2.3.2. 
 
3.2.5 Identification of chromatin states and RNA-seq tracks of the EOMES locus 
Chromatin immunoprecipitation sequencing (ChIP-seq) data from antibodies detecting 
histone modifications H3K4me, H3K4me1m, H3K27ac, H3K36me3, H3K27me3, and 
H3K9me3 was downloaded from the Blueprint Epigenome Consortium (The BLUEPRINT 
Consortium 2016, www.blueprint-epigenome.eu) for the following cell types: CD8+ memory T-
cells, CD8+ T-cells, CD4+ memory T-cells, CD4+ T-cells, NK cells, naïve B-cells, germinal 
center (GC) B-cells, memory B-cells, plasma cells, mature neutrophils, eosinophils and 
monocytes. Chromatin state assignment was performed using the chromHMM pipeline (Ernst 
and Kellis 2012; Beekman et al. 2018), and all profiles were corrected using their 
corresponding input. Each chromatin state was assigned for a 200 bp window. In addition, 
.bigWig tracks from the above-mentioned cell subtypes were downloaded from the Blueprint 
Epigenome Consortium, and aligned to the GRCh38 genome using unique mappings. The 
chromatin state assignments and RNA-seq alignments were performed by Dr. Vicente 
Chapaprieta from the Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS, 
Barcelona). 
 
3.2.6 Mass Cytometry by Time of Flight (CyTOF) analysis  
Sample preparation, data acquisition and initial data processing described in 3.2.6.1, 
3.2.6.2, and 3.2.6.3 were performed by Dr. Marina Wierz from the Department of Oncology in 
the Luxembourg Institute of Health (LIH, Luxembourg) as part of a cooperation project. 
 
3.2.6.1 CyTOF panel and metal labeling of antibodies 
A panel of 42 heavy metal-labeled antibodies for detection of both surface and intracellular 
proteins was adopted from Bengsch et al. and modified based on literature research in order 
to characterize diverse T-cell phenotypes (Bengsch et al. 2018). The complete list of proteins 
detected and the heavy metal-conjugated antibodies used are listed in Table 3. Where no 
heavy metal-conjugated antibodies were commercially available, coupling of heavy metal to 
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respective antibodies was performed using the Maxpar® X8 Multimetal Labeling kit (Fluidigm, 
201300) following the manufacturer’s instructions. 
 
3.2.6.2 Sample preparation 
Frozen cell suspensions were thawed and washed prior to incubation in 15 mL of pre-
heated RPMI 1640 (Sigma-Aldrich, R8758) containing 10 % FBS (Sigma-Aldrich, F7524) in a 
roller incubator for 30 min at room temperature. Cells were filtered through a 100 µm cell 
strainer (CellTrics, 04-004-2328) to remove dead cells. Next, B-cell depletion was performed 
using human CD19 microbead (Miltenyi Biotec, 130-050-301) labeling according to the 
manufacturer’s protocol. In brief, cells were incubated with CD19 Microbeads for 15 min at 4 
°C, washed, resuspended in MACS buffer (Miltenyi, 130-091-221) and loaded onto MACS® 
LS Columns (Miltenyi Biotec, 130-042-401) placed in a MidiMACSTM Separator (Miltenyi 
Biotec). Finally, the flow-through fraction containing unlabeled CD19- cells was collected, 
washed in MACS buffer, filtered through a 70 µm cell MACS SMartStrainer (Miltenyi Bitec, 
130-098-462), and counted prior to mass cytometry processing. 
 
3.2.6.3 Cell staining and CyTOF sample acquisition 
CD19-depleted single-cell suspensions were stained as previously described (Wierz et al. 
2018). Briefly, cells were stained with 5 µM cisplatin (Cell-ID Cisplatin, Fluidigm, 201064) for 5 
min in order to label dead cells. Cells were then washed with PBS + 0.5 % FBS and centrifuged 
at 500 g for 10 min. Cell surface staining was performed by adding the antibody-cocktail and 
incubating for 30 min at room temperature. After a washing step, cells were fixed with 
Fixation/Permeabilization buffer (Thermo Fisher Scientific, 88-8824-00) following the 
manufacturer’s instructions. Intracellular staining was performed by incubating the antibody-
cocktail for 30 min at room temperature. After a washing step, cells were stained with cell-ID 
Intercalator-Ir (Fluidigm, 201192A) in fixation and permeabilization solution, followed by 
another two washing steps with PBS and ddH2O, respectively. Prior to acquisition, cells were 
resuspended at a concentration of 5 x 105 cells/mL in ddH2O with 1:10 calibration beads (EQ 
Four Element Calibration Beads, Fluidigm, 201078). Samples were analyzed at a flow rate of 
0.03 mL/min with the Helios mass cytometer (Fluidigm) at the National Cytometry Platform 
(NCP) of the Luxembourg Institute of Health (LIH, Luxembourg). Initial data processing and 
quality control were performed by the NCP, where flow cytometry standard (FCS) files were 
normalized with EQ beads using the HELIOS instrument acquisition software (Fluidigm, 
version 6.7.1014). 
As a first analysis step, samples were pre-gated as follows: gates were placed on cells 
(Beads vs. Ir191), singlets (Ir193 vs. Ir191) and live cells (Pt195-). Next, non-B immune cells 
(CD19- CD45+) and CD3+ T-cells (CD3+ NCAM-) were selected, and finally, either CD4+ or 
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CD8+ (CD4+ vs. CD8+) cells were gated and exported as .fcs files. CD4+ and CD8+ cells were 
further analyzed in close collaboration with Dr. Yashna Paul. The present study focuses on the 
analysis of CD8+ T-cells, whereas a detailed investigation of the CD4+ T-cell dataset can be 
found elsewhere (Paul 2020). 
 
3.2.6.4 Mass cytometry data processing and sample clustering 
All raw data .fcs files together with their metadata files containing sample ID and staining 
information were merged into a flowSet object using flowCore package (Hahne et al. 2009). 
Signal intensities for each marker were arcsinh-transformed using a co-factor of 5 (default) 
(Bruggner et al. 2014). Sample quality was assessed based on library size per sample and an 
analysis of cell counts, with the later ranging from 333 to 1.57 x 105 cells. Multi-dimension 
scaling (MDS) plotting using median arcsinh-transformed marker expression for all cells in 
each sample was used for sample clustering analysis. Data processing and analysis was 
performed by Dr. Yashna Paul from the Molecular Genetics Division (B060) in the German 
Cancer Research Center (DKFZ, Heidelberg).  
 
3.2.6.5 Mass cytometry single-cell clustering  
Cytometry data analysis tools (CATALYST, (Chevrier et al. 2018)) R package containing 
FlowSOM (Van Gassen et al. 2015) and ConsensusClusterPlus (Wilkerson and Hayes 2010) 
metaclustering methods was used for cell cluster identification using all cells from all samples. 
Clustering was performed using arcsinh-transformed expression of 32 markers, i.e., excluding 
the markers that were utilized for cell population gating. The maximum number of clusters 
allowed to be evaluated was set to maxK = 14, after biological relevance of obtained clusters 
was assessed, and k < 14 and k > 14 were verified to be underfitting or overfitting, respectively. 
Cell clustering was visualized using a t-distributed stochastic neighbor embedding (t-SNE) 
algorithm, displaying 1 x103 random cells from each sample in order to reduce computation 
time. The robustness of this approach was evaluated by repeatedly plotting an increasing 
number of randomly picked cells from each sample, with a range of 200 to 1,000 cells, and 
evaluating the similarity of the 14 subpopulations recognized in the respective t-SNE plots. 
Bioinformatic data analysis was performed in collaboration with Dr. Yashna Paul. For cell 
subset annotation, combined expression of lineage markers as well as unique expression of 
activation and exhaustion-related markers was considered.  
 
3.2.6.6 Correlation of cluster proportions with clinical data 
The clinical data summarized in Table 1 was correlated with the cluster abundance for every 
CLL patient sample. Briefly, the following clinical parameters were categorized into the 
following balanced sets: sex (female/ male), IGHV mutation status (mutated/ unmutated), Binet 
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stage (A/ B, C), Rai stage (0, I/ II, III, IV), time to first treatment (> 16.4 months/ <16.4 months), 
and treatment status (treated/ untreated). Next, the enrichment or depletion of clusters in each 
condition was calculated using a Mann-Whitney U test. Additionally, the parameters age, % of 
tumor cells, and time to first treatment were correlated with cluster abundances using Pearson 
correlations. 
 
3.2.7 Single-cell transcriptome analyses  
3.2.7.1 Single-cell RNA sequencing of CD3+ T-cells from lymph nodes of CLL patients 
Three CLL LN samples were processed for single-cell RNA sequencing. CD3+ T-cells and 
CLL cells from these samples were sorted as described in Section 3.2.3.4, and single-cell 
transcriptomes were generated using the Chromium Next GEM Single Cell V(D)J Reagent Kits 
v1.1 (10x Genomics, PN-1000167, PN-1000020, PN-1000005, PN-1000127, PN-1000213) 
following the manufacturer’s protocol. Briefly, for a target cell recovery of 5,000 cells, the 
concentration of T-cells was adjusted to 1 x103 cells/µL and tumor cells were added at a ratio 
of 1:20. Cells were then loaded into the Single Cell A Chip (Chromium™ Single Cell A Chip 
Kit, 10x Genomics, PN-1000009) together with Reverse Transcription (RT) Master Mix (10x 
Genomics, PN-1000011). Gel beads (10x Genomics, PN-1000010) and partitioning oil (10x 
Genomics, PN-1000009) were subsequently loaded into respective wells of the chip, before 
placing it into the Chromium Controller (10x Genomics). In the Chromium Controller, nanoliter 
scale Gel Beads-in-emulsion (GEMs) are generated, each containing a single cell. Inside the 
GEM, the cell is lysed and its polyadenylated transcripts bind the barcoded bead. Such 
barcodes consist of a unique 10 nucleotide sequence named unique molecular identifier (UMI), 
which are later used during the data analysis process to link each transcript to its respective 
cell. 
Next, GEMs were retrieved from the chip, placed in PCR tubes, and reverse transcription 
of poly-adenylated mRNA was performed in a thermal cycler (Bio-Rad Laboratories) with the 
following protocol: 
Step Temperature Time (hh:mm:ss) 
1 53 °C 00:45:00 
2 85 °C 00:05:00 
3 4 °C Hold 
 
GEMs were subsequently broken by addition of Recovery Agent (10x Genomics, PN-
1000009), and pooled cDNA was purified from GEM-RT reaction mixture as follows: 
Dynabeads Cleanup Mix (10x Genomics, PN-2000048) were added, and a 10x Magnetic 
Separator (10x Genomics) was used to pool beads for removal of supernatant containing 
GEM-RT reagents. After washing with 80 % ethanol, Elution Solution I (10x Genomics, PN-
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1000011) was added for recovery of 5’ Gene Expression (GEX) cDNA. Full length GEX cDNA 
was subsequently amplified by adding cDNA Amplification Mix (10x Genomics, PN-1000011) 
and incubated in a thermal cycler following the protocol below. 
Step Temperature Time (hh:mm:ss) 
1 98 °C 00:00:45 
2 98 °C 00:00:20 
3 67 °C 00:00:30 
4 72 °C 00:01:00 
5 Go to Step 2, 13x (14 cycles) 
6 72 °C 00:01:00 
7 4 °C Hold 
 
Amplified GEX cDNA was purified using Agencourt AMPure beads (Beckman Coulter, 
A63881) and 80 % ethanol in a 10x Magnetic Separator (10x Genomics, PN-230003) before 
proceeding to quality control (QC) and quantification in a 4200 TapeStation (Agilent 
Technologies). Next, 2 µL cDNA were transferred to new tubes for target enrichment of V(D)J 
segments via PCR amplification using CDR3 region-specific primers (10x Genomics, PN- 
1000005). In brief, Target Enrichment 1 Reaction Mix (10x Genomics, PN-1000011 and 
1000005) was added and samples were incubated in a thermal cycler with the following 
protocol: 
Step Temperature Time (hh:mm:ss) 
1 98 °C 00:00:45 
2 98 °C 00:00:20 
3 67 °C 00:00:30 
4 72 °C 00:01:00 
5 Go to Step 2, 9x (10 cycles) 
 
6 72 °C 00:01:00 
7 4 °C Hold 
 
Amplified V(D)J-enriched cDNA was then cleaned using Agencourt AMPure beads and 80 
% ethanol in a 10x Magnetic Separator prior to the addition of Target Enrichment 2 Reaction 
Mix (10x Genomics, PN-1000011 and 1000005) and incubating in a thermal cycler using the 
protocol listed as above. Enriched cDNA was cleaned, and size selected using Agencourt 
AMPure beads and 80 % ethanol in a 10x Magnetic Separator prior to QC and quantification 
in a 4200 TapeStation (Agilent Technologies). Library preparation from 50 ng of V(D)J-
enriched cDNA was performed by adding Fragmentation Mix (10x Genomics, PN-1000011) to 
the samples and placing them into a thermal cycler with the following settings: 
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Step Temperature Time (hh:mm:ss) 
Fragmentation 32 °C 00:02:00 
End Repair & A-tailing 65 °C 00:30:00 
Hold 4 °C Hold 
 
Subsequently, Adaptor Ligation Mix (10x Genomics, PN-1000011) was added and samples 
were further incubated as detailed: 
Step Temperature Time (hh:mm:ss) 
1 20 °C 00:15:00 
2 4 °C Hold 
 
Reaction reagents were removed using Agencourt AMPure beads and 80 % ethanol in a 
10x Magnetic Separator, and Sample Index PCR Mix (10x Genomics, PN-1000011 and PN-
120262) was added prior to incubation in a thermal cycler with the following settings: 
Step Temperature Time (hh:mm:ss) 
1 98 °C 00:00:45 
2 98 °C 00:00:20 
3 54 °C 00:00:30 
4 72 °C 00:00:20 
5 Go to Step 2, 8x (9 cycles) 
6 72 °C 00:01:00 
7 4 °C Hold 
 
The library was cleaned up with Agencourt AMPure beads and 80 % ethanol in a 10x 
Magnetic Separator, and final QC and quantification were performed before sequencing. 
 
For library construction of GEX cDNA, Fragmentation Mix was added to 50 ng of sample, 
and the resulting mixture was incubated in a thermal cycler as follows: 
Step Temperature Time (hh:mm:ss) 
Fragmentation 32 °C 00:05:00 
End Repair & A-tailing 65 °C 00:30:00 
Hold 4 °C Hold 
 
Samples were next size-selected using Agencourt AMPure beads and 80 % ethanol in a 
10x Magnetic Separator, prior to addition of Adaptor Ligation Mix and incubation in a thermal 
cycler with the following settings: 
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Step Temperature Time (hh:mm:ss) 
1 20 °C 00:15:00 
2 4 °C Hold 
   
A cleaning step using Agencourt AMPure beads and 80 % ethanol in a 10x Magnetic 
Separator was performed before adding Sample Index PCR Mix and incubating in a thermal 
cycler with the following settings: 
Step Temperature Time (hh:mm:ss) 
1 98 °C 00:00:45 
2 98 °C 00:00:20 
3 54 °C 00:00:30 
4 72 °C 00:00:20 
5 Go to Step 2, 15x (16 cycles) 
6 72 °C 00:01:00 
7 4 °C Hold 
 
Constructed libraries were purified by using Agencourt AMPure beads and 80 % ethanol in 
a 10x Magnetic Separator, and QC was performed before sequencing. 
GEX libraries were sequenced on a HiSeq 4000 machine (Illumina) using a Paired-End (26 
+ 74 bp) setup or on a NovaSeq 6000 (Illumina) with a Paired-End (28+94 bp) S1 setup, and 
V(D)J-enriched libraries were sequenced on a NextSeq 550 (Illumina) using a Paired-End (150 
bp) configuration at the High Throughput Sequencing Unit of the Genomics and Proteomics 
Core Facility at the German Cancer Research Center (DKFZ, Heidelberg). 
 
3.2.7.2 Single-cell RNA sequencing of CD3+ T-cells from splenocytes of TCL1 AT 
mouse model 
Two TCL1 AT mouse spleen samples were processed for single-cell RNA sequencing. Mice 
were euthanized and dissected spleens were processed as described in Section 3.2.2.5. 
Samples were subsequently FACS-sorted as described in Section 3.2.3.4. Sorted CD3+ T-
cells were resuspended to a concentration of 1 x103 cells/mL and tumor cells were added at a 
ratio of 1:20. Single-cell transcriptomes were generated using the Chromium Single Cell V(D)J 
Reagent Kits (10X Genomics, PN-1000014, PN-1000020, PN-1000071, PN-1000009 and PN-
120262) following the manufacturer’s instructions. The utilized protocol is detailed in Section 
3.2.7.1 with a minor modification: Target Enrichment 1 Reaction Mix and Target Enrichment 2 
Reaction Mix (both from 10x Genomics, PN-1000011) contained mouse-specific primers for 
V(D)J region amplification (10x Genomics, PN-1000071). GEX libraries were sequenced on a 
NovaSeq 6000 machine (Illumina) with a Paired-End (28+94 bp) S1 setup, and V(D)J-enriched 
libraries were sequenced on a NextSeq 550 (Illumina) using a Paired-End (150 bp) setup at 
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the High Throughput Sequencing Unit of the Genomics and Proteomics Core Facility at the 
German Cancer Research Center (DKFZ, Heidelberg). 
 
3.2.7.3 Data processing, dimensional reduction, cell cluster visualization and 
identification of differentially expressed genes 
Raw reads in .fastq format were aligned to the GRCh38 human reference genome or mm10 
mouse reference genome using the Cell Ranger pipeline (10x Genomics). Sparse count 
matrices for each sample were generated as output files, as well as a quality control report, 
including the estimated number of cells sequenced, mean reads per cell, median genes per 
cell, and Q30 quality score. 
For data normalization, scaling and dimensionality reduction and cell clustering, the Seurat 
v3 toolkit (Butler et al. 2018; Stuart et al. 2019) in R3.5 (The R Fundation, version 3.5) was 
used. First, cells with low-quality data were removed based on the number of genes expressed 
and mitochondrial gene content. Specifically, cells with < 200 genes and cells with > 3,000 
genes, which were considered doublets, as well as cells with > 10 % mitochondrial genes were 
removed. In addition, genes present in < 2 cells were excluded for downstream analysis. 
Hereafter, datasets of the same species (i.e. the three human datasets and the two mouse 
datasets) were merged, and data was transformed and normalized utilizing SCTransform() 
function. Per default the 3,000 most variable genes from each sample were identified and 
considered for canonical correlation analysis (CCA) using the RunCCA() function, and merged 
data sets were integrated into a new dimensional reduction space. The 3,000 most variable 
genes were next selected for principal component (PC) analysis via RunPCA() function. 
Between 15 – 18 PCs were considered for further cell clustering. Using the FindNeighbors() 
function, a shared nearest neighbor graph (SNN) was created, and a hierarchical clustering 
using Louvain algorithm was generated with the FindClusters() function, with the resolution 
parameter set to 0.6. Non-linear dimensional reduction using t-SNE was performed in order to 
visualize the datasets. Finally, FindMarkers() and FindAllMarkers() functions using the non-
parametric Wilcoxon rank sum test identified differentially expressed genes for each cluster, 
with an adjusted (Bonferroni correction) p-value of 0.05 set for considering significance. 
Bioinformatic processing and analysis of the data was performed by Dr. Yashna Paul.  
 
3.2.7.4 Computational separation of CD3+ T-cells into CD8+ and CD4+ cells 
In addition to analysis and cell clustering of total CD3+ T-cells, computational separation of 
CD8+ and CD4+ T-cells was carried out in order to perform a re-clustering and identify further 
cell subsets. For the human CLL LN dataset, cell splitting was performed selecting CD8A- and 
CD4-expressing clusters. For splitting CD8+ and CD4+ cells present in the same cluster, the 
Seurat function CellSelector() was used. The TCL1 AT mouse dataset comprised multiple 
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clusters containing both CD4+ and CD8+ cells, which required cell separation based on a 
calculation of pairwise distances between gene counts and centroids of the 3,000 most 
variable genes between CD4+ and CD8+ specific clusters. Bioinformatic cell separation was 
performed by Dr. Yashna Paul. 
 
3.2.7.5 V(D)J T-cell analysis 
V(D)J transcripts from single cells were aligned and counted using the Cell Ranger pipeline, 
which also generated a quality control report providing the approximate number of cells 
analyzed, mean read pairs per cell, a number of cells with a productive V-J spanning pair, as 
well as a Q30 quality score. In addition, an output file containing TCR α- and β-chain CDR3 
nucleotide sequences and a cell barcode for all single cells was generated. Only productive 
rearrangements were evaluated, and 3 or more cells containing the same α- and β-chain CDR3 
consensus nucleotide sequences were considered cell clones. Because both V(D)J transcripts 
and gene expression data contained common cell barcode IDs, the Seurat workflow allowed 
the mapping of the TCR information into the single-cell t-SNEs. Bioinformatic pipelines for this 
analysis were implemented by Dr. Yashna Paul. 
The VDJdb browser (Bagaev et al. 2020) was used in order to identify CDR3 regions from 
the V(D)J single-cell dataset whose antigen-specificity has been reported. Both TCR α- and β-
chain CDR3 amino acid sequences of the 10 most abundant clones from each sample were 
used for the literature analysis aimed at identifying previously described binding epitopes. 
 
3.2.7.6 Intercellular communication analysis by CellPhoneDB  
The CellPhoneDB pipeline (Vento-Tormo et al. 2018; Efremova et al. 2020) was used in 
order to determine intercellular communications between the identified clusters. A count matrix 
file containing gene expression values for each cell, and a count meta file with cell type 
annotations were used as input, while only considering those genes, for which at least 10 % 
of cells expressed it. The number of statistical iterations was set to 10, and a p-value < 0.05 
was considered significant when determining whether a given interaction is cell-type-specific. 
The bioinformatic pipeline for CellPhoneDB analysis was implemented in collaboration with Dr. 
Murat Iskar from the Molecular Genetics Division (B060) at the German Cancer Research 
Center (DKFZ, Heidelberg). 
 
3.2.8 Correlation between CD8+ T-cells clusters from single-cell RNA 
sequencing and mass cytometry 
For correlating the CD8+ T-cells clusters identified with both single-cell RNA-seq and mass 
cytometry experiments, only the genes and proteins common in both datasets were 
considered. Next, the average profiles per cluster were calculated and these values were 
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mean-centered in comparison to all clusters defined for each of the datasets. The Pearson 
correlation coefficient was next calculated for each pair of mass cytometry versus single-cell 
RNA-seq clusters to identify the most similar between the two datasets. The bioinformatic 
pipeline for subset correlation was programmed by Dr. Murat Iskar from the Molecular Genetics 
Division (B060) at the German Cancer Research Center (DKFZ, Heidelberg). 
 
3.2.9 Statistical analysis 
The Mann-Whitney U test was used to investigate significant differences between two 
groups, while one-way analysis of variance (ANOVA) was used to determine differences 
between more than two groups. Pearson correlation was applied to examine linear correlation 
between cluster proportions per patient and clinical information. All these tests were calculated 
using GraphPad Prism (GraphPad Software). The statistical test used in each case is indicated 
in the corresponding figure legend. A confidence interval of 95 % (p-value of < 0.05) was 
considered for rejection of the null hypothesis. 
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4 Results 
 Dissecting the CD8+ T-cell compartment of CLL using mass 
cytometry and single-cell RNA-seq analyses 
Single-cell technologies are increasingly being used to decipher the complexity of the tumor 
microenvironment of numerous cancers (Tirosh et al. 2016; Zheng et al. 2017; Azizi et al. 2018; 
Guo et al. 2018). The use of such methodologies has revealed a considerable heterogeneity 
of T-cell phenotypes within and between patients (Chevrier et al. 2017; Li et al. 2019; Wagner 
et al. 2019), the understanding of which is crucial to better predict therapy response. In order 
to comprehensively characterize the T-cell compartment associated with CLL, a large-scale 
and high-dimensional analysis of T-cells from CLL patients as well as healthy controls (HC) 
was conducted using both single-cell immunophenotype and transcriptome analyses. 
Specifically, CLL lymph nodes (LNs) together with paired peripheral blood (PB) and bone 
marrow (BM) samples, as well as reactive LNs (rLNs) from HC were investigated using mass 
cytometry with a panel of 42 antibodies. Additionally, single-cell RNA-seq analyses of T-cells 
from 3 CLL LN samples enabled the simultaneous study of their transcriptome and complete 
TCR sequences. The use of this approach facilitated the identification of diverse CLL T-cell 
subtypes with a distinct clonal expansion state, their association with clinical characteristics, 
and their potential cross-talk with tumor cells (Figure 7). This project was conducted in close 
collaboration with Dr. Yashna Paul, who focused her work on the description of the CD4+ T-
cells analyzed (Paul 2020). The present work concentrates on the examination of CD8+ T-
cells, and results obtained are explained in detail in the succeeding sections 4.2 and 4.3.  
Figure 7: Overview of the experimental design to characterize the T-cell compartment 
in CLL. Workflow detailing the processing and number of samples analyzed by single-cell 
RNA-seq and mass cytometry (CyTOF) techniques. The precise methodology used for data 
acquisition and analysis is described in Sections 3.2.6 and 3.2.7. HC = healthy controls, LN = 
lymph node, rLN = reactive lymph node, PB = peripheral blood, BM = bone marrow. 
4 Results   4.2 Global CD8+ T-cell profiling of CLL and control tissues by mass cytometry 
 72 
 Global CD8+ T-cell profiling of CLL and control tissues by mass 
cytometry 
Phenotypic alterations in the T-cell compartment in CLL patients have been extensively 
reported in PB samples (Totterman et al. 1989; Riches et al. 2013; Palma et al. 2017), but 
corresponding analyses are missing for LN tissue, despite the fact that it represents the main 
location of tumor-T-cell interactions (Burger 2011; Herishanu et al. 2011). To generate a 
complete characterization of the CD8+ T-cell landscape in CLL, 48 samples from CLL LNs, PB, 
BM, as well as rLN of individuals without cancer were investigated using time of flight mass 
spectrometry (CyTOF) with a panel of 42 antibodies. Sample processing and data acquisition 
was performed in collaboration with Dr. Marina Wierz, from Luxembourg Institute of Health 
(LIH), Luxembroug, while data processing and analysis was performed in collaboration with 
Dr. Yashna Paul from the German Research Center (DKFZ), Heidelberg. The analysis yielded 
approximately 1.35 x106 CD8+ T-cells, with a median of 1.11 x104 cells per sample. Using the 
t-SNE algorithm for dimensional reduction (Maaten and Hinton 2008), cells were classified into 
14 clusters which were annotated based on the differential expression of the detected markers 
(Figure 8A and B). The expression of CD45RA, CD45RO and C-C chemokine receptor type 
(CCR) 7 (CCR7) was measured for general T-cell classification, which resulted into 1 naïve 
(TN, CD45RA+, CD45RO-, CCR7+), 1 central memory (TCM, CD45RA-, CD45RO+, CCR7+), 6 
effector memory (TEM, CD45RA-, CD45RO+, CCR7-), and 2 effector (TEF, CD45RA+, CD45RO- , 
CCR7-) subsets. In addition, 3 CD4+ CD8+ double positive (DP) and 1 KI-67+ proliferating 
(Prolif.) clusters were identified. DP2 and PD3 subsets constituted less than 1 % of cells in all 
samples except for two samples, and were therefore not further examined. A more detailed 
analysis of the expression of several markers comprising co-stimulatory (CD244, ICOS, CD27, 
KLRG1, and OX-40) and inhibitory receptors (PD-1, TIGIT and CTLA-4), ectoenzymes (CD73, 
CD39 and CD38), transcription factors (TCF7, TOX, HELIOS, TBET and EOMES) and the 
cytokine GZMK, allowed the identification of several cell subsets, which were hierarchically 
clustered in three subgroups (Figure 8B).  
The first group comprised the two effector subsets, TEF1 and TEF2, and the effector memory 
subset TEM3. These were characterized by a moderate expression of TIGIT, KLRG1 and a high 
expression of the transcription factor TBET. In addition, TEF1 had higher expression levels of 
GZMK and CD27, while TEF2 presented greater expression of both TBET and HELIOS TFs 
(Figure 8B).  
The second group was comprised of subsets with a distinctive high expression of IL7R, 
CCR7 and TCF7, and no expression of activation or exhaustion markers, as expected for naïve 
and central memory cells (Gattinoni et al. 2017). Notably, two effector memory subsets 
presented a similar expression pattern but with significant differences between each other. 
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While TEM4 contained cells with specifically high levels of ICOS and some GZMK expression, 
the other cluster was characterized by the expression of CD25, CTLA-4, as well as CXCR5, 
and was subsequently defined as a subset of follicular CD8+ cells (TFC) (Yu and Ye 2018). 
Interestingly, TFC cells exhibited intermediate expression of both inhibitory and co-stimulatory 
receptors, as well as naïve-related markers like TCF7, CCR7 and IL7R (Figure 8B).  
Figure 8: CD8+ T-cell landscape of CLL patients. (A) t-SNE plot of the 14 clusters identified 
with all analyzed samples. 1 x103 cells of each sample are depicted. (B) Heatmap showing 
median (arcsinh-transformed) protein expression of the 30 markers considered (columns) for 
each cluster (rows) identified. Both markers and clusters were grouped based on hierarchical 
clustering (with Pearson correlation and complete linkage). The three groups of clusters are 
indicated. (C) Hierarchical clustering (with Pearson correlation and complete linkage) of 
samples based on the CD8+ T-cell subset abundances in each sample. The five groups of 
samples identified are indicated. Cell subsets are color-coded as defined in (A). Row 
annotations (left) indicate sample condition (tumor or control), tissue of origin (BM, bone 
marrow, LN, lymph node, and PB, peripheral blood), tumor load (TL), IGHV mutation status 
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The third group was characterized by clusters with an intermediate to high expression of 
exhaustion markers including PD-1, TIGIT, CD39, CD38, FAS, TOX and EOMES. More 
specifically, TEM1 and TEM2 GZMK+ clusters presented moderate levels for these proteins and 
higher expression of GZMK, resembling a pre-dysfunctional effector memory population that 
expresses GZMK as well as intermediate levels of inhibitory molecules. The third cluster was 
defined as exhausted (TEX) based on the higher expression of PD-1, TIGIT, and CD39 (McLane 
et al. 2019). Of note, proliferating cells had a very similar phenotype to TEX cells, suggesting 
they could constitute a dividing subset of these cells. Intriguingly, DP1 cells expressed the 
highest levels of exhaustion markers (i.e. PD-1, FAS; TIGIT, TOX, and CD38), as well as 
markers of follicular cells, like CXCR5 and CTLA-4 (Figure 8B). 
To investigate the heterogeneity of T-cell immunophenotypes across samples, frequencies 
of the identified T-cell subsets were determined for each individual sample and a hierarchical 
clustering based on compositional similarity was performed. As shown in Figure 8C, in addition 
to a high inter-sample heterogeneity, five distinct groups were identified: one first group 
containing a high proportion of TEM3 KLRG1+ TBET+ cells, comprised PB and BM samples; a 
second group of samples, which presented high amounts of naïve cells, was mainly composed 
of HC LN samples; a third group with elevated percentages of TEX cells contained only CLL LN 
samples; and the fourth and fifth groups, harbored no enrichment of a specific cell subset, 
organ or sample condition (Figure 8C). The definition of the five groups was not related to any 
clinical condition such as tumor load or IGHV mutation status. Instead, samples of younger 
age appeared to be enriched in group 2, suggesting that age might influence the CD8+ T-cell 
phenotype present in LNs (Figure 8C). The effect of age in sample composition is further 
discussed in Section 4.2.3. 
Taken together, these results provide a global picture of the CD8+ T-cell landscape present 
in CLL patients, composed of subsets ranging from undifferentiated naïve cells, to central 
memory, effector, and effector memory cells with a diverse degree of activation and 
exhaustion. Besides, sample clustering based on subset frequencies revealed noticeable 
differences between tissues, as well as CLL samples compared to HC. 
 
4.2.1 T-cells in CLL LNs exhibit a distinct immunophenotype compared to PB 
and BM tissues 
The immunophenotypic analysis of the CD8+ T-cell compartment revealed a tissue-related 
grouping of samples (Figure 8C), indicating that tissue cues significantly determine T-cell 
composition. In line with this, a higher presence of T-cells with an exhausted phenotype in LNs 
compared to PB has recently been suggested (Hanna et al. 2019). However, additional studies 
exhaustively analyzing the phenotypical differences between these two tissues are lacking, 
and the T-cell composition in CLL BM have not been characterized thus far. Therefore, for a 
comprehensive assessment of CD8+ T-cell phenotypic differences among the three tissues, 
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cluster frequencies between LN, PB and BM samples from CLL patients were compared 
(Figure 9). Notably, TN, TCM, TEF1 CD27+, TEM1, and DP1 TEX CXCR5+ cell subsets were present 
in similar frequencies in the different tissues (Figure 9). Instead, PB and BM samples, which 
did not significantly differ between each other, showed an enrichment of TEF2 TBET+ and TEM3 
KLRG1+ TBET+ in contrast to LN samples. Interestingly, CLL LNs exhibited higher proportions 
of TEM2 GZMK+, TEX CD39+ and proliferating cells, indicating an enhanced activated and 
exhausted phenotype of CD8+ T-cells in this tissue. Moreover, TEM4 ICOS+ and TFC CD39+ 
subsets were also enriched in LNs (Figure 9). 
In addition to defining tissue-related differences, an intra-patient correlation for the identified 
T-cell subsets was determined, by comparing the frequencies of cell subsets in PB and LN 
samples (Figure 10). A significant positive correlation was identified for TN, TCM and TEM1 
subsets, clusters with high frequencies in both tissues. In contrast, percentages of the other 
TN TCM TEF1 CD27+ TEF2 TBET+
TEM1 TEM2 GZMK+ TEM3 KLRG1+ TBET+ TEM4 ICOS+






















































































































































































































Figure 9: T-cells from LNs have a distinct phenotype compared to PB and BM. 
Percentage of cells belonging to a given cluster out of total CD8+ T-cells for each sample were 
compared between LN (n = 21), PB (n = 8) and BM (n = 3) samples (*p<0.05, **<0.01, 
***<0.001, Kruskal-Wallis test with multiple comparisons). 
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effector and effector memory subtypes and importantly, of TEX and proliferating cells present 
in LN tissue, did not correlate with their frequencies in PB (Figure 10), underscoring a 
differential compartmentalization for certain cell subsets, including exhausted T-cells. 
Overall, these results confirm that CD8+ T-cell phenotype differences exist between PB and 
LNs, and provide a first account of the similarities of CD8+ T-cell distribution in PB and BM of 
CLL patients. In addition, they underscore the limited correlation between LNs and PB and 
indicate the accumulation of exhausted T-cells in CLL LNs rather than in PB and BM.  
 
Figure 10: T-cell subset abundances in PB do not completely correlate with those in LN 
samples. Cluster abundances were correlated (Pearson correlation) using paired LN (x-axis) 
and PB (y-axis) samples from CLL patients (n = 8). Pearson correlation coefficient and p-
values (p) are depicted correspondingly. 
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4.2.2 CD8+ T-cells from CLL and HC LNs are phenotypically distinct 
In order to identify the CLL-specific T-cell phenotypical changes, the comparison of CLL 
LNs with non-malignant LNs is essential. However, such comparison has not previously been 
performed. Consequently, the CD8+ T-cell composition of CLL LNs was compared to that of 
rLN samples. As shown in Figure 5, non-malignant LNs were composed of a significantly 
higher frequency of TN, with an average frequency of 40.59 % per sample, in contrast to 11.35 
% in CLL LNs. TEF1 cells, as well as DP1 cells, despite being overall less abundant in the LNs, 
were also found significantly enriched in control samples, with the latter being almost absent 
in CLL samples (Figure 11). Importantly, CLL LNs were significantly enriched in TEX, with an 
average frequency of 30.49 % in comparison to 11.33 % in control samples. Besides, TEM3 
KLRG1+ TBET+ and proliferating cells were also found in greater frequencies in CLL LNs 
(Figure 11).  
Figure 11: T-cells from CLL LNs have a distinct phenotype compared to HC LNs. 
Abundance of cells of a given cluster out of total CD8+ T-cells for each sample in CLL LNs (n 

























































TN TCM TEF1 CD27+ TEF2 TBET+
TEM1 TEM2 GZMK+ TEM3 KLRG1+ TBET+ TEM4 ICOS+









































































































































































4 Results   4.2 Global CD8+ T-cell profiling of CLL and control tissues by mass cytometry 
 78 
Collectively, these results illustrate the CD8+ T-cell phenotypic similarities between LNs 
from CLL patients and HCs, but at the same time provide evidence for the existence of CLL-
specific effector and exhausted CD8+ T-cell states. 
 
4.2.3 Clinical associations with CD8+ T-cell distribution in CLL LNs 
Previous studies have identified a CD8+ T-cell effector memory phenotype in CLL blood 
samples that is related to a progressive disease (Palma et al. 2017; Gonnord et al. 2019). To 
ascertain the relationship between the identified CD8+ T-cell subsets with disease outcome in 
the studied cohort, cell subset frequencies in LN samples were correlated with the clinical 
parameters Binet and Rai staging, tumor load, IGHV mutation status, treatment-free survival, 
and overall survival. Similar to previous studies (Novak et al. 2015; Gonnord et al. 2019), no 
correlation between cell subtype percentage and Binet and Rai stage, treatment-free survival 
or overall survival data were identified (data not shown). On the other hand, TEM1 cell 
frequencies were positively associated with tumor load (Figure 12A). This was in line with a 
negative correlation between naïve T-cell percentages and tumor load (Figure 12B), thus 
indicating an increase of antigen-experienced T-cells in CLL LNs accompanying tumor growth. 
Mutational status of the IGHV gene in CLL cells has been shown to have a minor impact on 
expression of immune checkpoint and activation markers in T-cells isolated from peripheral 
blood mononuclear cells (PBMCs) of CLL patients (Palma et al. 2017). Intriguingly, levels of 
TEM4 ICOS+ cells were significantly decreased in IGHV-unmutated compared to mutated 
samples (Figure 12C), which provides evidence for an impact of the IGHV mutational status in 
CLL cells on shaping the nodal TME. 
The average age of the studied CLL patient cohort is significantly higher than that of controls 
(Figure 13A), which represents a confounding factor for the identification of changes in T-cell 
phenotypes. In order to determine the contribution of this factor to the cell subset distribution, 
age of patients and HCs at sampling was correlated with cell cluster abundances. While CLL 
Figure 12: Relationship between CD8+ landscape and clinical outcomes. (A-B) Pearson 
correlation of (A) naïve and (B) TEM1 subset abundances with tumor load (in %) in CLL LN 
samples (n = 21). (C) Boxplot showing TEM4 ICOS+ subset abundances in LNs of IGHV 
unmutated (n = 9) versus mutated CLL patients (n = 10) (*p<0.05, Mann-Whitney U test). U = 
IGHV unmutated, M = IGHV mutated, TL = tumor load. 
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samples of older age patients showed increased percentages of TEX cells, this association was 
not present in control samples (Figure 13B). In addition, proportions of TN cells negatively 
correlated with age in both control and CLL samples (Figure 13C), in accordance with the 
previously described shrinkage of the naïve T-cell compartment during aging (Goronzy et al. 
2015).  
In summary, these data underscore the limited impact of the T-cell compartment on the 
clinical outcome of CLL patients. Besides, they confirm the existence of an effector memory 
population that expands in response to tumor growth, and reveal a previously unrecognized 
difference in the abundance of CD8+ TEM4 ICOS+ cells between IGHV-mutated and -unmutated 
CLL patients. The age of the sample donors as a confounding factor, in addition, is shown to 
have a minor impact in T-cell subset differences between CLL patients and HCs. 
 
 Single-cell transcriptome profiling of nodal T-cells from CLL 
patients 
4.3.1 Characterization of the T-cell transcriptome from CLL LNs 
Single-cell transcriptome studies of intratumoral T-cells enable an unbiased examination of 
the vast heterogeneity of T-cell states found both within and between cancer patients (Zheng 
et al. 2017; Azizi et al. 2018; Li et al. 2019). Transcriptional profiling of T-cells from three CLL 
LNs was performed in order to characterize their distinct T-cell subsets and their clonal 
diversity. CD3+ T-cells and CLL cells of CLL LNs were FACS-sorted and subjected to single-
cell RNA-seq using the 10x Genomics platform. Data processing and analysis was conducted 
in collaboration with Dr. Yashna Paul from the German Research Center (DKFZ), Heidelberg. 
After QC filtering (see Section 3.2.7.3), approximately 6.6 x103 CD3+ T-cells, with an average 
of 131,234 reads per cell and a median of 1,447 genes per cell, were further analyzed. The t-
Figure 13: Average age differences between CLL patients and HCs have a limited effect 
as confounding factor. (A) Age of CLL patient (n = 21) and HC (n = 13) samples at sampling 
(***p<0.001, Mann-Whitney U test). (B-C) Pearson correlation plot of percentage of (B) TEX 
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SNE algorithm was used for dimensional reduction and unbiased cell clustering yielding the 
formation of 10 subsets based on their gene expression profiles (Figure 14A). These clusters 
were comprised of 5 CD4+ T-cell clusters, 2 CD8+ T-cell clusters, 2 clusters which contained 
both, CD4+ and CD8+ T-cells, and one cluster of spiked-in CLL cells (Figure 14A-B). More 
specifically, both CD4+ and CD8+ naïve cells were identified based on the expression of marker 
genes such as CCR7, lymphoid enhancer-binding factor 1 (LEF1), selectin L (SELL) and 
transcription factor 7 (TCF7) (Figure 14C) (Gattinoni et al. 2017). Subsets identified as effector 
memory CD8+ (CD8+ TEM1) and cytotoxic T-cells (TTOX), were characterized by a similarly high 
expression of effector molecules like granzymes (GZMA, GZMK, GZMH), with CD8+ TEM 
expressing slightly higher levels of cytokines like CCL4, CCL5, IFNG and PRF1 (Figure 14C). 
In contrast, CD4+ TEM1 cells showed higher expression of TFs related to T-cell activation (FOS, 
JUN, FOSB) (Yukawa et al. 2020), and activation-related genes (CD69, ICOS, CD40L) (Azizi 
et al. 2018). A second CD4+ TEM2 subset expressed genes related to cytokine signaling such 
Figure 14: Transcriptional profiling of nodal T-cells from CLL patients. (A) t-SNE plot of 
CD3+ T-cells and CLL cells color-coded according to the clusters identified (B) Gene 
expression (UMI) counts) of CD4 and CD8A genes in all cells. Exp = UMIs. (C) Heatmap 
depicting the top most differentially expressed genes for each cluster. Each column represents 
a single cell and each row a single gene, with the annotation of 1-2 marker genes per cluster. 
Clusters are ordered based on their size. Expression is shown as logarithm of counts per 
million reads (log CPM). (D) t-SNE plot depicting sample distribution (left) and cell subset 
abundances in each sample (right). Colors correspond to those shown in (A). BC0, BC1, BC3 
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as CCR6, IL7R, and lymphotoxin b (LTB) (O'Shea and Murray 2008; Lee and Korner 2019; 
Piao et al. 2019). Tregs were identified based on the expression of FOXP3, CTLA4 and IL2RA, 
and further subdivided into resting Treg (rTregs), and active Treg (aTregs) cells. While the 
former subgroup was characterized by a higher expression of naïve-related genes, the later 
expressed higher levels of inhibitory receptors (TIGIT, ICOS) and genes involved in the 
TNFRSF- NF-κB-pathway (TNFRSF4, TNFRSF1B, BIRC3) (Zemmour et al. 2018; Miragaia et 
al. 2019) (Figure 14C). In addition, a cell subset with a gene signature characteristic of CD4+ 
TFH was identified, overexpressing both inhibitory receptors, including PDCD1 and TIGIT, and 
genes like TOX2 and CD200 (Crotty 2011; Dorfman and Shahsafaei 2011; Roider et al. 2020). 
Surprisingly, however, it included both CD4+ and CD8+ T-cells (Figure 14B). Finally, CLL cells 
were easily recognizable by the expression of multiple immunoglobulin genes (such as IGKV3-
20 and IGKC), genes encoding the HMC (HLA-DR, HLA-DRB1, CD74), and the BCR 
complexes (CD79A, CD79B) (Figure 14C). As previously observed in the analysis of mass 
cytometry data, a substantial heterogeneity existed between the three patients analyzed, with 
one sample containing significantly more CD8+ TEM1 cells than the other two (Figure 14D). 
 
The above analysis provides a general overview of the T-cell subsets present in the LNs of 
CLL patients, but delivers limited information on the different CD8+ T-cell states. Hence, to gain 
further insight into CD8+ T-cell heterogeneity, CD4- CD8+ T-cells were clustered separately. As 
shown in Figure 15A, 8 transcriptionally distinct CD8+ T-cell clusters could be identified based 
on differentially expressed marker genes. Subsets of naïve cells were identified as in the 
previous analysis. Interestingly, CD8+ follicular T-cells (TFC) showed the most discrete 
phenotype, with a high expression of inhibitory receptors, a moderate expression of naïve-
related genes, and no expression of effector molecules, like granzymes or cytokines (Yu and 
Ye 2018) (Figure 15B). From the previously identified CD8+ TEM cell cluster, 5 new subsets 
emerged: a TCM subset was classified based on the moderate expression of naïve-associated 
genes, and the low expression of effector molecules. In addition, a TEM subset with strong 
expression of heat-shock proteins (e.g. HSP90AA1, HSPA1A) was identified (Figure 15B). Of 
note, a very small set of cells (11 cells, representing the 0.48 % of total cells), which expressed 
high levels of mitochondrial genes (e.g. MT1F, MT1X), and only slightly exceeded the 
threshold for the exclusion of low-quality cells, was considered a technical artifact and 
therefore excluded from further analyses. Finally, and as the previous analysis suggested, the 
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differences between the 3 remaining TEM subsets were subtle, and only small gene expression 
differences separated these clusters. Specifically, TEM2 CCL4+ expressed slightly higher levels 
of CCL4 and annexin A1 (ANXA1), and the AP-1 TF subunits JUN and FOS; TEM3 GZMK+ 
expressed increased levels of GZMK, KLRG1, and C-X-C motif chemokine ligand 1 (XCL1), 
as well as slightly higher levels of PDCD1 and LAG3; and TEM4 GZMH+ showed a higher 
expression of GZMH and X-C motif chemokine ligand 2 (XCL2) (Figure 15B). Interestingly, the 
higher percentage of CD8+ TEM cells previously recognized in the BC1 sample corresponded 
to a specifically increased frequency of TEM2 CCL4+, rather than a general higher percentage 
of the different TEM subsets (Figure 15C). 
Altogether, the single-cell transcriptome analysis of T-cells from CLL LNs provides an 
unbiased account of CLL-associated T-cell phenotypes. Similar to the mass cytometry 
analysis, single-cell RNA-seq identifies subsets of CD8+ TN, TCM, TFC and TEM, but at the same 
time, it underscores the high degree of similarity between the CD8+ TEM cell subsets and the 
distinct transcriptional profile of the TFC cells. 
 
4.3.2 Integration of the mass cytometry and single-cell RNA sequencing data 
reveals general cell subset overlap 
Using both single-cell RNA-seq and mass cytometry analyses identified CD8+ T-cell subsets 
with distinct phenotypes, thus raising the question, whether the same populations exist at the 
transcriptome and proteome level respectively. To answer this question, the CD8+ T-cell profile 
of all clusters identified at the transcriptome and proteome level were integrated (see Methods, 
Section 3.2.8). As shown in Figure 16A, general cell subsets (i.e. TN, TCM, TFC, and TEM) found 
Figure 15: Characterization of CD8+ T-cells from CLL LNs. (A) t-SNE map clustering CD8+ 
T-cells form 3 CLL LNs. Each dot represents a single cell, colored according to cluster identity. 
(B) Heatmap displaying enrichment (Z-score) of most differentially expressed genes in each 
cluster (color-coded as in (A)). Marker genes per cluster are noted (right). (C) Cell subset 
frequencies for each sample. Colors correspond to clusters as annotated in (A). BC0, BC1 and 
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in both datasets positively correlated. Because only a limited number of marker genes 
differentiating TEM subsets in the single-cell RNA-seq dataset were present in the mass 
cytometry dataset, no one-to-one equivalent TEM cluster could be assigned (Figure 16A). In 
addition, proliferating and effector cells, which were only defined using mass cytometry 
analysis, did not correlate with any single-cell RNA-seq cluster. Importantly, cell subset 
frequencies were comparable between the two methodologies (Figure 16B), and significantly 
correlated with each other in the two LN samples present in both datasets (Figure 16C). 
Overall, the above analysis validates that mass cytometry and single-cell RNA-seq 
analyses capture similar CD8+ T-cell subsets, underscoring their robustness and discarding 
the possibility of a detection bias towards any specific cell subset (i.e. naïve, effector memory, 
central memory, effector, and follicular) by the techniques.  
 
4.3.3 T-cell clonality in CLL is associated with an effector memory CD8+ T-cell 
phenotype 
The reconstruction of T-cell receptor (TCR) sequences at the single-cell level and overlap 
with their transcriptional profiles allows the identification of clonal diversity within identified T-
cell subsets. With this approach, an enrichment of clonally-expanded cells with cytotoxic and 
dysfunctional phenotypes has been reported in several tumors (Guo et al. 2018; Zhang et al. 
2018b; Li et al. 2019; Yost et al. 2019). To assess the degree of clonality in the analyzed CLL 
LN samples, T-cells with both transcriptome and productive TCR sequence information were 
Figure 16: Correspondence of mass cytometry clusters with single-cell RNA-seq 
clusters. (A) Heatmap showing Pearson correlation between each pair of clusters identified 
with single-cell RNA-seq and mass cytometry. Average profile values for each cluster were 
calculated and mean-centered in comparison to the rest of the clusters from the dataset. 
Clusters of > 1 % in BC1 and BC3 samples are depicted from the mass cytometry dataset. 
Color scale and dot size depict correlation coefficient. (B) Cell subset distribution of the major 
cell subsets TFC, TCM, TEF, TN, TEM (including TEM1, TEM2, TEM3 and TEX) and TEM GZMK+ in 
samples BC1 and BC3 present in both single-cell RNA-seq and mass cytometry datasets. (C) 
Pearson correlation of major cell subset percentages determined with mass cytometry and 
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classified based on the distribution of identical paired α and β chains shared between one, 
two, or three and more cells (Figure 17A). A diverse degree of clonal expansion (i.e. an 
identical TCR present in at least three cells) was observed in the three samples, being 2.44, 
13.20 or 37.66 % of total cells (Figure 17A), with no shared TCR clones amongst them. 
Besides, clonal diversity differed greatly between patients, with little clonal expansion in the 
BC0 sample, a strongly dominating clone in BC1, and a wider repertoire of smaller clones in 
the BC3 sample (Figure 17B). Since CD4+ T-cells showed negligible clonal enrichment, and 
because a significant proportion of CD8+ T-cells were clonally expanded (Figure 17A), the 
clonal composition across CD8+ T-cell subsets was examined. Interestingly, considerable 
percentage (between 31.82 and 58.04 %) of cells from the 4 TEM clusters were constituted by 
clones, in contrast to the little clonal expansion found in the TN, TCM and TFC cell subsets (Figure 
Figure 17: Clonal expansion is restricted to TEM CD8+ T-cells. (A) Number of total CD3+ T-
cells belonging to clonotypes with 1, 2, or 3 and more cells with the same TCR sequence in 
each sample. Left: absolute numbers, right: percentage out of total cells. The distinction 
between CD4+ and CD8+ T-cells is made in the left graph. (B) T-cell conal composition in the 
3 CLL LNs samples. Percentages and cell numbers are given for the 10 most abundant clones. 
The total number of expanded clones is shown below the chart. * marks BST2-recognizing 
TCR. (C) Percentage of expanded clones per CD8+ T-cell cluster. The contribution from each 
of the three samples is color-coded. (D) t-SNE plot of CD8+ T-cells from the 10 most expanded 
clones (color-coded, n = 885). Cells with no shared TCR are depicted in grey. BC0, BC1 and 
BC3 = sample IDs. 
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17C and D). Importantly, expanded clones were not restricted to a specific cluster, but 
distributed between several subsets, with TEM2 CCL4+ and TEM4 GZMH+ sharing most of them 
(Figure 17C).  
In order to identify TCR clones recognizing known epitopes, CDR3 amino acid sequences 
for the 10 most abundant clones in each sample were compared against the VDJdb database 
including CDR3 regions known or likely to react against reported epitopes (Bagaev et al. 2020). 
TCR sequences described to recognize the pp65 gene epitope from cytomegalovirus (CMV) 
were found in the BC0 and BC1 samples, including the latter’s most abundant clone (Table 
11). In addition, matrix protein 1 (M1) from Influenza virus and mRNA export factor ICP29 
(BMLF1) from Epstein-Barr-Virus (EBV) were found in BC0 and BC1, respectively (Table 11). 
Available clinical data of these samples indicated no CMV positivity at time of sampling but at 
earlier stages of disease (Table S13), suggesting a persistence of viral-reacting T-cells over 
time. Intriguingly, sample BC3 contained a TCR described to recognize the bone marrow 
stromal cell antigen 2 (BST2) protein, mostly present in the TEM3 GZMK+ cluster. This 
transmembrane protein, originally described to regulate B-cell development (Goto et al. 1994; 
Ishikawa et al. 1995), has been reported to be overexpressed in CLL (Gong et al. 2015) and 
several other malignancies, including lung and breast cancer (Wang et al. 2009; Mahauad-
Fernandez et al. 2014), as well as multiple myeloma, where it has been suggested as a 
therapeutic target (Ozaki et al. 1997; Tai et al. 2012). The presence of a putative T-cell clone 
binding to a CLL-overexpressed protein thus constitutes further evidence of the existence of 
CLL-reactive T-cells with a pre-exhausted phenotype.  
 
Table 11: List of known and putative epitope-reactive TCRs.  
  Clone ID 
Fraction 
(%, AC) CDR3  V  J  Epitope  Gene  Sp 
BC0 
CL9 4.29 (3) 
TRA: CASYNTDKLIF TRAV38-2/DV8 TRAJ34 GILGFVFTL M1 Influenza 
TRB: CASSLALNYGYTF           
CL7 4.29 (3) 
TRA: CAALRDDKIIF TRAV12-2 TRAJ30 NLVPMVATV pp65 CMV 
TRB: CASSFGSYNEQFF           
CL11 4.29 (3) 
TRA: CAVRTSGYSTLTF TRAV21 TRAJ11 NLVPMVATV pp65 CMV 
TRB: CASCPGQGNTGELFF           
BC1 
CL1 65.81 (360) 
TRA: CAASFSGTYKYIF TRAV29/DV5 TRAJ40 NLVPMVATV pp65 CMV 
TRB: CASSPSPGGVEKLFF           
CL8 2.19 (12) 
TRB: CASSQSPGGTQYF TRBV14 TRBJ2-5 GLCTLVAML BMLF1 EBV 
TRA: CALSEGDSGNTPLVF           
CL10 1.65 (9) 
TRA: CAGASNTGKLIF TRAV27 TRAJ37 NLVPMVATV pp65 CMV 
TRB: CASSLAQGSGANVLTF           
BC3 CL8 3.36 (9) 
TRA: CAVSLSNFGNEKLTF TRAV12-2 TRAJ48 LLLGIGILV BST2 Homo S. 
TRB: CASSYGDRGSNQPQHF           
Note: AC = absolute number of cells, Sp = species, TRA = T-cell receptor a chain, TRB = T-
cell receptor b chain. 
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Altogether, this data reveals a broad TCR repertoire from CLL LNs, which illustrates a 
heterogeneous clonal diversity between patients as well as a phenotypically diverse clonal 
expansion restricted to CD8+ TEM cells. In addition, the distinction of specific TCR sequences 
recognizing previously described epitopes underscores an anti-viral, and potentially anti-
tumoral reactivity. 
 
4.3.4 Decoding the interactome between CLL cells and T-cells in the CLL LN 
niche 
Tumor-associated changes in the CLL TME are considered to benefit CLL cells, as they 
largely depend on their interactions with neighboring cells for receiving proliferation and 
survival signals in the SLOs (Burger 2011). Hence, to predict the cell-cell interactions occurring 
in the CLL LNs, CellPhoneDB, a computational tool for the identification of cell subset-specific 
expression of ligand and receptor pairs in the transcriptome (Vento-Tormo et al. 2018), was 
used (see Methods Section 3.2.7.6). Interestingly, the highest number of interactions were 
predicted between CLL cells and TTOX, TFC, and CD8+ TEM1 cells (Figure 18A), subsets that 
also generally established a higher number of interactions with any given subset. The other 
clusters, in contrast, and specially CD4+ TN and rTregs, interacted comparably less with any 
cell subpopulation (Figure 18A).  
To gain insight into the CLL-T-cell interactome, the specific interactions between CLL cells 
and all the T-cell subsets were investigated. On the one hand, well-known pro-survival and 
proliferation signals for CLL cells, such as CD40- CD40L, IL2 secretion, and TRAIL- TRAILR1 
(Secchiero et al. 2005; Decker et al. 2010; Pascutti et al. 2013), were found between CLL cells 
and CD4+ T subsets, as well as TF cells (Figure 18B). CLL cells additionally interacted with 
Tregs through the expression of the adhesion molecule L-selectin. Moreover, as a result of 
their activated and effector state, CD8+ TEM1 and TTOX cells specifically secreted TNFa and 
IFNg, the receptors of which were expressed by CLL cells. On the other hand, other 
interactions reported to induce CLL programmed cell death, including binding of signal 
regulatory protein gamma (SIRPG) to CD47 (Martinez-Torres et al. 2015) or inhibition thereof 
by leukocyte associated Ig like receptor 1 (LAIR1) to leukocyte Ig like receptor B4 (LILRB4) 
(Zurli et al. 2017), were observed between CLL cells and CD4+ T-cells, TTOX, and TFC cells 
(Figure 18B). Interestingly, CD52 glycoprotein, which is therapeutically targeted with 
alemtuzumab, was found to interact with sialic acid binding Ig like lectin 10 (SIGLEC10) not 
only among CLL cells, but also in several T-cell subsets and specially CD4+ TEM2 cells. 
Furthermore, the crosstalk between CLL cells and T-cells was not unidirectional, as T-cells 
also received signals from leukemia cells, the effect of which has not been investigated in CLL. 
In short, signals were mediated by CD28- CD86 interaction, and CD44 binding to L-galectin 9 
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Figure 18: Decoding the crosstalk between CLL cells and T-cells in the LN niche. (A) 
Heatmap depicting the number of predicted interactions between cell clusters identified by 
single-cell RNA-seq. (B) Significant curated ligand-receptor interactions between CLL and T-
cell subsets depicted as a dot plot. Dot color represents log2 mean of the combined expression 
of ligand and receptor pair. Dot sizes represent p-values, which were determined using a 
permutation test. Gene names were substituted by protein names for CD45 (PTPRC), CD39 
(ENTPD1), CD270 (TNFRSF14), TNFR2 (TNFRSF1B), CD97 (ADRGE5), 4-1BB ligand 
(TNFSF9), 4-1BB (TNFRSF9), TRAILR1 (TNFRSF10A), TRAIL (TNFSF10), TIM-3 (HAVCR2), 
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(LGALS9) in activated cells. In addition, CD8+ TEM1, TTOX, aTregs and TFC cells interacted with 
CLL cells via 4-1BB- 4-1BB ligand, and CD160 in case of CD8+ TEM1 cells. Specific recruitment 
of CD8+ TEM1 and aTreg cells by CLL cells might result from CXCL16- CXCR6 interaction. In 
contrast, T-cells also received coinhibitory signals via LAIR1, and specifically via TIM-3 for 
TTOX cells. Of note, the T-cell inhibitory signals expected from the interactions PD-1- PD-L1 
and TIGIT- PVR were not found amongst the significant CLL cell-type specific interactions, but 
were present in the list of detected interactions in the dataset, indicating a more ubiquitous 
expression of the ligands also in the T-cells. 
Overall, these results reveal a complex cellular network of interactions, where T-cells and 
leukemic cells establish a cross-talk consisting of both positive and negative signals, 
contributing to an impaired anti-tumor T-cell response, and altered normal immune function in 
CLL patients. 
 
 Single-cell RNA-seq-based T-cell profiling of the TCL1 AT mouse 
model  
4.4.1 Characterization of the transcriptome of T-cells from TCL1 AT spleen 
The TCL1 AT mouse model represents a valuable tool for studying CLL pathomechanisms 
(Hamblin 2010). To gain insight into the T-cell heterogeneity of the TCL1 AT mouse and 
validate its resemblance to human CLL T-cells, splenic T-cells from 2 TCL1 AT mice with a TL 
of approximately 92 % were analyzed. More specifically, CD3+ T-cells were FACS-sorted and 
subjected to single-cell RNA-seq using 10x Genomics. Data processing and analysis was 
performed in collaboration with Dr. Yashna Paul from the German Research Center (DKFZ, 
Heidelberg). After QC filtering, a total of 8.5 x103 T-cells, with an average of 77,268 reads per 
cell and a median of 1,861 genes per cell, were considered for clustering and cell subset 
investigation. Thirteen clusters were identified based on to their differential gene expression 
(Figure 19A), which comprised CD4+ and CD8+ T-cells, CLL cells, and myeloid cells. The latter 
population, which expressed no Cd3, Cd4, Cd8a, or Cd19, but expressed multiple genes 
related to innate cells, including the Fc fragment of IgE receptor Ig (Fcer1g), lysozyme C-2 
(Lyz2), and colony stimulating factor 1 receptor (Csf1r), was likely a result of a lower purity of 
the cell sorting prior the single-cell RNA-seq. Only few of the T-cell clusters could be 
unequivocally subdivided into CD4+ or CD8+ T-cells (Figure 19A), since most of them contained 
both T-cell types. Even though CD4+ and CD8+ T-cells did not overlap in the t-SNE clustering, 
due to the strong exclusive expression of Cd4 and Cd8a (Figure 19B), such grouping indicates 
that the two T-cell types share highly similar transcriptomic phenotypes.  
Subsequently, the 11 T-cell clusters were characterized according to their transcriptome 
profile. The overexpression of naïve marker genes, including Ccr7 and Lef1, identified 4 
clusters of TN cells, with one exclusively containing CD8+ T-cells, another CD4+, and two small 
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clusters including both (TN2-3) (Figure 19C). CD8+ memory T-cells (TM) were determined based 
on the expression of Cd7, interleukin-2 receptor subunit beta (Il2rb) and lymphocyte antigen 
6c2 (Ly6c2) (Aandahl et al. 2003; Istaces et al. 2019), and the lower expression of both naïve 
and effector-related genes in relation to other clusters. In addition, CD4+ Treg cells were 
recognized by the expression of Foxp3 and tumor necrosis factor receptor superfamily member 
4 (Tnfrsf4). Importantly, an exhausted T-cell subset (TEX), which contained mostly CD4+ T-
cells, but also CD8+ cells, was recognized based on the elevated expression of inhibitory 
receptors like Tigit, Lag3, and Pdcd1, as well as several effector molecules, including 
chemokine ligand 5 (Ccl5) and Gzmk (Figure 19C). Moreover, two other CD4+ effector (TEF1-2) 
subsets were remarkably similar to TEX cells at the transcriptomic level, but specifically 
expressed T-cell receptor a and b genes (i.e. Trbv23 together with Trav6-3, and Trbv13-3 with 
Trav19 respectively), suggesting they represent expanded T-cell clones (Figure 19C). 
Intriguingly, a small cluster including both CD4+ and CD8+ cells, with a very distinct 
Figure 19: Transcriptome profiling of T-cells from TCL1 AT mice. (A) t-SNE plot of CD3+ 
T-cells and CLL cells. The 13 clusters identified are depicted with distinctive colors. (B) Gene 
expression (UMI counts) of Cd4 and Cd8a genes in all cells. (C) Heatmap showing 2-5 most 
differentially expressed genes between the identified clusters. Each column denotes a cell and 
each row a gene. Between 1 and 2 marker genes are annotated per cluster. Expression is 
represented as logarithm counts per million reads (log CPM). (D) t-SNE plot depicting the cell 
distribution according to the mouse of origin (left) and cluster fractions in each sample (right), 
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transcriptional signature was also identified. This subset expressed genes related to type I 
interferon response, including interferon induced protein with tetratricopeptide repeats 1 and 3 
(Ifit1, Ifit3), signal transducer and activator of transcription 1 (Stat1), and interferon regulatory 
factor 7 (Irf7). Besides, the top 50 differentially expressed genes of this cluster showed an 
enrichment for the gene ontology (GO) biological process term ‘type I interferon signaling 
pathway’ (GO:0060337, adjusted p-value = 7.15 x10-18) defining this cluster as TIFN cells. 
Finally, cells with high levels of cell-cycle associated genes, like stathmin (Stmn1), high 
mobility group box 2 (Hmgb2), and marker of proliferation KI-67 (Mki67), were denoted as 
proliferating cells. These cells also expressed effector molecules like Gzmk and granzyme B 
(Gzmb), indicating an on-going proliferation of effector cells.  
It is worth noting, that even though the two mice analyzed (M107 and M110) were injected 
with the same TCL1 tumor clone and presented comparable tumor load at time of sampling 
(both with >90 % CLL cells out of CD45+ cells in spleen), their T-cell response appeared to be 
remarkably different: on the one hand, M107 seemed to have an overall stronger T-cell 
reaction, as all cells from TEF1-2 and most of TEX cluster originate from this mouse (Figure 19D). 
In contrast, more than 50 % of cells in M110 were naïve cells, and the abundance of TEX, or 
proliferating cells was comparably lower in this sample (Figure 19D). This observation reveals 
a previously unrecognized high heterogeneous inter-sample T-cell response, regardless of the 
transplanted TCL1 tumor clone.  
Taken together, this data provides a comprehensive account of the T-cell phenotypes 
acquired upon leukemia development in the TCL1 AT mouse model of CLL. 
 
4.4.2 Limited clonal expansion of CD8+ T-cells from TCL1 AT mouse 
splenocytes 
The existence of a clonally expanded CD8+ T-cell population in blood of CLL patients as 
well as in spleens of TCL1 AT mice has been reported by previous studies (Serrano et al. 
1997; Vardi et al. 2017; Blanco et al. 2018; Hanna et al. 2019). To confirm these results, as 
well as to compare the T-cell clonality profile of the TCL1 AT mouse model to the one of LNs 
from CLL patients identified in this work, selective enrichment and single-cell RNA-seq of the 
TCR region was performed. 
Several interesting observations were made upon inspection of the clonal distribution in the 
murine samples. First, a clearly distinct clonal expansion pattern occurred in the two samples 
analyzed (Figure 20A-B), in line with the previously recognized dissimilar cluster distribution 
between the two mice. In M107, out of all T-cells, approximately 20 % represented clonal cells 
(Figure 20A), with two dominant clones constituting 50 % of the expanded cells (Figure 20B). 
In contrast, only a 4 % of cells were clonally expanded in M110 (Figure 20A), characterized by 
small and non-dominant clones (Figure 20B). Second, and surprisingly, clonal cells were 
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mostly CD4+ T-cells (Figure 20A), as opposed to the dominant CD8+ T-cell clonal expansion 
occurring in human CLL LN samples (see Section 4.3.3, Figure 17). Last, clonal T-cell 
expansion was confined to several cell subsets: CD4+ TEF1 and TEF2 exclusively contained 
clonal cells, and the CD4+ and CD8+-containing TEX cluster likewise comprised numerous 
clones (Figure 20C-D). In addition, the TIFN cluster and proliferating cells, followed by Treg and 
TN2 cells, also contained some clonally expanded cells, suggesting that a tumor T-cell 
response involves a reaction of multiple T-cell phenotypes in the TCL1 AT mice. 
In sum, a heterogeneous and of predominantly CD4+ T-cells clonal expansion was 
ascertained in the TCL1 AT mouse model, an observation that is clearly distinct from the 
Figure 20: Clonal expansion in the TCL1 AT mouse model occurs in the CD4+ T-cell 
compartment. (A) Total number of non-expanded (n < 3) or clonally expanded (n ≥ 3) CD3+ 
T-cells (left), and percentage out of total cells (right) in each mouse sample. Distinction 
between CD4+ and CD8+ T-cells is made in the left graph. (B) Clonal composition of mouse 
samples M107 and M110. Fractions and numbers of cells for the 10 most abundant clones are 
given next to the plots. The total number of clones is annotated below the chart (C) Percentage 
of cells associated with a clone out of total cells per cluster. Sample contribution is color-coded. 
(D) t-SNE plot of CD3+ T-cells, CLL and myeloid cells from M107 and M110 samples with all 















































































































4 Results   4.4 Single-cell RNA-seq-based T-cell profiling of the TCL1 AT mouse model 
 92 
human situation, and which underscores the complex, variable, and tumor-dependent immune 
response to leukemia growth. 
 
4.4.3 Interactions between CLL cells and the T-cell compartment in the TCL1 AT 
mouse model 
In order to investigate the cellular crosstalk between CLL cells and the T-cell subsets 
characterized in the murine samples, the CellPhoneDB approach was used, akin to the human 
analysis. Notably, CLL cells established the highest number of interactions, especially with 
TIFN, CD8+ TM, Tregs and myeloid cells. Besides, myeloid cells and activated T-cell subsets 
showed a higher amount of interactions in comparison to naïve subsets (Figure 21A).  
Additionally, by examining the specific intercellular network between CLL cells and their 
microenvironment, known pro-leukemic signals were identified (Figure 21B). As an example, 
CLL cells appeared to receive survival signals via the interactions of CD40- CD40L provided 
by CD4+ T-cell subsets, SELL- SELPLG by TEX and CD4+ TEF1-2, and CD80- CD274 by Tregs, 
TIFN, and myeloid cells (Figure 21B). Other interactions that have been shown to promote a 
homing environment to CLL cells included CD74 (Binsky et al. 2007), as well as several integrin 
complexes and semaphorins (i.e. SEMA4D and SEMA7A) (Ten Hacken and Burger 2016), the 
ligands of which were mainly expressed by myeloid cells. Interestingly, and as observed in the 
human samples, CLL cells expressed the receptors for the pro-inflammatory molecules IFNg, 
TNFa, and CCL5, produced by the activated T-cell subsets, namely CD4+ TEF1-2, TIFN, TEX, and 
proliferating cells. Instead, signals that have been reported to inhibit CLL cell proliferation, like 
CD47- SIRPG or TGF-b secretion (Lagneaux et al. 1998; Martinez-Torres et al. 2015), were 
expressed by CD8+ TN, CD8+ TM, TN2, TIFN, myeloid, and proliferating cells. Of note, CD52 was 
expressed by both CLL cells and activated T-cell subsets, comparably to LNs of CLL patients 
(Figure 21B). 
On the other hand, T-cells – specifically TEX, CD4+ TEF1-2 and proliferating cells – were 
predicted to receive a variety of signals from CLL cells, including co-stimulatory ones via 
sialophorin (SPN) and integrin subunit alpha L (ITGAL) binding to intercellular adhesion 
molecule 1 (ICAM1) (Figure 21B). However, these subsets were also exposed to many other 
inhibitory signals, such as CD39- ADORA2A, PD-1 binding to both PD-L1 and PD-L2, and 
binding of lymphotoxin a (LTA) to TNFR1 and TNFR2 (Figure 21B).  
Overall, this data shows a complex intercellular relationship between TCL1 leukemic cells 
and their microenvironment, which was similarly identified in the human samples used in this 
work. Thus, it proves that the mouse model largely recapitulates the pathogenic situation taking 
place in CLL patients. 
4 Results   4.4 Single-cell RNA-seq-based T-cell profiling of the TCL1 AT mouse model 
 93 
 
Figure 21: Interactions between CLL cells and their microenvironment in the TCL1 AT 
mouse model resemble those in the human system. (A) Heatmap showing the number of 
predicted interactions between cell subsets. (B) Plot depicting significant curated ligand-
receptor interactions between CLL cells and all cell subsets. Dot color indicates combined log2 
mean expression of ligand and receptor. Size of the dots represents the p-value, calculated by 
permutation test. Gene names were substituted for the respective protein names for CD39 
(ENTPD1), CD45 (PTPRC), PD-1 (PDCD1), PD-L1 (CD274), PD-L2 (PDCD1LG2), TNFR1 
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 EOMES is necessary for anti-tumor activity of CD8+ T-cells in 
CLL 
4.5.1 EOMES expression in T-cells is associated with accessible chromatin  
Whole genome association studies have shown that a single-nucleotide polymorphism 
(SNP) located 13 kb 5’ upstream of the EOMES gene (rs9880772) is associated with a 
significantly increased risk to develop CLL (Berndt et al. 2016; Speedy et al. 2019). To identify 
cell types with a euchromatic state at the EOMES locus that could hence be functionally 
affected by the SNP, chromatin status as well as RNA expression of the EOMES gene were 
investigated in mature hematopoietic cells. This was performed in collaboration with Dr. 
Vicente Chapaprieta, from the Institut d’Investigacions Biomèdiques August Pi i Sunyer, 
Barcelona. More precisely, chromatin states resulting from the presence of the six histone 
marks H3K4me3, H3K4me1m, H3K27ac, H3K36me3, H3K27me3, or H3K9me3, together with 
RNA-seq data included in the reference epigenomes produced by the Blueprint project (The 
BLUEPRINT Consortium 2016), were examined. Open chromatin and active promoters, as 
well as RNA transcripts at the EOMES locus were mostly detected in NK-cells and T-cells, with 
memory CD8+ T-cells and NK cells presenting the highest RNA expression (Figure 22A). In 
contrast, a heterochromatic state and no EOMES expression were observed in B-cells at 
different maturation states. Next, EOMES mRNA expression in cell subsets from the 3 CLL 
LNs analyzed by single-cell RNA-seq was examined. In agreement with the previous 
observations, EOMES expression was highest in CD8+ TEM1, but was also present in CD4+ 
TEM1, TTOX and TF cell subsets. Notably, no expression was detected in CLL cells (Figure 22B). 
EOMES is a TF that regulates T-cell effector function (Intlekofer et al. 2008; Banerjee et al. 
2010; Pipkin et al. 2010) and has been associated with T-cell exhaustion in chronic infections 
and cancer (Li et al. 2018; Weulersse et al. 2020). To assess its role in CLL, the previously 
investigated mass cytometry data of CLL LNs was used to profile EOMES expression in CD8+ 
T-cells. The single-cell analyses showed that EOMES protein was mostly expressed in effector 
(TEF1 and TEF2), effector memory (TEM1, and TEM2), proliferating, and exhausted TEX cells, with 
the latter two showing the highest levels (Figure 22C, D). Intriguingly, TEM3 and TEM4 cells did 
express substantially less EOMES (Figure 22C), suggesting the existence of an alternative 
mechanism for memory differentiation and/or persistence. Notably, median EOMES protein 
expression was significantly higher in LNs of CLL samples in contrast to HC samples (Figure 
22E), likely as a reflection of the earlier reported higher frequencies of TEX, TEF1, and 
proliferating subsets (Figure 11D).  
Collectively, these data suggest that T-cells, but not CLL cells harbor open chromatin at the 
EOMES locus, thus enabling EOMES expression. Besides, EOMES protein levels are highest 
in CLL-derived exhausted CD8+ T-cells.  
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Figure 22: EOMES chromatin and transcriptomic status in hematopoietic cells. (A) 
Chromatin state at the EOMES locus derived from the integration of H3K4me3, H3K4me1 
H3K27ac, H3K36me3, H3K27me3 and H3K9me3 histone marks in hematopoietic cells of 
healthy individuals (n = 3, upper panel), together with RNA-seq signal from the reference 
epigenomes generated in the Blueprint project database (n = 3, scale = log2 RPKM) (lower 
panel). Data was generated in collaboration with Dr. Vicente Chapaprieta, from the Institut 
d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona (B) Violin plot depicting EOMES 
gene expression (UMI counts) in single-cell clusters identified in LNs from 3 CLL patients. (C) 
Violin plot showing EOMES signal intensity (SI) in clusters defined with mass cytometry 
analyses. (D) t-SNE plot depicting protein levels of EOMES, PD-1, CD39 and GZMK in CD8+ 
T-cells measured by mass cytometry. (E) Median EOMES protein levels in CLL (n = 21) 
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4.5.2 EOMES+ CD8+ T-cells accumulate in the Eµ-TCL1 mouse model and 
exhibit an exhausted phenotype 
To further characterize the role of EOMES in CLL, its expression was investigated in both 
the Eµ-TCL1 and the TCL1 AT mouse models of CLL. Importantly, Eomes transcripts in the 
single-cell transcriptome dataset of TCL1 AT mice were restricted to effector and memory T-
cells, but absent in CLL and myeloid cells (Figure 23A). Besides, they were most abundant in 
TEX cells co-expressing Pdcd1 and Lag3 genes, as observed in human T-cells.  
Figure 23: EOMES+ CD8+ T-cells accumulate in the TCL1 mouse models. (A) Gene 
expression (UMI counts) of Eomes, Pdcd1 and Lag3 in single-cell data from TCL1 AT mice. 
(B) Fraction of EOMES+ cells out of CD8+ T-cells in TCL1 AT (n = 5) and respective control 
mice (n = 7). (C) Percentage of naïve, memory and effector cells in WT compared to TCL1 AT 
mice. (D) Normalized fluorescence intensity (nMFI) of EOMES in effector and memory PD-1- 
LAG3- and PD-1+ LAG3+ CD8+ T-cells form TCL1 AT mice (n = 4). (E) Fraction of EOMES+ out 
of CD8+ T-cells in age- and sex- matched Eµ-TCL1 (n= 8) and WT mice (n = 8). (F) Percentage 
of naïve, memory and effector cells in WT and Eµ-TCL1 mice. (G) EOMES nMFI values in PD-
1- LAG3- and respective double positive effector and memory CD8+ T-cells in Eµ-TCL1 mice. 
Mean and SEM are depicted, and single dots represent each mouse analyzed (*p<0.05, 
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At the protein level, flow cytometry analyses revealed an increase of EOMES+ CD8+ T-cells 
in TCL1 AT compared to age- and sex-matched WT mice (Figure 23B), likely as a result of the 
known T-cell skewing towards antigen-experienced effector and memory T-cells (Figure 23C) 
(McClanahan et al. 2015b; Hanna et al. 2019). EOMES levels in exhausted T-cells were next 
examined in tumor-bearing mice. In concordance with the transcriptomic data, PD-1+ LAG3+ 
effector and memory CD8+ T-cells exhibited higher EOMES levels in comparison with their 
double-negative counterparts (Figure 23D). Lastly, similar results were detected in the 
transgenic Eµ-TCL1 mice (Figure 23E-F), which, as a consequence of their disease onset at 
advanced age, exhibited an overall higher percentage of EOMES+ cells. Moreover, EOMES 
levels were likewise significantly increased in exhausted PD-1+ LAG3+ T-cells compared to 
non-exhausted memory and effector cells in these mice (Figure 23G). 
Taken together, these results illustrate that both the Eµ-TCL1 and the TCL1 AT mouse 
models recapitulate the accumulation of EOMES+ CD8+ T-cells in the TME of CLL patients, 
and its higher expression in exhausted T-cells.  
 
4.5.3 Eomes-deficient CD8+ T-cells fail to expand and control CLL development 
in the TCL1 AT mouse model 
Following the previous observations, the question arises whether EOMES has an effect on 
CLL-tumor control via regulation of T-cell function. To investigate the role of EOMES in T-cell-
mediated control of CLL, Eomes knock-out (Eomes-/-) BM chimera were generated using 
Rag2-/- mice, which fail to produce mature T- and B-cells (Shinkai et al. 1992). Next, mice were 






























































Figure 24: Eomes-deficiency in the TME of TCL1 AT mice leads to impaired tumor 
control. Rag2-/- mice were irradiated and subsequently injected with either WT or Eomes-/- BM 
cells. Next day, mice were injected with leukemia cells from TCL1 mice. (A) Absolute counts 
of CD5+ CD19+ CLL cells in peripheral blood 2 and 4 weeks after tumor injection in Eomes-/- 
BM chimera (n = 7) and WT BM chimera mice (n = 8) as determined by flow cytometry. (B) 
Spleen weight and (C) absolute counts of CLL cells in spleen at experimental endpoint (4 
weeks after tumor injection). Horizontal and vertical bars display mean and SEM respectively. 
Each dot symbolizes one mouse (**p<0.01, ***<0.001, Mann-Whitney U test). 
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were examined by flow cytometry. Surprisingly, tumors developed faster in mice with an 
Eomes-deficient hematopoietic system compared to WT BM chimeric Rag2-/- mice, as 
measured in PB over time (Figure 24A). In accordance with this, Eomes-/- mice also presented 
a higher tumor burden in spleen at the experimental end-point 4 weeks later, with both 
increased spleen weight (Figure 24B) and CLL numbers per spleen (Figure 24C).  
This enhanced tumor growth in Eomes BM-deficient mice was accompanied by diminished 
CD8+ T-cell numbers in spleen (Figure 25A) and a reduced percentage of KI-67+ CD8+ T-cells 
(Figure 25B), hinting at an impaired tumor control due to a lack of expansion of these cells. 
However, CD8+ T-cells did not differ in their phenotype, as similar proportions of naïve, memory 
Figure 25: CD8+ T-cells from Eomes-/- BM chimeric mice fail to expand upon leukemic 
cell transplantation. (A) Absolute counts of CD8+ T-cell per spleen in WT versus Eomes-
deficient BM chimeric Rag2-/- mice. (B) Representative histograms and percentages of KI-67+ 
cells among CD8+ T-cells in spleen. (C) Percentage naïve, memory and effector subsets out 
of total CD8+ T-cells. (D) Representative histogram and precentages of PD-1+ CD8+ T-cells. 
(E) Frequencies of TNFa+, (F) GZMB+, and (G) IFNg+ cells among CD8+ T-cells after ex vivo 
stimulation with PMA and ionomycin for 6 hours. Graphs show mean ± SEM, with each dot 
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and effector T-cells were identified (Figure 25C). Besides, comparable frequencies of cells 
expressed the effector molecules GZMB, TNFa and IFNg after ex vivo stimulation with phorbol 
myristate acetate (PMA) and ionomycin (Figure 25D-F). Intriguingly, the lack of EOMES was 
associated with a higher frequency of CD8+ T-cells expressing PD-1 (Figure 25G). These 
results indicate that lack of CD8+ T-cell expansion is involved in the impaired tumor control of 
Eomes-deficient mice. 
To corroborate these observations and exclude the implication of other cells in the 
microenvironment, such as CD4+ T-cells, Eomes-/- or WT CD8+ T-cells were injected in Rag2-/- 
mice. The following day, these mice were injected with TCL1 leukemic cells, and tumor 
development was monitored. Similar to the Eomes-/- BM chimera, leukemia development 
occurred significantly faster in mice that had received Eomes-/- CD8+ T-cells compared to mice 
injected with WT CD8+ T-cells. This was determined based on absolute numbers of CLL cells 
in PB over time (Figure 26A), as well as by an increased spleen weight and tumor content in 
this organ at experimental end-point, 4 weeks after tumor cell injection (Figure 26B-C).  
Likewise, CD8+ T-cells lacking EOMES expanded significantly less in leukemic Rag2-/- mice 
than their WT counterparts, as they were present in lower numbers in spleen (Figure 27A). 
The frequency of naïve, memory and effector subsets remained unchanged (Figure 27B), as 
well as the proportion of cells expressing the effector molecules TNFa, GZMB and IFNg after 
ex vivo stimulation with PMA and Ionomycin (Figure 27C-E). 
In summary, these observations reveal an essential role of EOMES for CD8+ T-cell 
expansion and maintenance in mice that develop CLL-like disease, which results in an 

































































Figure 26: Leukemia development is enhanced in Rag2-/- mice transplanted with 
Eomes- /- CD8+ T-cells. WT or Eomes-/- CD8+ T-cells were injected into Rarg2-/- mice prior 
leukemia cell transplantation. (A) Absolute numbers of CD5+ CD19+ CLL cells in PB 2 and 3 
weeks after tumor injection of Rag2-/- mice injected with Eomes-/- (n = 5) or WT (n = 5) CD8+ 
T-cells as measured by flow cytometry. (B) Spleen weight of injected mice at experimental 
end-point. (C) Absolute counts of CLL cells in spleen. Graphs display mean ± SEM, and each 
dot represents one mouse (*p>0.05, Mann-Whitney U test). 
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 The anti-tumor activity of CD4+ T regulatory type 1 cells is 
controlled by EOMES and IL-10 
4.6.1 CLL LNs exhibit increased numbers of EOMES+ PD-1+ TR1-like CD4+ T-
cells 
EOMES has been described to regulate the development of CD4+ type 1 regulatory T-cells 
(TR1) (Zhang et al. 2017; Gruarin et al. 2019). These cells characteristically produce IL-10, 
GZMK and IFNg (Gruarin et al. 2019; Mazzoni et al. 2019), express several inhibitory receptors 
such as PD-1, TIGIT, CD39 and LAG3, and have immunosuppressive functions (Roncarolo et 
al. 2018). However, their role in tumor development remains elusive and completely undefined 
in CLL. Hence, the presence of CD4+ TR1 was investigated in CLL patients. First, examination 
of CD4+ T-cells from CLL LNs analyzed by single-cell RNA-seq identified 9 clusters, which 
included naïve, Tregs, memory, and effector memory T-cells (Figure 28A). Interestingly, a 
cluster of cells differentially expressed PDCD1, TIGIT and several granzymes, including GZMK 
(Figure 28B). 
Figure 27: Eomes-/- CD8+ T-cells fail to expand upon CLL cell transplantation into Rag2-/- 
mice. (A) CD8+ T-cells numbers per spleen in mice injected with Eomes-/- or WT CD8+ T-cells. 
(B) Pecentage of naïve, memory and effector CD8+ T-cells. (C-E) Frequency of (C) TNFa+, (D) 
GZMB+, and (E) IFNg+ CD8+ T-cells after ex vivo stimulation with PMA and Ionomycin for 6 
hours. Graphs display mean ± SEM and each dot represents one mouse (*p>0.05, **>0.01, 
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In addition, these cells expressed EOMES, LAG3 and IL10 genes (Figure 28B-C), thus highly 
resembling TR1 cells. Next, and further confirming the presence of TR1 cells in CLL LNs, a 
subset of effector memory CD4+ T-cells co-expressing EOMES+ PD-1+ was identified with 
mass cytometry analyses of CD4+ T-cells (Figure 28D-E). This subset also expressed other 
inhibitory receptors like TIGIT and CD39, and produced GZMK (Figure 28E). Last, the 
distribution of TR1 cells in the different tissues, as well as sample condition – i.e. CLL versus 
control samples – was inspected. Intriguingly, a significantly higher frequency of TR1-like cells 
was found in LNs compared to PB and BM (Figure 28F), underscoring an implication of these 
cells in the CLL TME niche. Moreover, TR1 cells were significantly enriched in CLL LNs 
compared to healthy controls (Figure 28G). 
Altogether, these results confirm the accumulation of TR1 cells in the LNs of CLL patients, 
and thus suggest the possibility of a pathological involvement of this cell subset in CLL.  
 
4.6.2 TR1 cells accumulate in the Eµ-TCL1 mouse model 
To further investigate the role of TR1 cells in CLL, their presence was analyzed in the Eµ-
TCL1 and TCL1 AT mouse models of CLL. For this purpose, splenocytes from end-stage 
diseased mice were isolated, stained, and analyzed by flow cytometry. In both models, a 
significantly higher fraction of EOMES+ PD-1+ TR1-like cells was measured in the leukemia-
bearing mice compared to their respective age- and sex-matched WT controls (Figure 29A). 
Interestingly, the frequency of TR1 cells was higher in aged Eµ-TCL1 mice compared to the 
younger TCL1 AT mice, in line with a previously described accumulation of EOMES+ CD4+ T-
cells with age (Lupar et al. 2015). Additionally, the majority of TR1 cells in TCL1 AT mice 
expressed LAG3 (Figure 29B), further corroborating their TR1 phenotype (Gagliani et al. 2013). 
Next, the Il-10 reporter mice Fir x Tiger were used to investigate IL-10 production upon 
leukemia development. Interestingly, an accumulation of FOXP3- IL-10-producing CD4+ T-cells 
co-expressing PD-1 was detected in all leukemic mice while being completely absent in 
unchallenged controls (Figure 29C), thus indicating a CLL-specific increase of IL-10-producing 
TR1 cells.  
Figure 28: EOMES+ PD-1+ TR1-like cells accumulate in CLL LNs. (A) t-SNE plot of CD4+ T-
cells analyzed by single-cell RNA-seq. Identified clusters are distinguished with different 
colors. (B) RNA expression of EOMES, PDCD1, TIGIT, LAG3 and GZMK in CD4+ T-cells. (C) 
Violin plots depicting IL10 RNA expression in the CD4+ T-cell clusters (D) t-SNE plot of 1 x103 
CD4+ T-cells analyzed by mass cytometry displaying the 15 identified clusters classified 
according to differential protein expression. Clusters are given with different colors. (E) Protein 
expression of EOMES, PD-1, TIGIT, CD39 and GZMK in CD4+ T-cells. (F) Frequency of TR1 
cells in LN (n = 22), PB (n = 8) and BM (n = 3) of CLL patients. (G) Frequency of TR1 cells in 
LN (n = 21), compared to HC (n = 13) (*p<0.05, **<0.01, Mann-Whitney U test). A complete 
characterization of the CD4+ T-cell compartment has been described elsewhere (Paul 2020). 
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In summary, this data thus shows that IL-10 producing TR1 cells accumulate upon leukemia 
development in the Eµ-TCL1 and TCL1 AT mouse models of CLL. 
 
4.6.3 EOMES is essential for TR1-mediated tumor control in TCL1 AT mice 
Even though numerous reports describe an accumulation of TR1 cells in several types of 
cancers, including Hodgkin’s lymphoma, head and neck squamous cell carcinoma, and 
colorectal cancer, the role of TR1 cells in the tumor microenvironment remains under debate 
(Bergmann et al. 2008; Dennis et al. 2013; Scurr et al. 2014). In order to investigate the impact 
of TR1 cells on leukemia progression, the conditional Eomes-/- mice were used, as EOMES has 
an essential role for the development of functional TR1 cells (Zhang et al. 2017; Gruarin et al. 
2019). For this purpose, Rag2-/- mice were transplanted with CD4+ T-cells isolated from 
Figure 29: IL-10 producing TR1 cells expand in TCL1 leukemic mice. (A) Representative 
dot plots (left and center panels) as well as proportion (right graph) of TR1 (EOMES+ PD-1+) 
cells among CD4+ T-cells in Eµ-TCL1 (n = 8) (upper row) and TCL1 AT (n = 7) (lower row) 
mice including respective WT controls (n = 8, n = 5, respectively). (B) Representative 
histogram (upper panel) and proportion of LAG3+ among TR1 cells in WT (n = 5) and TCL1 AT 
mice (n = 7) (lower graph). (C) Representative dot plots (left and center panels) and percentage 
of IL-10-GFP+ PD-1+ cells out of FOXP3- CD4+ T-cells in WT (n = 2) and TCL1 AT FIR x Tiger 
mice (n = 5) (right panel) (**p<0.01, ***<0.001, Man-Whitney test). Data was generated in 
collaboration with Dr. Philipp Rößner and Dr. Bola Hanna from the Department of Molecular 
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spleens of either Eomes-/- or Eomes+/+ Il10-GFP reporter mice, prior to adoptive transfer of 
TCL1 leukemia cells. Surprisingly, significantly higher amounts of CLL cells were measured in 
PB of mice injected with Eomes-/- CD4+ T-cells compared to those injected with WT CD4+ T-
cells (Figure 30A). In line with this, mice injected with Eomes-deficient CD4+ T-cells showed 
higher spleen weight (Figure 30B) and tumor load in this organ (Figure 30C). 
Monitoring the expansion and phenotype of the transplanted CD4+ T-cells revealed a higher 
amount of Eomes-/- CD4+ T-cells compared to WT cells in PB of leukemic mice over time 
(Figure 31A). However, Eomes-/- CD4+ T-cell absolute counts per spleen (Figure 31B), as well 
as counts per CLL cell (Figure 31C) were significantly lower when measured at the 
experimental end-point. Accordingly, a lower fraction of Eomes-deficient T-cells proliferated in 
the spleen, as measured by KI-67 staining (Figure 31D), further indicating that EOMES is 
associated with TR1 expansion in CLL. Moreover, lack of EOMES resulted in an inferior fraction 
of CD4+ T-cells expressing the TR1 marker proteins LAG3 (Figure 31E), and IL10 (Figure 31F), 
as well as IFNg (Figure 31G), CD107A, and GZMB (Figure 31H) molecules, involved in effector 
function. 
Collectively, these data highlight an essential role of EOMES for the control of CLL 







































































Figure 30: Leukemia growth is enhanced in Rag2-/- mice transplanted with Eomes-/- CD4+ 
T-cells. Rag2-/- mice were transplanted with Eomes-/- or WT CD4+ T-cells prior injection of 
leukemia cells the following day. (A) Leukemic CD5+ CD19+ cell count in peripheral blood of 
Rag2-/- mice injected with WT (n = 6) or Eomes-/- (n = 8) CD4+ T-cells as measured by flow 
cytometry over time. (B) Spleen weight of mice at experimental end-point. (C) Absolute CLL 
cell counts per spleen at experimental end-point. Graphs show mean ± SEM and each dot 
represents one mouse (*p>0.05, ***>0.001, Mann-Whitney U test). 
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4.6.4 IL10 receptor is essential for the tumor-control function of TR1 
IL-10 receptor (IL10R) signaling has been shown to be essential for TR1 function 
(Brockmann et al. 2017). To investigate the role of IL10R-mediated signaling in TR1 cells and 
its impact in CLL control, either Il10rb-/- or Il10rb+/+ CD4+ T-cells were injected into Rag2-/- mice 
prior to TCL1 adoptive transfer. Interestingly, mice injected with Il10rb-deficient CD4+ T-cells 











































































































































































































Figure 31: EOMES is necessary for TR1-mediated tumor control in TCL1 AT mice. (A)   
Absolute numbers of CD5+ CD19+ CLL cells in PB of Rag2-/- mice injected with Eomes-/- or WT 
CD4+ T-cells over time. (B) CD4+ T-cell counts per spleen as well as (C) per CLL cell at 
experimental end-point (4 weeks after leukemia injection). (D) Fraction of KI-67+ among CD4+ 
cells. (E) Percentage of LAG3+ cells among PD-1+ CD4+ T-cells. (F) Representative histogram 
(left panel) and quantification (right graph) of the percentage of IL10-GFP expressing PD1+ 
CD4+ T-cells. (G) Representative histogram (left) and fraction of IFNg+ cells among PD-1 CD4+ 
T-cells, as well as (H) nMFI of CD107A and GZMB among PD-1 CD4+ T-cells after ex vivo 
stimulation with PMA and Ionomycin. Graphs display mean ± SEM and each dot represents 
one mouse (**p>0.01, ***>0.001, Mann-Whitney U test). 
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point in spleen (Figure 32B-C), indicating that Il10rb-/- CD4+ T-cells control tumor growth less 
efficiently than their WT counterparts. 
To further assess the contribution of CD4+ T-cells in the observed decrease of tumor control, 
T-cell expansion was monitored over time in PB. CD4+ T-cell counts were increased in mice 
injected with Il10rb-/- CD4+ T-cells compared to those injected with WT CD4+ T-cells three and 
four weeks after tumor transplantation (Figure 33A). A similar trend was observed in spleen at 
the experimental end point (Figure 33B), possibly due to the bigger spleen size (Figure 32B), 
as the number of CD4+ T-cells per CLL cell was reduced in these mice (Figure 33C). In 
addition, no significant difference in proliferation of CD4+ T-cells was found between the two 
groups (Figure 33D). Since the proportion of TR1 cells was significantly higher in mice that had 
received Il10rb-deficient CD4+ T-cells (Figure 33E), the effect of IL10R signaling on TR1 
phenotype and effector function was subsequently analyzed. Clustering of FOXP3- CD4+ T-
cells based on the expression of KI-67, LAG3, PD-1 and EOMES as measured by flow 
cytometry, revealed phenotypic differences between the EOMES+ PD-1+ TR1-like cells of 
Il10rb-/- origin and the WT TR1 cells (Figure 33F), likely driven by a higher expression of PD-1 
(Figure 33G). Moreover, a reduced cytotoxic function of Il10rb-/- EOMES+ PD-1+ CD4+ T-cells 
compared to WT TR1 cells was identified, as measured by IFNg, CD107A and GZMB 
expression upon ex vivo stimulation (Figure 33H, I). 
Altogether, these results underscore that EOMES is indispensable for the accumulation of 





Figure 32: CLL progression is enhanced in Rag2-/- mice injected with Il10rb-/- CD4+ 
T-cells. Rag2-/- mice were injected with WT or Il10rb-/- CD4+ T-cells or PBS and transplanted 
with TCL1 leukemia cells the following day. (A) CD5+ CD19+ CLL cell counts over time in 
PB of Rag2-/- mice injected with Il10rb-/-, WT CD4+ T-cells or PBS. (B) Spleen weight and 
(C) CLL cell counts in this organ at experimental end-point (4 weeks after leukemia 
injection). Mean ± SEM is shown, and each dot represents one mouse (*p>0.05, **>0.01, 















































































Figure 33: IL10R signaling is essential for TR1-mediated control of CLL in Rag2-/- mice. 
(A) CD4+ T-cell counts over time in PB of Rag2-/- mice transplanted with either Il10rb-/- (n = 6) 
or WT (n = 5) CD4+ T-cells. (B-C) CD4+ T-cell numbers (B) per spleen and (C) per CLL cell at 
experimental end-point (4 weeks after leukemia transplantation). (D) Percentage of KI-67+ cells 
out of CD4+ T-cells. (E) Fraction of TR1 cells out of CD4+ T-cells. (F) A t-SNE plot with 
concatenated WT and Il10rb-/- CD4+ T-cells based on the expression of KI-67, LAG3, PD-1 and 
EOMES was generated. Marker expression for clustered CD4+ T-cells is shown. (G) 
Distribution of Il10rb-/- (top left) and WT (bottom left) TR1 (EOMES+ PD-1+) cells in the t-SNE 
plot, and highlighted in green and black, over the rest of CD4+ T-cells, in grey (middle plot). 
Histograms of marker expression in TR1 cells are shown (right panels). (H) Representative 
histogram (left panel) and percentage (right graph) of IFNg-expressing TR1 cells, as well as (I) 
CD107A and GZMB+ cells after ex vivo stimulation with PMA and Ionomycin. Mean ± SEM is 
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5 Discussion 
Knowledge of CLL-associated changes in the T-cell compartment has rapidly evolved over 
the last few decades. Even though it is currently clear that CLL development elicits an 
accumulation of both CD4+ and CD8+ antigen-experienced T-cells (Totterman et al. 1989; 
Brusa et al. 2013; Hanna et al. 2019), it remains uncertain whether they support CLL-cell 
survival and proliferation, or instead, control disease progression. In addition, discouraging 
results obtained in clinical trials using immune checkpoint inhibitors and CAR-T-cell treatments 
(Porter et al. 2015; Ding et al. 2017) highlight the need for a deeper understanding of the 
distinct T-cell phenotypes associated with CLL. Finally, further investigation of the T-cells 
residing in the secondary lymphoid organs, where interactions between leukemic cells and 
their microenvironment occur, is especially necessary. 
To address these unresolved questions, the present work aimed at characterizing the 
distribution, phenotype, and function of T-cells from CLL patients using single-cell 
transcriptome and mass cytometry analyses. These data were complemented with studies 
using the TCL1 mouse model, in order to resolve the role of specific T-cell subsets in CLL. 
This work constitutes the first study to examine CLL T-cells at the single-cell level, thereby 
unraveling the distinct T-cell subsets present in CLL and their differential compartmentalization 
in lymphoid tissues. Besides, it identifies an EOMES-dependent tumor-control function for both 
CD8+ T-cells and CD4+ TR1 cells. 
 
 Single-cell analyses identify the CLL lymph node as a distinct 
niche where exhausted CD8+ T-cells accumulate 
Single-cell technologies have provided valuable insight into T-cell heterogeneity and 
function in cancer, with the aim to improve immunotherapeutic interventions. While mass 
cytometry analyses permit an unsupervised clustering of a substantial number of cells based 
on their protein expression, it requires the a priori selection of a limited number of markers, 
restricting the investigation of cell phenotypes. Conversely, single-cell RNA-seq is a completely 
unbiased approach, but is currently limited by its high cost, and the reported modest correlation 
between mRNA transcripts and protein levels (Maier et al. 2009; Schwanhausser et al. 2011). 
The combinatorial use of both technologies in this work thus allowed a sophisticated and 
multilevel analysis, while limiting the individual shortcomings of the two techniques. 
Importantly, the integration of the two methods confirmed that they identify equivalent cell 
subsets in comparable frequencies, which validates the analyses performed using either 
approach.  
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On the one hand, the mass cytometry analyses performed herein allowed to go beyond the 
investigation of the canonical TN, TCM, TEF and TEM CD8+ T-cell subsets, as typically done with 
flow cytometry, and shed light into the degree of heterogeneity present within these cell 
subtypes. More specifically, two subsets of TEF cells, as well as six TEM subsets were defined, 
each exhibiting a distinct immunophenotype. In addition, a subset of CD8+ TFC cells, with 
intermediate levels of both exhaustion and naïve markers was newly identified in CLL LNs. 
Similar CXCR5+ CD8+ T-cells have been characterized in tonsils, or LN samples from patients 
with follicular lymphoma, diffuse large B-cell lymphoma, and Hodgkin lymphoma (Tang et al. 
2017; Le et al. 2018; Chu et al. 2019); but also as tumor-infiltrating lymphocytes in several 
solid tumor entities, such as lung, colorectal, and pancreatic cancers (Bai et al. 2017; 
Brummelman et al. 2018; E et al. 2018). In these contexts, CD8+ TFC cells exert an anti-tumor 
function via cytokine secretion and direct tumor-cell killing (Bai et al. 2017; Tang et al. 2017; 
Brummelman et al. 2018; E et al. 2018). Besides, these CXCR5+ CD8+ T-cells harbor stem-
like features and have been suggested to be equivalent to the precursor exhausted TCF7+ PD-
1int CD8+ T-cells identified in chronically infected mice (Brummelman et al. 2018). In the present 
work, however, the absence of effector molecules at the single-cell transcriptome and protein 
level failed to provide any evidence that the described CD8+ TFC cells kill CLL cells. Instead, 
the gene expression profile and the cell-cell interaction analyses suggested that they might 
have functions similar to germinal center-residing CD4+ TFH cells, which promote maturation 
and proliferation of B-cells via CD40 ligation (Grewal and Flavell 1998; Gaspal et al. 2006; 
Vinuesa et al. 2016). At the same time, neither the immunophenotypic nor the transcriptomic 
characteristics of these CD8+ TFC cells provided any indication that they constitute a precursor 
state of exhausted T-cells.  
Intriguingly, the present work described a subset of T-cells that are both CD4+ and CD8+ 
double positive (DP cells), and express high levels of PD-1 and other exhaustion-related 
markers. DP cells have been detected in samples of healthy LNs, breast cancer, melanoma, 
Hodgkin lymphoma, and colorectal cancer (Rahemtullah et al. 2006; Desfrancois et al. 2009; 
Desfrancois et al. 2010; Sarrabayrouse et al. 2011; Overgaard et al. 2015), but an exhausted-
like state as the one herein recognized has not been previously described in these cells.  
Finally, the identification of a TEM cluster with an exhaustion phenotype is of particular 
relevance, given the implication of exhausted T-cells for the success of immunotherapies (Im 
et al. 2016; Utzschneider et al. 2016; Miller et al. 2019; Siddiqui et al. 2019). Exhausted T-cells 
are commonly defined by an increased expression of inhibitory receptors and a reduced 
cytotoxicity (Wherry 2011). The present work does not provide a direct functional assessment 
of the identified TEX cells, and thus whether they retain effector capabilities remains unclear. 
Nevertheless, the elevated protein expression of the inhibitory receptors PD-1 and TIGIT, as 
well as the exhaustion markers CD39, EOMES, and TOX, and the reduced levels of GZMK, 
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highly resemble the phenotype of TEX cells defined in several tumor entities (Chevrier et al. 
2017; Lavin et al. 2017; Bengsch et al. 2018). Interestingly, TEM1 and TEM2 GZMK+ subsets, 
which showed intermediate levels of the exhaustion markers and higher GZMK expression, 
likely correspond to an intermediate functional state, as previously described by inferred 
developmental trajectories in single-cell studies in melanoma, liver cancer, breast cancer, and 
non-small-cell lung cancer (Zheng et al. 2017; Guo et al. 2018; Li et al. 2019; Wagner et al. 
2019). The application of similar methods to ascertain cell differentiation dynamics would be 
useful to confirm the relation of TEM1 and TEM2 GZMK+ subsets with TEX cells.  
 
On the other hand, single-cell RNA-seq analyses of T-cells from CLL LNs determined cell 
subsets based on their differential gene expression. In general, the transcriptome profile of the 
identified cell clusters strongly resembled that of subsets described in numerous studies 
investigating T-cell heterogeneity in various tumor types, where similar marker genes denoted 
TN, cytotoxic T-cells, Tregs, follicular T-cells, as well as CD8+ and CD4+ TEM cells (Tirosh et al. 
2016; Chung et al. 2017; Puram et al. 2017; Li et al. 2019; Aoki et al. 2020; Kim et al. 2020; 
Roider et al. 2020). The presence of similar phenotypes therefore suggests that a largely 
analogous T-cell response is elicited upon tumor growth in solid and hematopoietic cancers 
(van der Leun et al. 2020).  
However, clustering of all cells including CLL cells and both CD4+ and CD8+ T-cells 
delivered limited information on the different CD8+ T-cell subsets. Thus, further CD8+ T-cell-
specific clustering allowed to inspect the transcriptomic differences between these cells. 
Specifically, CD8+ TEM cells could be divided in several subsets, which differed in the 
expression of several genes related to cytotoxic function, including granzymes and 
chemokines, as well as heat-shock proteins. Although a cluster of cells expressing heat-shock 
proteins has been described in melanoma (Sade-Feldman et al. 2018), an interpretation of its 
biological relevance should be taken with caution, since heat-shock and stress response gene 
expression changes could originate from technical artifacts linked to sample preparation 
(O'Flanagan et al. 2019). Independently of this, differential protein levels of granzymes and 
other cytokines have been reported in CD8+ T-cells from PB upon antigen recognition 
(Sandberg et al. 2001; Bade et al. 2005), indicating the existence of CD8+ T-cell subsets with 
distinct cytotoxic properties. Interestingly, the observation that individual TCR clones were 
shared by the TEM2 CCL4+ and TEM4 GZMH+ subsets suggests that these cells are not 
completely independent of each other, but might constitute cell state transitions. Indeed, the 
existence of such relationship between T-cell subsets sharing the same TCR sequences has 
been further supported with trajectory analyses on CD8+ T-cells from non-small-cell lung 
cancer (Guo et al. 2018). The identification of TEM3 GZMK+ cells may, in turn, represent further 
evidence for the presence of the above-mentioned pre-dysfunctional population in CLL. 
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Notably, no TEM subset overexpressed inhibitory receptors or other exhaustion-related 
markers, hampering the definition of a TEX subset. This observation differs from numerous 
single-cell RNA-seq studies of infiltrating T-cells in solid tumors, in which a subset of T-cells 
displaying features of exhaustion was described (Tirosh et al. 2016; Zheng et al. 2017; Sade-
Feldman et al. 2018; Li et al. 2019). The lack of a specific TEX subset in the present work might 
be explained by the lower number of cells and samples analyzed, which could have hindered 
the identification of small cell populations, especially if their phenotype is highly similar to other 
subsets, like TEM3 GZMK+ cells.  
 
In addition to immunophenotyping the CD8+ T-cells from PB, BM and LNs of CLL patients, 
the analysis of the cell subset distribution revealed significant differences between the three 
compartments, underlining the effect of the tissue environment on the diversity of T-cell states. 
PB samples contained increased frequencies of TEF2 TBET+ and TEM3 KLRG1+ TBET+ subsets, 
in line with a reported expansion of TBET-expressing effector CD8+ T-cells in blood versus 
LNs of CLL patients (Riches et al. 2013; de Weerdt et al. 2019; Hanna et al. 2019). Intriguingly, 
BM tissue composition resembled that of PB rather than LN. This observation together with 
the previously described lower CLL cell proliferation rate in this tissue suggests that BM is not 
a central location for leukemia development and interactions between malignant B-cells and 
their TME (van Gent et al. 2008; Herndon et al. 2017). Nevertheless, a contamination of T-
cells from PB during biopsy acquisition, which would mask the real BM composition, cannot 
be excluded, and thus future experiments should validate these observations.  
Interestingly, the unique presence of several T-cell subsets in LNs defined this tissue as a 
distinct niche. On the one hand, CD8+ TFC and TEM4 ICOS+ were found in higher percentages 
in LNs, in accordance with their physiological function in the formation and maintenance of 
GCs in SLOs (Crotty 2011; Wikenheiser and Stumhofer 2016). On the other hand, earlier 
studies have described an enrichment of TEM cells in LN compared to PB of CLL patients, as 
well as an increased percentage of PD-1-expressing cells (de Weerdt et al. 2019; Hanna et al. 
2019). Importantly, the results of the present work confirm and further expand on these 
observations, reporting higher frequencies of TEM2 GZMK+, TEX, and proliferating cells in LNs. 
Given the increased interactions occurring between CLL cells and their surrounding cells in 
LNs compared to PB (Herishanu et al. 2011; Pasikowska et al. 2016; Herndon et al. 2017), it 
is tempting to speculate that the LN niche facilitates chronic TCR stimulation by constant 
antigen exposure and persistence of inflammatory signals, thereby contributing to T-cell 
exhaustion (Wherry 2011). Overall, the divergence between the two tissues, and specially the 
accumulation of TEX cells in LNs, which is poorly reflected in PB, highlights that biomarkers 
based on blood T-cells might not accurately reflect the LN T-cell composition. Thus, further 
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evaluation of T-cell phenotypic characteristics particularly in this tissue is needed in order to 
better understand the functional role of the diverse T-cell subsets in leukemia progression.  
 
Finally, one fascinating observation was made upon association of CD8+ T-cell subset 
frequencies with clinical factors: different percentages of CD8+ TEM4 ICOS+ cells were found 
between IGHV-mutated and unmutated patients. Importantly, an analogous CD4+ TEM ICOS+ 
population identified upon CD4+ T-cell investigation, was likewise enriched in IGHV-mutated 
compared to unmutated CLL patients (data not shown, described by Paul, 2020), suggesting 
that ICOS expression in T-cells is linked to IGHV mutational status in CLL. ICOS is a member 
of the immunoglobulin family of co-receptor molecules that is rapidly induced upon TCR 
activation (Hutloff et al. 1999; Yoshinaga et al. 1999; McAdam et al. 2000) and has been 
described to play a co-stimulatory function in T-cell adaptive immunity (Arimura et al. 2002). In 
addition, it has also been linked with the generation of class-switched antibodies and germinal 
center reaction when binding to ICOSL in APCs (Yoshinaga et al. 2000; Hu et al. 2011). Given 
the aforementioned function, it is tempting to speculate that the distinctive presence of ICOS-
expressing T-cells in IGHV-mutated and unmutated cases might be linked to the proposed 
different cellular origin of CLL cells (Seifert et al. 2012). Accordingly, post-GC IGHV-mutated 
CLL cells might promote the accumulation of ICOS+ T-cells, whereas pre-GC IGHV-unmutated 
ones would not. Future studies should focus on understanding the role of ICOS+ T-cells in the 
TME niche in CLL, including additional experimental validation of these results with a larger 
patient cohort. 
 
 CLL elicits a tumor-specific CD8+ T-cell response 
It has been extensively described that increased numbers of antigen-experienced CD8+ T-
cells are found in patients with CLL in comparison to healthy individuals (Nunes et al. 2012; 
Brusa et al. 2013; Gothert et al. 2013; Riches et al. 2013; Palma et al. 2017). However, the 
question whether these cells are bystanders that accumulate as a consequence of tumor-
related microenvironmental changes, or whether they recognize and react against CLL cells is 
still under debate. In addition, because SLOs are also the site of effector T-cell accumulation 
during infections, leukemia-associated alterations can be masked by co-occurring immune 
responses against pathogens. Infections are, in fact, especially prevalent in CLL patients, in 
which leukemia-induced immunosuppression often leads to reactivation of EBV or CMV 
infections (Riches and Gribben 2013; Forconi and Moss 2015; Garcia-Barchino et al. 2018). 
Partly addressing this question, studies have reported an association between CD8+ T-cell 
numbers and tumor load (Catovsky et al. 1974; Totterman et al. 1989; Hanna et al. 2019), and 
the CD8+ T-cell per CLL-cell ratio has been linked to improved overall survival of CLL patients 
(Gonzalez-Rodriguez et al. 2010). In addition, Kowalewski et al. identified CLL-specific 
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antigens and demonstrated that a T-cell immune recognition of tumor cells occurred only in 
patients and not in healthy controls, and that the patients displaying such immune responses 
had, in turn, a survival benefit (Kowalewski et al. 2015). With these observations, the 
hypothesis that CD8+ T-cells react against malignant cells has been increasingly gaining 
attention. However, most of these studies have only investigated cells isolated from PB, and 
have not compared T-cell phenotypes between CLL and tumor-free LN samples. The present 
work provides four novel layers of evidence that further support a leukemia-directed T-cell 
immune response. 
First, changes in subset frequencies distinguished CLL LNs from rLNs of cancer-free 
donors, emphasizing the existence of specific CLL-associated changes in the T-cell 
compartment. More precisely, the decreased percentage of TN cells in CLL LNs largely 
contributed to the separation of CLL from control samples. In addition, one of the central 
findings of this work is that exhausted T-cells accumulate in CLL LNs compared to healthy 
controls, as observed by the increased frequency of TEX CD39+ and proliferating cells, together 
with a tendency of higher TEM2 GZMK+ numbers in patient samples. This observation would 
not only support the idea of the accumulation of tumor-reactive T-cells but also confirm the 
existence of a dysfunctional T-cell subset induced by CLL cells. In fact, CD39 has recently 
been described to be present on tumor antigen-specific T-cells but absent on virus-specific 
ones across several tumor entities, suggesting CD39 as a surrogate marker for exhausted, 
tumor-reactive T-cells (Canale et al. 2018; Duhen et al. 2018; Simoni et al. 2018).  
Second, the association of T-cell phenotypes with the clinical parameters of patients 
revealed that TEM1 subset frequencies in LNs positively correlated with TL, while at the same 
time, the number of TN cells decreased with higher TL percentages. These correlations suggest 
that with increasing leukemia cell amounts, higher numbers of TN cells get activated upon 
antigen recognition and acquire a TEM phenotype. Similar associations have been described 
in blood of CLL patients (Palma et al. 2017; Hanna et al. 2019), which indicates that the on-
going anti-tumor reactivity from the LNs is partly reflected in the periphery. 
This idea is supported by the third layer of evidence: the investigation of TCR sequences at 
the single-cell level showed that clonally expanded T-cells predominantly consisted of CD8+ 
TEM cells. In line with this, an increased T-cell oligoclonality in the blood of CLL patients 
compared to healthy controls has previously been reported based on bulk RNA-seq of the TCR 
beta chain (Serrano et al. 1997; Vardi et al. 2017; Blanco et al. 2018). Even though T-cell 
clonality alone cannot be used as a proxy for tumor-reactivity, as evidenced by the presence 
of virus-specific TCRs, the identification of a T-cell clone recognizing the CLL-overexpressed 
BST2 protein in this study further reinforces these findings (Gong et al. 2015; Bagaev et al. 
2020). 
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Fourth, the use of the TCL1 AT mouse model showed that lack of CD8+ T-cell expansion 
due to a lack of EOMES led to a significantly enhanced leukemia development, underlining 
that CD8+ T-cells exert some control of CLL growth. The available evidence for the role of 
EOMES in regulating CD8+ T-cell activation and exhaustion is further discussed in Section 5.5. 
Altogether, the results obtained in this study indicate that the accumulation of CD8+ TEM 
cells in CLL does not result from unspecific stimulatory cues present in the CLL 
microenvironment, but occurs as a consequence of an antigen-specific recognition of leukemia 
cells.  
 
Following the consideration of the enrichment of TEX as well as the correlation of TEM cells 
with tumor load in CLL LNs, the questions arise whether a developmental relationship between 
antigen-experienced TEM and TEX cells exists, and which factors underlay T-cell exhaustion in 
CLL. As discussed earlier, the investigation of state differentiation trajectories using single-cell 
data as well as in vivo validation would help resolve the former. Because frequencies of TEX 
cells were not directly associated with TL, additional factors to tumor antigen load likely 
determine the differentiation and accumulation of TEX cells. Similar to what has been described 
in chronic viral infections, secreted factors like IL-10, TGF-b, and type I IFNs (Brooks et al. 
2006; Ejrnaes et al. 2006; Tinoco et al. 2009; Teijaro et al. 2013; Wilson et al. 2013), or the 
TCR stimulation strength (Blattman et al. 2009; Martinez-Usatorre et al. 2018), might also 
regulate T-cell exhaustion in CLL. In addition, whether the accumulation of TEX cells has a 
clinical impact remains to be elucidated. Even though no direct correlation between TEX cells 
and clinical outcome could be established in this work, an implication of these cells in disease 
development should not be excluded. Along this line, studies with larger patient cohorts have 
found higher levels of PD-1+ antigen-experienced T-cells in blood of progressive CLL patients 
(Palma et al. 2017), and patients with a more advanced disease stage presented increased 
levels of terminally differentiated CD8+ T-cells (Brusa et al. 2013). Because tumor-reactive TEX 
cells are promising targets for immunotherapy, follow-up experiments with larger patient 
cohorts should elucidate the origin and functional role of TEX cells in LNs of CLL patients. 
Ultimately, a better understanding of the transcriptomic and functional characteristics of tumor-
reactive T-cells will significantly aid in improving existing and novel immunotherapy 
approaches for CLL. 
 
Finally, it is important to underline that there are some limitations to the results obtained 
using single-cell analyses in this work. First, the comparison performed between CLL and 
healthy control groups bears a sample collection bias. On the one hand, even though rLN are 
classified as tumor-free, dissections of these tissues are performed in case of persistent LN 
enlargement, which might occur due to an acute inflammation (Slack 2016; Tzankov and 
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Dirnhofer 2018). Such condition likely impacts the T-cell subset composition and therefore 
these samples do not accurately represent a LN of a healthy individual. As an example, the 
increased percentages of TEF1 CD27+ an DP1 TEX CXCR5+ in rLNs in comparison to CLL LNs 
may be a consequence of an on-going immune response (Hendriks et al. 2000; Kitchen et al. 
2004; Nascimbeni et al. 2004). Consequently, some additional CLL-induced changes which 
also occur during acute infections could remain undetected. On the other hand, LN biopsies 
from CLL patients are not routinely performed, but only obtained to examine cases with 
lymphadenopathy, or when the progression into a lymphoma is suspected. Therefore, the 
phenotypical characterization herein identified might only represent a fraction of CLL patients 
whit enlarged LNs. 
Second, a significant difference in the average age between HC and CLL samples exists in 
the studied cohort, representing a confounding factor in the comparison of these two groups. 
Although a contribution of age in all subset frequency differences cannot be completely 
excluded, the association between these two factors suggests that only the differences 
observed in TEX and TN subsets might be directly influenced by age. Shrinkage of the naïve T-
cell compartment as a consequence of aging has been widely described (Goronzy et al. 2015), 
making it difficult to distinguish between the contributions of disease state and age. Instead, 
TEX cell percentages do not increase along with age in HC donors, and CLL patients of older 
age display a wide range of TEX percentages, which suggests that leukemia development might 
determine, in part, the accumulation of these cells. A future analysis of the T-cell phenotype 
differences between CLL LNs and HC avoiding an age bias should therefore confirm the 
reported observations. 
Third, even though single-cell technologies are becoming standard laboratory 
methodologies, technical as well as analysis-related challenges may still affect the quality of 
the generated data. In general, factors that influence data quality in single-cell studies include 
the cell isolation procedure, the number of cells analyzed, the transcript capture efficiency, the 
doublet cell rate, and the sequencing depth (Lahnemann et al. 2020). At the computational 
level, regardless of the technology used, bioinformatic processing, including dimensionality 
reduction and cell clustering, requires the selection of various parameters (e.g. clustering 
resolution) which may also impact the results and the interpretation of the data. As only vague 
guidelines for these metrics exist to date, the range of results that can be obtained remains 
excessive (Kiselev et al. 2019). In the present work, an optimized experimental processing of 
the samples and a sequencing coverage saturation minimized technical noise. However, the 
analysis of only three samples via single-cell RNA-seq likely limited both the identification of 
all existing T-cell states in CLL patients and the significance of the described clusters. At the 
same time, the relatively small number of cells examined likely prevented the discovery of 
minor T-cell subpopulations present in the CLL LNs (Szabo et al. 2019; Le et al. 2020). 
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Regarding the mass cytometry dataset, even though it provided a good general impression of 
the CLL-associated T-cell changes, its small sample size restricted the statistical power of the 
downstream analyses. With respect to the bioinformatic analyses, despite following various 
approaches to define the true dimensionality and number of clusters for the two datasets 
(Butler et al. 2018; Stuart et al. 2019), the determined number of cell subsets likely does not 
represent the biological ground truth. Ultimately, whether the herein described subsets 
precisely reflect existing T-cell types – with the definition of a cell type being an interesting 
question by itself – will require the generation of larger single-cell datasets and additional 
functional assays.  
 
 The cellular crosstalk between CLL cells and T-cells in the LN 
niche is composed of both stimulatory and inhibitory signals 
CLL cells essentially depend on their microenvironment in the SLOs for receiving pro-
survival and proliferation signals from neighboring cells (Burger 2011). Through 
microenvironmental interactions, LN-resident CLL cells upregulate gene sets of the NF-kB 
pathway, resulting in increased anti-apoptotic signaling (Herishanu et al. 2011) and protection 
from chemotherapeutical agents (Vogler et al. 2009). Upon these observations, there has been 
an intense effort to characterize the interactions responsible for the transcriptional changes in 
CLL cells, in order to modulate them and thus achieve the complete eradication of malignant 
cells. However, up until now, most studies used bulk transcriptomic approaches, as well as in 
vitro co-culturing systems, utilizing cells isolated form PB (Burger et al. 2000; Vogler et al. 
2009; Herishanu et al. 2011; Pascutti et al. 2013). Under these conditions, the complexity of 
the microenvironmental connections is likely underestimated, and the contribution from 
specific cells residing in the LNs cannot be recognized. Hence, single-cell transcriptome 
analyses represent a valuable tool for assessing the cross-talk between CLL cells and T-cell 
subsets, where not only the signals regulating leukemia cell growth, but also those modulating 
T-cell function can be identified. 
The data obtained in this work provide a first account of the specific cellular interactions that 
are likely established between T-cells and CLL cells in the LNs. As normal B-cells depend on 
signals from follicular helper T-cells in germinal centers (Qi 2016; Vinuesa et al. 2016), CLL 
cells similarly benefit from these interactions, including the above-mentioned pro-survival 
signals from CD40- CD40L binding (Kitada et al. 1999; Pascutti et al. 2013). Crucially, the 
performed single-cell analyses elucidated that all CD4+ subsets, aside of TFH cells, provide pro-
survival signals to CLL cells by expressing CD40L. Furthermore, these subsets appeared to 
establish additional interactions with CLL cells, such as CD28 binding to CD86, IL-2 secretion, 
as well as TRAILR binding to TRAIL, the signaling of which have been shown to stimulate 
leukemia cells (Suvas et al. 2002; Secchiero et al. 2005; Rau et al. 2009; Decker et al. 2010). 
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Tregs additionally interacted with CLL cells via SELL- SELPLG, which has been reported to 
promote malignant B-cell adhesion (Csanaky et al. 1994). Importantly, CD8+ TEM and TTOX cells 
expressed CD28, and secreted TNFa and INFg, while CLL cells expressed the respective 
receptors for these molecules. With this finding, the idea of CD8+ T-cells exerting only an anti-
tumoral function is confronted by the fact that these interactions have been shown to promote 
survival and proliferation on CLL cells (Buschle et al. 1993; Reittie et al. 1996). Simultaneously, 
the cell subsets inducing CLL cell survival and proliferation could provide apoptotic signals via 
LAIR1-LILRB4 and SIRPG- CD47 interactions, a mechanism suggested to be involved in 
restraining tumor growth in long-term non-progressing patients (Martinez-Torres et al. 2015; 
Zurli et al. 2017). 
In addition to the identification of the signals affecting CLL cells, this analysis was able to 
describe the mechanisms by which CLL cells modulate their microenvironment, evading 
immune surveillance by inhibitory signal induction on T-cells. For example, CLL cells interacted 
with CD4+ TEM via LILRB4- LAIR1, and with TTOX cells by galectin-9 binding to TIM-3, the 
signaling of which have been shown to inhibit T-cell effector function (Meyaard et al. 1997; Das 
et al. 2017).  
Altogether, these observations illustrate the existence of an intricate network of stimulatory 
and inhibitory signals established between T-cells and CLL cells. The single-cell component 
of this approach, in addition, helps to discriminate at cell-subset level the specificity of these 
interactions, and underscores the difficulties of classifying T-cells as strictly pro- or anti-
tumoral. A significant limitation of the present analysis, however, is that the ligands and 
receptors expressed in a general or cell subset-unspecific manner were not further 
investigated, but could still significantly impact the signalome of leukemic cells and surrounding 
T-cells. Moreover, it remains unclear whether the interactions that were identified play a 
determinant role in disease progression. Future work should thus focus on analyzing the 
complete CLL interactome, including interactions established between all cell subsets present 
in the tissue, and should compare the cross-talk established between cells in LNs from CLL 
patients to that found in healthy lymph nodes. Such approach would undoubtedly facilitate the 
identification of signals that are specific to or increased during leukemia development. The use 
of imaging-based spatial single-cell technologies at the protein level (Giesen et al. 2014) would 
for example prove the specificity as well as relevance of the identified interactions, which could 
ultimately be tested experimentally in mouse models. The knowledge acquired with these 
studies could be central for the identification of new therapeutic targets for CLL and 
significantly improve the response to existing therapies. 
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 The suitability and limitations of the TCL1 AT mouse model of 
CLL 
Since its generation almost 20 years ago (Bichi et al. 2002), the Eµ-TCL1 mouse model has 
contributed substantially to the characterization of CLL pathogenic mechanisms as well as the 
development and testing of novel therapeutic approaches (Bresin et al. 2016). Notably, 
previous research reported evidence that the fully immunocompetent mouse line and the 
adoptive transfer model recapitulate the complex TME in the different organs and thus 
represent a valuable tool for investigating the leukemia-associated niche. For example, with 
the aim of comparing the tumor-induced T-cell defects between the Eµ-TCL1 mouse model 
and CLL patients, Gorgun et al. using bulk RNA microarrays observed that the gene-
expression patterns in splenic CD4+ and CD8+ T-cells of leukemic mice highly resembled those 
from respective cells in PB of CLL patients (Gorgun et al. 2009). Succeeding efforts by other 
groups identified in the murine model a marked T-cell subset skewing from naïve to antigen 
experienced cells, and a CLL-induced exhausted phenotype, analogous to human CLL 
(Hofbauer et al. 2011; Gassner et al. 2015; McClanahan et al. 2015a; McClanahan et al. 
2015b; Wierz et al. 2018; Hanna et al. 2019). Adding to this knowledge, the results obtained 
in this work describe at the single-cell level the acquired phenotypes of splenic T-cells from 
end-stage diseased TCL1 AT mice, thereby detailing the similarities and disparities between 
the mouse model and CLL patients. Importantly, clustering of murine T-cells based on their 
transcriptomic profile identified an overall T-cell phenotype comparable to LN-derived T-cells 
from CLL patients: murine T-cells were constituted by a high percentage of naïve cells, and 
subsets of effector and memory cells, as well as Tregs. Conversely, cell subsets containing 
CD4+ and CD8+ T-cells in a proliferating and exhausted state were exclusively identified in the 
murine samples. In line with the above-mentioned reports, the presence of these cells in the 
murine model provide further evidence for the existence of these cells in CLL. 
Additionally, the identification of a subset of T-cells with a distinct transcriptomic profile 
induced by IFN type I signaling is intriguing and poses several fascinating questions about 
their origin and role in the CLL TME. A similar type I IFN-driven CD4+ T-cell population has 
been identified in single-cell studies of different tumors and of allergy, in both human and 
mouse, suggesting that these cells can be generally induced by tissue inflammation (Magen 
et al. 2019; Szabo et al. 2019; Tibbitt et al. 2019). On the one hand, Szabo et al. proposed that 
type I IFN-responding cells represent a TCR-induced early activation state of CD4+ T-cells 
prior to initiation of proliferation (Szabo et al. 2019). Instead, another study found these cells 
to be at the end of the inferred differentiation path (Magen et al. 2019), thus leaving the 
question of their origin unanswered. Regarding their function, type I IFN signaling has been 
linked to cancer immunosurveillance by increasing PRF1 and GZMB gene expression, and 
promoting cell survival of cytotoxic T lymphocytes (Curtsinger et al. 2005; Guillot et al. 2005; 
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Ilander et al. 2014). Despite this, IFNa administration to pre-treated CLL patients did not have 
any effect on progression-free survival or CD4+ T-cell counts (O'Brien et al. 1995). Additional 
studies will be therefore necessary to confirm the presence of this subset in patients and to 
assess its role in CLL.  
In contrast, follicular T-cells including both CD8+ TFC and CD4+ TFH, which were readily 
distinguished in LNs of CLL patients with a very distinct transcriptomic profile, were not 
detected in spleen of TCL1 AT mice. The fact that these cells were not recognized in murine 
samples might be due to the low number of cells and samples analyzed, and thus additional 
samples should be examined to exclude this possibility. Additionally, CD4+ TFH cells and CD8+ 
CXCR5+ cells have previously been detected in LNs and spleen of mice (Im et al. 2016; Miles 
et al. 2016; Yu and Ye 2018; Magen et al. 2019), and therefore, a complete absence of these 
cells in the spleen of TCL1 mice seems unlikely. Because research of CD8+ TFC cells is scarce 
in CLL patients, and given their described role in anti-tumor immunity in other cancers, the 
identification and subsequent characterization of these cells in mouse will be of great 
importance for determining their pro- or anti-tumor role in CLL. 
 
Further contributing to the hypothesis of a tumor-specific T-cell reaction in CLL, an 
enrichment of clonally expanded CD4+ and CD8+ T-cells has previously been observed in 
TCL1 mice (Hofbauer et al. 2011; Hanna et al. 2019), similar to what was described for patients 
(Vardi et al. 2017; Blanco et al. 2018). For CD8+ T-cells, this enrichment was shown to be 
specific to effector cells (Hanna et al. 2019). In line with this, the evaluation of T-cell clonality 
based on the single-cell data obtained herein revealed that the clonal expansion of murine 
CD8+ T-cells is restricted to TEX cells. Strikingly, however, the complete picture of the clonal 
status of all T-cell subtypes in the TCL1 AT mouse model underscored that clonally expanded 
T-cells were predominantly CD4+ T-cells, in sharp contrast to human LNs, where CD8+ T-cells 
represented the clonally expanded fraction. While this observation should be taken with 
caution, as it is based on the analysis of only two murine samples, such a disparity raises 
important questions about the suitability of the mouse model to precisely recapitulate the T-
cell immune response of CLL patients. Hence, it will be crucial to validate these observations 
with the analysis of additional samples. 
Interestingly, T-cell expansion clearly occurred to a greater extent in one of the analyzed 
mouse samples versus the other, despite the fact that both mice were transplanted with CLL 
cells from the same donor mouse and had a similar tumor load at time of sampling. This 
disparate response could derive from the heterogeneous CLL clone dynamics occurring in the 
mouse model (Zaborsky et al. 2019), with some tumor clones eliciting a stronger immune 
reaction compared to others (McGranahan et al. 2016). 
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Last, and most importantly, the cellular interactions found in the CLL TME of the TCL1 AT 
mouse model largely resembled those of the CLL LNs. Both CLL-supportive and inhibitory 
signals were found to be present in the respective murine subsets, mainly CD4+ T-cells, but 
also TIFN, TEX, and CD8+ TM cells. In addition, inhibitory signals for T-cells, including CD39- 
ADORA2A and PD-1- PD-L1 and PD-L2, could be observed in the mouse data set, which is in 
line with a previously described improvement of leukemia immune control when blocking these 
interactions (McClanahan et al. 2015a; Arruga et al. 2020). 
The additional presence of myeloid cells highlights the role of these cells in providing 
support to CLL cells, as they expressed multiple signals including ligands that bind to integrins 
and semaphorins in CLL cells, which have been shown to promote proliferation and survival 
of malignant B-cells (Vincent et al. 1996; Granziero et al. 2003; Deaglio et al. 2005). At the 
same time, these cells also aggravate T-cell inhibition by expressing PD-L1 and ADORA2A 
(data not shown, (Hanna et al. 2016). Given these observations, it would be interesting to 
examine the interactome of the complete CLL TME in order to identify the most prominent 
interactions promoting both leukemia cell survival and T-cell exhaustion.  
Overall, the analysis performed here underlines that the T-cell distribution and phenotype 
in the TCL1 mouse model largely recapitulates the pathogenic situation in CLL patients, and 
thus represents an effective tool for the study of the functional role of T-cells in CLL 
progression.  
 
 EOMES is necessary for CD8+ T-cell expansion and control of 
CLL development 
As previously mentioned, CLL has a strong component of heritability, with an approximately 
8.5-fold increased risk for first-degree relatives of CLL patients (Goldin et al. 2009). Among 
numerous genetic alterations, genome-wide association studies have identified several SNPs 
increasing susceptibility to CLL (Berndt et al. 2013; Berndt et al. 2016). One of these, 
rs9880772, is located in close proximity to the EOMES gene and, based on their H3K27ac 
profiles, appears to be in a heterochromatic region in CLL cells (Speedy et al. 2019). The 
examination of the chromatin state based on six histone modifications (H3K4me3, H3K4me1, 
H3K27ac, H3K36me3, H3K27me3, and H3K9me3) of several B-cell subsets in this work 
corroborated this observation. Adding further evidence, both bulk RNA and single-cell RNA-
seq identified no EOMES transcript in B-cell subsets and CLL cells, respectively. Altogether, 
these observations point towards the exciting possibility that the abovementioned EOMES 
SNP might be related to CLL pathogenesis through its expression in cells from the TME rather 
than in the neoplastic cell itself. In other words, the EOMES SNP could lead to an inferior 
capacity of microenvironmental cells to control malignant B-cells. Following this idea, the 
rs9880772 genotype was obtained for 14 LN samples analyzed by mass cytometry. However, 
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risk allele frequency was too low (1 out of 14) to statistically assess the relationship with 
EOMES protein levels (See Supplementary Section 6.1). Of note, the odds-ratio of this SNP 
is only 1.17 (Berndt et al. 2013), and accordingly, a dramatic effect on EOMES expression or 
function cannot be expected. Ultimately, the exact effect of rs9880772 in EOMES remains 
unanswered, and would need to be assessed in a sufficiently large cohort of CLL patients. 
Confirming that EOMES is expressed in cells of the tumor microenvironment, memory CD8+ 
T-cell, as well as NK cells, exhibited open chromatin at the EOMES locus, and 
correspondingly, expression of the gene. Importantly, the single-cell RNA sequencing analysis 
of CLL LNs showed that EOMES is expressed in CD8+ TEM1 cells but also in the CD4+ TEM1, 
TTOX, and TF cells, the identification of which would have otherwise been missed with the bulk 
microarray data. Hence, a SNP-driven effect on CLL control through all these cells is possible. 
While the role of EOMES in CD8+ and CD4+ T-cells has been investigated in the present work, 
its function in NK cells in the CLL context has not been addressed. Given that EOMES 
regulates NK cell proliferation and effector function (Gordon et al. 2012; Daussy et al. 2014; 
Zhang et al. 2018a), the EOMES SNP is likely to also affect these cells, and thus this question 
should be addressed in future studies. 
EOMES regulates the transcriptional program that promotes CD8+ T-cell effector cytolytic 
differentiation, and maintains memory T-cell homeostasis by regulating IL-2RB expression 
(Intlekofer et al. 2008; Cruz-Guilloty et al. 2009; Banerjee et al. 2010; Pipkin et al. 2010). 
Besides, its expression has been reported highest in exhausted T-cells in several tumors, 
including colorectal cancer, melanoma, non-small cell lung cancer and acute myeloid leukemia 
(O'Brien et al. 1995; Sade-Feldman et al. 2018; Zhang et al. 2018b; Jia et al. 2019; Li et al. 
2019). Accordingly, EOMES protein levels were detected in all TEF, TEM subsets in mass 
cytometry analyses and its expression was highest in TEX and proliferating cells. Thus, the 
higher EOMES levels in CLL LN samples compared to rLN are unsurprising, given the 
significantly higher frequency of TEX and proliferating cells in CLL patients. In addition, these 
results were mirrored in the Eµ-TCL1 and TCL1 AT mouse models, where leukemic mice 
showed higher frequencies of EOMES+ CD8+ T-cells compared to WT mice. Such difference 
is a result of a disease-driven T-cell skewing towards effector and memory T-cells. Notably, 
the discrepancy in subset frequencies and consequently EOMES levels between the two 
mouse models can likely be explained by the dynamics of the disease development. Eµ-TCL1 
mice develop a CLL-like disease over the duration of one year and thus pronounced TM 
changes may result from acquired memory to some tumor clones (Landau et al. 2013). 
Conversely, a more acute immune reaction against CLL cells might be present in the TCL1 AT 
model. Importantly, higher expression of EOMES in exhausted T-cells was demonstrated with 
both single-cell RNA-seq and flow cytometric analyses in both mouse models, in agreement 
with the expression pattern observed in human T-cells. 
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Crucially, the presented data show that EOMES-deficiency leads to an impaired CD8+ T-
cell proliferation and, consequently, to faster CLL development, providing evidence for a CD8+ 
T-cell-mediated control of CLL. These results are in agreement with a previous study showing 
that constitutive expression of EOMES enhances CD8+ T-cell expansion and survival, thereby 
improving tumor control in a mouse model of lymphoma (Furusawa et al. 2018). Instead, no 
significant impact of EOMES on the differentiation or functional capacity of CD8+ T-cells was 
observed in the TCL1 AT mice, diverging from the described involvement of EOMES in 
regulating the expression of effector molecules such as perforin, granzyme B and IFNg, as well 
as memory formation (Intlekofer et al. 2008; Cruz-Guilloty et al. 2009; Banerjee et al. 2010; 
Pipkin et al. 2010). It is important to keep in mind, however, that EOMES plays distinct roles 
under acute and chronic inflammatory conditions. On the one hand, the above-mentioned 
function in promoting the expression of effector genes is explained under an acute immune 
response to viral infection. On the other hand, EOMES has been suggested to induce a specific 
distinct set of genes associated with T-cell exhaustion in chronic viral infection (Doering et al. 
2012). In this context, depletion of EOMES in CMV-reacting CD8+ T-cells leads to a decreased 
exhaustion phenotype, including lower expression of PD-1, and increased levels of TNFa+ 
IFNg+ cells (Paley et al. 2012). In cancer, Li et al. reported that tumor-infiltrating lymphocytes 
lacking Eomes fail to expand and produce effector molecules, but also express lower levels of 
the inhibitory receptors PD-1 and TIM-3 (Li et al. 2018). Further complicating the situation, this 
disparity might partly be due to the overlapping function of EOMES with the phylogenetically-
related TF TBET (encoded by TBX21), which has been described to induce expression of 
effector molecules during acute infections in a similar manner as EOMES (Intlekofer et al. 
2005; Intlekofer et al. 2008), but does not induce an exhausted phenotype under chronic viral 
infections (Kao et al. 2011). Hence, the interplay of several factors likely masks the specific 
role of EOMES in controlling T-cell effector function and exhaustion in the CLL mouse model. 
Additional studies will be necessary to elucidate the specific conditions under which this TF 
contributes to the acquisition of a cytotoxic or dysfunctional state of CD8+ T-cells. For example, 
the employment of single-cell ATAC-seq and ChIP-seq techniques will significantly aid in 
unraveling the gene regulatory network of EOMES at every T-cell differentiation state 
(Grosselin et al. 2019; Satpathy et al. 2019).  
 
 TR1 cells control CLL progression and are regulated by EOMES 
and IL10R signaling 
As discussed above, the single-cell RNA-seq analyses performed in this work revealed that 
EOMES is expressed in CD4+ T-cell subsets, thus indicating that these cells could also be 
functionally affected by the rs9880772 SNP. In fact, EOMES promotes the development of 
CD4+ TR1 cells (Zhang et al. 2017; Gruarin et al. 2019), a cell subset with potent 
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immunosuppressive properties (Roncarolo et al. 1988; Bacchetta et al. 1994; Groux et al. 
1997). In a collaborative effort with Dr. Yashna Paul, the characterization of the CD4+ T-cell 
compartment in both single-cell RNA-seq and mass cytometry data sets of CLL LNs identified 
a subset resembling TR1 cells (Paul 2020). Since the use of different terminology to describe 
this cell population has often generated confusion, Roncarolo et al. proposed four criteria to 
be considered for defining TR1 cells. These four criteria are (1) the production of IL-10, (2), a 
suppressive function, (3) expression of inhibitory receptors, including PD-1 and LAG3, and (4) 
the absence of FOXP3 expression (Roncarolo et al. 2018). In agreement with these 
characteristics, the identified CD4+ EOMES+ cells expressed the inhibitory receptors PD-1, 
LAG3, CD39, and TIGIT, and the cytokine IL-10, but no FOXP3. Furthermore, one of the 
described immunosuppressive mechanisms of TR1 cells involves the secretion of granzymes 
and perforin 1, and subsequent killing of APCs (Tree et al. 2010; Magnani et al. 2011). 
Crucially, these effector molecules were also present in the TR1 cell subset, thus fulfilling all 
four criteria for their classification as TR1.  
Importantly, TR1 cells were more abundant in LNs of CLL patients rather than PB or BM, 
where they are likely to interact with CLL cells and contribute to disease progression or control. 
In addition, their frequencies were increased in CLL LNs in comparison to rLNs from non-
cancer individuals, indicating that leukemia induces the accumulation of these cells. This was 
further evidenced by the examination of the TCL1 mouse model, in which increased 
frequencies of TR1 cells were observed upon leukemia development in both Eµ-TCL1 and 
TCL1 AT models. Notably, TR1 expansion was accompanied with a higher IL-10 expression 
by these cells in TCL1 AT mice compared to non-leukemic mice, confirming their 
immunosuppressive phenotype. Moreover, work performed by Dr. Ekaterina Lupar and Dr. 
Ana Izcue from the Max-Planck Institute (Freiburg), showed that the transcriptional profile of 
the identified EOMES+ TR1-like murine cells overlaps with that of human TR1 cells (data not 
shown, (Roessner et al. 2020a)). 
In cooperation with the TF BLIMP1, EOMES transcriptionally activates IL-10, represses T-
helper lineage differentiation (Neumann et al. 2014), and similarly to CD8+ T-cells, induces the 
expression of effector molecules (Zhang et al. 2017). The adoptive transfer of Eomes-/- CD4+ 
T-cells together with CLL cells in Rag2-/- mice confirmed that EOMES is indispensable for TR1 
differentiation, as CD4+ T-cells expanded significantly less and produced lower levels of IL-10, 
as well as effector molecules. Of note, several integrins were found among EOMES-regulated 
genes (Roessner et al. 2020a), which might influence cell migration and homing, and 
consequently, be responsible for the increased numbers of Eomes-/- CD4+ T-cells in PB of the 
leukemic mice. Surprisingly, the lack of TR1 cells led to an enhanced CLL development, 
indicating that these cells control leukemia growth. Since IL-10 has been shown to be essential 
for maintaining the function and IL-10 production of TR1 cells (Brockmann et al. 2017), IL-10R 
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signaling was investigated to further understand the regulation of these cells. Interestingly, 
Il10rb-/- CD4+ T-cells proliferated similarly to WT CD4+ T-cells, but Il10rb-/- TR1 cells displayed 
higher expression of PD-1 along with reduced levels of cytotoxic molecules, indicating an 
enhanced exhaustion phenotype. These results might seem inconsistent with the commonly 
described immunosuppressive role of IL-10 (Brooks et al. 2006; Ni et al. 2015), but several 
studies have reported that IL-10 signaling through STAT3 prevents dysfunction in CD8+ T-cells 
(Naing et al. 2016; Gorby et al. 2020), Hanna et al. unpublished work). Thus, a similar 
mechanism could be active in CD4+ T-cells. Furthermore, Il10rb-deficient CD4+ T-cells showed 
a reduced control of CLL development, suggesting that IL-10-mediated signaling in TR1 cells 
is necessary for their effector activity and CLL control. 
The herein reported anti-leukemic role of TR1 cells might appear to be in contradiction with 
the reported function of TR1 cells in several tumor entities, where they have been shown to 
exert immunosuppression and thereby facilitate tumor growth (Bergmann et al. 2008; Dennis 
et al. 2013; Pedroza-Gonzalez et al. 2015; Yan et al. 2017; Song et al. 2018). It is crucial to 
consider, however, that the same regulatory mechanisms might lead to a different outcome in 
the CLL context, where the leukemic cells themselves are APCs (Hall et al. 2005; Mayr et al. 
2006; Os et al. 2013), and therefore, subjected to the immunosuppressive effect of TR1 cells. 
In other words, while in solid tumors the killing of APCs by TR1 cells might imply a negative 
regulatory effect for tumor immune control, in this context, it could lead to the killing of CLL 
cells and thereby a better outcome.  
The role of CD4+ T-cells in CLL, in fact, remains under intense debate. Numerous in vitro 
studies based on the co-culturing of autologous CD4+ T-cells and CLL cells describe a reduced 
apoptosis or enhanced CLL cell proliferation induced by CD4+ T-cell-derived cues, including 
IFNg, IL-4 or CD40L (Buschle et al. 1993; Os et al. 2013; Pascutti et al. 2013; Bhattacharya et 
al. 2015). The striking discrepancy from the results reported herein can be explained by the 
fact that these studies used CD4+ T-cells isolated from PB, where, as observed in this work, 
TR1 cells might be present in very low frequencies. On the contrary, in vivo studies using the 
TCL1 AT model, which captures the complex CLL immune microenvironment, reported either 
a faster or no difference in CLL development in the absence of CD4+ T-cells (Kocher et al. 
2016; Hanna et al. 2019; Roessner et al. 2020b). As discussed above, a direct anti-tumor role 
of TR1 cells in CLL seems plausible. Nevertheless, the lack of CD8+ T-cells in Rag2-/- mice 
made it impossible to assess the effect of TR1 cells on CD8+ T-cells, and hence, the assumption 
that increased TR1 cell numbers would lead to a better tumor control should be taken with 
caution. In fact, given the suppressive characteristics of TR1 cells, a scenario where the 
negative impact on tumor-reactive CD8+ T-cells would compensate or even overturn the direct 
anti-tumor role of TR1 cells should be considered. Besides, total CD4+ T-cells from spleens of 
either WT, Eomes-/- or Il10rb-/- mice were injected into recipient mice, which implies that other 
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CD4+ T-cell subsets, apart from TR1 cells, might have expanded and thus impacted on tumor 
growth. For example, TBET-expressing TH1 cells have been shown to accumulate in the TCL1 
mouse model (Roessner et al. 2020b). These cells produce increasing levels of IFNg along 
with disease progression (Roessner et al. 2020b), which have been shown to promote CLL 
cell survival and proliferation (Buschle et al. 1993). Although the data obtained in this work 
represent a good starting point for the characterization of TR1 cells in CLL, additional studies 
using a fully immunocompetent mouse model and nodal samples from CLL patients will be 
necessary to fully elucidate their relevance in this disease. 
 
 A novel layer for uncovering the pathological role of T-cells in 
CLL 
Collectively, the results obtained in this work comprehensively characterize the 
heterogeneous T-cell compartment of CLL patients, and significantly contribute to our 
understanding of the disease’s complex microenvironment. Based on the integration of several 
single-cell approaches and the use of the TCL1 mouse model, they describe the distinct 
phenotypic T-cell states acquired under pathogenic conditions, identify previously 
unrecognized, novel populations, and decipher the role of CD8+ TEM and TR1 T-cells in 
controlling CLL progression. While requiring additional experimental validation, these cellular 
and mechanistic insights represent a pivotal starting point for future studies evaluating the 
contribution of the microenvironmental niche to leukemia control or/and development. At the 
same time, these results raise a number of fascinating conceptual and translational questions, 
the answers to which will help to significantly improve the therapeutic options for CLL patients, 
and perhaps, other B-cell malignancies.  
Single-cell technologies have provided the crucial ability to ascertain the degree of 
heterogeneity present within CD8+ and CD4+ T-cells, and importantly, delineate the potential 
contribution of each subset to the milieu of the CLL LN. One of the subsequent questions, for 
example, is how the T-cell compartment is shaped upon tumor development. Even though CLL 
is a typically indolent disease, characterized by long periods of observation without treatment, 
progression eventually occurs (Hallek et al. 2018). Thus, longitudinal sample analysis from 
individual patients will be central to recognize molecular and cellular patterns determining the 
course of leukemia development. 
A similar question in relation to treatment-induced changes in the CLL microenvironment 
should be also addressed. Earlier studies reporting immune alterations under ibrutinib or 
idelalisib treatment indicate that the balance or interactions between cell subsets are likely 
affected under these treatments (Dubovsky et al. 2013; Dong et al. 2014; Furman et al. 2014; 
Lampson et al. 2016; Niemann et al. 2016). Because some kinase inhibitors were reported to 
negatively affect T-cell survival and function (Dong et al. 2014; Hofland et al. 2019), the impact 
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of these novel inhibitors on individual immune cell subsets should be assessed. Along this line, 
Rendeiro et al. profiled for the first time the temporal dynamics of immune cells from CLL 
patients under ibrutinib treatment with a multi-omics approach (Rendeiro et al. 2020). 
Analyzing single-cell RNA-seq data generated from PBMCs of 4 patients at several time-points 
over the course of 8 months of treatment, they describe a downregulation of genes related to 
T-cell activation and an acquired quiescence-like gene signature in CD8+, and to a lesser 
extent, CD4+ T-cells upon treatment. Following a similar approach with a larger patient cohort 
would allow linking the phenotypical T-cell alterations to leukemic cell subclonal heterogeneity 
and treatment outcome. 
 
The evidence for an enrichment of a CD8+ TEX CD39+ population along with a potential pre-
dysfunctional axis in CLL LNs raises several key questions. First, owing to the expression of 
inhibitory receptors including PD-1, CD39, and TIGIT, this subset might be a promising target 
for immune checkpoint blockade therapy. In this context, a pre-clinical study using the TCL1 
AT mouse model reported an improved leukemia control as well as a restored T-cell cytotoxic 
phenotype under anti-PD-L1 therapy (McClanahan et al. 2015a). However, as previously 
mentioned, single anti-PD-1 therapy in CLL patients has led to unsatisfactory results, with only 
some patients with Richter transformation showing response to treatment (Ding et al. 2017). 
Hence, research efforts currently focus on identifying combination therapies of several immune 
checkpoints, or with small molecule inhibitors already in use in CLL. In murine experiments, 
combined PD-1 and LAG3 blockade, as well as treatment with ibrutinib and aPD-1/PD-L1, 
reduced tumor burden more efficiently than monotherapy (Wierz et al. 2018; Hanna et al. 
2020). Besides, several clinical trials combining immune checkpoint blockade with kinase 
inhibitors are being conducted (NCT02329847, NCT02332980, NCT02362035, 
NCT02420912, NCT03514017, NCT03153203 and NCT03283137), and first results point 
towards a response rate of 61 % (Younes et al. 2019), indicating that targeting immune 
checkpoints in combinations with other therapies might significantly improve the clinical 
outcome of CLL patients.  
Targeting of CD39 in CLL has increasingly gained attention, as it is expressed in both CLL 
cells and T-cells, with the abundance of the latter correlating with disease severity (Pulte et al. 
2011; Perry et al. 2012). Despite having minor effects on leukemia development, the fact that 
CD39 receptor (ADORA2A) blockade in TCL1 AT mice has been shown to restore T-cell 
responses and repolarize monocytes to M1-like phenotype represents an encouraging 
strategy for combination-based therapeutic approaches (Arruga et al. 2020). 
The effect of antibody-based blocking of TIGIT has not been investigated in CLL, yet its 
immunosuppressive role makes it a promising novel target for immunotherapy. In pre-clinical 
studies, blockade of both TIGIT and PD-L1 in in the murine CT26 tumor model resulted in 
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reestablishment of T-cell function and complete tumor rejection (Johnston et al. 2014). Similar 
effects on improving T-cell cytotoxicity were described upon ex vivo combined blockade of 
TIGIT and PD-1 in tumor-infiltrating lymphocytes from melanoma patients (Chauvin et al. 
2015), and several clinical trials in solid or metastatic tumors are being conducted 
(NCT04047862, NCT03563716, NCT03628677 and NCT02913313). Importantly, aTIGIT 
treatment in mice with multiple myeloma also reduced tumor burden and increased T-cell 
function (Guillerey et al. 2018), indicating that blocking of TIGIT could also hold promise for 
the treatment of other B-cell malignancies including CLL.  
 
Last, another question which arises from the identification of CD8+ TEX CD39+ cells in this 
work is whether they constitute a potential biomarker for response to immune checkpoint 
blockade therapies, as stratification criteria for identifying CLL patients who could benefit from 
these therapies have not yet been established. In recent work evaluating the clinical response 
to PD-1 blockade in non-small-cell lung cancer and melanoma patients, the presence of CD8+ 
T-cells expressing elevated levels of PD-1 or PD-1 and CTLA-4, respectively, was reported to 
be predictive of a response to the therapy (Daud et al. 2016; Thommen et al. 2018). 
Additionally, in another melanoma cohort, the presence of EOMES+ CD69+ CD8+ TEM was 
indicative of a response to both aPD-1 monotherapy or combined aPD-1 and aCTLA-4 therapy 
(Gide et al. 2019). Since the frequency of CD8+ TEX CD39+ cells significantly varied between 
CLL patients, their abundance could have some prognostic power for categorizing patients 
who would respond to immune checkpoint blockade. Hence, future investigations should focus 
on the immune composition of pre-treatment LNs samples and its association with response 
to therapy. 
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 Conclusion 
The current work aimed to comprehensively describe the phenotype, distribution and 
function of T-cells in CLL patients based on integrative single-cell RNA-seq and mass 
cytometry analyses of LNs, PB, and BM samples from CLL patients and healthy controls. The 
central finding is that CLL LNs constitute a distinct niche where clonally-expanded CD8+ TEM 
cells become more abundant with tumor development, and T-cells with an exhausted state 
accumulate. In this nodal microenvironment, CLL cells establish a cross-talk with different T-
cell subsets, receiving and inducing both pro-survival and inhibitory signals. Moreover, an 
EOMES-dependent role of CD8+ TEM in controlling CLL progression was determined using the 
TCL1 mouse model. Finally, TR1 cells were newly described in CLL patients, and their 
dependency on EOMES and IL-10 receptor signaling for regulating CLL development in TCL1 
mice was demonstrated. Altogether, these data help characterizing the phenotypical changes 
in the CD8+ T-cell compartment of CLL at an unprecedented resolution and significantly 
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6 Appendix 
 Profiling of rs9880772 SNP in samples of CLL patients using 
Sanger Sequencing 
DNA from 13 LNs samples analyzed by mass cytometry was isolated using the QIAamp 
DNA Micro Kit (Qiagen, 56304) following the instructions provided by the manufacturer. Next, 
100 ng of DNA were mixed with 0.5mM of forward (5’-GTCTTTATCACTACTAGCAACATGC-
3’) and reverse (5’-GCACGACCTTTGCTCCTTTT-3’) primers and 1X Prima Amp Hot Start 
Master Mix (Steinbenner Laborsysteme, SL-9714-10ml). The PCR reaction was run with the 
following protocol: 
Step Temperature Time (hh:mm:ss) 
1 96 °C 00:02:00 
2 96 °C 00:00:30 
3 51 °C 00:00:15 
4 60 °C 00:04:00 
5 Go to Step 2, 24x (25 cycles) 
6 15 °C Hold 
 
Samples were subsequently run on a 2 % agarose gel, and amplified bands were cut and 
cleaned using the QIAquick PCR Purification Kit (Qiagen, 28104). Purified samples were 
submitted to Sanger sequencing with the aforementioned primers.  
The presence of the rs9880772 SNP (G>A) was examined in all 13 samples. The results 
are indicated in Table S12. 
 
Table S12: Analysis of rs9880772 genotype in samples of CLL patients. 













Note: The region of the EOMES gene spanning rs9880772 SNP was amplified with gene-
specific primers and Sanger-sequenced. 13 CLL samples were classified according to allele 
presence (G>A / G>C). 
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 Supplementary patient information 
Information regarding viral infection positivity at the time of sample collection was available 
for samples of CLL patients obtained from the Hospital Clínic (Barcelona) (Table S13). 
Immunohistochemical staining and in situ hybridization (EBERs) methods were used for EBV 
and CMV, respectively. 
 
Table S13: Detection of CMV- and EBV-positive cells in CLL patient samples. 
Patient ID EBV CMV 
BC1 NA CMV+ 
BC10 EBV- CMV+ 
BC2 NA NA 
BC3 EBV+ CMV+ 
BC4 EBV- CMV- 
BC5 EBV+ NA 
BC6 NA CMV+ 
BC7 NA NA 
BC8 NA CMV low (2004) 
BC9 NA CMV- 
Note: NA = not available, EBV = Epstein-Barr-virus, CMV = cytomegalovirus. 
 
 
  132 
7 List of Publications 
Llaó Cid L, Roessner PM, Chapaprieta V, Roider T, Bordas M, Öztürk S, Hanna BS, Izcue 
A, Dietrich S, Colomer D, Stilgenbauer S, Martín-Subero JI, Seiffert M. EOMES is essential for 
anti-tumor activity of CD8+ T-cells in chronic lymphocytic leukemia. Leukemia (under revision). 
 
Aydin E, Faehling S, Saleh M, Llaó Cid L, Seiffert M, Roessner PM. PI3K signaling in the 
tumor microenvironment: What needs to be considered when treating CLL with PI3K 
inhibigtors? Frontiers in Immunology (under revision) (2020).  
 
Hanna BS, Llaó Cid L, Iskar M, Roessner PM, Klett L, Öztürk S, Mack N, Kalter V, Colomer 
D, Campo E, Bloehdorn J, Stilgenbauer S, Dietrich S, Schmidt M, Gabriel R, Rippe K, Zapatka 
M, Feuerer M, Lichter P, Seiffert M. IL-10 receptor signaling alters chromatin accessibility in 
CD8+ T-cells preventing their exhaustion and immune escape in chronic lymphocytic 
leukemia. Immunity (under revision). 
 
Roessner PM*, Llaó Cid L*, Lupar E*, Roider T, Bordas M, Schifflers C, Gaupel AC, Kilpert 
F, Krötschel M, Arnold SJ, Sellner L, Stilgenbauer S, Dietrich S, Lichter P, Izcue A, Seiffert M. 
EOMES and IL-10 regulate anti-tumor activity of T regulatory type 1 CD4+ T-cells in chronic 
lymphocytic leukemia. Leukemia (accepted) (2020). *These authors contributed equally to this 
work.  
 
Llaó Cid L, Hanna BS, Iskar M, Roessner PM, Öztürk S, Lichter P, Seiffert M. CD8+ T-cells 
of CLL-bearing mice acquire a transcriptional program of T-cell activation and exhaustion. Leuk 
Lymphoma (2020). 
 
Roessner PM, Hanna BS, Öztürk S, Schulz R, Llaó Cid L, Yazdanparast H, Scheffold A, 
Colomer D, Stilgenbauer S, Lichter P, Seiffert M. TBET-expressing Th1 CD4+ T cells 
accumulate in chronic lymphocytic leukaemia without affecting disease progression in Eµ-
TCL1 mice. Br J Haematol. (2020). 
 
Haderk, F, Schulz, R, Iskar, M, Llaó Cid, L, Worst T, Willmund KV, Schulz A, Warnken U, 
Seiler J, Benner A, Nessling M, Zenz T, Göbel M, Dürig J, Diederichs S, Paggetti J, Moussay 
E, Stilgenbauer S, Zapatka M, Lichter P, Seiffert M. Tumor-derived exosomes modulate PD-
L1 expression in monocytes. Sci Immunol (2017). 
 
 
  133 
8 References 
Aandahl EM, Sandberg JK, Beckerman KP, Tasken K, Moretto WJ, Nixon DF. 2003. CD7 is a 
differentiation marker that identifies multiple CD8 T cell effector subsets. J Immunol 
170: 2349-2355. 
Aguirre-Ghiso JA. 2007. Models, mechanisms and clinical evidence for cancer dormancy. Nat 
Rev Cancer 7: 834-846. 
Ahearne MJ, Willimott S, Pinon L, Kennedy DB, Miall F, Dyer MJ, Wagner SD. 2013. 
Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 
and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic 
leukaemia. Br J Haematol 162: 360-370. 
Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Deniz 
G, Valenta R, Fiebig H et al. 2004. Immune responses in healthy and allergic 
individuals are characterized by a fine balance between allergen-specific T regulatory 
1 and T helper 2 cells. J Exp Med 199: 1567-1575. 
Alfei F, Zehn D. 2017. T Cell Exhaustion: An Epigenetically Imprinted Phenotypic and 
Functional Makeover. Trends Mol Med 23: 769-771. 
Allsup DJ, Kamiguti AS, Lin K, Sherrington PD, Matrai Z, Slupsky JR, Cawley JC, Zuzel M. 
2005. B-cell receptor translocation to lipid rafts and associated signaling differ between 
prognostically important subgroups of chronic lymphocytic leukemia. Cancer Res 65: 
7328-7337. 
Aoki T, Chong LC, Takata K, Milne K, Hav M, Colombo A, Chavez EA, Nissen M, Wang X, 
Miyata-Takata T et al. 2020. Single-Cell Transcriptome Analysis Reveals Disease-
Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma. 
Cancer Discov 10: 406-421. 
Arimura Y, Kato H, Dianzani U, Okamoto T, Kamekura S, Buonfiglio D, Miyoshi-Akiyama T, 
Uchiyama T, Yagi J. 2002. A co-stimulatory molecule on activated T cells, H4/ICOS, 
delivers specific signals in T(h) cells and regulates their responses. Int Immunol 14: 
555-566. 
Arruga F, Serra S, Vitale N, Guerra G, Papait A, Gyau BB, Tito F, Efremov D, Vaisitti T, Deaglio 
S. 2020. Targeting of the A2A adenosine receptor counteracts immunosuppression in 
vivo in a mouse model of chronic lymphocytic leukemia. Haematologica 
doi:10.3324/haematol.2019.242016. 
Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D, Majid A, Dyer M, Siebert 
R, Taylor AM et al. 2007. Mutation status of the residual ATM allele is an important 
determinant of the cellular response to chemotherapy and survival in patients with 
chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 25: 5448-5457. 
Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, Nainys J, Wu K, 
Kiseliovas V, Setty M et al. 2018. Single-Cell Map of Diverse Immune Phenotypes in 
the Breast Tumor Microenvironment. Cell 174: 1293-1308 e1236. 
Bacchetta R, Bigler M, Touraine JL, Parkman R, Tovo PA, Abrams J, de Waal Malefyt R, de 
Vries JE, Roncarolo MG. 1994. High levels of interleukin 10 production in vivo are 
associated with tolerance in SCID patients transplanted with HLA mismatched 
hematopoietic stem cells. J Exp Med 179: 493-502. 
Bade B, Boettcher HE, Lohrmann J, Hink-Schauer C, Bratke K, Jenne DE, Virchow JC, Jr., 
Luttmann W. 2005. Differential expression of the granzymes A, K and M and perforin 
in human peripheral blood lymphocytes. Int Immunol 17: 1419-1428. 
Badoux X, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger J, O'Brien S, Ferrajoli A, Keating MJ, 
Estrov Z. 2011. Cross-talk between chronic lymphocytic leukemia cells and bone 
marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum 
Pathol 42: 1989-2000. 
Bagaev DV, Vroomans RMA, Samir J, Stervbo U, Rius C, Dolton G, Greenshields-Watson A, 
Attaf M, Egorov ES, Zvyagin IV et al. 2020. VDJdb in 2019: database extension, new 
analysis infrastructure and a T-cell receptor motif compendium. Nucleic Acids Res 48: 
D1057-D1062. 
8 References    
 134 
Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PE, Simone R, Chum P, Yan XJ, 
Allen SL, Kolitz JE et al. 2011. A novel adoptive transfer model of chronic lymphocytic 
leukemia suggests a key role for T lymphocytes in the disease. Blood 117: 5463-5472. 
Bai M, Zheng Y, Liu H, Su B, Zhan Y, He H. 2017. CXCR5(+) CD8(+) T cells potently infiltrate 
pancreatic tumors and present high functionality. Exp Cell Res 361: 39-45. 
Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, Wieckowski S, 
Bouzourene H, Deplancke B, Romero P et al. 2011. Exhaustion of tumor-specific 
CD8(+) T cells in metastases from melanoma patients. J Clin Invest 121: 2350-2360. 
Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, Larrayoz M, Kminkova 
J, Agathangelidis A, Davis Z et al. 2015. Recurrent mutations refine prognosis in 
chronic lymphocytic leukemia. Leukemia 29: 329-336. 
Bancroft GJ, Schreiber RD, Unanue ER. 1991. Natural immunity: a T-cell-independent 
pathway of macrophage activation, defined in the scid mouse. Immunol Rev 124: 5-24. 
Banerjee A, Gordon SM, Intlekofer AM, Paley MA, Mooney EC, Lindsten T, Wherry EJ, Reiner 
SL. 2010. Cutting edge: The transcription factor eomesodermin enables CD8+ T cells 
to compete for the memory cell niche. J Immunol 185: 4988-4992. 
Baumgarth N. 2017. A Hard(y) Look at B-1 Cell Development and Function. J Immunol 199: 
3387-3394. 
Beekman R, Chapaprieta V, Russinol N, Vilarrasa-Blasi R, Verdaguer-Dot N, Martens JHA, 
Duran-Ferrer M, Kulis M, Serra F, Javierre BM et al. 2018. The reference epigenome 
and regulatory chromatin landscape of chronic lymphocytic leukemia. Nat Med 24: 868-
880. 
Bengsch B, Ohtani T, Khan O, Setty M, Manne S, O'Brien S, Gherardini PF, Herati RS, Huang 
AC, Chang KM et al. 2018. Epigenomic-Guided Mass Cytometry Profiling Reveals 
Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48: 1029-1045 e1025. 
Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang S, Johnson JT, Whiteside TL. 2008. 
T regulatory type 1 cells in squamous cell carcinoma of the head and neck: 
mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14: 
3706-3715. 
Berndt SI Camp NJ Skibola CF Vijai J Wang Z Gu J Nieters A Kelly RS Smedby KE Monnereau 
A et al. 2016. Meta-analysis of genome-wide association studies discovers multiple loci 
for chronic lymphocytic leukemia. Nat Commun 7: 10933. 
Berndt SI Skibola CF Joseph V Camp NJ Nieters A Wang Z Cozen W Monnereau A Wang SS 
Kelly RS et al. 2013. Genome-wide association study identifies multiple risk loci for 
chronic lymphocytic leukemia. Nat Genet 45: 868-876. 
Bertilaccio MT, Simonetti G, Dagklis A, Rocchi M, Rodriguez TV, Apollonio B, Mantovani A, 
Ponzoni M, Ghia P, Garlanda C et al. 2011. Lack of TIR8/SIGIRR triggers progression 
of chronic lymphocytic leukemia in mouse models. Blood 118: 660-669. 
Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, Knolle PA, Thomas RK, von 
Bergwelt-Baildon M, Debey S et al. 2005. Reduced frequencies and suppressive 
function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic 
leukemia after therapy with fludarabine. Blood 106: 2018-2025. 
Bhattacharya N, Reichenzeller M, Caudron-Herger M, Haebe S, Brady N, Diener S, Nothing 
M, Dohner H, Stilgenbauer S, Rippe K et al. 2015. Loss of cooperativity of secreted 
CD40L and increased dose-response to IL4 on CLL cell viability correlates with 
enhanced activation of NF-kB and STAT6. Int J Cancer 136: 65-73. 
Biancotto A, Dagur PK, Fuchs JC, Wiestner A, Bagwell CB, McCoy JP, Jr. 2012. Phenotypic 
complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia. 
Mod Pathol 25: 246-259. 
Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, Russo G, Hardy RR, Croce CM. 
2002. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 
expression. Proc Natl Acad Sci U S A 99: 6955-6960. 
Binder M, Lechenne B, Ummanni R, Scharf C, Balabanov S, Trusch M, Schluter H, Braren I, 
Spillner E, Trepel M. 2010. Stereotypical chronic lymphocytic leukemia B-cell receptors 
recognize survival promoting antigens on stromal cells. PLoS One 5: e15992. 
8 References    
 135 
Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, 
Colona P, Oberling F et al. 1981. A new prognostic classification of chronic lymphocytic 
leukemia derived from a multivariate survival analysis. Cancer 48: 198-206. 
Binsky I, Haran M, Starlets D, Gore Y, Lantner F, Harpaz N, Leng L, Goldenberg DM, Shvidel 
L, Berrebi A et al. 2007. IL-8 secreted in a macrophage migration-inhibitory factor- and 
CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc 
Natl Acad Sci U S A 104: 13408-13413. 
Bissell MJ, Hines WC. 2011. Why don't we get more cancer? A proposed role of the 
microenvironment in restraining cancer progression. Nat Med 17: 320-329. 
Blanco G, Vardi A, Puiggros A, Gomez-Llonin A, Muro M, Rodriguez-Rivera M, Stalika E, 
Abella E, Gimeno E, Lopez-Sanchez M et al. 2018. Restricted T cell receptor repertoire 
in CLL-like monoclonal B cell lymphocytosis and early stage CLL. Oncoimmunology 7: 
e1432328. 
Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, 
Restifo NP et al. 2019. Defining 'T cell exhaustion'. Nat Rev Immunol 19: 665-674. 
Blattman JN, Wherry EJ, Ha SJ, van der Most RG, Ahmed R. 2009. Impact of epitope escape 
on PD-1 expression and CD8 T-cell exhaustion during chronic infection. J Virol 83: 
4386-4394. 
Brack C, Hirama M, Lenhard-Schuller R, Tonegawa S. 1978. A complete immunoglobulin gene 
is created by somatic recombination. Cell 15: 1-14. 
Bresin A, D'Abundo L, Narducci MG, Fiorenza MT, Croce CM, Negrini M, Russo G. 2016. 
TCL1 transgenic mouse model as a tool for the study of therapeutic targets and 
microenvironment in human B-cell chronic lymphocytic leukemia. Cell Death Dis 7: 
e2071. 
Brockmann L, Gagliani N, Steglich B, Giannou AD, Kempski J, Pelczar P, Geffken M, Mfarrej 
B, Huber F, Herkel J et al. 2017. IL-10 Receptor Signaling Is Essential for TR1 Cell 
Function In Vivo. J Immunol 198: 1130-1141. 
Bronte V, Zanovello P. 2005. Regulation of immune responses by L-arginine metabolism. Nat 
Rev Immunol 5: 641-654. 
Brooks DG, Ha SJ, Elsaesser H, Sharpe AH, Freeman GJ, Oldstone MB. 2008. IL-10 and PD-
L1 operate through distinct pathways to suppress T-cell activity during persistent viral 
infection. Proc Natl Acad Sci U S A 105: 20428-20433. 
Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. 2006. 
Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 12: 1301-
1309. 
Bruggner RV, Bodenmiller B, Dill DL, Tibshirani RJ, Nolan GP. 2014. Automated identification 
of stratifying signatures in cellular subpopulations. Proc Natl Acad Sci U S A 111: 
E2770-2777. 
Brummelman J, Mazza EMC, Alvisi G, Colombo FS, Grilli A, Mikulak J, Mavilio D, Alloisio M, 
Ferrari F, Lopci E et al. 2018. High-dimensional single cell analysis identifies stem-like 
cytotoxic CD8(+) T cells infiltrating human tumors. J Exp Med 215: 2520-2535. 
Brusa D, Serra S, Coscia M, Rossi D, D'Arena G, Laurenti L, Jaksic O, Fedele G, Inghirami G, 
Gaidano G et al. 2013. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic 
lymphocytic leukemia. Haematologica 98: 953-963. 
Buggins AG, Patten PE, Richards J, Thomas NS, Mufti GJ, Devereux S. 2008. Tumor-derived 
IL-6 may contribute to the immunological defect in CLL. Leukemia 22: 1084-1087. 
Burger JA. 2011. Nurture versus nature: the microenvironment in chronic lymphocytic 
leukemia. Hematology Am Soc Hematol Educ Program 2011: 96-103. 
Burger JA. 2020. Treatment of Chronic Lymphocytic Leukemia. N Engl J Med 383: 460-473. 
Burger JA, Burger M, Kipps TJ. 1999. Chronic lymphocytic leukemia B cells express functional 
CXCR4 chemokine receptors that mediate spontaneous migration beneath bone 
marrow stromal cells. Blood 94: 3658-3667. 
Burger JA, Chiorazzi N. 2013. B cell receptor signaling in chronic lymphocytic leukemia. 
Trends Immunol 34: 592-601. 
Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ, Rosenwald A. 2009. 
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic 
8 References    
 136 
leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 113: 
3050-3058. 
Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. 2000. Blood-derived 
nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous 
apoptosis through stromal cell-derived factor-1. Blood 96: 2655-2663. 
Burkle A, Niedermeier M, Schmitt-Graff A, Wierda WG, Keating MJ, Burger JA. 2007. 
Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell 
chronic lymphocytic leukemia. Blood 110: 3316-3325. 
Burnet FM. 1970. The concept of immunological surveillance. Prog Exp Tumor Res 13: 1-27. 
Burnet M. 1957. Cancer: a biological approach. III. Viruses associated with neoplastic 
conditions. IV. Practical applications. Br Med J 1: 841-847. 
Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK. 1993. Interferon 
gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 
177: 213-218. 
Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. 2018. Integrating single-cell 
transcriptomic data across different conditions, technologies, and species. Nat 
Biotechnol 36: 411-420. 
Butler JM, Kobayashi H, Rafii S. 2010. Instructive role of the vascular niche in promoting 
tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 10: 138-146. 
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan 
SP, Jaeger U et al. 2014. Ibrutinib versus ofatumumab in previously treated chronic 
lymphoid leukemia. N Engl J Med 371: 213-223. 
Caligaris-Cappio F. 1996. B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. 
Blood 87: 2615-2620. 
Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli C, Zanesi N, 
Garzon R, Aqeilan RI et al. 2008. MiR-15a and miR-16-1 cluster functions in human 
leukemia. Proc Natl Acad Sci U S A 105: 5166-5171. 
Cambier JC, Gauld SB, Merrell KT, Vilen BJ. 2007. B-cell anergy: from transgenic models to 
naturally occurring anergic B cells? Nat Rev Immunol 7: 633-643. 
Campregher C, Luciani MG, Gasche C. 2008. Activated neutrophils induce an hMSH2-
dependent G2/M checkpoint arrest and replication errors at a (CA)13-repeat in colon 
epithelial cells. Gut 57: 780-787. 
Canale FP, Ramello MC, Nunez N, Araujo Furlan CL, Bossio SN, Gorosito Serran M, Tosello 
Boari J, Del Castillo A, Ledesma M, Sedlik C et al. 2018. CD39 Expression Defines 
Cell Exhaustion in Tumor-Infiltrating CD8(+) T Cells. Cancer Res 78: 115-128. 
Catakovic K, Gassner FJ, Ratswohl C, Zaborsky N, Rebhandl S, Schubert M, Steiner M, 
Gutjahr JC, Pleyer L, Egle A et al. 2017. TIGIT expressing CD4+T cells represent a 
tumor-supportive T cell subset in chronic lymphocytic leukemia. Oncoimmunology 7: 
e1371399. 
Catovsky D, Miliani E, Okos A, Galton DA. 1974. Clinical significance of T-cells in chronic 
lymphocytic leukaemia. Lancet 2: 751-752. 
Cerhan JR, Slager SL. 2015. Familial predisposition and genetic risk factors for lymphoma. 
Blood 126: 2265-2273. 
Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, Kirkwood JM, Chen TH, 
Maurer M, Korman AJ et al. 2015. TIGIT and PD-1 impair tumor antigen-specific 
CD8(+) T cells in melanoma patients. J Clin Invest 125: 2046-2058. 
Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, 
Viner JL, Weiner LM et al. 2009. The prioritization of cancer antigens: a national cancer 
institute pilot project for the acceleration of translational research. Clin Cancer Res 15: 
5323-5337. 
Chen J, Lopez-Moyado IF, Seo H, Lio CJ, Hempleman LJ, Sekiya T, Yoshimura A, Scott-
Browne JP, Rao A. 2019. NR4A transcription factors limit CAR T cell function in solid 
tumours. Nature 567: 530-534. 
Chen SS, Chang BY, Chang S, Tong T, Ham S, Sherry B, Burger JA, Rai KR, Chiorazzi N. 
2016. BTK inhibition results in impaired CXCR4 chemokine receptor surface 
8 References    
 137 
expression, signaling and function in chronic lymphocytic leukemia. Leukemia 30: 833-
843. 
Chevrier S, Crowell HL, Zanotelli VRT, Engler S, Robinson MD, Bodenmiller B. 2018. 
Compensation of Signal Spillover in Suspension and Imaging Mass Cytometry. Cell 
Syst 6: 612-620 e615. 
Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett 
MAS, Moch H et al. 2017. An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell 
169: 736-749 e718. 
Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, Oscier D, Stamatopoulos 
K, Papadaki T, Berger F et al. 2013. Two main genetic pathways lead to the 
transformation of chronic lymphocytic leukemia to Richter syndrome. Blood 122: 2673-
2682. 
Chiorazzi N, Ferrarini M. 2011. Cellular origin(s) of chronic lymphocytic leukemia: cautionary 
notes and additional considerations and possibilities. Blood 117: 1781-1791. 
Christopoulos P, Pfeifer D, Bartholome K, Follo M, Timmer J, Fisch P, Veelken H. 2011. 
Definition and characterization of the systemic T-cell dysregulation in untreated 
indolent B-cell lymphoma and very early CLL. Blood 117: 3836-3846. 
Chu CC, Catera R, Hatzi K, Yan XJ, Zhang L, Wang XB, Fales HM, Allen SL, Kolitz JE, Rai 
KR et al. 2008. Chronic lymphocytic leukemia antibodies with a common stereotypic 
rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 112: 5122-5129. 
Chu F, Li HS, Liu X, Cao J, Ma W, Ma Y, Weng J, Zhu Z, Cheng X, Wang Z et al. 2019. 
CXCR5(+)CD8(+) T cells are a distinct functional subset with an antitumor activity. 
Leukemia 33: 2640-2653. 
Chung W, Eum HH, Lee HO, Lee KM, Lee HB, Kim KT, Ryu HS, Kim S, Lee JE, Park YH et 
al. 2017. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling 
in primary breast cancer. Nat Commun 8: 15081. 
Clark WH, Jr., Elder DE, Guerry Dt, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern 
AC. 1989. Model predicting survival in stage I melanoma based on tumor progression. 
J Natl Cancer Inst 81: 1893-1904. 
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. 2009. Cancer-related inflammation, 
the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30: 1073-
1081. 
Cols M, Barra CM, He B, Puga I, Xu W, Chiu A, Tam W, Knowles DM, Dillon SR, Leonard JP 
et al. 2012. Stromal endothelial cells establish a bidirectional crosstalk with chronic 
lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. 
J Immunol 188: 6071-6083. 
Coussens LM, Tinkle CL, Hanahan D, Werb Z. 2000. MMP-9 supplied by bone marrow-derived 
cells contributes to skin carcinogenesis. Cell 103: 481-490. 
Crotty S. 2011. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 29: 621-663. 
Crowther-Swanepoel D, Broderick P, Di Bernardo MC, Dobbins SE, Torres M, Mansouri M, 
Ruiz-Ponte C, Enjuanes A, Rosenquist R, Carracedo A et al. 2010. Common variants 
at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. 
Nat Genet 42: 132-136. 
Cruz-Guilloty F, Pipkin ME, Djuretic IM, Levanon D, Lotem J, Lichtenheld MG, Groner Y, Rao 
A. 2009. Runx3 and T-box proteins cooperate to establish the transcriptional program 
of effector CTLs. J Exp Med 206: 51-59. 
Csanaky G, Vass JA, Milosevits J, Ocsovszki I, Szomor A, Schmelczer M. 1994. Expression 
and function of L-selectin molecules (LECAM-1) in B-cell chronic lymphocytic leukemia. 
Haematologica 79: 132-136. 
Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra FM, 
Ballester S, Garcia-Marco J, Jorda J, Durantez A. 2004. A sustained activation of 
PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B 
cells. Leukemia 18: 1391-1400. 
Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. 2005. Type I IFNs provide a 
third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 
174: 4465-4469. 
8 References    
 138 
D'Arena G, Laurenti L, Minervini MM, Deaglio S, Bonello L, De Martino L, De Padua L, Savino 
L, Tarnani M, De Feo V et al. 2011. Regulatory T-cell number is increased in chronic 
lymphocytic leukemia patients and correlates with progressive disease. Leuk Res 35: 
363-368. 
Dal Bo M, Rossi FM, Rossi D, Deambrogi C, Bertoni F, Del Giudice I, Palumbo G, Nanni M, 
Rinaldi A, Kwee I et al. 2011. 13q14 deletion size and number of deleted cells both 
influence prognosis in chronic lymphocytic leukemia. Genes Chromosomes Cancer 50: 
633-643. 
Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar 
K, Kolitz J et al. 1999. Ig V gene mutation status and CD38 expression as novel 
prognostic indicators in chronic lymphocytic leukemia. Blood 94: 1840-1847. 
Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, Diop M, Scourzic L, 
Shiraishi Y, Chiba K et al. 2014. Acquired initiating mutations in early hematopoietic 
cells of CLL patients. Cancer Discov 4: 1088-1101. 
Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. 1992. Interleukin 4 
protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates 
Bcl-2 expression. J Exp Med 176: 1319-1326. 
Das M, Zhu C, Kuchroo VK. 2017. Tim-3 and its role in regulating anti-tumor immunity. 
Immunol Rev 276: 97-111. 
Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, 
Nardo L, Alvarado MD et al. 2016. Tumor immune profiling predicts response to anti-
PD-1 therapy in human melanoma. J Clin Invest 126: 3447-3452. 
Daussy C, Faure F, Mayol K, Viel S, Gasteiger G, Charrier E, Bienvenu J, Henry T, Debien E, 
Hasan UA et al. 2014. T-bet and Eomes instruct the development of two distinct natural 
killer cell lineages in the liver and in the bone marrow. J Exp Med 211: 563-577. 
de la Fuente MT, Casanova B, Moyano JV, Garcia-Gila M, Sanz L, Garcia-Marco J, Silva A, 
Garcia-Pardo A. 2002. Engagement of alpha4beta1 integrin by fibronectin induces in 
vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 
71: 495-502. 
De Obaldia ME, Bhandoola A. 2015. Transcriptional regulation of innate and adaptive 
lymphocyte lineages. Annu Rev Immunol 33: 607-642. 
de Totero D, Reato G, Mauro F, Cignetti A, Ferrini S, Guarini A, Gobbi M, Grossi CE, Foa R. 
1999. IL4 production and increased CD30 expression by a unique CD8+ T-cell subset 
in B-cell chronic lymphocytic leukaemia. Br J Haematol 104: 589-599. 
de Visser KE, Eichten A, Coussens LM. 2006. Paradoxical roles of the immune system during 
cancer development. Nat Rev Cancer 6: 24-37. 
de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. 1991. Interleukin 10(IL-10) 
inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 
produced by monocytes. J Exp Med 174: 1209-1220. 
de Weerdt I, Hofland T, de Boer R, Dobber JA, Dubois J, van Nieuwenhuize D, Mobasher M, 
de Boer F, Hoogendoorn M, Velders GA et al. 2019. Distinct immune composition in 
lymph node and peripheral blood of CLL patients is reshaped during venetoclax 
treatment. Blood Adv 3: 2642-2652. 
Deaglio S, Malavasi F. 2009. Chronic lymphocytic leukemia microenvironment: shifting the 
balance from apoptosis to proliferation. Haematologica 94: 752-756. 
Deaglio S, Vaisitti T, Bergui L, Bonello L, Horenstein AL, Tamagnone L, Boumsell L, Malavasi 
F. 2005. CD38 and CD100 lead a network of surface receptors relaying positive signals 
for B-CLL growth and survival. Blood 105: 3042-3050. 
Decker T, Bogner C, Oelsner M, Peschel C, Ringshausen I. 2010. Antiapoptotic effect of 
interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors. Ann Hematol 
89: 1125-1132. 
Del Giudice I, Chiaretti S, Tavolaro S, De Propris MS, Maggio R, Mancini F, Peragine N, 
Santangelo S, Marinelli M, Mauro FR et al. 2009. Spontaneous regression of chronic 
lymphocytic leukemia: clinical and biologic features of 9 cases. Blood 114: 638-646. 
Dennis KL, Blatner NR, Gounari F, Khazaie K. 2013. Current status of interleukin-10 and 
regulatory T-cells in cancer. Curr Opin Oncol 25: 637-645. 
8 References    
 139 
Desfrancois J, Derre L, Corvaisier M, Le Mevel B, Catros V, Jotereau F, Gervois N. 2009. 
Increased frequency of nonconventional double positive CD4CD8 alphabeta T cells in 
human breast pleural effusions. Int J Cancer 125: 374-380. 
Desfrancois J, Moreau-Aubry A, Vignard V, Godet Y, Khammari A, Dreno B, Jotereau F, 
Gervois N. 2010. Double positive CD4CD8 alphabeta T cells: a new tumor-reactive 
population in human melanomas. PLoS One 5: e8437. 
Di Bernardo MC, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, Sullivan K, 
Vijayakrishnan J, Wang Y, Pittman AM et al. 2008. A genome-wide association study 
identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 40: 1204-
1210. 
Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, Leporrier M, Jaubert J, 
Lepeu G, Dreyfus B et al. 1998. Chlorambucil in indolent chronic lymphocytic leukemia. 
French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 338: 
1506-1514. 
Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-
Rademacher J, Feldman AL et al. 2017. Pembrolizumab in patients with CLL and 
Richter transformation or with relapsed CLL. Blood 129: 3419-3427. 
Ding W, Nowakowski GS, Knox TR, Boysen JC, Maas ML, Schwager SM, Wu W, Wellik LE, 
Dietz AB, Ghosh AK et al. 2009. Bi-directional activation between mesenchymal stem 
cells and CLL B-cells: implication for CLL disease progression. Br J Haematol 147: 
471-483. 
Doering TA, Crawford A, Angelosanto JM, Paley MA, Ziegler CG, Wherry EJ. 2012. Network 
analysis reveals centrally connected genes and pathways involved in CD8+ T cell 
exhaustion versus memory. Immunity 37: 1130-1144. 
Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, 
Stilgenbauer S et al. 1995. p53 gene deletion predicts for poor survival and non-
response to therapy with purine analogs in chronic B-cell leukemias. Blood 85: 1580-
1589. 
Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, 
Lichter P. 2000. Genomic aberrations and survival in chronic lymphocytic leukemia. N 
Engl J Med 343: 1910-1916. 
Dong S, Guinn D, Dubovsky JA, Zhong Y, Lehman A, Kutok J, Woyach JA, Byrd JC, Johnson 
AJ. 2014. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic 
lymphocytic leukemia cells. Blood 124: 3583-3586. 
Dorfman DM, Shahsafaei A. 2011. CD200 (OX-2 membrane glycoprotein) is expressed by 
follicular T helper cells and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 
35: 76-83. 
Dreger P, Dohner H, Ritgen M, Bottcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert 
J, Hegenbart U et al. 2010. Allogeneic stem cell transplantation provides durable 
disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD 
results of the German CLL Study Group CLL3X trial. Blood 116: 2438-2447. 
Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu 
TM, Chang BY, Larkin KM et al. 2013. Ibrutinib is an irreversible molecular inhibitor of 
ITK driving a Th1-selective pressure in T lymphocytes. Blood 122: 2539-2549. 
Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, 
Sherry R, Restifo NP, Hubicki AM et al. 2002. Cancer regression and autoimmunity in 
patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854. 
Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, Goodall CP, Blair TC, Fox 
BA, McDermott JE et al. 2018. Co-expression of CD39 and CD103 identifies tumor-
reactive CD8 T cells in human solid tumors. Nat Commun 9: 2724. 
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. 2002. Cancer immunoediting: from 
immunosurveillance to tumor escape. Nat Immunol 3: 991-998. 
Dvorak HF. 1986. Tumors: wounds that do not heal. Similarities between tumor stroma 
generation and wound healing. N Engl J Med 315: 1650-1659. 
8 References    
 140 
E J, Yan F, Kang Z, Zhu L, Xing J, Yu E. 2018. CD8(+)CXCR5(+) T cells in tumor-draining 
lymph nodes are highly activated and predict better prognosis in colorectal cancer. 
Hum Immunol 79: 446-452. 
Efremova M, Vento-Tormo M, Teichmann SA, Vento-Tormo R. 2020. CellPhoneDB: inferring 
cell-cell communication from combined expression of multi-subunit ligand-receptor 
complexes. Nat Protoc 15: 1484-1506. 
Egeblad M, Werb Z. 2002. New functions for the matrix metalloproteinases in cancer 
progression. Nat Rev Cancer 2: 161-174. 
Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, Crotty S, von Herrath MG. 2006. 
Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 
203: 2461-2472. 
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. 2013. Inflammation-induced cancer: 
crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 13: 
759-771. 
Elston L, Fegan C, Hills R, Hashimdeen SS, Walsby E, Henley P, Pepper C, Man S. 2020. 
Increased frequency of CD4(+) PD-1(+) HLA-DR(+) T cells is associated with disease 
progression in CLL. Br J Haematol 188: 872-880. 
Epstein NA, Fatti LP. 1976. Prostatic carcinoma: some morphological features affecting 
prognosis. Cancer 37: 2455-2465. 
Ernst J, Kellis M. 2012. ChromHMM: automating chromatin-state discovery and 
characterization. Nat Methods 9: 215-216. 
Fabbri G, Dalla-Favera R. 2016. The molecular pathogenesis of chronic lymphocytic 
leukaemia. Nat Rev Cancer 16: 145-162. 
Fabbri G, Khiabanian H, Holmes AB, Wang J, Messina M, Mullighan CG, Pasqualucci L, 
Rabadan R, Dalla-Favera R. 2013. Genetic lesions associated with chronic lymphocytic 
leukemia transformation to Richter syndrome. J Exp Med 210: 2273-2288. 
Facciabene A, Motz GT, Coukos G. 2012. T-regulatory cells: key players in tumor immune 
escape and angiogenesis. Cancer Res 72: 2162-2171. 
Facciotti F, Gagliani N, Haringer B, Alfen JS, Penatti A, Maglie S, Paroni M, Iseppon A, Moro 
M, Crosti MC et al. 2016. IL-10-producing forkhead box protein 3-negative regulatory 
T cells inhibit B-cell responses and are involved in systemic lupus erythematosus. J 
Allergy Clin Immunol 137: 318-321 e315. 
Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, Kurzrock R. 2001. Interleukin-
6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic 
characteristics and outcome. Blood 97: 256-263. 
Ferrer G, Montserrat E. 2018. Critical molecular pathways in CLL therapy. Mol Med 24: 9. 
Fesnak AD, June CH, Levine BL. 2016. Engineered T cells: the promise and challenges of 
cancer immunotherapy. Nat Rev Cancer 16: 566-581. 
Fluckiger AC, Rossi JF, Bussel A, Bryon P, Banchereau J, Defrance T. 1992. Responsiveness 
of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell 
tropic factors. Blood 80: 3173-3181. 
Foa R, Massaia M, Cardona S, Tos AG, Bianchi A, Attisano C, Guarini A, di Celle PF, Fierro 
MT. 1990. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic 
leukemia cells: a possible regulatory role of TNF in the progression of the disease. 
Blood 76: 393-400. 
Folkman J. 1974. Tumor angiogenesis. Adv Cancer Res 19: 331-358. 
Folkman J, Watson K, Ingber D, Hanahan D. 1989. Induction of angiogenesis during the 
transition from hyperplasia to neoplasia. Nature 339: 58-61. 
Forconi F, Moss P. 2015. Perturbation of the normal immune system in patients with CLL. 
Blood 126: 573-581. 
Forconi F, Potter KN, Wheatley I, Darzentas N, Sozzi E, Stamatopoulos K, Mockridge CI, 
Packham G, Stevenson FK. 2010. The normal IGHV1-69-derived B-cell repertoire 
contains stereotypic patterns characteristic of unmutated CLL. Blood 115: 71-77. 
Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. 2000. Modulation of NF-
kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 164: 
2200-2206. 
8 References    
 141 
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, 
Zelenetz AD, Kipps TJ, Flinn I et al. 2014. Idelalisib and rituximab in relapsed chronic 
lymphocytic leukemia. N Engl J Med 370: 997-1007. 
Furusawa A, Reiser J, Sadashivaiah K, Simpson H, Banerjee A. 2018. Eomesodermin 
Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an 
Adoptive Transfer Model of Cancer Immunotherapy. J Immunother 41: 53-63. 
Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. 1999. Antibodies to vascular 
endothelial growth factor enhance the efficacy of cancer immunotherapy by improving 
endogenous dendritic cell function. Clin Cancer Res 5: 2963-2970. 
Gabrilovich DI, Nagaraj S. 2009. Myeloid-derived suppressor cells as regulators of the immune 
system. Nat Rev Immunol 9: 162-174. 
Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, Guo B, Herbert DR, 
Bulfone A, Trentini F et al. 2013. Coexpression of CD49b and LAG-3 identifies human 
and mouse T regulatory type 1 cells. Nat Med 19: 739-746. 
Galletti G, Scielzo C, Barbaglio F, Rodriguez TV, Riba M, Lazarevic D, Cittaro D, Simonetti G, 
Ranghetti P, Scarfo L et al. 2016. Targeting Macrophages Sensitizes Chronic 
Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. Cell Rep 14: 
1748-1760. 
Garcia-Barchino MJ, Sarasquete ME, Panizo C, Morscio J, Martinez A, Alcoceba M, Fresquet 
V, Gonzalez-Farre B, Paiva B, Young KH et al. 2018. Richter transformation driven by 
Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic 
lymphocytic leukaemia. J Pathol 245: 61-73. 
Gaspal FM, McConnell FM, Kim MY, Gray D, Kosco-Vilbois MH, Raykundalia CR, Botto M, 
Lane PJ. 2006. The generation of thymus-independent germinal centers depends on 
CD40 but not on CD154, the T cell-derived CD40-ligand. Eur J Immunol 36: 1665-1673. 
Gasser S, Orsulic S, Brown EJ, Raulet DH. 2005. The DNA damage pathway regulates innate 
immune system ligands of the NKG2D receptor. Nature 436: 1186-1190. 
Gassner FJ, Zaborsky N, Catakovic K, Rebhandl S, Huemer M, Egle A, Hartmann TN, Greil 
R, Geisberger R. 2015. Chronic lymphocytic leukaemia induces an exhausted T cell 
phenotype in the TCL1 transgenic mouse model. Br J Haematol 170: 515-522. 
Gatti RA, Good RA. 1971. Occurrence of malignancy in immunodeficiency diseases. A 
literature review. Cancer 28: 89-98. 
Gattinoni L, Speiser DE, Lichterfeld M, Bonini C. 2017. T memory stem cells in health and 
disease. Nat Med 23: 18-27. 
Gaudio E, Spizzo R, Paduano F, Luo Z, Efanov A, Palamarchuk A, Leber AS, Kaou M, Zanesi 
N, Bottoni A et al. 2012. Tcl1 interacts with Atm and enhances NF-kappaB activation 
in hematologic malignancies. Blood 119: 180-187. 
Gehrke I, Gandhirajan RK, Poll-Wolbeck SJ, Hallek M, Kreuzer KA. 2011. Bone marrow 
stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic 
lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance 
of cultured CLL cells. Mol Med 17: 619-627. 
Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, Chambert K, 
Mick E, Neale BM, Fromer M et al. 2014. Clonal hematopoiesis and blood-cancer risk 
inferred from blood DNA sequence. N Engl J Med 371: 2477-2487. 
Ghiotto F, Fais F, Valetto A, Albesiano E, Hashimoto S, Dono M, Ikematsu H, Allen SL, Kolitz 
J, Rai KR et al. 2004. Remarkably similar antigen receptors among a subset of patients 
with chronic lymphocytic leukemia. J Clin Invest 113: 1008-1016. 
Giannoni P, Pietra G, Travaini G, Quarto R, Shyti G, Benelli R, Ottaggio L, Mingari MC, Zupo 
S, Cutrona G et al. 2014. Chronic lymphocytic leukemia nurse-like cells express 
hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and 
display features of immunosuppressive type 2 skewed macrophages. Haematologica 
99: 1078-1087. 
Giannopoulos K, Schmitt M, Wlasiuk P, Chen J, Bojarska-Junak A, Kowal M, Rolinski J, 
Dmoszynska A. 2008. The high frequency of T regulatory cells in patients with B-cell 
chronic lymphocytic leukemia is diminished through treatment with thalidomide. 
Leukemia 22: 222-224. 
8 References    
 142 
Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic 
R, Wongchenko M et al. 2019. Distinct Immune Cell Populations Define Response to 
Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell 
35: 238-255 e236. 
Giesen C, Wang HA, Schapiro D, Zivanovic N, Jacobs A, Hattendorf B, Schuffler PJ, 
Grolimund D, Buhmann JM, Brandt S et al. 2014. Highly multiplexed imaging of tumor 
tissues with subcellular resolution by mass cytometry. Nat Methods 11: 417-422. 
Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, 
Tigelaar RE, Hayday AC. 2001. Regulation of cutaneous malignancy by gammadelta 
T cells. Science 294: 605-609. 
Goldin LR, Bjorkholm M, Kristinsson SY, Turesson I, Landgren O. 2009. Elevated risk of 
chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among 
relatives of patients with chronic lymphocytic leukemia. Haematologica 94: 647-653. 
Gong S, Osei ES, Kaplan D, Chen YH, Meyerson H. 2015. CD317 is over-expressed in B-cell 
chronic lymphocytic leukemia, but not B-cell acute lymphoblastic leukemia. Int J Clin 
Exp Pathol 8: 1613-1621. 
Gonnord P, Costa M, Abreu A, Peres M, Ysebaert L, Gadat S, Valitutti S. 2019. Multiparametric 
analysis of CD8(+) T cell compartment phenotype in chronic lymphocytic leukemia 
reveals a signature associated with progression toward therapy. Oncoimmunology 8: 
e1570774. 
Gonzalez-Rodriguez AP, Contesti J, Huergo-Zapico L, Lopez-Soto A, Fernandez-Guizan A, 
Acebes-Huerta A, Gonzalez-Huerta AJ, Gonzalez E, Fernandez-Alvarez C, Gonzalez 
S. 2010. Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic 
leukemia. Leuk Lymphoma 51: 1829-1836. 
Gorby C, Sotolongo Bellon J, Wilmes S, Warda W, Pohler E, Fyfe PK, Cozzani A, Ferrand C, 
Walter MR, Mitra S et al. 2020. Engineered IL-10 variants elicit potent 
immunomodulatory effects at low ligand doses. Sci Signal 13. 
Gordon SM, Chaix J, Rupp LJ, Wu J, Madera S, Sun JC, Lindsten T, Reiner SL. 2012. The 
transcription factors T-bet and Eomes control key checkpoints of natural killer cell 
maturation. Immunity 36: 55-67. 
Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. 2005. Chronic lymphocytic 
leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin 
Invest 115: 1797-1805. 
Gorgun G, Ramsay AG, Holderried TA, Zahrieh D, Le Dieu R, Liu F, Quackenbush J, Croce 
CM, Gribben JG. 2009. E(mu)-TCL1 mice represent a model for immunotherapeutic 
reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad 
Sci U S A 106: 6250-6255. 
Goronzy JJ, Fang F, Cavanagh MM, Qi Q, Weyand CM. 2015. Naive T cell maintenance and 
function in human aging. J Immunol 194: 4073-4080. 
Gothert JR, Eisele L, Klein-Hitpass L, Weber S, Zesewitz ML, Sellmann L, Roth A, Pircher H, 
Duhrsen U, Durig J. 2013. Expanded CD8+ T cells of murine and human CLL are driven 
into a senescent KLRG1+ effector memory phenotype. Cancer Immunol Immunother 
62: 1697-1709. 
Goto T, Kennel SJ, Abe M, Takishita M, Kosaka M, Solomon A, Saito S. 1994. A novel 
membrane antigen selectively expressed on terminally differentiated human B cells. 
Blood 84: 1922-1930. 
Granziero L, Circosta P, Scielzo C, Frisaldi E, Stella S, Geuna M, Giordano S, Ghia P, 
Caligaris-Cappio F. 2003. CD100/Plexin-B1 interactions sustain proliferation and 
survival of normal and leukemic CD5+ B lymphocytes. Blood 101: 1962-1969. 
Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, Hauben E, Roncarolo 
MG. 2010. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 
requires the IL-10-dependent ILT4/HLA-G pathway. Blood 116: 935-944. 
Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M. 2004. 
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated 
cancer. Cell 118: 285-296. 
8 References    
 143 
Grewal IS, Flavell RA. 1998. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 
16: 111-135. 
Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, Freedman AS, 
Mauch P, Schlossman R, Sequist LV et al. 2005. Autologous and allogeneic stem cell 
transplantations for poor-risk chronic lymphocytic leukemia. Blood 106: 4389-4396. 
Grivennikov SI, Greten FR, Karin M. 2010. Immunity, inflammation, and cancer. Cell 140: 883-
899. 
Grosselin K, Durand A, Marsolier J, Poitou A, Marangoni E, Nemati F, Dahmani A, Lameiras 
S, Reyal F, Frenoy O et al. 2019. High-throughput single-cell ChIP-seq identifies 
heterogeneity of chromatin states in breast cancer. Nat Genet 51: 1060-1066. 
Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG. 1997. A 
CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. 
Nature 389: 737-742. 
Gruarin P, Maglie S, De Simone M, Haringer B, Vasco C, Ranzani V, Bosotti R, Noddings JS, 
Larghi P, Facciotti F et al. 2019. Eomesodermin controls a unique differentiation 
program in human IL-10 and IFN-gamma coproducing regulatory T cells. Eur J 
Immunol 49: 96-111. 
Guillerey C, Harjunpaa H, Carrie N, Kassem S, Teo T, Miles K, Krumeich S, Weulersse M, 
Cuisinier M, Stannard K et al. 2018. TIGIT immune checkpoint blockade restores 
CD8(+) T-cell immunity against multiple myeloma. Blood 132: 1689-1694. 
Guillot B, Portales P, Thanh AD, Merlet S, Dereure O, Clot J, Corbeau P. 2005. The expression 
of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and 
increased by interferon-alpha treatment. Br J Dermatol 152: 690-696. 
Guo X, Zhang Y, Zheng L, Zheng C, Song J, Zhang Q, Kang B, Liu Z, Jin L, Xing R et al. 2018. 
Global characterization of T cells in non-small-cell lung cancer by single-cell 
sequencing. Nat Med 24: 978-985. 
Gupta PK, Godec J, Wolski D, Adland E, Yates K, Pauken KE, Cosgrove C, Ledderose C, 
Junger WG, Robson SC et al. 2015. CD39 Expression Identifies Terminally Exhausted 
CD8+ T Cells. PLoS Pathog 11: e1005177. 
Haderk F, Schulz R, Iskar M, Cid LL, Worst T, Willmund KV, Schulz A, Warnken U, Seiler J, 
Benner A et al. 2017. Tumor-derived exosomes modulate PD-L1 expression in 
monocytes. Sci Immunol 2. 
Hahne F, LeMeur N, Brinkman RR, Ellis B, Haaland P, Sarkar D, Spidlen J, Strain E, 
Gentleman R. 2009. flowCore: a Bioconductor package for high throughput flow 
cytometry. BMC Bioinformatics 10: 106. 
Hall AM, Vickers MA, McLeod E, Barker RN. 2005. Rh autoantigen presentation to helper T 
cells in chronic lymphocytic leukemia by malignant B cells. Blood 105: 2007-2015. 
Halle S, Halle O, Forster R. 2017. Mechanisms and Dynamics of T Cell-Mediated Cytotoxicity 
In Vivo. Trends Immunol 38: 432-443. 
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, 
Keating M, Montserrat E, Chiorazzi N et al. 2018. iwCLL guidelines for diagnosis, 
indications for treatment, response assessment, and supportive management of CLL. 
Blood 131: 2745-2760. 
Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, Schick HD, Kuhn-Hallek 
I, Emmerich B. 1996. Serum beta(2)-microglobulin and serum thymidine kinase are 
independent predictors of progression-free survival in chronic lymphocytic leukemia 
and immunocytoma. Leuk Lymphoma 22: 439-447. 
Hamblin TJ. 2010. The TCL1 mouse as a model for chronic lymphocytic leukemia. Leuk Res 
34: 135-136. 
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. 1999. Unmutated Ig V(H) genes 
are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94: 
1848-1854. 
Hanahan D, Coussens LM. 2012. Accessories to the crime: functions of cells recruited to the 
tumor microenvironment. Cancer Cell 21: 309-322. 
Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144: 646-674. 
8 References    
 144 
Hanna BS, McClanahan F, Yazdanparast H, Zaborsky N, Kalter V, Rossner PM, Benner A, 
Durr C, Egle A, Gribben JG et al. 2016. Depletion of CLL-associated patrolling 
monocytes and macrophages controls disease development and repairs immune 
dysfunction in vivo. Leukemia 30: 570-579. 
Hanna BS, Roessner PM, Yazdanparast H, Colomer D, Campo E, Kugler S, Yosifov D, 
Stilgenbauer S, Schmidt M, Gabriel R et al. 2019. Control of chronic lymphocytic 
leukemia development by clonally-expanded CD8(+) T-cells that undergo functional 
exhaustion in secondary lymphoid tissues. Leukemia 33: 625-637. 
Hanna BS, Yazdanparast H, Demerdash Y, Roessner PM, Schulz R, Lichter P, Stilgenbauer 
S, Seiffert M. 2020. Combining ibrutinib and checkpoint blockade improves CD8+ T-
cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice. 
Haematologica doi:10.3324/haematol.2019.238154. 
Hashimoto M, Kamphorst AO, Im SJ, Kissick HT, Pillai RN, Ramalingam SS, Araki K, Ahmed 
R. 2018. CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for 
Interventions. Annu Rev Med 69: 301-318. 
Hayakawa K, Formica AM, Brill-Dashoff J, Shinton SA, Ichikawa D, Zhou Y, Morse HC, 3rd, 
Hardy RR. 2016. Early generated B1 B cells with restricted BCRs become chronic 
lymphocytic leukemia with continued c-Myc and low Bmf expression. J Exp Med 213: 
3007-3024. 
Hayakawa Y, Kelly JM, Westwood JA, Darcy PK, Diefenbach A, Raulet D, Smyth MJ. 2002. 
Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is 
dependent upon perforin. J Immunol 169: 5377-5381. 
Heinemann C, Heink S, Petermann F, Vasanthakumar A, Rothhammer V, Doorduijn E, 
Mitsdoerffer M, Sie C, Prazeres da Costa O, Buch T et al. 2014. IL-27 and IL-12 oppose 
pro-inflammatory IL-23 in CD4+ T cells by inducing Blimp1. Nat Commun 5: 3770. 
Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J. 2000. CD27 
is required for generation and long-term maintenance of T cell immunity. Nat Immunol 
1: 433-440. 
Herishanu Y, Katz BZ, Lipsky A, Wiestner A. 2013. Biology of chronic lymphocytic leukemia in 
different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin 
North Am 27: 173-206. 
Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, 
Lee E, Stennett L et al. 2011. The lymph node microenvironment promotes B-cell 
receptor signaling, NF-kappaB activation, and tumor proliferation in chronic 
lymphocytic leukemia. Blood 117: 563-574. 
Herling M, Patel KA, Khalili J, Schlette E, Kobayashi R, Medeiros LJ, Jones D. 2006. TCL1 
shows a regulated expression pattern in chronic lymphocytic leukemia that correlates 
with molecular subtypes and proliferative state. Leukemia 20: 280-285. 
Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ, Jones D. 2009. High TCL1 
levels are a marker of B-cell receptor pathway responsiveness and adverse outcome 
in chronic lymphocytic leukemia. Blood 114: 4675-4686. 
Herndon TM, Chen SS, Saba NS, Valdez J, Emson C, Gatmaitan M, Tian X, Hughes TE, Sun 
C, Arthur DC et al. 2017. Direct in vivo evidence for increased proliferation of CLL cells 
in lymph nodes compared to bone marrow and peripheral blood. Leukemia 31: 1340-
1347. 
Herve M, Xu K, Ng YS, Wardemann H, Albesiano E, Messmer BT, Chiorazzi N, Meffre E. 
2005. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive 
B cell precursors despite expressing different antibody reactivity. J Clin Invest 115: 
1636-1643. 
Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E, Walczak H, Kalthoff H, 
Ungefroren H. 2000. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- 
and TRAIL-receptor-mediated apoptosis. Oncogene 19: 5477-5486. 
Hodge-Dufour J, Noble PW, Horton MR, Bao C, Wysoka M, Burdick MD, Strieter RM, Trinchieri 
G, Pure E. 1997. Induction of IL-12 and chemokines by hyaluronan requires adhesion-
dependent priming of resident but not elicited macrophages. J Immunol 159: 2492-
2500. 
8 References    
 145 
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert 
C, Schadendorf D, Hassel JC et al. 2010. Improved survival with ipilimumab in patients 
with metastatic melanoma. N Engl J Med 363: 711-723. 
Hofbauer JP, Heyder C, Denk U, Kocher T, Holler C, Trapin D, Asslaber D, Tinhofer I, Greil R, 
Egle A. 2011. Development of CLL in the TCL1 transgenic mouse model is associated 
with severe skewing of the T-cell compartment homologous to human CLL. Leukemia 
25: 1452-1458. 
Hofland T, de Weerdt I, Ter Burg H, de Boer R, Tannheimer S, Tonino SH, Kater AP, Eldering 
E. 2019. Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of 
Healthy and Malignant Lymphocytes. J Immunol 203: 2100-2109. 
Holler C, Pinon JD, Denk U, Heyder C, Hofbauer S, Greil R, Egle A. 2009. PKCbeta is essential 
for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse 
model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. 
Blood 113: 2791-2794. 
Howlader N NA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis 
DR, Chen HS, Feuer EJ, Cronin KA. 2017. SEER Cancer Statistics Review, 1975-
2017. National Cancer Institute. Bethesda, MD. 
Hu H, Wu X, Jin W, Chang M, Cheng X, Sun SC. 2011. Noncanonical NF-kappaB regulates 
inducible costimulator (ICOS) ligand expression and T follicular helper cell 
development. Proc Natl Acad Sci U S A 108: 12827-12832. 
Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. 1994. Role of bone 
marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 
961-965. 
Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA. 
1999. ICOS is an inducible T-cell co-stimulator structurally and functionally related to 
CD28. Nature 397: 263-266. 
Ilander M, Kreutzman A, Rohon P, Melo T, Faber E, Porkka K, Vakkila J, Mustjoki S. 2014. 
Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid 
leukemia patients who have successfully discontinued IFN-alpha monotherapy. PLoS 
One 9: e87794. 
Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q, Hale JS, Lee J, Nasti 
TH et al. 2016. Defining CD8+ T cells that provide the proliferative burst after PD-1 
therapy. Nature 537: 417-421. 
Intlekofer AM, Banerjee A, Takemoto N, Gordon SM, Dejong CS, Shin H, Hunter CA, Wherry 
EJ, Lindsten T, Reiner SL. 2008. Anomalous type 17 response to viral infection by 
CD8+ T cells lacking T-bet and eomesodermin. Science 321: 408-411. 
Intlekofer AM, Takemoto N, Wherry EJ, Longworth SA, Northrup JT, Palanivel VR, Mullen AC, 
Gasink CR, Kaech SM, Miller JD et al. 2005. Effector and memory CD8+ T cell fate 
coupled by T-bet and eomesodermin. Nat Immunol 6: 1236-1244. 
Ishikawa J, Kaisho T, Tomizawa H, Lee BO, Kobune Y, Inazawa J, Oritani K, Itoh M, Ochi T, 
Ishihara K et al. 1995. Molecular cloning and chromosomal mapping of a bone marrow 
stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 
26: 527-534. 
Istaces N, Splittgerber M, Lima Silva V, Nguyen M, Thomas S, Le A, Achouri Y, Calonne E, 
Defrance M, Fuks F et al. 2019. EOMES interacts with RUNX3 and BRG1 to promote 
innate memory cell formation through epigenetic reprogramming. Nat Commun 10: 
3306. 
Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. 2002. Involvement of PD-L1 on 
tumor cells in the escape from host immune system and tumor immunotherapy by PD-
L1 blockade. Proc Natl Acad Sci U S A 99: 12293-12297. 
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel 
CH, Burtt N, Chavez A et al. 2014. Age-related clonal hematopoiesis associated with 
adverse outcomes. N Engl J Med 371: 2488-2498. 
Jemal A, Siegel R, Xu J, Ward E. 2010. Cancer statistics, 2010. CA Cancer J Clin 60: 277-
300. 
8 References    
 146 
Jia B, Zhao C, Rakszawski KL, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Wang M, 
Shike H, Bayerl MG et al. 2019. Eomes(+)T-bet(low) CD8(+) T Cells Are Functionally 
Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid 
Leukemia. Cancer Res 79: 1635-1645. 
Jin HT, Anderson AC, Tan WG, West EE, Ha SJ, Araki K, Freeman GJ, Kuchroo VK, Ahmed 
R. 2010. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral 
infection. Proc Natl Acad Sci U S A 107: 14733-14738. 
Jitschin R, Braun M, Buttner M, Dettmer-Wilde K, Bricks J, Berger J, Eckart MJ, Krause SW, 
Oefner PJ, Le Blanc K et al. 2014. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-
derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood 124: 
750-760. 
Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, 
Irving B et al. 2014. The immunoreceptor TIGIT regulates antitumor and antiviral 
CD8(+) T cell effector function. Cancer Cell 26: 923-937. 
Kalluri R, Zeisberg M. 2006. Fibroblasts in cancer. Nat Rev Cancer 6: 392-401. 
Kamanaka M, Kim ST, Wan YY, Sutterwala FS, Lara-Tejero M, Galan JE, Harhaj E, Flavell 
RA. 2006. Expression of interleukin-10 in intestinal lymphocytes detected by an 
interleukin-10 reporter knockin tiger mouse. Immunity 25: 941-952. 
Kao C, Oestreich KJ, Paley MA, Crawford A, Angelosanto JM, Ali MA, Intlekofer AM, Boss JM, 
Reiner SL, Weinmann AS et al. 2011. Transcription factor T-bet represses expression 
of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during 
chronic infection. Nat Immunol 12: 663-671. 
Karin M, Greten FR. 2005. NF-kappaB: linking inflammation and immunity to cancer 
development and progression. Nat Rev Immunol 5: 749-759. 
Kataoka T, Schroter M, Hahne M, Schneider P, Irmler M, Thome M, Froelich CJ, Tschopp J. 
1998. FLIP prevents apoptosis induced by death receptors but not by 
perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol 161: 
3936-3942. 
Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, Defrance T, Ajchenbaum-
Cymbalista F, Simonin PY, Feldblum S et al. 2004. Involvement of BAFF and APRIL in 
the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103: 679-
688. 
Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, Werner MT, Huang AC, 
Alexander KA, Wu JE et al. 2019. TOX transcriptionally and epigenetically programs 
CD8(+) T cell exhaustion. Nature 571: 211-218. 
Kikushige Y, Ishikawa F, Miyamoto T, Shima T, Urata S, Yoshimoto G, Mori Y, Iino T, 
Yamauchi T, Eto T et al. 2011. Self-renewing hematopoietic stem cell is the primary 
target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20: 246-
259. 
Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, Lee JI, Suh YL, Ku BM, Eum HH et al. 
2020. Single-cell RNA sequencing demonstrates the molecular and cellular 
reprogramming of metastatic lung adenocarcinoma. Nat Commun 11: 2285. 
King C, Tangye SG, Mackay CR. 2008. T follicular helper (TFH) cells in normal and 
dysregulated immune responses. Annu Rev Immunol 26: 741-766. 
Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, 
Rai K. 2017. Chronic lymphocytic leukaemia. Nat Rev Dis Primers 3: 16096. 
Kiselev VY, Andrews TS, Hemberg M. 2019. Challenges in unsupervised clustering of single-
cell RNA-seq data. Nat Rev Genet 20: 273-282. 
Kitada S, Zapata JM, Andreeff M, Reed JC. 1999. Bryostatin and CD40-ligand enhance 
apoptosis resistance and induce expression of cell survival genes in B-cell chronic 
lymphocytic leukaemia. Br J Haematol 106: 995-1004. 
Kitchen SG, Jones NR, LaForge S, Whitmire JK, Vu BA, Galic Z, Brooks DG, Brown SJ, 
Kitchen CM, Zack JA. 2004. CD4 on CD8(+) T cells directly enhances effector function 
and is a target for HIV infection. Proc Natl Acad Sci U S A 101: 8727-8732. 
Klein U, Dalla-Favera R. 2008. Germinal centres: role in B-cell physiology and malignancy. 
Nat Rev Immunol 8: 22-33. 
8 References    
 147 
Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, Ambesi-Impiombato A, Califano A, 
Migliazza A, Bhagat G et al. 2010. The DLEU2/miR-15a/16-1 cluster controls B cell 
proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17: 28-
40. 
Klein U, Rajewsky K, Kuppers R. 1998. Human immunoglobulin (Ig)M+IgD+ peripheral blood 
B cells expressing the CD27 cell surface antigen carry somatically mutated variable 
region genes: CD27 as a general marker for somatically mutated (memory) B cells. J 
Exp Med 188: 1679-1689. 
Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, Freedman A, Inghirami G, 
Cro L, Baldini L et al. 2001. Gene expression profiling of B cell chronic lymphocytic 
leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 
194: 1625-1638. 
Kocher T, Asslaber D, Zaborsky N, Flenady S, Denk U, Reinthaler P, Ablinger M, Geisberger 
R, Bauer JW, Seiffert M et al. 2016. CD4+ T cells, but not non-classical monocytes, 
are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg 
murine model. Leukemia 30: 1409-1413. 
Kowalewski DJ, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, Salih HR, Rammensee HG, 
Stevanovic S, Stickel JS. 2015. HLA ligandome analysis identifies the underlying 
specificities of spontaneous antileukemia immune responses in chronic lymphocytic 
leukemia (CLL). Proc Natl Acad Sci U S A 112: E166-175. 
Kulis M, Heath S, Bibikova M, Queiros AC, Navarro A, Clot G, Martinez-Trillos A, Castellano 
G, Brun-Heath I, Pinyol M et al. 2012. Epigenomic analysis detects widespread gene-
body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 44: 1236-1242. 
Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, 
Estrov Z, Keating MJ et al. 2009. Diverse marrow stromal cells protect CLL cells from 
spontaneous and drug-induced apoptosis: development of a reliable and reproducible 
system to assess stromal cell adhesion-mediated drug resistance. Blood 114: 4441-
4450. 
Kurtulus S, Madi A, Escobar G, Klapholz M, Nyman J, Christian E, Pawlak M, Dionne D, Xia 
J, Rozenblatt-Rosen O et al. 2019. Checkpoint Blockade Immunotherapy Induces 
Dynamic Changes in PD-1(-)CD8(+) Tumor-Infiltrating T Cells. Immunity 50: 181-194 
e186. 
Labanieh L, Majzner RG, Mackall CL. 2018. Programming CAR-T cells to kill cancer. Nat 
Biomed Eng 2: 377-391. 
Lagneaux L, Delforge A, Bernier M, Stryckmans P, Bron D. 1998. TGF-beta activity and 
expression of its receptors in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 31: 
99-106. 
Lahnemann D, Koster J, Szczurek E, McCarthy DJ, Hicks SC, Robinson MD, Vallejos CA, 
Campbell KR, Beerenwinkel N, Mahfouz A et al. 2020. Eleven grand challenges in 
single-cell data science. Genome Biol 21: 31. 
Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman 
AS, Jacobson CA, Armand P et al. 2016. Idelalisib given front-line for treatment of 
chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 
128: 195-203. 
Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, 
Stewart C, Sivachenko A, Wang L et al. 2013. Evolution and impact of subclonal 
mutations in chronic lymphocytic leukemia. Cell 152: 714-726. 
Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, 
Lawrence M, Bottcher S et al. 2015. Mutations driving CLL and their evolution in 
progression and relapse. Nature 526: 525-530. 
Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, Remark R, Sweeney R, 
Becker CD, Levine JH et al. 2017. Innate Immune Landscape in Early Lung 
Adenocarcinoma by Paired Single-Cell Analyses. Cell 169: 750-765 e717. 
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, 
Stewart C, Mermel CH, Roberts SA et al. 2013. Mutational heterogeneity in cancer and 
the search for new cancer-associated genes. Nature 499: 214-218. 
8 References    
 148 
Le J, Park JE, Ha VL, Luong A, Branciamore S, Rodin AS, Gogoshin G, Li F, Loh YE, Camacho 
V et al. 2020. Single-Cell RNA-Seq Mapping of Human Thymopoiesis Reveals Lineage 
Specification Trajectories and a Commitment Spectrum in T Cell Development. 
Immunity 52: 1105-1118 e1109. 
Le KS, Ame-Thomas P, Tarte K, Gondois-Rey F, Granjeaud S, Orlanducci F, Foucher ED, 
Broussais F, Bouabdallah R, Fest T et al. 2018. CXCR5 and ICOS expression identifies 
a CD8 T-cell subset with TFH features in Hodgkin lymphomas. Blood Adv 2: 1889-
1900. 
Le Roy C, Deglesne PA, Chevallier N, Beitar T, Eclache V, Quettier M, Boubaya M, Letestu R, 
Levy V, Ajchenbaum-Cymbalista F et al. 2012. The degree of BCR and NFAT activation 
predicts clinical outcomes in chronic lymphocytic leukemia. Blood 120: 356-365. 
Leach DR, Krummel MF, Allison JP. 1996. Enhancement of antitumor immunity by CTLA-4 
blockade. Science 271: 1734-1736. 
LeBien TW. 2000. Fates of human B-cell precursors. Blood 96: 9-23. 
Lee AYS, Korner H. 2019. The CCR6-CCL20 axis in humoral immunity and T-B cell 
immunobiology. Immunobiology 224: 449-454. 
Levings MK, Sangregorio R, Galbiati F, Squadrone S, de Waal Malefyt R, Roncarolo MG. 
2001. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. 
J Immunol 166: 5530-5539. 
Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi ACJ, van den Braber 
M, Rozeman EA, Haanen J, Blank CU et al. 2019. Dysfunctional CD8 T Cells Form a 
Proliferative, Dynamically Regulated Compartment within Human Melanoma. Cell 176: 
775-789 e718. 
Li J, He Y, Hao J, Ni L, Dong C. 2018. High Levels of Eomes Promote Exhaustion of Anti-
tumor CD8(+) T Cells. Front Immunol 9: 2981. 
Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. 2006. Transforming growth factor-beta 
regulation of immune responses. Annu Rev Immunol 24: 99-146. 
Lia M, Carette A, Tang H, Shen Q, Mo T, Bhagat G, Dalla-Favera R, Klein U. 2012. Functional 
dissection of the chromosome 13q14 tumor-suppressor locus using transgenic mouse 
lines. Blood 119: 2981-2990. 
Lipponen PK, Eskelinen MJ, Jauhiainen K, Harju E, Terho R. 1992. Tumour infiltrating 
lymphocytes as an independent prognostic factor in transitional cell bladder cancer. 
Eur J Cancer 29A: 69-75. 
Lotz M, Ranheim E, Kipps TJ. 1994. Transforming growth factor beta as endogenous growth 
inhibitor of chronic lymphocytic leukemia B cells. J Exp Med 179: 999-1004. 
Lupar E, Brack M, Garnier L, Laffont S, Rauch KS, Schachtrup K, Arnold SJ, Guery JC, Izcue 
A. 2015. Eomesodermin Expression in CD4+ T Cells Restricts Peripheral Foxp3 
Induction. J Immunol 195: 4742-4752. 
Maaten Lvd, Hinton G. 2008. Visualizing data using t-SNE. Journal of machine learning 
research 9: 2579-2605. 
MacMicking J, Xie QW, Nathan C. 1997. Nitric oxide and macrophage function. Annu Rev 
Immunol 15: 323-350. 
Maffei R, Bulgarelli J, Fiorcari S, Bertoncelli L, Martinelli S, Guarnotta C, Castelli I, Deaglio S, 
Debbia G, De Biasi S et al. 2013. The monocytic population in chronic lymphocytic 
leukemia shows altered composition and deregulation of genes involved in 
phagocytosis and inflammation. Haematologica 98: 1115-1123. 
Maffei R, Fiorcari S, Bulgarelli J, Martinelli S, Castelli I, Deaglio S, Debbia G, Fontana M, 
Coluccio V, Bonacorsi G et al. 2012. Physical contact with endothelial cells through 
beta1- and beta2- integrins rescues chronic lymphocytic leukemia cells from 
spontaneous and drug-induced apoptosis and induces a peculiar gene expression 
profile in leukemic cells. Haematologica 97: 952-960. 
Magen A, Nie J, Ciucci T, Tamoutounour S, Zhao Y, Mehta M, Tran B, McGavern DB, 
Hannenhalli S, Bosselut R. 2019. Single-Cell Profiling Defines Transcriptomic 
Signatures Specific to Tumor-Reactive versus Virus-Responsive CD4(+) T Cells. Cell 
Rep 29: 3019-3032 e3016. 
8 References    
 149 
Magnani CF, Alberigo G, Bacchetta R, Serafini G, Andreani M, Roncarolo MG, Gregori S. 
2011. Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel 
mechanism of suppression by human Tr1 cells. Eur J Immunol 41: 1652-1662. 
Mahauad-Fernandez WD, DeMali KA, Olivier AK, Okeoma CM. 2014. Bone marrow stromal 
antigen 2 expressed in cancer cells promotes mammary tumor growth and metastasis. 
Breast Cancer Res 16: 493. 
Maier T, Guell M, Serrano L. 2009. Correlation of mRNA and protein in complex biological 
samples. FEBS Lett 583: 3966-3973. 
Majzner RG, Mackall CL. 2019. Clinical lessons learned from the first leg of the CAR T cell 
journey. Nat Med 25: 1341-1355. 
Man K, Gabriel SS, Liao Y, Gloury R, Preston S, Henstridge DC, Pellegrini M, Zehn D, 
Berberich-Siebelt F, Febbraio MA et al. 2017. Transcription Factor IRF4 Promotes 
CD8(+) T Cell Exhaustion and Limits the Development of Memory-like T Cells during 
Chronic Infection. Immunity 47: 1129-1141 e1125. 
Mansouri L, Sutton LA, Ljungstrom V, Bondza S, Arngarden L, Bhoi S, Larsson J, Cortese D, 
Kalushkova A, Plevova K et al. 2015. Functional loss of IkappaBepsilon leads to NF-
kappaB deregulation in aggressive chronic lymphocytic leukemia. J Exp Med 212: 833-
843. 
Martinez GJ, Pereira RM, Aijo T, Kim EY, Marangoni F, Pipkin ME, Togher S, Heissmeyer V, 
Zhang YC, Crotty S et al. 2015. The transcription factor NFAT promotes exhaustion of 
activated CD8(+) T cells. Immunity 42: 265-278. 
Martinez-Torres AC, Quiney C, Attout T, Boullet H, Herbi L, Vela L, Barbier S, Chateau D, 
Chapiro E, Nguyen-Khac F et al. 2015. CD47 agonist peptides induce programmed cell 
death in refractory chronic lymphocytic leukemia B cells via PLCgamma1 activation: 
evidence from mice and humans. PLoS Med 12: e1001796. 
Martinez-Usatorre A, Donda A, Zehn D, Romero P. 2018. PD-1 Blockade Unleashes Effector 
Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells. J Immunol 201: 792-
803. 
Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, 
Lele S, Shrikant P et al. 2010. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are 
negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci 
U S A 107: 7875-7880. 
Matzinger P. 1994. Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-
1045. 
Mayr C, Bund D, Schlee M, Bamberger M, Kofler DM, Hallek M, Wendtner CM. 2006. MDM2 
is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ 
autologous T lymphocytes. Exp Hematol 34: 44-53. 
Mazzoni A, Maggi L, Siracusa F, Ramazzotti M, Rossi MC, Santarlasci V, Montaini G, Capone 
M, Rossettini B, De Palma R et al. 2019. Eomes controls the development of Th17-
derived (non-classic) Th1 cells during chronic inflammation. Eur J Immunol 49: 79-95. 
McAdam AJ, Chang TT, Lumelsky AE, Greenfield EA, Boussiotis VA, Duke-Cohan JS, 
Chernova T, Malenkovich N, Jabs C, Kuchroo VK et al. 2000. Mouse inducible 
costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and 
regulates differentiation of CD4+ T cells. J Immunol 165: 5035-5040. 
McClanahan F, Hanna B, Miller S, Clear AJ, Lichter P, Gribben JG, Seiffert M. 2015a. PD-L1 
checkpoint blockade prevents immune dysfunction and leukemia development in a 
mouse model of chronic lymphocytic leukemia. Blood 126: 203-211. 
McClanahan F, Riches JC, Miller S, Day WP, Kotsiou E, Neuberg D, Croce CM, Capasso M, 
Gribben JG. 2015b. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in 
the context of aging-related immune defects in the Emicro-TCL1 CLL mouse model. 
Blood 126: 212-221. 
McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, 
Wilson GA, Birkbak NJ, Hiley CT et al. 2016. Clonal neoantigens elicit T cell 
immunoreactivity and sensitivity to immune checkpoint blockade. Science 351: 1463-
1469. 
8 References    
 150 
McLane LM, Abdel-Hakeem MS, Wherry EJ. 2019. CD8 T Cell Exhaustion During Chronic 
Viral Infection and Cancer. Annu Rev Immunol 37: 457-495. 
Medzhitov R. 2008. Origin and physiological roles of inflammation. Nature 454: 428-435. 
Melchers F. 2015. Checkpoints that control B cell development. J Clin Invest 125: 2203-2210. 
Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, Murphy EJ, Koduru P, 
Ferrarini M, Zupo S et al. 2005. In vivo measurements document the dynamic cellular 
kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 115: 755-764. 
Methot SP, Di Noia JM. 2017. Molecular Mechanisms of Somatic Hypermutation and Class 
Switch Recombination. Adv Immunol 133: 37-87. 
Meyaard L, Adema GJ, Chang C, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. 1997. 
LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. 
Immunity 7: 283-290. 
Miles B, Miller SM, Folkvord JM, Levy DN, Rakasz EG, Skinner PJ, Connick E. 2016. Follicular 
Regulatory CD8 T Cells Impair the Germinal Center Response in SIV and Ex Vivo HIV 
Infection. PLoS Pathog 12: e1005924. 
Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik 
GS et al. 2019. Subsets of exhausted CD8(+) T cells differentially mediate tumor control 
and respond to checkpoint blockade. Nat Immunol 20: 326-336. 
Miragaia RJ, Gomes T, Chomka A, Jardine L, Riedel A, Hegazy AN, Whibley N, Tucci A, Chen 
X, Lindeman I et al. 2019. Single-Cell Transcriptomics of Regulatory T Cells Reveals 
Trajectories of Tissue Adaptation. Immunity 50: 493-504 e497. 
Mok CL, Gil-Gomez G, Williams O, Coles M, Taga S, Tolaini M, Norton T, Kioussis D, Brady 
HJ. 1999. Bad can act as a key regulator of T cell apoptosis and T cell development. J 
Exp Med 189: 575-586. 
Monserrat J, Sanchez MA, de Paz R, Diaz D, Mur S, Reyes E, Prieto A, de la Hera A, Martinez 
AC, Alvarez-Mon M. 2014. Distinctive patterns of naive/memory subset distribution and 
cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients. 
Cytometry B Clin Cytom 86: 32-43. 
Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, Keating MJ, Wierda WG. 2005. Increased 
expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-
cell chronic lymphocytic leukemia. Leukemia 19: 1788-1793. 
Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF. 2009. Programmed 
death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell 
exhaustion and disease progression. Blood 114: 1528-1536. 
Nabhan C, Rosen ST. 2014. Chronic lymphocytic leukemia: a clinical review. JAMA 312: 2265-
2276. 
Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, 
Whiteside M, Rasco DR et al. 2016. Safety, Antitumor Activity, and Immune Activation 
of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced 
Solid Tumors. J Clin Oncol 34: 3562-3569. 
Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. 1998. CD8+ T cells 
infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. 
Cancer Res 58: 3491-3494. 
Nascimbeni M, Shin EC, Chiriboga L, Kleiner DE, Rehermann B. 2004. Peripheral 
CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. 
Blood 104: 478-486. 
Neumann C, Heinrich F, Neumann K, Junghans V, Mashreghi MF, Ahlers J, Janke M, Rudolph 
C, Mockel-Tenbrinck N, Kuhl AA et al. 2014. Role of Blimp-1 in programing Th effector 
cells into IL-10 producers. J Exp Med 211: 1807-1819. 
Nganga VK, Palmer VL, Naushad H, Kassmeier MD, Anderson DK, Perry GA, Schabla NM, 
Swanson PC. 2013. Accelerated progression of chronic lymphocytic leukemia in Emu-
TCL1 mice expressing catalytically inactive RAG1. Blood 121: 3855-3866, S3851-
3816. 
Ni G, Wang T, Walton S, Zhu B, Chen S, Wu X, Wang Y, Wei MQ, Liu X. 2015. Manipulating 
IL-10 signalling blockade for better immunotherapy. Cell Immunol 293: 126-129. 
8 References    
 151 
Niemann CU, Herman SE, Maric I, Gomez-Rodriguez J, Biancotto A, Chang BY, Martyr S, 
Stetler-Stevenson M, Yuan CM, Calvo KR et al. 2016. Disruption of in vivo Chronic 
Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings 
from an Investigator-Initiated Phase II Study. Clin Cancer Res 22: 1572-1582. 
Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, Reed JC, Zvaifler NJ, Kipps TJ. 2005. 
Nurselike cells express BAFF and APRIL, which can promote survival of chronic 
lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. 
Blood 106: 1012-1020. 
Noguchi M, Ropars V, Roumestand C, Suizu F. 2007. Proto-oncogene TCL1: more than just 
a coactivator for Akt. FASEB J 21: 2273-2284. 
Novak M, Prochazka V, Turcsanyi P, Papajik T. 2015. Numbers of CD8+PD-1+ and CD4+PD-
1+ Cells in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Are 
Independent of Binet Stage and Are Significantly Higher Compared to Healthy 
Volunteers. Acta Haematol 134: 208-214. 
Nozawa H, Chiu C, Hanahan D. 2006. Infiltrating neutrophils mediate the initial angiogenic 
switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 103: 
12493-12498. 
Nunes C, Wong R, Mason M, Fegan C, Man S, Pepper C. 2012. Expansion of a CD8(+)PD-
1(+) replicative senescence phenotype in early stage CLL patients is associated with 
inverted CD4:CD8 ratios and disease progression. Clin Cancer Res 18: 678-687. 
O'Brien S, Kantarjian H, Beran M, Robertson LE, Koller C, Lerner S, Keating MJ. 1995. 
Interferon maintenance therapy for patients with chronic lymphocytic leukemia in 
remission after fludarabine therapy. Blood 86: 1298-1300. 
O'Flanagan CH, Campbell KR, Zhang AW, Kabeer F, Lim JLP, Biele J, Eirew P, Lai D, 
McPherson A, Kong E et al. 2019. Dissociation of solid tumor tissues with cold active 
protease for single-cell RNA-seq minimizes conserved collagenase-associated stress 
responses. Genome Biol 20: 210. 
O'Shea JJ, Murray PJ. 2008. Cytokine signaling modules in inflammatory responses. Immunity 
28: 477-487. 
Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, Wang Q, Imbusch CD, 
Serva A, Koser SD et al. 2016. DNA methylation dynamics during B cell maturation 
underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat 
Genet 48: 253-264. 
Okamura T, Sumitomo S, Morita K, Iwasaki Y, Inoue M, Nakachi S, Komai T, Shoda H, 
Miyazaki J, Fujio K et al. 2015. TGF-beta3-expressing CD4+CD25(-)LAG3+ regulatory 
T cells control humoral immune responses. Nat Commun 6: 6329. 
Okazaki IM, Kotani A, Honjo T. 2007. Role of AID in tumorigenesis. Adv Immunol 94: 245-273. 
Ono M, Torisu H, Fukushi J, Nishie A, Kuwano M. 1999. Biological implications of macrophage 
infiltration in human tumor angiogenesis. Cancer Chemother Pharmacol 43 Suppl: 
S69-71. 
Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, Hamblin TJ, Staudt 
LM, Oscier DG. 2004. ZAP-70 expression and prognosis in chronic lymphocytic 
leukaemia. Lancet 363: 105-111. 
Orsini E, Guarini A, Chiaretti S, Mauro FR, Foa R. 2003. The circulating dendritic cell 
compartment in patients with chronic lymphocytic leukemia is severely defective and 
unable to stimulate an effective T-cell response. Cancer Res 63: 4497-4506. 
Os A, Burgler S, Ribes AP, Funderud A, Wang D, Thompson KM, Tjonnfjord GE, Bogen B, 
Munthe LA. 2013. Chronic lymphocytic leukemia cells are activated and proliferate in 
response to specific T helper cells. Cell Rep 4: 566-577. 
Ouillette P, Collins R, Shakhan S, Li J, Li C, Shedden K, Malek SN. 2011. The prognostic 
significance of various 13q14 deletions in chronic lymphocytic leukemia. Clin Cancer 
Res 17: 6778-6790. 
Overgaard NH, Jung JW, Steptoe RJ, Wells JW. 2015. CD4+/CD8+ double-positive T cells: 
more than just a developmental stage? J Leukoc Biol 97: 31-38. 
8 References    
 152 
Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, Matsumoto T. 1997. Immunotherapy 
of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific 
antigen, HM1.24. Blood 90: 3179-3186. 
Ozturk S, Roessner PM, Schulze-Edinghausen L, Yazdanparast H, Kalter V, Lichter P, Hanna 
BS, Seiffert M. 2019. Rejection of adoptively transferred Emicro-TCL1 chronic 
lymphocytic leukemia cells in C57BL/6 substrains or knockout mouse lines. Leukemia 
33: 1514-1539. 
Pahler JC, Tazzyman S, Erez N, Chen YY, Murdoch C, Nozawa H, Lewis CE, Hanahan D. 
2008. Plasticity in tumor-promoting inflammation: impairment of macrophage 
recruitment evokes a compensatory neutrophil response. Neoplasia 10: 329-340. 
Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE, Bikoff EK, Robertson 
EJ, Lauer GM, Reiner SL et al. 2012. Progenitor and terminal subsets of CD8+ T cells 
cooperate to contain chronic viral infection. Science 338: 1220-1225. 
Palma M, Gentilcore G, Heimersson K, Mozaffari F, Nasman-Glaser B, Young E, Rosenquist 
R, Hansson L, Osterborg A, Mellstedt H. 2017. T cells in chronic lymphocytic leukemia 
display dysregulated expression of immune checkpoints and activation markers. 
Haematologica 102: 562-572. 
Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. 1996. Human bone marrow 
stromal cells prevent apoptosis and support the survival of chronic lymphocytic 
leukaemia cells in vitro. Br J Haematol 92: 97-103. 
Parikh SA. 2018. Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer J 8: 
93. 
Pascutti MF, Jak M, Tromp JM, Derks IA, Remmerswaal EB, Thijssen R, van Attekum MH, 
van Bochove GG, Luijks DM, Pals ST et al. 2013. IL-21 and CD40L signals from 
autologous T cells can induce antigen-independent proliferation of CLL cells. Blood 
122: 3010-3019. 
Pasikowska M, Walsby E, Apollonio B, Cuthill K, Phillips E, Coulter E, Longhi MS, Ma Y, Yallop 
D, Barber LD et al. 2016. Phenotype and immune function of lymph node and 
peripheral blood CLL cells are linked to transendothelial migration. Blood 128: 563-573. 
Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, Drake AM, Chen Z, Sen 
DR, Kurachi M et al. 2016. Epigenetic stability of exhausted T cells limits durability of 
reinvigoration by PD-1 blockade. Science 354: 1160-1165. 
Paul Y. 2020. Clonal Evolution Dynamics and Tumor Microenvironment Composition of 
Chronic Lymphocytic Leukemia. pp. 66 - 116, Heidelberg. 
Pedroza-Gonzalez A, Zhou G, Vargas-Mendez E, Boor PP, Mancham S, Verhoef C, Polak 
WG, Grunhagen D, Pan Q, Janssen H et al. 2015. Tumor-infiltrating plasmacytoid 
dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. 
Oncoimmunology 4: e1008355. 
Pekarsky Y, Koval A, Hallas C, Bichi R, Tresini M, Malstrom S, Russo G, Tsichlis P, Croce 
CM. 2000. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. 
Proc Natl Acad Sci U S A 97: 3028-3033. 
Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U, Rassenti L, 
Kipps T, Croce CM. 2008. Tcl1 functions as a transcriptional regulator and is directly 
involved in the pathogenesis of CLL. Proc Natl Acad Sci U S A 105: 19643-19648. 
Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder 
H, Liu CG, Rassenti L et al. 2006. Tcl1 expression in chronic lymphocytic leukemia is 
regulated by miR-29 and miR-181. Cancer Res 66: 11590-11593. 
Penn I, Starzl TE. 1970. Malignant lymphomas in transplantation patients: a review of the world 
experience. Int Z Klin Pharmakol Ther Toxikol 3: 49-54. 
Perry C, Hazan-Halevy I, Kay S, Cipok M, Grisaru D, Deutsch V, Polliack A, Naparstek E, 
Herishanu Y. 2012. Increased CD39 expression on CD4(+) T lymphocytes has clinical 
and prognostic significance in chronic lymphocytic leukemia. Ann Hematol 91: 1271-
1279. 
Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, 
Rabe KG, Stilgenbauer S et al. 2014. Development of a comprehensive prognostic 
index for patients with chronic lymphocytic leukemia. Blood 124: 49-62. 
8 References    
 153 
Piao W, Xiong Y, Famulski K, Brinkman CC, Li L, Toney N, Wagner C, Saxena V, Simon T, 
Bromberg JS. 2019. Author Correction: Regulation of T cell afferent lymphatic migration 
by targeting LTbetaR-mediated non-classical NFkappaB signaling. Nat Commun 10: 
2927. 
Pieper K, Grimbacher B, Eibel H. 2013. B-cell biology and development. J Allergy Clin Immunol 
131: 959-971. 
Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-
Shoval S, Galun E, Ben-Neriah Y. 2004. NF-kappaB functions as a tumour promoter in 
inflammation-associated cancer. Nature 431: 461-466. 
Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A. 2010. Interleukin-2 
and inflammation induce distinct transcriptional programs that promote the 
differentiation of effector cytolytic T cells. Immunity 32: 79-90. 
Podhorecka M, Dmoszynska A, Rolinski J, Wasik E. 2002. T type 1/type 2 subsets balance in 
B-cell chronic lymphocytic leukemia--the three-color flow cytometry analysis. Leuk Res 
26: 657-660. 
Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien 
S, Chiorazzi N, Burger JA. 2012. The Bruton tyrosine kinase inhibitor PCI-32765 
thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in 
vivo. Blood 119: 1182-1189. 
Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen 
A, Gonzalez V et al. 2015. Chimeric antigen receptor T cells persist and induce 
sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl 
Med 7: 303ra139. 
Pot C, Jin H, Awasthi A, Liu SM, Lai CY, Madan R, Sharpe AH, Karp CL, Miaw SC, Ho IC et 
al. 2009. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and 
the costimulatory receptor ICOS that coordinately act together to promote 
differentiation of IL-10-producing Tr1 cells. J Immunol 183: 797-801. 
Puente XS, Bea S, Valdes-Mas R, Villamor N, Gutierrez-Abril J, Martin-Subero JI, Munar M, 
Rubio-Perez C, Jares P, Aymerich M et al. 2015. Non-coding recurrent mutations in 
chronic lymphocytic leukaemia. Nature 526: 519-524. 
Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, Escaramis G, Jares P, 
Bea S, Gonzalez-Diaz M et al. 2011. Whole-genome sequencing identifies recurrent 
mutations in chronic lymphocytic leukaemia. Nature 475: 101-105. 
Pulte D, Furman RR, Broekman MJ, Drosopoulos JH, Ballard HS, Olson KE, Kizer JR, Marcus 
AJ. 2011. CD39 expression on T lymphocytes correlates with severity of disease in 
patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 11: 367-
372. 
Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, Rodman C, Luo CL, Mroz EA, 
Emerick KS et al. 2017. Single-Cell Transcriptomic Analysis of Primary and Metastatic 
Tumor Ecosystems in Head and Neck Cancer. Cell 171: 1611-1624 e1624. 
Qi H. 2016. T follicular helper cells in space-time. Nat Rev Immunol 16: 612-625. 
Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, Ramsay AJ, Bea S, 
Pinyol M, Martinez-Trillos A et al. 2011. Exome sequencing identifies recurrent 
mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat 
Genet 44: 47-52. 
Quesada V, Ramsay AJ, Lopez-Otin C. 2012. Chronic lymphocytic leukemia with SF3B1 
mutation. N Engl J Med 366: 2530. 
Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, Caccamo M, Oukka M, 
Weiner HL. 2008. Control of T(reg) and T(H)17 cell differentiation by the aryl 
hydrocarbon receptor. Nature 453: 65-71. 
Rahemtullah A, Reichard KK, Preffer FI, Harris NL, Hasserjian RP. 2006. A double-positive 
CD4+CD8+ T-cell population is commonly found in nodular lymphocyte predominant 
Hodgkin lymphoma. Am J Clin Pathol 126: 805-814. 
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. 1975. Clinical 
staging of chronic lymphocytic leukemia. Blood 46: 219-234. 
8 References    
 154 
Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, Zhang W, Sougnez C, 
Cibulskis K, Sidney J et al. 2014. Systematic identification of personal tumor-specific 
neoantigens in chronic lymphocytic leukemia. Blood 124: 453-462. 
Ramsay AG, Clear AJ, Fatah R, Gribben JG. 2012. Multiple inhibitory ligands induce impaired 
T-cell immunologic synapse function in chronic lymphocytic leukemia that can be 
blocked with lenalidomide: establishing a reversible immune evasion mechanism in 
human cancer. Blood 120: 1412-1421. 
Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, Byrd JC, Gribben JG. 2008. 
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation 
that can be reversed with an immunomodulating drug. J Clin Invest 118: 2427-2437. 
Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai 
KR, Byrd JC et al. 2004. ZAP-70 compared with immunoglobulin heavy-chain gene 
mutation status as a predictor of disease progression in chronic lymphocytic leukemia. 
N Engl J Med 351: 893-901. 
Rau FC, Dieter J, Luo Z, Priest SO, Baumgarth N. 2009. B7-1/2 (CD80/CD86) direct signaling 
to B cells enhances IgG secretion. J Immunol 183: 7661-7671. 
Redondo-Munoz J, Escobar-Diaz E, Samaniego R, Terol MJ, Garcia-Marco JA, Garcia-Pardo 
A. 2006. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 
integrin or CXCR4 engagement via distinct signaling pathways, localizes to 
podosomes, and is involved in cell invasion and migration. Blood 108: 3143-3151. 
Reittie JE, Yong KL, Panayiotidis P, Hoffbrand AV. 1996. Interleukin-6 inhibits apoptosis and 
tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. Leuk 
Lymphoma 22: 83-90, follow 186, color plate VI. 
Rendeiro AF, Krausgruber T, Fortelny N, Zhao F, Penz T, Farlik M, Schuster LC, Nemc A, 
Tasnady S, Reti M et al. 2020. Chromatin mapping and single-cell immune profiling 
define the temporal dynamics of ibrutinib response in CLL. Nat Commun 11: 577. 
Ribas A, Wolchok JD. 2018. Cancer immunotherapy using checkpoint blockade. Science 359: 
1350-1355. 
Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG, Gribben JG. 
2013. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity 
for cytokine production. Blood 121: 1612-1621. 
Riches JC, Gribben JG. 2013. Understanding the immunodeficiency in chronic lymphocytic 
leukemia: potential clinical implications. Hematol Oncol Clin North Am 27: 207-235. 
Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Menard 
S, Pierotti MA, Testori A. 1991. Prognostic significance of HER-2/neu expression in 
breast cancer and its relationship to other prognostic factors. Int J Cancer 49: 44-49. 
Ringshausen I, Dechow T, Schneller F, Weick K, Oelsner M, Peschel C, Decker T. 2004. 
Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and 
survival of B-CLL cells on bone marrow stromal cells. Leukemia 18: 1964-1970. 
Rodriguez PC, Ochoa AC. 2008. Arginine regulation by myeloid derived suppressor cells and 
tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 222: 180-
191. 
Roessner PM, Cid LL, Lupar E, Roider T, Bordas M, Schifflers C, Gaupel A-C, Kilpert F, 
Krötschel M, Arnold SJ et al. 2020a. EOMES and IL-10 regulate anti-tumor activity of 
PD-1<sup>+</sup> CD4<sup>+</sup> T-cells in B-cell Non-Hodgkin lymphoma. 
bioRxiv doi:10.1101/2020.03.09.983098: 2020.2003.2009.983098. 
Roessner PM, Hanna BS, Ozturk S, Schulz R, Llao Cid L, Yazdanparast H, Scheffold A, 
Colomer D, Stilgenbauer S, Lichter P et al. 2020b. TBET-expressing Th1 CD4(+) T 
cells accumulate in chronic lymphocytic leukaemia without affecting disease 
progression in Emicro-TCL1 mice. Br J Haematol 189: 133-145. 
Roider T, Seufert J, Uvarovskii A, Frauhammer F, Bordas M, Abedpour N, Stolarczyk M, Mallm 
JP, Herbst SA, Bruch PM et al. 2020. Dissecting intratumour heterogeneity of nodal B-
cell lymphomas at the transcriptional, genetic and drug-response levels. Nat Cell Biol 
22: 896-906. 
Romano M, Fanelli G, Albany CJ, Giganti G, Lombardi G. 2019. Past, Present, and Future of 
Regulatory T Cell Therapy in Transplantation and Autoimmunity. Front Immunol 10: 43. 
8 References    
 155 
Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F, Defrance T, Bonelli 
P, Tuccillo F, Turco MC et al. 1998. Triggering of CD40 antigen inhibits fludarabine-
induced apoptosis in B chronic lymphocytic leukemia cells. Blood 92: 990-995. 
Roncarolo MG, Gregori S, Bacchetta R, Battaglia M. 2014. Tr1 cells and the counter-regulation 
of immunity: natural mechanisms and therapeutic applications. Curr Top Microbiol 
Immunol 380: 39-68. 
Roncarolo MG, Gregori S, Bacchetta R, Battaglia M, Gagliani N. 2018. The Biology of T 
Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated 
Diseases. Immunity 49: 1004-1019. 
Roncarolo MG, Yssel H, Touraine JL, Betuel H, De Vries JE, Spits H. 1988. Autoreactive T 
cell clones specific for class I and class II HLA antigens isolated from a human chimera. 
J Exp Med 167: 1523-1534. 
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo 
NP, Robbins PF, Wunderlich JR et al. 2011. Durable complete responses in heavily 
pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. 
Clin Cancer Res 17: 4550-4557. 
Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, 
Rassenti LZ, Powell J et al. 2001. Relation of gene expression phenotype to 
immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 
194: 1639-1647. 
Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, 
Mauro FR, Morabito F et al. 2015. Molecular prediction of durable remission after first-
line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood 
126: 1921-1924. 
Russo G, Isobe M, Gatti R, Finan J, Batuman O, Huebner K, Nowell PC, Croce CM. 1989. 
Molecular analysis of a t(14;14) translocation in leukemic T-cells of an ataxia 
telangiectasia patient. Proc Natl Acad Sci U S A 86: 602-606. 
Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen 
JH, Frederick DT, Barzily-Rokni M et al. 2018. Defining T Cell States Associated with 
Response to Checkpoint Immunotherapy in Melanoma. Cell 175: 998-1013 e1020. 
Sadik A, Somarribas Patterson LF, Ozturk S, Mohapatra SR, Panitz V, Secker PF, Pfander P, 
Loth S, Salem H, Prentzell MT et al. 2020. IL4I1 Is a Metabolic Immune Checkpoint 
that Activates the AHR and Promotes Tumor Progression. Cell 182: 1252-1270 e1234. 
Sahin U, Tureci O. 2018. Personalized vaccines for cancer immunotherapy. Science 359: 
1355-1360. 
Sandberg JK, Fast NM, Nixon DF. 2001. Functional heterogeneity of cytokines and cytolytic 
effector molecules in human CD8+ T lymphocytes. J Immunol 167: 181-187. 
Sarrabayrouse G, Corvaisier M, Ouisse LH, Bossard C, Le Mevel B, Potiron L, Meurette G, 
Gervois N, Jotereau F. 2011. Tumor-reactive CD4+ CD8alphabeta+ CD103+ 
alphabetaT cells: a prevalent tumor-reactive T-cell subset in metastatic colorectal 
cancers. Int J Cancer 128: 2923-2932. 
Satpathy AT, Granja JM, Yost KE, Qi Y, Meschi F, McDermott GP, Olsen BN, Mumbach MR, 
Pierce SE, Corces MR et al. 2019. Massively parallel single-cell chromatin landscapes 
of human immune cell development and intratumoral T cell exhaustion. Nat Biotechnol 
37: 925-936. 
Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P. 1999. Somatic ATM mutations 
indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 94: 
748-753. 
Schatz DG, Oettinger MA, Baltimore D. 1989. The V(D)J recombination activating gene, RAG-
1. Cell 59: 1035-1048. 
Schetter AJ, Heegaard NH, Harris CC. 2010. Inflammation and cancer: interweaving 
microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 31: 37-49. 
Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt 
DG, Knoblaugh SE, Hammerling GJ et al. 2016. Tumor-Specific T Cell Dysfunction Is 
a Dynamic Antigen-Driven Differentiation Program Initiated Early during 
Tumorigenesis. Immunity 45: 389-401. 
8 References    
 156 
Schreiber RD, Old LJ, Smyth MJ. 2011. Cancer immunoediting: integrating immunity's roles in 
cancer suppression and promotion. Science 331: 1565-1570. 
Schreiber RD, Pace JL, Russell SW, Altman A, Katz DH. 1983. Macrophage-activating factor 
produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to 
gamma-interferon. J Immunol 131: 826-832. 
Schulz A, Toedt G, Zenz T, Stilgenbauer S, Lichter P, Seiffert M. 2011. Inflammatory cytokines 
and signaling pathways are associated with survival of primary chronic lymphocytic 
leukemia cells in vitro: a dominant role of CCL2. Haematologica 96: 408-416. 
Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. 
2011. Global quantification of mammalian gene expression control. Nature 473: 337-
342. 
Scielzo C, Bertilaccio MT, Simonetti G, Dagklis A, ten Hacken E, Fazi C, Muzio M, Caiolfa V, 
Kitamura D, Restuccia U et al. 2010. HS1 has a central role in the trafficking and 
homing of leukemic B cells. Blood 116: 3537-3546. 
Scurr M, Ladell K, Besneux M, Christian A, Hockey T, Smart K, Bridgeman H, Hargest R, 
Phillips S, Davies M et al. 2014. Highly prevalent colorectal cancer-infiltrating LAP(+) 
Foxp3(-) T cells exhibit more potent immunosuppressive activity than Foxp3(+) 
regulatory T cells. Mucosal Immunol 7: 428-439. 
Secchiero P, Tiribelli M, Barbarotto E, Celeghini C, Michelutti A, Masolini P, Fanin R, Zauli G. 
2005. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. 
J Cell Physiol 205: 246-252. 
Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, Durig J, Kuppers R. 2012. Cellular 
origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med 209: 2183-
2198. 
Seiffert M, Schulz A, Ohl S, Dohner H, Stilgenbauer S, Lichter P. 2010. Soluble CD14 is a 
novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is 
induced by CLL cells in vitro and present at abnormally high levels in vivo. Blood 116: 
4223-4230. 
Serrano D, Monteiro J, Allen SL, Kolitz J, Schulman P, Lichtman SM, Buchbinder A, 
Vinciguerra VP, Chiorazzi N, Gregersen PK. 1997. Clonal expansion within the 
CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia. J 
Immunol 158: 1482-1489. 
Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE, Nowakowski GS, Zent CS, 
Call TG, Laplant B, Dewald GW et al. 2008. CD49d expression is an independent 
predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic 
parameter with therapeutic potential. Br J Haematol 140: 537-546. 
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. 2001. 
IFNgamma and lymphocytes prevent primary tumour development and shape tumour 
immunogenicity. Nature 410: 1107-1111. 
Shapiro-Shelef M, Calame K. 2005. Regulation of plasma-cell development. Nat Rev Immunol 
5: 230-242. 
Sharma P, Allison JP. 2015. The future of immune checkpoint therapy. Science 348: 56-61. 
Sharma S, Rai KR. 2019. Chronic lymphocytic leukemia (CLL) treatment: So many choices, 
such great options. Cancer 125: 1432-1440. 
Sheil AG. 1986. Cancer after transplantation. World J Surg 10: 389-396. 
Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M, Charron J, Datta M, Young 
F, Stall AM et al. 1992. RAG-2-deficient mice lack mature lymphocytes owing to inability 
to initiate V(D)J rearrangement. Cell 68: 855-867. 
Shukla V, Ma S, Hardy RR, Joshi SS, Lu R. 2013. A role for IRF4 in the development of CLL. 
Blood 122: 2848-2855. 
Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira 
D, Carmona SJ, Scarpellino L, Gfeller D, Pradervand S et al. 2019. Intratumoral 
Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in 
Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity 50: 195-
211 e110. 
8 References    
 157 
Simonetti G, Bertilaccio MT, Ghia P, Klein U. 2014. Mouse models in the study of chronic 
lymphocytic leukemia pathogenesis and therapy. Blood 124: 1010-1019. 
Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW, Yeong JPS, Nahar R, Zhang T, 
Kared H et al. 2018. Bystander CD8(+) T cells are abundant and phenotypically distinct 
in human tumour infiltrates. Nature 557: 575-579. 
Slack GW. 2016. The Pathology of Reactive Lymphadenopathies: A Discussion of Common 
Reactive Patterns and Their Malignant Mimics. Arch Pathol Lab Med 140: 881-892. 
Slager SL, Skibola CF, Di Bernardo MC, Conde L, Broderick P, McDonnell SK, Goldin LR, 
Croft N, Holroyd A, Harris S et al. 2012. Common variation at 6p21.31 (BAK1) 
influences the risk of chronic lymphocytic leukemia. Blood 120: 843-846. 
Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K. 
2001. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to 
interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp 
Med 193: 661-670. 
Smyth MJ, Dunn GP, Schreiber RD. 2006. Cancer immunosurveillance and immunoediting: 
the roles of immunity in suppressing tumor development and shaping tumor 
immunogenicity. Adv Immunol 90: 1-50. 
Song Z, Zhang T, Li G, Tang Y, Luo Y, Yu G. 2018. Tr1 responses are elevated in 
asymptomatic H. pylori-infected individuals and are functionally impaired in H. pylori-
gastric cancer patients. Exp Cell Res 367: 251-256. 
Speedy HE, Beekman R, Chapaprieta V, Orlando G, Law PJ, Martin-Garcia D, Gutierrez-Abril 
J, Catovsky D, Bea S, Clot G et al. 2019. Insight into genetic predisposition to chronic 
lymphocytic leukemia from integrative epigenomics. Nat Commun 10: 3615. 
Speedy HE, Di Bernardo MC, Sava GP, Dyer MJ, Holroyd A, Wang Y, Sunter NJ, Mansouri L, 
Juliusson G, Smedby KE et al. 2014. A genome-wide association study identifies 
multiple susceptibility loci for chronic lymphocytic leukemia. Nat Genet 46: 56-60. 
Speiser DE, Utzschneider DT, Oberle SG, Munz C, Romero P, Zehn D. 2014. T cell 
differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat 
Rev Immunol 14: 768-774. 
Spencer SD, Di Marco F, Hooley J, Pitts-Meek S, Bauer M, Ryan AM, Sordat B, Gibbs VC, 
Aguet M. 1998. The orphan receptor CRF2-4 is an essential subunit of the interleukin 
10 receptor. J Exp Med 187: 571-578. 
Stall AM, Farinas MC, Tarlinton DM, Lalor PA, Herzenberg LA, Strober S, Herzenberg LA. 
1988. Ly-1 B-cell clones similar to human chronic lymphocytic leukemias routinely 
develop in older normal mice and young autoimmune (New Zealand Black-related) 
animals. Proc Natl Acad Sci U S A 85: 7312-7316. 
Stamatopoulos K, Agathangelidis A, Rosenquist R, Ghia P. 2017. Antigen receptor stereotypy 
in chronic lymphocytic leukemia. Leukemia 31: 282-291. 
Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, Belhoul L, 
Stella S, Stavroyianni N, Crespo M et al. 2007. Over 20% of patients with chronic 
lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and 
clinical correlations. Blood 109: 259-270. 
Stankovic T, Skowronska A. 2014. The role of ATM mutations and 11q deletions in disease 
progression in chronic lymphocytic leukemia. Leuk Lymphoma 55: 1227-1239. 
Stein JV, Lopez-Fraga M, Elustondo FA, Carvalho-Pinto CE, Rodriguez D, Gomez-Caro R, De 
Jong J, Martinez AC, Medema JP, Hahne M. 2002. APRIL modulates B and T cell 
immunity. J Clin Invest 109: 1587-1598. 
Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. 2011. B-cell receptor signaling in 
chronic lymphocytic leukemia. Blood 118: 4313-4320. 
Stilgenbauer S, Zenz T, Winkler D, Buhler A, Schlenk RF, Groner S, Busch R, Hensel M, 
Duhrsen U, Finke J et al. 2009. Subcutaneous alemtuzumab in fludarabine-refractory 
chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the 
CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 
27: 3994-4001. 
8 References    
 158 
Strati P, Abruzzo LV, Wierda WG, O'Brien S, Ferrajoli A, Keating MJ. 2015. Second cancers 
and Richter transformation are the leading causes of death in patients with trisomy 12 
chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 15: 420-427. 
Strati P, Shanafelt TD. 2015. Monoclonal B-cell lymphocytosis and early-stage chronic 
lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood 126: 454-
462. 
Street SE, Cretney E, Smyth MJ. 2001. Perforin and interferon-gamma activities independently 
control tumor initiation, growth, and metastasis. Blood 97: 192-197. 
Strid J, Roberts SJ, Filler RB, Lewis JM, Kwong BY, Schpero W, Kaplan DH, Hayday AC, 
Girardi M. 2008. Acute upregulation of an NKG2D ligand promotes rapid reorganization 
of a local immune compartment with pleiotropic effects on carcinogenesis. Nat Immunol 
9: 146-154. 
Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, 3rd, Hao Y, Stoeckius 
M, Smibert P, Satija R. 2019. Comprehensive Integration of Single-Cell Data. Cell 177: 
1888-1902 e1821. 
Suvas S, Singh V, Sahdev S, Vohra H, Agrewala JN. 2002. Distinct role of CD80 and CD86 in 
the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 277: 7766-
7775. 
Swerdlow SH. 2017. WHO classification of tumours of haematopoietic and lymphoid tissues. 
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles 
GA, Zelenetz AD et al. 2016. The 2016 revision of the World Health Organization 
classification of lymphoid neoplasms. Blood 127: 2375-2390. 
Szabo PA, Levitin HM, Miron M, Snyder ME, Senda T, Yuan J, Cheng YL, Bush EC, Dogra P, 
Thapa P et al. 2019. Single-cell transcriptomics of human T cells reveals tissue and 
activation signatures in health and disease. Nat Commun 10: 4706. 
Taghiloo S, Allahmoradi E, Tehrani M, Hossein-Nataj H, Shekarriz R, Janbabaei G, 
Abediankenari S, Asgarian-Omran H. 2017. Frequency and functional characterization 
of exhausted CD8(+) T cells in chronic lymphocytic leukemia. Eur J Haematol 98: 622-
631. 
Tai YT, Horton HM, Kong SY, Pong E, Chen H, Cemerski S, Bernett MJ, Nguyen DH, Karki S, 
Chu SY et al. 2012. Potent in vitro and in vivo activity of an Fc-engineered humanized 
anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood 
119: 2074-2082. 
Takai A, Toyoshima T, Uemura M, Kitawaki Y, Marusawa H, Hiai H, Yamada S, Okazaki IM, 
Honjo T, Chiba T et al. 2009. A novel mouse model of hepatocarcinogenesis triggered 
by AID causing deleterious p53 mutations. Oncogene 28: 469-478. 
Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita 
H, Okumura K. 2001. Involvement of tumor necrosis factor-related apoptosis-inducing 
ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7: 94-
100. 
Tang J, Zha J, Guo X, Shi P, Xu B. 2017. CXCR5(+)CD8(+) T cells present elevated capacity 
in mediating cytotoxicity toward autologous tumor cells through interleukin 10 in diffuse 
large B-cell lymphoma. Int Immunopharmacol 50: 146-151. 
Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, Schreiber RD, de la Torre JC, 
Oldstone MB. 2013. Persistent LCMV infection is controlled by blockade of type I 
interferon signaling. Science 340: 207-211. 
Ten Hacken E, Burger JA. 2016. Microenvironment interactions and B-cell receptor signaling 
in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and 
treatment. Biochim Biophys Acta 1863: 401-413. 
Terabe M, Berzofsky JA. 2004. Immunoregulatory T cells in tumor immunity. Curr Opin 
Immunol 16: 157-162. 
The BLUEPRINT Consortium. 2016. Blueprint Epigenome. Vol 2020. 
Thomas S, Prendergast GC. 2016. Cancer Vaccines: A Brief Overview. Methods Mol Biol 
1403: 755-761. 
Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, 
Schill C, Hess C et al. 2018. A transcriptionally and functionally distinct PD-1(+) CD8(+) 
8 References    
 159 
T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 
blockade. Nat Med 24: 994-1004. 
Tibbitt CA, Stark JM, Martens L, Ma J, Mold JE, Deswarte K, Oliynyk G, Feng X, Lambrecht 
BN, De Bleser P et al. 2019. Single-Cell RNA Sequencing of the T Helper Cell 
Response to House Dust Mites Defines a Distinct Gene Expression Signature in Airway 
Th2 Cells. Immunity 51: 169-184 e165. 
Tinoco R, Alcalde V, Yang Y, Sauer K, Zuniga EI. 2009. Cell-intrinsic transforming growth 
factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence 
in vivo. Immunity 31: 145-157. 
Tirosh I, Izar B, Prakadan SM, Wadsworth MH, 2nd, Treacy D, Trombetta JJ, Rotem A, 
Rodman C, Lian C, Murphy G et al. 2016. Dissecting the multicellular ecosystem of 
metastatic melanoma by single-cell RNA-seq. Science 352: 189-196. 
Tobin G, Thunberg U, Karlsson K, Murray F, Laurell A, Willander K, Enblad G, Merup M, Vilpo 
J, Juliusson G et al. 2004. Subsets with restricted immunoglobulin gene rearrangement 
features indicate a role for antigen selection in the development of chronic lymphocytic 
leukemia. Blood 104: 2879-2885. 
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, 
Carvajal RD, Sosman JA, Atkins MB et al. 2012. Safety, activity, and immune correlates 
of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454. 
Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, Nishioka Y, Sone S, Kuwano M. 
2000. Macrophage infiltration correlates with tumor stage and angiogenesis in human 
malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int J Cancer 
85: 182-188. 
Totterman TH, Carlsson M, Simonsson B, Bengtsson M, Nilsson K. 1989. T-cell activation and 
subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood 
74: 786-792. 
Tree TI, Lawson J, Edwards H, Skowera A, Arif S, Roep BO, Peakman M. 2010. Naturally 
arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 
regulate proinflammatory T-cell responses via linked suppression. Diabetes 59: 1451-
1460. 
Trentin L, Cerutti A, Zambello R, Sancretta R, Tassinari C, Facco M, Adami F, Rodeghiero F, 
Agostini C, Semenzato G. 1996. Interleukin-15 promotes the growth of leukemic cells 
of patients with B-cell chronic lymphoproliferative disorders. Blood 87: 3327-3335. 
Troeger A, Johnson AJ, Wood J, Blum WG, Andritsos LA, Byrd JC, Williams DA. 2012. RhoH 
is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice 
and humans. Blood 119: 4708-4718. 
Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. 2002. Distinctive features of "nurselike" cells that 
differentiate in the context of chronic lymphocytic leukemia. Blood 99: 1030-1037. 
Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld 
S et al. 2017. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated 
With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of 
Ibrutinib. J Clin Oncol 35: 3010-3020. 
Tzankov A, Dirnhofer S. 2018. A pattern-based approach to reactive lymphadenopathies. 
Semin Diagn Pathol 35: 4-19. 
Utzschneider DT, Charmoy M, Chennupati V, Pousse L, Ferreira DP, Calderon-Copete S, 
Danilo M, Alfei F, Hofmann M, Wieland D et al. 2016. T Cell Factor 1-Expressing 
Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections. 
Immunity 45: 415-427. 
van der Leun AM, Thommen DS, Schumacher TN. 2020. CD8(+) T cell states in human 
cancer: insights from single-cell analysis. Nat Rev Cancer 20: 218-232. 
Van Gassen S, Callebaut B, Van Helden MJ, Lambrecht BN, Demeester P, Dhaene T, Saeys 
Y. 2015. FlowSOM: Using self-organizing maps for visualization and interpretation of 
cytometry data. Cytometry A 87: 636-645. 
van Gent R, Kater AP, Otto SA, Jaspers A, Borghans JA, Vrisekoop N, Ackermans MA, Ruiter 
AF, Wittebol S, Eldering E et al. 2008. In vivo dynamics of stable chronic lymphocytic 
8 References    
 160 
leukemia inversely correlate with somatic hypermutation levels and suggest no major 
leukemic turnover in bone marrow. Cancer Res 68: 10137-10144. 
Vardi A, Agathangelidis A, Sutton LA, Ghia P, Rosenquist R, Stamatopoulos K. 2014. 
Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations 
about ontogeny and clinical evolution. Cancer Res 74: 4211-4216. 
Vardi A, Vlachonikola E, Karypidou M, Stalika E, Bikos V, Gemenetzi K, Maramis C, Siorenta 
A, Anagnostopoulos A, Pospisilova S et al. 2017. Restrictions in the T-cell repertoire of 
chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by 
shared antigenic elements. Leukemia 31: 1555-1561. 
Vento-Tormo R, Efremova M, Botting RA, Turco MY, Vento-Tormo M, Meyer KB, Park JE, 
Stephenson E, Polanski K, Goncalves A et al. 2018. Single-cell reconstruction of the 
early maternal-fetal interface in humans. Nature 563: 347-353. 
Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. 2011. Natural innate and adaptive 
immunity to cancer. Annu Rev Immunol 29: 235-271. 
Victora GD, Nussenzweig MC. 2012. Germinal centers. Annu Rev Immunol 30: 429-457. 
Vincent AM, Cawley JC, Burthem J. 1996. Integrin function in chronic lymphocytic leukemia. 
Blood 87: 4780-4788. 
Vinuesa CG, Linterman MA, Yu D, MacLennan IC. 2016. Follicular Helper T Cells. Annu Rev 
Immunol 34: 335-368. 
Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, Cohen GM. 2009. 
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold 
resistance to ABT-737 in chronic lymphocytic leukemia. Blood 113: 4403-4413. 
Wagner J, Rapsomaniki MA, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, Rees M, 
Ramaswamy A, Muenst S, Soysal SD et al. 2019. A Single-Cell Atlas of the Tumor and 
Immune Ecosystem of Human Breast Cancer. Cell 177: 1330-1345 e1318. 
Wan YY, Flavell RA. 2005. Identifying Foxp3-expressing suppressor T cells with a bicistronic 
reporter. Proc Natl Acad Sci U S A 102: 5126-5131. 
Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, Werner L, Sivachenko 
A, DeLuca DS, Zhang L et al. 2011. SF3B1 and other novel cancer genes in chronic 
lymphocytic leukemia. N Engl J Med 365: 2497-2506. 
Wang W, Nishioka Y, Ozaki S, Jalili A, Abe S, Kakiuchi S, Kishuku M, Minakuchi K, Matsumoto 
T, Sone S. 2009. HM1.24 (CD317) is a novel target against lung cancer for 
immunotherapy using anti-HM1.24 antibody. Cancer Immunol Immunother 58: 967-
976. 
Wang Y, Liu J, Burrows PD, Wang JY. 2020. B Cell Development and Maturation. Adv Exp 
Med Biol 1254: 1-22. 
Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. 2003. 
Predominant autoantibody production by early human B cell precursors. Science 301: 
1374-1377. 
Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux 
P. 1994. p53 mutations are associated with resistance to chemotherapy and short 
survival in hematologic malignancies. Blood 84: 3148-3157. 
Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. 2020. Dendritic cells in 
cancer immunology and immunotherapy. Nat Rev Immunol 20: 7-24. 
Weulersse M, Asrir A, Pichler AC, Lemaitre L, Braun M, Carrie N, Joubert MV, Le Moine M, 
Do Souto L, Gaud G et al. 2020. Eomes-Dependent Loss of the Co-activating Receptor 
CD226 Restrains CD8(+) T Cell Anti-tumor Functions and Limits the Efficacy of Cancer 
Immunotherapy. Immunity 53: 824-839 e810. 
Wherry EJ. 2011. T cell exhaustion. Nat Immunol 12: 492-499. 
Wherry EJ, Ahmed R. 2004. Memory CD8 T-cell differentiation during viral infection. J Virol 
78: 5535-5545. 
Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, 
Barber DL, Ahmed R. 2007. Molecular signature of CD8+ T cell exhaustion during 
chronic viral infection. Immunity 27: 670-684. 
Wierz M, Pierson S, Guyonnet L, Viry E, Lequeux A, Oudin A, Niclou SP, Ollert M, Berchem 
G, Janji B et al. 2018. Dual PD1/LAG3 immune checkpoint blockade limits tumor 
8 References    
 161 
development in a murine model of chronic lymphocytic leukemia. Blood 131: 1617-
1621. 
Wikenheiser DJ, Stumhofer JS. 2016. ICOS Co-Stimulation: Friend or Foe? Front Immunol 7: 
304. 
Wilkerson MD, Hayes DN. 2010. ConsensusClusterPlus: a class discovery tool with 
confidence assessments and item tracking. Bioinformatics 26: 1572-1573. 
Williams MA, Bevan MJ. 2007. Effector and memory CTL differentiation. Annu Rev Immunol 
25: 171-192. 
Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, Aronow BJ, Karp CL, 
Brooks DG. 2013. Blockade of chronic type I interferon signaling to control persistent 
LCMV infection. Science 340: 202-207. 
Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, 
Zhao W, Rassenti L et al. 2014. Prolonged lymphocytosis during ibrutinib therapy is 
associated with distinct molecular characteristics and does not indicate a suboptimal 
response to therapy. Blood 123: 1810-1817. 
Wu J, Xu X, Lee EJ, Shull AY, Pei L, Awan F, Wang X, Choi JH, Deng L, Xin HB et al. 2016a. 
Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated 
with epigenetic reprogramming. Oncotarget 7: 40558-40570. 
Wu T, Ji Y, Moseman EA, Xu HC, Manglani M, Kirby M, Anderson SM, Handon R, Kenyon E, 
Elkahloun A et al. 2016b. The TCF1-Bcl6 axis counteracts type I interferon to repress 
exhaustion and maintain T cell stemness. Sci Immunol 1. 
Yan H, Zhang P, Kong X, Hou X, Zhao L, Li T, Yuan X, Fu H. 2017. Primary Tr1 cells from 
metastatic melanoma eliminate tumor-promoting macrophages through granzyme B- 
and perforin-dependent mechanisms. Tumour Biol 39: 1010428317697554. 
Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E, Petlickovski A, Efremov 
DG, Croce CM, Chiorazzi N. 2006. B cell receptors in TCL1 transgenic mice resemble 
those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc 
Natl Acad Sci U S A 103: 11713-11718. 
Yao C, Sun HW, Lacey NE, Ji Y, Moseman EA, Shih HY, Heuston EF, Kirby M, Anderson S, 
Cheng J et al. 2019. Single-cell RNA-seq reveals TOX as a key regulator of CD8(+) T 
cell persistence in chronic infection. Nat Immunol 20: 890-901. 
Yin S, Gambe RG, Sun J, Martinez AZ, Cartun ZJ, Regis FFD, Wan Y, Fan J, Brooks AN, 
Herman SEM et al. 2019. A Murine Model of Chronic Lymphocytic Leukemia Based on 
B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. Cancer Cell 35: 283-
296 e285. 
Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, Horan T, Shih G, Zhang M, 
Coccia MA, Kohno T et al. 1999. T-cell co-stimulation through B7RP-1 and ICOS. 
Nature 402: 827-832. 
Yoshinaga SK, Zhang M, Pistillo J, Horan T, Khare SD, Miner K, Sonnenberg M, Boone T, 
Brankow D, Dai T et al. 2000. Characterization of a new human B7-related protein: 
B7RP-1 is the ligand to the co-stimulatory protein ICOS. Int Immunol 12: 1439-1447. 
Yosifov DY, Wolf C, Stilgenbauer S, Mertens D. 2019. From Biology to Therapy: The CLL 
Success Story. Hemasphere 3: e175. 
Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, McNamara KL, Granja JM, 
Sarin KY, Brown RA et al. 2019. Clonal replacement of tumor-specific T cells following 
PD-1 blockade. Nat Med 25: 1251-1259. 
Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, 
Ozcan M, Avivi I, Bosch F et al. 2019. Safety and activity of ibrutinib in combination 
with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic 
leukaemia: a phase 1/2a study. Lancet Haematol 6: e67-e78. 
Yu D, Ye L. 2018. A Portrait of CXCR5(+) Follicular Cytotoxic CD8(+) T cells. Trends Immunol 
39: 965-979. 
Yu H, Pardoll D, Jove R. 2009. STATs in cancer inflammation and immunity: a leading role for 
STAT3. Nat Rev Cancer 9: 798-809. 
8 References    
 162 
Yukawa M, Jagannathan S, Vallabh S, Kartashov AV, Chen X, Weirauch MT, Barski A. 2020. 
AP-1 activity induced by co-stimulation is required for chromatin opening during T cell 
activation. J Exp Med 217. 
Zaborsky N, Gassner FJ, Hopner JP, Schubert M, Hebenstreit D, Stark R, Asslaber D, Steiner 
M, Geisberger R, Greil R et al. 2019. Exome sequencing of the TCL1 mouse model for 
CLL reveals genetic heterogeneity and dynamics during disease development. 
Leukemia 33: 957-968. 
Zapata JM, Krajewska M, Morse HC, 3rd, Choi Y, Reed JC. 2004. TNF receptor-associated 
factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic 
lymphocytic leukemia in transgenic mice. Proc Natl Acad Sci U S A 101: 16600-16605. 
Zemmour D, Zilionis R, Kiner E, Klein AM, Mathis D, Benoist C. 2018. Single-cell gene 
expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR. 
Nat Immunol 19: 291-301. 
Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. 2010. From pathogenesis to 
treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10: 37-50. 
Zhang F, Zhou X, DiSpirito JR, Wang C, Wang Y, Shen H. 2014. Epigenetic manipulation 
restores functions of defective CD8(+) T cells from chronic viral infection. Mol Ther 22: 
1698-1706. 
Zhang J, Marotel M, Fauteux-Daniel S, Mathieu AL, Viel S, Marcais A, Walzer T. 2018a. T-bet 
and Eomes govern differentiation and function of mouse and human NK cells and ILC1. 
Eur J Immunol 48: 738-750. 
Zhang L, Yu X, Zheng L, Zhang Y, Li Y, Fang Q, Gao R, Kang B, Zhang Q, Huang JY et al. 
2018b. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. 
Nature 564: 268-272. 
Zhang P, Lee JS, Gartlan KH, Schuster IS, Comerford I, Varelias A, Ullah MA, Vuckovic S, 
Koyama M, Kuns RD et al. 2017. Eomesodermin promotes the development of type 1 
regulatory T (TR1) cells. Sci Immunol 2. 
Zhang Y, Huang S, Gong D, Qin Y, Shen Q. 2010. Programmed death-1 upregulation is 
correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-
small cell lung cancer. Cell Mol Immunol 7: 389-395. 
Zheng C, Zheng L, Yoo JK, Guo H, Zhang Y, Guo X, Kang B, Hu R, Huang JY, Zhang Q et al. 
2017. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell 
Sequencing. Cell 169: 1342-1356 e1316. 
Zhu J, Paul WE. 2008. CD4 T cells: fates, functions, and faults. Blood 112: 1557-1569. 
Zhu J, Yamane H, Paul WE. 2010. Differentiation of effector CD4 T cell populations (*). Annu 
Rev Immunol 28: 445-489. 
Zurli V, Wimmer G, Cattaneo F, Candi V, Cencini E, Gozzetti A, Raspadori D, Campoccia G, 
Sanseviero F, Bocchia M et al. 2017. Ectopic ILT3 controls BCR-dependent activation 




  163 
9 Acknowledgments 
This project would not have come to a conclusion without the valuable contribution of many 
people, whom I would like to acknowledge accordingly. 
 
First, I would like to express my deepest gratitude to Dr. Martina Seiffert, for her direct 
supervision and ongoing support throughout my PhD studies. Her tremendous knowledge 
coupled with her excellent guidance, constructive input and trust were of immense help for the 
development of this work. Moreover, her honesty and positive spirit crucially foster a fantastic 
working atmosphere in the team. To me, she represents a role model, whose high standards 
on both a scientific and a professional level, I aim to follow in my future career. 
 
I would also like to extend my sincere thanks to Prof. Dr. Peter Lichter, for giving me the 
opportunity to perform my PhD work in his Division and thus be part of this team of outstanding 
scientists. He was always willing to share scientific and strategic advice, for which I am truly 
thankful for. 
 
It was a great pleasure to join forces with Dr. Yashna Paul and later Dr. Murat Iskar to bring 
the single-cell project to life. I highly appreciate their enthusiastic commitment and invaluable 
bioinformatic expertise, which were essential for the development of the project. At the same 
time, I would like to thank Dr. Marc Zapatka for his patience and essential contributions to the 
project. 
 
Furthermore, I would like to further thank our collaborators Prof. Dr. Elias Campo, Dr. Dolors 
Colomer, Dr. José Ignacio Martín, and Dr. Vicente Chapaprieta from the Hospital Clínic of 
Barcleona, and Dr. Sascha Dietrich and Dr. Tobias Roider from the University Clinic of 
Heidelberg, not only for the precious samples and analyses they provided, but also for their 
wholehearted and knowledgeable discussions. Of equal importance was the time and effort 
invested by Dr. Marina Wierz, Dr. Jérôme Paggetti, and Dr. Etienne Moussay from the 
Luxembourg Institute of Heath, as well as Dr. Ekaterina Lupar and Dr. Ana Izcue from the Max-
Plank Institute in Freiburg in the single-cell and TR1 projects, respectively. It was a pleasure to 
stablish such fruitful collaborations with all of them.  
 
I would like to offer my special thanks to Prof. Dr. Stefan Wiemann, and Dr. Sascha Dietrich 
for their valuable input and scientific discussions as part of my Thesis Advisory Committee. 
Likewise, I would like to thank Prof. Dr. Stefan Wiemann, Dr. Michael Milsom, and Prof. Dr. 
9 Acknowledgments    
 164 
Rüdiger Hell for their willingness to evaluate and discuss my PhD thesis as part of my 
examination committee. 
 
With respect to the scientific and practical support, I would like to emphasize the contribution 
of Verena Kalter, Norman Mack and Sybille Ohl who efficiently provided essential technical 
assistance during the course of this project. Similarly, I highly value the role of Frauke Devens, 
Petra Schröter, Magdalena Schlotter, Andrea Wittmann, and Achim Stephan for their 
eagerness to assist and efficiently manage the laboratory; and the skillful and essential IT 
support provided by Michael Hain. I would like to further thank Dr. Jan-Philipp Mallm, Dr. 
Michelle Liberio and Katharina Bauer from the ScOpenLab for their incredible support with the 
single-cell RNA-seq experiments. Equally important was the role of Dr. Steffen Schmitt, Dr. 
Marcus Eich, Klaus Hexel, Tobias Rubner, Florian Blum, and Daniel Sanzio Gimenes da Cruz 
from the Flow Cytometry Core Facility in providing very valuable flow cytometry and sorting 
trainings, and in maintaining such a high-standard facility; as well as the DKFZ Animal Facility 
for their relevant work in everyday care and breeding of mice. I would like to also thank Dr. 
Angela Schulz and the rest of the team from the High Throughput Sequencing Core Facility at 
the DKFZ, for providing excellent advice and services. 
 
I am very grateful to all the present and previous CLL group members Dr. Philipp Rößner, 
Dr. Selcen Ötürk, Dr. Lena Jassowicz, Dr. Bola Hanna, Dr. Ralph Schulz, Dr. Lavinia Arseni, 
Dr. Ebru Aydin, Marie Bordas, Mariana Coelho Mendes Martines, Dr. Franziska Haderk, Dr. 
Ibrahim Murathan Sektioglu, Dr. Haniyeh Yazdanparast, Cansu Eris, Lok Lam Ngai, Ramy 
Girgis, and Dr. Ann-Christin Gaupel for their generous contributions to this work, both at the 
practical and theoretical level, and for their supportive and cheerful attitude all along. I also 
would like to thank all current and former members of the B060/ B06X divisions, including 
Michael Periscke, Jasmin Mangei, Dr. Liliana Francois Martín del Campo, Dr. Lidia Silva, Dr. 
Niclas Kneisel, Theresa Schmid, Dr. Yashna Paul, Milena Simovic, Umar Khalid, Karol 
Urbanek, Dr. Manasi Ratnaparkhe, Dr. Christian Aichmüller, Dr. Emma Phlips, Tolga Lokumcu, 
Dr. Himanshu Soni, Pavle Boskovic, Ka Hou Man, and Yuan Peng, for contributing to make 
every moment in the laboratory not only enlightening and of high scientific value, but also fun 
and memorable. 
 
I would like to thank Christoph Schifflers and Mariam Mamdouh Shafik Saleh for crucially 
contributing to this work with their genuine interest and hardworking attitude. It was a privilege 
and great pleasure to supervise them during their master studies, which also represented an 
instructive experience for me.  
 
9 Acknowledgments    
 165 
I would also like to thank my friends, Michael Persicke, Franziska Haderk, Lidia Silva, 
Jasmin Mangei, Liliana Francois Martín del Campo, Marie Bordas, Christoph Schifflers, 
Mariam Mamdouh Shafik Saleh, Manuel Rodriguez-Paredes, Nicole Colaianni, Ona Sociats, 
Carla Codina, Jaume Fortuny, Anna Llorens, and Ricard Argelaguet, who were a source of 
inspiration and numerous joyful moments that made these last almost-four-and-a-half years a 
truly delightful and enriching experience. 
 
I would like to thank my family for their love and unwavering support: als meus pares Josep 
Ramón i Sabina, als meus germans Marina, Cecília i Gabriel, i al Fer, vull agrair-los l’escalf i 
l’amor transmès en cada pas del camí. Gràcies per ajudar-me a encarar els obstacles amb 
una actitud positiva i compartir l’alegria de cada propòsit aconseguit. A més, m ‘agradaria 
estendre aquest agraïment a la resta de la meva família, pel seu suport incondicional i per fer-
se sentir sempre a la vora. 
And last, my deepest thanks to Florian Köhler, who not only substantially contributed to this 
work with his constructive criticism and thoughtful advice, but also lit up every single day of 
these last four years with his enthusiastic, loving, and adventurous nature. Thank you for 
running with me through every winding forest path, steeper climb, and mountain trail that life 
brings, and for all those routes that are yet come to come. 
 
